Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
26100.0 | 2017-07-12 00:00:00 UTC | IPO Market Back On Track: ETFs to Tap | ABBV | https://www.nasdaq.com/articles/ipo-market-back-track-etfs-tap-2017-07-12 | nan | nan | After several lackluster quarters, the U.S. IPO market gained momentum in the second quarter of 2017, with 52 companies completing their IPOs raising nearly $11 billion. This marks the most active quarter in two years as per IPO research intelligence Renaissance Capital . The number is well above 25 IPOs in the first quarter and 34 in the year-ago quarter (read: How to Play the Hottest IPO Market in Years ).
In terms of deals, healthcare companies topped the list with 14 deals worth $1 billion, closely followed by technology companies with 12 deals worth $1.6 billion. The financial sector was in third position with eight deals valued at $0.9 billion.
The upsurge were credited to a surging stock market, improving economic fundamentals and increasing consumer sentiment that led to the appeal for new stocks with high growth potential. Most of the companies that went public last quarter have outperformed the broader markets and often generated over 40% returns.
The IPOs in the consumer discretionary sector led the way higher with the fast-growing specialty retailer Floor and Decor Holdings FND returning 87% since its debut on April 26. Technology IPOs also outperformed with a low-code software developer Appian Corp. APPN surging 51% since its debut on May 24 and a computing memory maker SMART Global Holdings SGH climbing 47.2% since it went public on May 23. In the healthcare space, Biohaven Pharmaceuticals BHVN and Athenex ATNX are up 47.1% and 45.5%, respectively since their IPOs.
Meanwhile, the largest IPO of the second quarter was cable provider Altice USA ATUS , which raised $1.9 billion and turned out the biggest US telecom IPO since 2000.
What's Hot on Wheels for 2H?
The solid IPO trends is likely to continue as a large number of companies that had already filed last year or in the first half this year are ready to come up with their IPOs in the second half. This is especially true, as 64 companies are currently in the pipeline of going public and seeking to raise a combined $19 billion. The biggest IPO deal will come from meat processor JBS Foods International (JBS), which could fetch over $2.5 billion (read: U.S. IPO ETFs Recoil in 2017, What Lies Ahead? ).
The IPO bunch of other well-known companies include sales and marketing firm Advantage Solutions (ADV), Alibaba-backed Chinese logistics firm Best, U.S. airline Frontier Group Holdings (FRNT), food supplier Dole Food Company (DOLE), online real estate brokerage Redfin (RDFN) and two large chemicals manufacturers, Venator Materials (VNTR) and PQ Group Holdings (PQJ).
How to Play?
With a large pipeline and some reputable companies likely to go public in the second half, 2017 is on track for 160-200 IPOs raising $40 billion or more. While investing in many IPOs at the same time could be difficult, investors could easily tap the IPO resurgence with the two domestic-focused ETFs discussed below:
Renaissance IPO ETF IPO
This fund provides exposure to the largest and most liquid newly listed companies by tracking the Renaissance IPO Index. New companies seek inclusion on a 'fast entry basis' on the fifth day of trading. The fund currently holds 45 stocks in its basket with each accounting for less than 10% exposure. From a sector look, technology and consumer discretionary are the top sectors accounting for 30% and 20% share, respectively, while industrials round off the top three with double-digit allocation.
The fund has amassed $13.7 million in its asset base while it trades in a light volume of less than 4,000 shares, probably implying additional cost beyond the expense ratio of 0.60%. The product has crushed the broader market in the year-to-date time frame, having returned 21.2% compared with 8.2% for SPY (see: all the Total U.S. Market ETFs here ).
First Trust US Equity Opportunities ETF FPX
This ETF focuses on the largest, best performing and most liquid U.S. IPOs and follows the IPOX-100 U.S. Index. New companies can find entry into the fund's holding after trading for a minimum of 100 days. In total, the fund holds 101 securities in its basket with the largest allocation going to the top two firms - AbbVie ABBV and The Kraft Heinz Company KHC - with over 9% share each. Other securities hold no more than 6% of the assets. The product has a nice mix of sectors, with the top four being information technology, health care, consumer discretionary and consumer staples.
The fund has accumulated $841.4 million in AUM and sees volume of about 74,000 shares per day. It charges 60 bps in fees a year and has been handily beating the broader market, gaining 10.3% so far this year.
Bottom Line
Considering the most anticipated offerings this year, investors seeking to take advantage of new growth stocks could definitely bank on these two ETFs. The huge success of the new listings and a prosperous IPO industry would further drive the funds.
Want key ETF info delivered straight to your inbox?
Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
RENAIS-IPO ETF (IPO): ETF Research Reports
FT-IPOX 100 (FPX): ETF Research Reports
The Kraft Heinz Company (KHC): Free Stock Analysis Report
Appian Corporation (APPN): Free Stock Analysis Report
BIOHAVEN PHARM (BHVN): Free Stock Analysis Report
SMART Global Holdings, Inc. (SGH): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In total, the fund holds 101 securities in its basket with the largest allocation going to the top two firms - AbbVie ABBV and The Kraft Heinz Company KHC - with over 9% share each. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report RENAIS-IPO ETF (IPO): ETF Research Reports FT-IPOX 100 (FPX): ETF Research Reports The Kraft Heinz Company (KHC): Free Stock Analysis Report Appian Corporation (APPN): Free Stock Analysis Report BIOHAVEN PHARM (BHVN): Free Stock Analysis Report SMART Global Holdings, Inc. (SGH): Free Stock Analysis Report To read this article on Zacks.com click here. The IPOs in the consumer discretionary sector led the way higher with the fast-growing specialty retailer Floor and Decor Holdings FND returning 87% since its debut on April 26. | In total, the fund holds 101 securities in its basket with the largest allocation going to the top two firms - AbbVie ABBV and The Kraft Heinz Company KHC - with over 9% share each. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report RENAIS-IPO ETF (IPO): ETF Research Reports FT-IPOX 100 (FPX): ETF Research Reports The Kraft Heinz Company (KHC): Free Stock Analysis Report Appian Corporation (APPN): Free Stock Analysis Report BIOHAVEN PHARM (BHVN): Free Stock Analysis Report SMART Global Holdings, Inc. (SGH): Free Stock Analysis Report To read this article on Zacks.com click here. In terms of deals, healthcare companies topped the list with 14 deals worth $1 billion, closely followed by technology companies with 12 deals worth $1.6 billion. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report RENAIS-IPO ETF (IPO): ETF Research Reports FT-IPOX 100 (FPX): ETF Research Reports The Kraft Heinz Company (KHC): Free Stock Analysis Report Appian Corporation (APPN): Free Stock Analysis Report BIOHAVEN PHARM (BHVN): Free Stock Analysis Report SMART Global Holdings, Inc. (SGH): Free Stock Analysis Report To read this article on Zacks.com click here. In total, the fund holds 101 securities in its basket with the largest allocation going to the top two firms - AbbVie ABBV and The Kraft Heinz Company KHC - with over 9% share each. After several lackluster quarters, the U.S. IPO market gained momentum in the second quarter of 2017, with 52 companies completing their IPOs raising nearly $11 billion. | In total, the fund holds 101 securities in its basket with the largest allocation going to the top two firms - AbbVie ABBV and The Kraft Heinz Company KHC - with over 9% share each. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report RENAIS-IPO ETF (IPO): ETF Research Reports FT-IPOX 100 (FPX): ETF Research Reports The Kraft Heinz Company (KHC): Free Stock Analysis Report Appian Corporation (APPN): Free Stock Analysis Report BIOHAVEN PHARM (BHVN): Free Stock Analysis Report SMART Global Holdings, Inc. (SGH): Free Stock Analysis Report To read this article on Zacks.com click here. Most of the companies that went public last quarter have outperformed the broader markets and often generated over 40% returns. |
26101.0 | 2017-07-11 00:00:00 UTC | AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for July 12, 2017 | ABBV | https://www.nasdaq.com/articles/abbvie-inc-abbv-ex-dividend-date-scheduled-july-12-2017-2017-07-11 | nan | nan | AbbVie Inc. ( ABBV ) will begin trading ex-dividend on July 12, 2017. A cash dividend payment of $0.64 per share is scheduled to be paid on August 15, 2017. Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 3rd quarter that ABBV has paid the same dividend. At the current stock price of $71.83, the dividend yield is 3.56%.
The previous trading day's last sale of ABBV was $71.83, representing a -2.5% decrease from the 52 week high of $73.67 and a 30.45% increase over the 52 week low of $55.06.
ABBV is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Pfizer, Inc. ( PFE ). ABBV's current earnings per share, an indicator of a company's profitability, is $3.86. Zacks Investment Research reports ABBV's forecasted earnings growth in 2017 as 14.62%, compared to an industry average of 3.6%.
For more information on the declaration, record and payment dates, visit the ABBV Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABBV through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABBV as a top-10 holding:
VanEck Vectors Pharmaceutical ETF ( PPH )
PowerShares Dynamic Pharmaceuticals ( PJP )
SPDR Select Sector Fund - Health Care ( XLV )
iShares U.S. Healthcare ETF ( IYH )
First Trust US Equity Opportunities ETF ( FPX ).
The top-performing ETF of this group is IYH with an increase of 8.56% over the last 100 days. PPH has the highest percent weighting of ABBV at 5.18%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABBV's forecasted earnings growth in 2017 as 14.62%, compared to an industry average of 3.6%. For more information on the declaration, record and payment dates, visit the ABBV Dividend History page. | The following ETF(s) have ABBV as a top-10 holding: VanEck Vectors Pharmaceutical ETF ( PPH ) PowerShares Dynamic Pharmaceuticals ( PJP ) SPDR Select Sector Fund - Health Care ( XLV ) iShares U.S. Healthcare ETF ( IYH ) First Trust US Equity Opportunities ETF ( FPX ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AbbVie Inc. ( ABBV ) will begin trading ex-dividend on July 12, 2017. | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABBV Dividend History page. The following ETF(s) have ABBV as a top-10 holding: VanEck Vectors Pharmaceutical ETF ( PPH ) PowerShares Dynamic Pharmaceuticals ( PJP ) SPDR Select Sector Fund - Health Care ( XLV ) iShares U.S. Healthcare ETF ( IYH ) First Trust US Equity Opportunities ETF ( FPX ). | ABBV's current earnings per share, an indicator of a company's profitability, is $3.86. The following ETF(s) have ABBV as a top-10 holding: VanEck Vectors Pharmaceutical ETF ( PPH ) PowerShares Dynamic Pharmaceuticals ( PJP ) SPDR Select Sector Fund - Health Care ( XLV ) iShares U.S. Healthcare ETF ( IYH ) First Trust US Equity Opportunities ETF ( FPX ). AbbVie Inc. ( ABBV ) will begin trading ex-dividend on July 12, 2017. |
26102.0 | 2017-07-11 00:00:00 UTC | Roche (RHHBY) Announces Positive Data on Hemophilia A Drug | ABBV | https://www.nasdaq.com/articles/roche-rhhby-announces-positive-data-on-hemophilia-a-drug-2017-07-11 | nan | nan | Roche Holdings AGRHHBY announced positive data from the phase III study, HAVEN 1, on hemophilia A candidate emicizumab. The data were published in The New England Journal of Medicine (NEJM) .
The study evaluated once-weekly subcutaneous emicizumab prophylaxis (preventative) in adults and adolescents with hemophilia A with inhibitors. The primary endpoint showed a clinically meaningful and statistically significant reduction in treated bleeds of 87% with emicizumab prophylaxis compared to on-demand bypassing agents (BPAs). In addition, all 12 secondary endpoints were positive, including a statistically significant reduction of 79% in treated bleeds in a subset of patients comparing two prophylaxis regimens (emicizumab and BPAs).
The data from the study, HAVEN 1 as well as the interim analysis of the phase III study, HAVEN 2, of emicizumab in children will be presented at the 26th International Society on Thrombosis and Haemostasis (ISTH) Congress.
The data from both studies have been submitted to the FDA and the EMA for approval. We remind investors that the FDA granted Breakthrough Therapy Designation for emicizumab in adults and adolescents with hemophilia A with inhibitors in Sep 2015.
Meanwhile, Roche is evaluating emicizumab in patients with hemophilia A both with and without inhibitors and evaluating less frequent dosing regimens as well.
Roche's share price shows that the company has underperformed the Zacks classified industry in the last year. The stock lost 4.6% compared with the Large Cap Pharmaceuticals industry's gain of 1.2%.
Along with emicizumab, Roche's hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin.
A few other companies are also developing treatments for hemophilia A. Last week, Shire SHPG filed an investigational new drug (IND) application with the FDA, seeking approval for recombinant factor VIII (FVIII) gene therapy candidate, SHP654. The drug will be used for the treatment of patients with hemophilia A.
Zacks Rank and Stock to Consider
Roche currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the health care sector is Enzo Biochem, Inc. ENZ , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Enzo Biochem's loss estimates have narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018 over the last 30 days. The company delivered positive earnings surprise in the last four quarters, with an average beat of 55.83%. Its shares have moved up 59.9% so far this year.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report
Shire PLC (SHPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Along with emicizumab, Roche's hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. The primary endpoint showed a clinically meaningful and statistically significant reduction in treated bleeds of 87% with emicizumab prophylaxis compared to on-demand bypassing agents (BPAs). | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Along with emicizumab, Roche's hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin. Roche Holdings AGRHHBY announced positive data from the phase III study, HAVEN 1, on hemophilia A candidate emicizumab. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Along with emicizumab, Roche's hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin. Roche Holdings AGRHHBY announced positive data from the phase III study, HAVEN 1, on hemophilia A candidate emicizumab. | Along with emicizumab, Roche's hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. The drug will be used for the treatment of patients with hemophilia A. Zacks Rank and Stock to Consider Roche currently carries a Zacks Rank #3 (Hold). |
26103.0 | 2017-07-10 00:00:00 UTC | Novartis' Cosentyx Superior to Stelara in Psoriasis Study | ABBV | https://www.nasdaq.com/articles/novartis-cosentyx-superior-to-stelara-in-psoriasis-study-2017-07-10 | nan | nan | Novartis AGNVS announced that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for psoriasis drug Cosentyx. The label update includes 52-week data from the CLEAR study which demonstrated the long-term superiority of Cosentyx over Johnson & Johnson's JNJ Stelara (ustekinumab) in psoriasis.
The study revealed that Cosentyx was superior to Stelara in achieving and sustaining a PASI 90 response (76% versus 61%) and was significantly better in achieving a PASI 100 (clear skin) response (46% versus 36%) at week 52.
Psoriasis drug, Cosentyx, was also approved for the treatment of two new indications - ankylosing spondylitis (AS) and psoriatic arthritis (PsA) - in the EU in 2016. Moreover, the FDA approved Cosentyx for AS and PsA in Jan 2016. The uptake of
Cosentyx has been strong and the company has grabbed market shares from rivals AbbVie's ABBV Humira and Amgen's AMGN Enbrel. Cosentyx achieved the blockbuster status in 2016 recording over $1 billion of sales.
Approximately 60 million patients globally are impacted by psoriasis. The addition of the study data in the product label reflects the benefit of Cosentyx for patients living with this chronic condition.
Novartis expects the next growth phase to begin in 2018 driven by Cosentyx (in all three indications psoriasis, psoriatic arthritis and ankylosing spondylitis) Entresto, and Kisqali and a deep pipeline with candidates like CTL019, BAF312, AMG 334, RTH258.
Novartis has outperformed the Zacks classified industry in the last six months. The stock has rallied 13.0% compared with the Large Cap Pharmaceuticals industry's 11.1% gain.
Going forward, we expect that the approval of new drugs and label expansion of existing ones will bode well for Novartis. Also, strong performance of growth products should be able to offset the impact of generic competition for Gleevec.
Zacks Rank
Novartis currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think. See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The uptake of Cosentyx has been strong and the company has grabbed market shares from rivals AbbVie's ABBV Humira and Amgen's AMGN Enbrel. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis AGNVS announced that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for psoriasis drug Cosentyx. | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The uptake of Cosentyx has been strong and the company has grabbed market shares from rivals AbbVie's ABBV Humira and Amgen's AMGN Enbrel. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The uptake of Cosentyx has been strong and the company has grabbed market shares from rivals AbbVie's ABBV Humira and Amgen's AMGN Enbrel. Novartis AGNVS announced that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for psoriasis drug Cosentyx. | The uptake of Cosentyx has been strong and the company has grabbed market shares from rivals AbbVie's ABBV Humira and Amgen's AMGN Enbrel. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis AGNVS announced that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for psoriasis drug Cosentyx. |
26104.0 | 2017-07-07 00:00:00 UTC | Bristol-Myers Gets FDA Nod for Orencia's Label Expansion | ABBV | https://www.nasdaq.com/articles/bristol-myers-gets-fda-nod-for-orencias-label-expansion-2017-07-07 | nan | nan | Bristol-Myers Squibb CompanyBMY announced that the FDA has approved Orencia for the treatment of adults with active psoriatic arthritis (PsA).
The approval was based on results from two randomized, double-blind, placebo-controlled trials. Per the data from the trials, Orencia improved (or reduced) disease activity in both TNF-naive and exposed patients suffering from increased disease activity, high tender and swollen jointsfor more than seven years.
Orencia is already indicated for adult patients with moderate to severe active rheumatoid arthritis (RA)as well as for reducing signs and symptoms in pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Sales of Orencia came in at $535 million in the first quarter of 2017, up from $475 million in the year-ago quarter. U.S. sales in the quarter were up 13% despite unfavorable inventory movement. However, demand was softer in the subcutaneous market in the beginning of the year due to early coverage resets.
A label expansion of the drug will further boost sales.
We note that in Sep 2016, Orencia became the first biologic therapy to gain EU approval specifically for the treatment of methotrexate (MTX)-naïve RA patients with highly active and progressive disease.
Competition is stiff in the psoriatic arthritis with the presence of drugs like AbbVie's ABBV Humira and Novartis' NVS Cosentyx.
While Bristol-Myers' share price has declined 5.4% year to date, the Zacks classified Large Cap Pharmaceuticals industry has gained 10.7%.
Bristol-Myers' key products - Opdivo, Orencia, Eliquis and Sprycel - should continue to fuel the company's top line. Meanwhile, Bristol-Myers is working on expanding the label of Opdivo which should boost performance further. The EC recently approved Opdivo as a monotherapy for the treatment of SCCHN in adults. However, Opdivo is facing competitive challenges in the U.S. With the FDA approving Merck's MRK Keytruda, for the first-line treatment of metastatic nonsquamous NSCLC, the company is expected to see further loss of market share.
Zacks Rank
Bristol-Myers currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank stocks here .
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Competition is stiff in the psoriatic arthritis with the presence of drugs like AbbVie's ABBV Humira and Novartis' NVS Cosentyx. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers Squibb CompanyBMY announced that the FDA has approved Orencia for the treatment of adults with active psoriatic arthritis (PsA). | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Competition is stiff in the psoriatic arthritis with the presence of drugs like AbbVie's ABBV Humira and Novartis' NVS Cosentyx. Bristol-Myers Squibb CompanyBMY announced that the FDA has approved Orencia for the treatment of adults with active psoriatic arthritis (PsA). | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Competition is stiff in the psoriatic arthritis with the presence of drugs like AbbVie's ABBV Humira and Novartis' NVS Cosentyx. Bristol-Myers Squibb CompanyBMY announced that the FDA has approved Orencia for the treatment of adults with active psoriatic arthritis (PsA). | Competition is stiff in the psoriatic arthritis with the presence of drugs like AbbVie's ABBV Humira and Novartis' NVS Cosentyx. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers Squibb CompanyBMY announced that the FDA has approved Orencia for the treatment of adults with active psoriatic arthritis (PsA). |
26105.0 | 2017-07-05 00:00:00 UTC | Vanguard High Dividend Yield ETF Experiences Big Outflow | ABBV | https://www.nasdaq.com/articles/vanguard-high-dividend-yield-etf-experiences-big-outflow-2017-07-05 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $193.9 million dollar outflow -- that's a 1.1% decrease week over week (from 234,912,905 to 232,443,563). Among the largest underlying components of VYM, in trading today Intel Corp (Symbol: INTC) is down about 0.5%, Wal-Mart Stores, Inc. (Symbol: WMT) is up about 0.4%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average:
Looking at the chart above, VYM's low point in its 52 week range is $69.96 per share, with $79.87 as the 52 week high point - that compares with a last trade of $78.28. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VYM, in trading today Intel Corp (Symbol: INTC) is down about 0.5%, Wal-Mart Stores, Inc. (Symbol: WMT) is up about 0.4%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average: Looking at the chart above, VYM's low point in its 52 week range is $69.96 per share, with $79.87 as the 52 week high point - that compares with a last trade of $78.28. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VYM, in trading today Intel Corp (Symbol: INTC) is down about 0.5%, Wal-Mart Stores, Inc. (Symbol: WMT) is up about 0.4%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average: Looking at the chart above, VYM's low point in its 52 week range is $69.96 per share, with $79.87 as the 52 week high point - that compares with a last trade of $78.28. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of VYM, in trading today Intel Corp (Symbol: INTC) is down about 0.5%, Wal-Mart Stores, Inc. (Symbol: WMT) is up about 0.4%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $193.9 million dollar outflow -- that's a 1.1% decrease week over week (from 234,912,905 to 232,443,563). For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average: Looking at the chart above, VYM's low point in its 52 week range is $69.96 per share, with $79.87 as the 52 week high point - that compares with a last trade of $78.28. | Among the largest underlying components of VYM, in trading today Intel Corp (Symbol: INTC) is down about 0.5%, Wal-Mart Stores, Inc. (Symbol: WMT) is up about 0.4%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance of VYM, versus its 200 day moving average: Looking at the chart above, VYM's low point in its 52 week range is $69.96 per share, with $79.87 as the 52 week high point - that compares with a last trade of $78.28. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
26106.0 | 2017-07-05 00:00:00 UTC | Galapagos-Gilead Begin Phase II Study on Uveitis Candidate | ABBV | https://www.nasdaq.com/articles/galapagos-gilead-begin-phase-ii-study-on-uveitis-candidate-2017-07-05 | nan | nan | Galapagos NVGLPG has announced initiation of a new phase II study, evaluating its lead pipeline candidate filgotinib for treatment of adult patients with non-infectious uveitis.
The study will be led by its partner Gilead Sciences, Inc. GILD . Note that, Galapagos had signed a collaboration agreement with Gilead in Dec 2015 to develop and commercialize filgotinib for inflammatory indications.
Shares of Galapagos have significantly outperformed the Zacks classified Medical-Biomed/Genetics industry so far this year. The stock has rallied 18.7% compared with the broader industry's decline of 2.2%.
The phase II trial is designed to evaluate the safety and efficacy of filgotinib in patients with active, non-infectious uveitis, compared with placebo. The study will be conducted on approximately 110 patients, who will be administered filgotinib or placebo for 52 weeks. The primary outcome of this analysis will be measured by the proportion of subjects failing to respond to treatment by week 24. This trial is an addition to the other ongoing researches on filgotinib.
We remind investors that in Apr 2017, Galapagos had initiated three new phase II proof-of-concept studies, evaluating filgotinib in Sjogren's syndrome, ankylosing spondylitis (AS) and psoriatic arthritis. Earlier in Aug 2016, Gilead had initiated a phase III program (FINCH) on filgotinib to heal rheumatoid arthritis (RA).
Apart from the FINCH program, Gilead's two more ongoing studies are, phase III assessment of filgotinib for treating Crohn's diseases and a phase II / III study for curing ulcerative colitis. Both studies had commenced in the third quarter of 2016.
Galapagos continues to progress on its cystic fibrosis (CF) candidate GLPG2737 with partner AbbVie Inc. ABBV , thus effecting a phase I review of the candidate which the company had initiated in Nov 2016. Notably, Galapagos and AbbVie had entered into a global collaboration agreement in Sep 2013, focused on the discovery, worldwide development and commercialization of potentiator and corrector molecules for treatment of CF.
Going forward, we expect investors' focus to remain on further pipeline updates from the company.
Galapagos NV Price
Galapagos NV Price | Galapagos NV Quote
Zacks Rank & Key Picks
Galapagos currently carries a Zacks Rank #3 (Hold). A better-ranked stock in healthcare sector is Bayer AG BAYRY , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Bayer's earnings per share estimates have inched up from $8.85 to $8.93 for 2017 and from $9.53 to $9.61 for 2018, over the last 30 days. The company has delievered positive earnings surprises in three of the four trailing quarters with an average beat of 10.25%. Shares of Bayer have soared 23.4% so far this year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Bayer AG (BAYRY): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Galapagos NV (GLPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Notably, Galapagos and AbbVie had entered into a global collaboration agreement in Sep 2013, focused on the discovery, worldwide development and commercialization of potentiator and corrector molecules for treatment of CF. Galapagos continues to progress on its cystic fibrosis (CF) candidate GLPG2737 with partner AbbVie Inc. ABBV , thus effecting a phase I review of the candidate which the company had initiated in Nov 2016. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report To read this article on Zacks.com click here. Galapagos continues to progress on its cystic fibrosis (CF) candidate GLPG2737 with partner AbbVie Inc. ABBV , thus effecting a phase I review of the candidate which the company had initiated in Nov 2016. Notably, Galapagos and AbbVie had entered into a global collaboration agreement in Sep 2013, focused on the discovery, worldwide development and commercialization of potentiator and corrector molecules for treatment of CF. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report To read this article on Zacks.com click here. Galapagos continues to progress on its cystic fibrosis (CF) candidate GLPG2737 with partner AbbVie Inc. ABBV , thus effecting a phase I review of the candidate which the company had initiated in Nov 2016. Notably, Galapagos and AbbVie had entered into a global collaboration agreement in Sep 2013, focused on the discovery, worldwide development and commercialization of potentiator and corrector molecules for treatment of CF. | Galapagos continues to progress on its cystic fibrosis (CF) candidate GLPG2737 with partner AbbVie Inc. ABBV , thus effecting a phase I review of the candidate which the company had initiated in Nov 2016. Notably, Galapagos and AbbVie had entered into a global collaboration agreement in Sep 2013, focused on the discovery, worldwide development and commercialization of potentiator and corrector molecules for treatment of CF. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report To read this article on Zacks.com click here. |
26107.0 | 2017-07-04 00:00:00 UTC | Bayer Starts Phase III Study for Uterine Fibroids' Candidate | ABBV | https://www.nasdaq.com/articles/bayer-starts-phase-iii-study-for-uterine-fibroids-candidate-2017-07-04 | nan | nan | Bayer AktiengesellschaftBAYRY announced that it has enrolled the first patient in a phase III study ASTEROID which will evaluate vilaprisan in women suffering from uterine fibroids.
Bayer's share price shows that the company has outperformed the Zacks classified Large Cap Pharmaceuticals industry year to date. The stock is up 23.4% compared with industry's gain of 12.1%.
Moving ahead, the ASTEROID study plans to enroll 3600 patients at about 900 centres and is expected to be complete in three years. The study will include several studies, and assess the efficacy and safety of vilaprisan 2mg in patients with symptomatic uterine fibroids. The efficacy measures will include the effect on heavy menstrual bleeding, reduction in fibroid size and improvement in quality of life.
ASTEROID 2 was a Phase IIb study that assessed vilaprisan in patients with symptomatic uterine fibroids compared to placebo and ulipristal acetate (Esmya). The study evaluates systematically the efficacy and safety of different treatment regimens of progesterone receptor modulators (PRMs) in women with uterine fibroids. First results of ASTEROID 2 will be presented at an upcoming scientific congress.
Bayer has a robust pipeline ranging from phase I to phase III development. Interesting late-stage candidates include BAY 1841788 (ODM-201, AR antagonist; non-metastatic castration-resistant prostate cancer), BAY 1841788 (ODM-201, AR antagonist; metastatic hormone-sensitive prostate cancer), copanlisib (PI3K inhibitor; various forms of non-Hodgkin lymphoma) and finerenone (MR antagonist; diabetic kidney disease) among others. Bayer believes six of its pipeline candidates -- vericiguat, finerenone, vilaprisan, BAY-1841788, anetumab ravtansine and copanlisib -- will hold combined peak sales potential of at least €6 billion. The company plans to launch at least 20 products by the end of 2023.
There are other companies that have been evaluating candidates for uterine fibroids. In Apr 2017, AbbVie Inc. ABBV along with Neurocrine Biosciences, Inc. NBIX announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids. Data from the study showed that elagolix met its primary endpoint by significantly reducing the number of heavy bleeding days rapidly within the assessment period of six months from the baseline in comparison to a placebo, utilizing the alkaline hematin method.
Bayer AG Price and Consensus
Bayer AG Price and Consensus | Bayer AG Quote
Zacks Rank & Key Picks
Bayer currently sports a Zacks Rank #1 (Strong Buy). Another health care stock with the same Zacks Rank is Enzo Biochem, Inc. ENZ . You can see the complete list of today's Zacks #1 Rank stocks here .
Enzo Biochem's loss per share estimates have narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018 over the last 30 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 61.1% year to date.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively. And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Bayer AG (BAYRY): Free Stock Analysis Report
Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In Apr 2017, AbbVie Inc. ABBV along with Neurocrine Biosciences, Inc. NBIX announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report To read this article on Zacks.com click here. Bayer believes six of its pipeline candidates -- vericiguat, finerenone, vilaprisan, BAY-1841788, anetumab ravtansine and copanlisib -- will hold combined peak sales potential of at least €6 billion. | In Apr 2017, AbbVie Inc. ABBV along with Neurocrine Biosciences, Inc. NBIX announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report To read this article on Zacks.com click here. Interesting late-stage candidates include BAY 1841788 (ODM-201, AR antagonist; non-metastatic castration-resistant prostate cancer), BAY 1841788 (ODM-201, AR antagonist; metastatic hormone-sensitive prostate cancer), copanlisib (PI3K inhibitor; various forms of non-Hodgkin lymphoma) and finerenone (MR antagonist; diabetic kidney disease) among others. | In Apr 2017, AbbVie Inc. ABBV along with Neurocrine Biosciences, Inc. NBIX announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report To read this article on Zacks.com click here. Bayer AG Price and Consensus Bayer AG Price and Consensus | Bayer AG Quote Zacks Rank & Key Picks Bayer currently sports a Zacks Rank #1 (Strong Buy). | In Apr 2017, AbbVie Inc. ABBV along with Neurocrine Biosciences, Inc. NBIX announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report To read this article on Zacks.com click here. The study will include several studies, and assess the efficacy and safety of vilaprisan 2mg in patients with symptomatic uterine fibroids. |
26108.0 | 2017-07-03 00:00:00 UTC | 10 Biotech Stocks With Game-Changing Dates in Q3 | ABBV | https://www.nasdaq.com/articles/10-biotech-stocks-with-game-changing-dates-in-q3-2017-07-03 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
For some investors, they've created small fortunes. For others, they've brought nothing but misery. For all investors, though, there's no denying the fact that biotech stocks have kept things interesting if only because they can always supply a binary even traders can treat like a coin toss. The third quarter of 2017 isn't going to be any different.
To be clear, the quarter that just got underway is a little bit different than the norm in the sense that not any of the major announcements in the queue are outright make-or-break events for their respective stocks; most of the announcements of consequence in the cards will come from the biggest of the biotech stocks that can survive bad news, and won't likely soar on good news.
6 Stocks That Will Crumple the Hardest in a Market Crash
Here's a closer look at the top-ten biggest announcements from the biotech arena between now and the end of September, in order of their projected release.
Biotech Stocks to Watch: Amgen (AMGN)
Source: Richard Masoner via Flickr
As of the most recent look, the FDA was expected to make a decision on osteoporosis treatment Evenity (or Romosozumab) from Amgen, Inc. (NASDAQ: AMGN ) on July 19. That's only a placeholder date, though.
The actual PDUFA date will likely be pushed back as the company also disclosed a safety concern when it posted Phase 3 results back in May 21. It's going to take some extra time to sort out the true scope of the observed cardiovascular risk
Evenity is a monoclonal antibody designed for postmenopausal women with elevated risk of fractures. It works well enough, but was linked to a 30% increase in the likelihood of heart attacks for those taking it. In short, the active component of the drug makes it easier for a body's arteries to clog.
Biotech Stocks to Watch: Dynavax Technologies (DVAX)
Source: Shutterstock
Amgen wasn't the only biopharma name to run into unexpected R&D problems of late. Dynavax Technologies Corporation (NASDAQ: DVAX ) has also had a string of trouble with its Heplisav-B, for the treatment of Hepatitis B.
Namely, it received a complete response letter from the FDA back in 2013, and then again in November of last year . In short, the agency needs more clarity on much of the data compiled for the drug's trials.
Hepatitis B has been a hot button of late. The pharmaceutical industry seemed disinterested for years, with the bulk of the new-drug focus taking aim at hepatitis C. Dynavax wisely took aim at the less-crowded $3 billion market , but has stumbled a few times in its effort to get to the end zone. It will be interesting to see if the company put finally put this one to bed.
7 All-American Stocks to Buy This 4th of July
There are two dates to watch here. The advisory panel that makes a yes/no recommendation to the FDA will meet on July 28, but the actual PDUFA date is Aug. 20. The FDA's committee usually takes the advice of the advisory panel.
Biotech Stocks to Watch: Sanofi (SNY)
Source: Mike Mozart via Flickr (Modified)
For as deep and wide as the diabetes epidemic has become, the pharmaceutical industry's solutions today aren't all that different than the first insulin Frederick Banting injected into a diabetic back in 1921 .
It would be hyperbole to say Sotagliflozin, from Sanofi SA (ADR) (NYSE: SNY ) would be a means of outright victory in the war against diabetes. But it would be wrong to dismiss the drug as just another entry into a crowded field.
Sotagliflozin, co-developed with Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ), is an inhibitor of sodium-glucose cotransporters , and ultimately lowers all-important HbA1c levels.
In two Phase 3 trials it's shown efficacy as a means of controlling diabetes . Data from a third Phase 3 trial is due sometime in mid-2017, though no firm date has been given yet. Whenever it is released though, Sotagliflozin's trials could proverbially run the table.
Biotech Stocks to Watch: AbbVie (ABBV)
Source: Black Stripe via Wikimedia (Modified)
As was the case with Sanofi, AbbVie Inc (NYSE: ABBV ) fans and followers may not necessarily want to etch Aug. 2 in stone. That's just an estimated PDUFA date for Glecaprevir/Pibrentasvir - AbbVie's newest hepatitis C treatment.
The drug was granted a priority review back on Feb. 2 , which more or less suggests a yes/no decision in early August. Just keep your ears open for a specific date as we approach the date. Glecaprevir, or Pibrentasvir, performed amazingly well in its recently completed phase 3 Expedition trial, achieving a sustained virologic response (at the 12-week mark) in 99% of patients with genotype 1, 2, 4, 5 or 6 chronic hepatitis C.
7 A-Rated Stocks to Buy for 2017's Second Half
Between its efficacy and the priority review, Abbvie has good reason to be optimistic.
Biotech Stocks to Watch: Bristol-Myers Squibb (BMY)
Source: A 4 via Flickr
Cancer drug Opdivo, from Bristol-Myers Squibb Co (NYSE: BMY ), is already on the market for a handful of cancers, but the company may be adding one to the list come Aug. 2. That's when the FDA is scheduled to make a decision about Opdivo as a treatment for microsatellite instability high (MSI-H) metastatic colorectal cancer .
If approved, it won't translate into a reversal of fortune for the company. Though this sliver of the cancer market is mostly an underserved one, Bristol-Myers can get along without it. Opdivo is slowly, but surely becoming a highly versatile solution though, nearing $1 billion in quarterly sales as it racks up new approved uses .
As was the case with AbbVie's Glecaprevir, this indication for Opdivo is under a priority review.
Biotech Stocks to Watch: Pfizer (PFE)
Source: Kojach Via Flickr
Add Pfizer Inc. (NYSE: PFE ) to the list of biotech stocks with approximate/likely PDUFA dates this quarter, but not a firm one yet.
The PDUFA date for Pfizer's adult lymphoblastic leukemia drug inotuzumab ozogamicin is presently believed to be Aug. 21 , based on the priority review granted back on Feb. 21. It may come before that though, as the NDA was accepted following a three-day weekend.
Whenever it happens, know that things thus far have looked favorable for inotuzumab ozogamicin. The drug is a monoclonal antibody, which acts as a delivery vehicle of a separate "warhead" that actually kills cancerous cells . Specifically, inotuzumab ozogamicin binds to a specific antigen found on malignant lymphoblastic leukemia cells, which then pulls an attached cytoxic agent into the cell … where it destroys that cell.
9 Companies That Might Not Survive to See 2018
Pfizer isn't the only pharma name working on the missile/payload idea. Inotuzumab ozogamicin is one of the more compelling applications of the premise though.
Biotech Stocks to Watch: Valeant Pharmaceuticals (VRX)
Source: Wikimedia (Modified)
There are arguably no other biotech stocks out there that need a win more than Valeant Pharmaceuticals Intl Inc (NYSE: VRX ) does.
VRX stock is done more than 90% since its September-2015 high for myriad reasons, most of which ended up accurately exposing what a trainwreck the company actually is . It could finally begin a move toward redemption on Aug. 24. That's when the FDA is expected to make a decision about its latanoprostene bunod for open angle glaucoma.
It won't be a game-changer in the sense that it's a breakthrough drug, but a moral victory could work miracles for Valeant. Conversely, a letdown could deflate any budding optimism, and latanoprostene bunod hasn't been flawless in terms of its path to approval. The company's first approval request was sent back when the FDA voiced concerns about the treatment's manufacturing process .
While it's encouraging that its efficacy wasn't questioned, Valeant isn't a company that can afford even the appearance of problems here.
Biotech Stocks to Watch: Celgene (CELG)
Source: Wikimedia (Modified)
Celgene Corporation (NASDAQ: CELG ) is yet-another one of those biotech stocks with a drug under priority review.
Namely, AG-221 - also called Enasidenib - for relapsed/refractory acute myeloid leukemia in patients with a isocitrate dehydrogenase 2 (IDH2) mutation will get a thumbs or a thumbs down from the Food and Drug Administration on Aug. 30.
Enasidenib has done pretty well in trials too. For this sliver of the AML market, its overall response rate was 41% , with a complete response in 18% of the patients in the trial.
The 7 Best Dividend Stocks to Buy for Q3 and Beyond
That's not an overwhelming result in a superficial sense, but the IDH2 mutation doesn't give these patients many other great options.
Biotech Stocks to Watch: Mylan (MYL)
Source: Shutterstock
Mylan N.V. (NASDAQ: MYL ), like Valeant Pharmaceuticals, is a name that needs a high-profile win. Unlike Valeant, it doesn't need a win to restore revenue growth.
It needs to put a trophy in the trophy case to restore some of the goodwill it lost with investors when its EpiPen debacle dinged its reputation . It may get that chance on Sept. 7. That's the scheduled PDUFA date for MYL-1401O , which is a biosimilar comparable to HER2+ breast cancer drug Trastuzumab.
It's a pretty big opportunity. Trastuzumab, perhaps better known as Herceptin, generated $6.8 billion in revenue in 2015 .
The introduction of generic biologics will hit their equivalent brand names as they usually do, but even generic biologics command a respectable price. Experts think Trastuzumab and its equivalents will still be collectively driving $4 billion worth of annual sales by 2022.
Biotech Stocks to Watch: Novo Nordisk (NVO)
Source: Shutterstock
Last but not least, mark September 29th on your calendar as a possible decision-day for aspart, from diabetes drug king Novo Nordisk A/S (ADR) (NYSE: NVO ). Actually, you may want to keep your ears open before Sept. 29. That's just the last likely PDUFA date for the fast-acting insulin. A decision could actually materialize sooner.
Aspart is another insulin, not unlike several that are already on the market. It's far more flexible than most though, usable by type 1 and type 2 diabetics, and faster acting than most other choices.
It's not been a terribly easy road to move down though. Novo Nordisk got a complete response letter from the FDA following its first approval request , with the agency asking for more details about the drug's immunogenicity.
7 ETFs That Can Make You Love Retirement
The CLR looked more procedural than problematic, however. In fact, it's already been approved in Europe as well as Canada. The insulin market is expected to be worth $39 billion by 2020 .
As of this writing, James Brumley did not hold a position in any of the aforementioned securities.
The post 10 Biotech Stocks With Game-Changing Dates in Q3 appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Glecaprevir, or Pibrentasvir, performed amazingly well in its recently completed phase 3 Expedition trial, achieving a sustained virologic response (at the 12-week mark) in 99% of patients with genotype 1, 2, 4, 5 or 6 chronic hepatitis C. 7 A-Rated Stocks to Buy for 2017's Second Half Between its efficacy and the priority review, Abbvie has good reason to be optimistic. Biotech Stocks to Watch: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) As was the case with Sanofi, AbbVie Inc (NYSE: ABBV ) fans and followers may not necessarily want to etch Aug. 2 in stone. That's just an estimated PDUFA date for Glecaprevir/Pibrentasvir - AbbVie's newest hepatitis C treatment. | Biotech Stocks to Watch: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) As was the case with Sanofi, AbbVie Inc (NYSE: ABBV ) fans and followers may not necessarily want to etch Aug. 2 in stone. That's just an estimated PDUFA date for Glecaprevir/Pibrentasvir - AbbVie's newest hepatitis C treatment. Glecaprevir, or Pibrentasvir, performed amazingly well in its recently completed phase 3 Expedition trial, achieving a sustained virologic response (at the 12-week mark) in 99% of patients with genotype 1, 2, 4, 5 or 6 chronic hepatitis C. 7 A-Rated Stocks to Buy for 2017's Second Half Between its efficacy and the priority review, Abbvie has good reason to be optimistic. | Biotech Stocks to Watch: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) As was the case with Sanofi, AbbVie Inc (NYSE: ABBV ) fans and followers may not necessarily want to etch Aug. 2 in stone. That's just an estimated PDUFA date for Glecaprevir/Pibrentasvir - AbbVie's newest hepatitis C treatment. Glecaprevir, or Pibrentasvir, performed amazingly well in its recently completed phase 3 Expedition trial, achieving a sustained virologic response (at the 12-week mark) in 99% of patients with genotype 1, 2, 4, 5 or 6 chronic hepatitis C. 7 A-Rated Stocks to Buy for 2017's Second Half Between its efficacy and the priority review, Abbvie has good reason to be optimistic. | Biotech Stocks to Watch: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) As was the case with Sanofi, AbbVie Inc (NYSE: ABBV ) fans and followers may not necessarily want to etch Aug. 2 in stone. That's just an estimated PDUFA date for Glecaprevir/Pibrentasvir - AbbVie's newest hepatitis C treatment. Glecaprevir, or Pibrentasvir, performed amazingly well in its recently completed phase 3 Expedition trial, achieving a sustained virologic response (at the 12-week mark) in 99% of patients with genotype 1, 2, 4, 5 or 6 chronic hepatitis C. 7 A-Rated Stocks to Buy for 2017's Second Half Between its efficacy and the priority review, Abbvie has good reason to be optimistic. |
26109.0 | 2017-06-30 00:00:00 UTC | Roche's (RHHBY) Leukemia Drug Gets Prime Status in EU | ABBV | https://www.nasdaq.com/articles/roches-rhhby-leukemia-drug-gets-prime-status-in-eu-2017-06-30 | nan | nan | The European Medicines Agency (EMA) granted PRIME (PRIorityMEdicines) designation to Roche Holdings AG 's RHHBY investigational drug polatuzumab vedotin in combination with MabThera and bendamustine. The drug will be used to treat patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL).
EMA grants the PRIME status to drugs that havea major therapeutic advantage over existing treatments, or benefit patients without treatment options.
We note that polatuzumab vedotin, an anti-CD79b antibody drug conjugate (ADC) consisting of an anti-CD79b monoclonal antibody is linked to a potent microtubule-disrupting agent. The candidate is being developed by Roche utilizing Seattle Genetics' SGEN ADC technology.
The PRIME designation is primarily based on results from the randomized phase II component of the GO29365 study in patients suffering from relapsed or refractory DLBCL that compared treatment with polatuzumab vedotin plus bendamustine and MabThera/Rituxan(rituximab) to bendamustine plus MabThera/Rituxan.
The successful development of the candidate will boost Roche's hematology portfolio which at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) apart from polatuzumab vedotin.
Roche's share price shows that the company has underperformed the Zacks classified industry year to date. The stock has moved up 11.5% compared with the Large Cap Pharmaceuticals industry's gain of 12.3%.
Roche has a strong presence in the oncology market. The company dominates the breast cancer space with strong demand for HER2 franchise drugs with candidates like Herceptin, Perjeta and Kadcyla.
We are also impressed by the company's efforts to develop its portfolio beyond oncology into immunology.
Zacks Rank & Key Pick
Roche currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the health care sector is VIVUS, Inc. VVUS , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
VIVUS' loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 60 days. The company deliveredpositive earnings surprises in each of the trailing four quarters, with an average beat of 233.69%.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
VIVUS, Inc. (VVUS): Free Stock Analysis Report
Seattle Genetics, Inc. (SGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The successful development of the candidate will boost Roche's hematology portfolio which at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) apart from polatuzumab vedotin. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report Seattle Genetics, Inc. (SGEN): Free Stock Analysis Report To read this article on Zacks.com click here. The European Medicines Agency (EMA) granted PRIME (PRIorityMEdicines) designation to Roche Holdings AG 's RHHBY investigational drug polatuzumab vedotin in combination with MabThera and bendamustine. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report Seattle Genetics, Inc. (SGEN): Free Stock Analysis Report To read this article on Zacks.com click here. The successful development of the candidate will boost Roche's hematology portfolio which at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) apart from polatuzumab vedotin. The European Medicines Agency (EMA) granted PRIME (PRIorityMEdicines) designation to Roche Holdings AG 's RHHBY investigational drug polatuzumab vedotin in combination with MabThera and bendamustine. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report Seattle Genetics, Inc. (SGEN): Free Stock Analysis Report To read this article on Zacks.com click here. The successful development of the candidate will boost Roche's hematology portfolio which at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) apart from polatuzumab vedotin. The European Medicines Agency (EMA) granted PRIME (PRIorityMEdicines) designation to Roche Holdings AG 's RHHBY investigational drug polatuzumab vedotin in combination with MabThera and bendamustine. | The successful development of the candidate will boost Roche's hematology portfolio which at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) apart from polatuzumab vedotin. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report Seattle Genetics, Inc. (SGEN): Free Stock Analysis Report To read this article on Zacks.com click here. The PRIME designation is primarily based on results from the randomized phase II component of the GO29365 study in patients suffering from relapsed or refractory DLBCL that compared treatment with polatuzumab vedotin plus bendamustine and MabThera/Rituxan(rituximab) to bendamustine plus MabThera/Rituxan. |
26110.0 | 2017-06-29 00:00:00 UTC | Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod | ABBV | https://www.nasdaq.com/articles/biotech-stock-roundup-eu-nod-regeneron-ra-drug-portola-soars-fda-nod-2017-06-29 | nan | nan | Biotech stocks have been in the news recently with expectations remaining high that steps taken by the Trump administration to drive down drug prices will not be as draconian as previously expected. Meanwhile, companies like Portola PTLA and Regeneron REGN provided regulatory updates.
Recap of the Week's Most Important Stories
Portola Soars on FDA Approval: Portola's shares shot up 46.6% with the FDA granting approval to the company's anticoagulant Bevyxxa (betrixaban). FDA approval makes Bevyxxa the first and only anticoagulant for hospital and extended duration prophylaxis (35 to 42 days) of venous thromboembolism (VTE) in acutely ill medical patients. Portola expects to launch the product between August and November this year.
EU Approval for Regeneron/Sanofi's RA Drug: Regeneron and partner Sanofi gained EU approval for their rheumatoid arthritis (RA) drug Kevzara. Kevzara has been approved for use in combination with methotrexate (MTX) for the treatment of moderately to severely active RA in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs), such as MTX.
Kevzara, an IL-6R antibody, was approved in the U.S. in May this year. While Kevzara has blockbuster potential, the RA market is highly crowded given the presence of treatments like Humira and Xeljanz among others. However, the patient population is huge with many patients spending years on different treatments without achieving their treatment goals. With RA affecting about 1.3 million Americans and 2.9 million people in Europe, Kevzara represents a new treatment option for patients.
Regeneron is a Zacks Rank #1 (Strong Buy) stock. The company has outperformed the Zacks-categorized Medical-Biomedical/Genetics industry year-to-date with the company gaining 39.8% while the industry is up 8.9%. You can see the complete list of today's Zacks #1 Rank stocks here .
AVEO Kidney Cancer Drug a Step Closer to EU Nod: AVEO Oncology AVEO is a step closer to gaining EU approval for its kidney cancer treatment, Fotivda (tivozanib), with the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), recommending its approval for the treatment for patients with advanced renal cell carcinoma (RCC). The European Commission (EC), which usually follows the CHMP's recommendation, will make a final decision in about 67 days.
AVEO has had its share of setbacks where Fotivda is concerned. The company had received a complete response letter for the drug in the U.S. in Jun 2013 and was asked to conduct an additional study. Then in 2014, Astellas returned rights to tivozanib. AVEO subsequently entered into a licensing agreement with EUSA. Meanwhile, results from a pivotal study in the U.S. for third-line RCC are expected in the first quarter of 2018 (Read more: AVEO's Kidney Cancer Candidate Gets CHMP Recommendation ).
CHMP Positive on Gilead and AbbVie HCV Drugs: Gilead GILD also got a positive opinion from the CHMP for Vosevi, an investigational, once-daily, single tablet regimen (sofosbuvir/velpatasvir/voxilaprevir - SOF/VEL/VOX) for the treatment of chronic hepatitis C virus (HCV)-infected patients. The regimen is under review in the U.S. as well where a response from the FDA is expected by Aug 8, 2017. Gilead's HCV franchise, which was a major contributor to sales, is under considerable strain due to new competition and pricing pressure.
AbbVie ABBV too got a positive CHMP opinion for Maviret (glecaprevir/pibrentasvir), an investigational, pan-genotypic treatment for HCV. Approval would provide patients with a ribavirin-free, shorter 8-week pan-genotypic once-daily option. A final response regarding approval should be out in the third quarter (Read more: AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU ).
Xenon/Teva Drug Fails in Mid-Stage Study: Xenon and partner Teva suffered a pipeline setback with their experimental post-herpetic neuralgia (PHN) treatment, topical TV-45070, failing in a mid-stage proof-of-concept study. The study failed to meet the primary as well as secondary endpoints. The data will be analyzed further to determine the path forward. We note that TV-45070 had previously failed in a mid-stage study in pain due to osteoarthritis of the knee (Read more: Teva/Xenon Nerve Pain Candidate Fails in Phase II Study ).
Alnylam's Givosiran to Move into Phase III Later this Year: Alnylam ALNY had some good news with the company reporting new positive interim results on givosiran, an investigational RNAi therapeutic targeting ALAS1 for the treatment of acute hepatic porphyrias.
Results showed that givosiran has the potential to prevent porphyria attacks in patients with acute intermittent porphyria (AIP) suffering with recurrent attacks. The company intends to move the candidate into late-stage development later this year. If developed successfully and approved, givosiran would provide patients with a potentially transformative treatment option that could prevent porphyria attacks and be administered once monthly.
Biogen's Humira Biosimilar Gets CHMP Backing: Another company that got a positive CHMP opinion is Biogen BIIB -- the company's biosimilar version of AbbVie's top-selling blockbuster drug, Humira, got a positive opinion. If approved, Imraldi (or SB5) would be used for a whole range of indications including rheumatoid arthritis, axial spondyloarthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, polyarticular juvenile idiopathic arthritis, active enthesitis-related arthritis, hidradenitis suppurativa and non-infectious uveitis.
Biogen has a joint venture with Samsung BioLogics for biosimilars and Imraldi is the third anti-TNF candidate to be submitted in the EU under the joint venture. We note that earlier this year, Amgen gained EU approval for Amgevita, its biosimilar version of Humira.
Performance
Medical - Biomedical and Genetics Industry 5YR % Return
Medical - Biomedical and Genetics Industry 5YR % Return
The NASDAQ Biotechnology Index gained 0.4% over the last five trading sessions. Among major biotech stocks, Gilead gained 6.6% while Vertex lost 2.8%. Over the last six months, Vertex was up 75.8% while Biogen was down 5.1% (See the last biotech stock roundup here: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt ).
What's Next in the Biotech World?
Watch out for the usual pipeline updates and data presentations from biotech companies.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
AVEO Pharmaceuticals, Inc. (AVEO): Free Stock Analysis Report
Portola Pharmaceuticals, Inc. (PTLA): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | CHMP Positive on Gilead and AbbVie HCV Drugs: Gilead GILD also got a positive opinion from the CHMP for Vosevi, an investigational, once-daily, single tablet regimen (sofosbuvir/velpatasvir/voxilaprevir - SOF/VEL/VOX) for the treatment of chronic hepatitis C virus (HCV)-infected patients. AbbVie ABBV too got a positive CHMP opinion for Maviret (glecaprevir/pibrentasvir), an investigational, pan-genotypic treatment for HCV. A final response regarding approval should be out in the third quarter (Read more: AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU ). | Biogen's Humira Biosimilar Gets CHMP Backing: Another company that got a positive CHMP opinion is Biogen BIIB -- the company's biosimilar version of AbbVie's top-selling blockbuster drug, Humira, got a positive opinion. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report AVEO Pharmaceuticals, Inc. (AVEO): Free Stock Analysis Report Portola Pharmaceuticals, Inc. (PTLA): Free Stock Analysis Report To read this article on Zacks.com click here. CHMP Positive on Gilead and AbbVie HCV Drugs: Gilead GILD also got a positive opinion from the CHMP for Vosevi, an investigational, once-daily, single tablet regimen (sofosbuvir/velpatasvir/voxilaprevir - SOF/VEL/VOX) for the treatment of chronic hepatitis C virus (HCV)-infected patients. | Biogen's Humira Biosimilar Gets CHMP Backing: Another company that got a positive CHMP opinion is Biogen BIIB -- the company's biosimilar version of AbbVie's top-selling blockbuster drug, Humira, got a positive opinion. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report AVEO Pharmaceuticals, Inc. (AVEO): Free Stock Analysis Report Portola Pharmaceuticals, Inc. (PTLA): Free Stock Analysis Report To read this article on Zacks.com click here. CHMP Positive on Gilead and AbbVie HCV Drugs: Gilead GILD also got a positive opinion from the CHMP for Vosevi, an investigational, once-daily, single tablet regimen (sofosbuvir/velpatasvir/voxilaprevir - SOF/VEL/VOX) for the treatment of chronic hepatitis C virus (HCV)-infected patients. | A final response regarding approval should be out in the third quarter (Read more: AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU ). Biogen's Humira Biosimilar Gets CHMP Backing: Another company that got a positive CHMP opinion is Biogen BIIB -- the company's biosimilar version of AbbVie's top-selling blockbuster drug, Humira, got a positive opinion. CHMP Positive on Gilead and AbbVie HCV Drugs: Gilead GILD also got a positive opinion from the CHMP for Vosevi, an investigational, once-daily, single tablet regimen (sofosbuvir/velpatasvir/voxilaprevir - SOF/VEL/VOX) for the treatment of chronic hepatitis C virus (HCV)-infected patients. |
26111.0 | 2017-06-28 00:00:00 UTC | AbbVie Has the Most Valuable Late-Stage Pipeline -- But Is Its Stock a Buy? | ABBV | https://www.nasdaq.com/articles/abbvie-has-most-valuable-late-stage-pipeline-its-stock-buy-2017-06-28 | nan | nan | According to a recent report from EvaluatePharma, AbbVie (NYSE: ABBV) has the most valuable late-stage clinical pipeline among the major drug manufacturers. Specifically, the company has four drug candidates landing in the top 20, totaling a net present value of $23.8 billion.
Data source: EvaluateGroup.
Of course, AbbVie's management has been trying to convey this positive message for months now, but it's been largely drowned out by the concerns over Humira's patent expiration. In fact, this drugmaker's shares are trading at a forward price-to-earnings ratio of 11.1, one of the lowest in the industry -- despite also sporting one of the fastest-growing dividends and top lines over the past four years, and despite owning the most valuable late-stage clinical pipeline as well.
With this theme in mind, let's consider if AbbVie's positives outweigh the risks presented by the biosimilar threat to Humira.
The bull case
Another interesting tidbit of EvaluatePharma's report is that it has Humira's revenue remaining fairly steady until 2022, whereas other analysts have suggested that Amgen 's (NASDAQ: AMGN) FDA-approved biosimilar Amjevita, and perhaps others, will start to carve into the drug's enormous market share by as early as 2019.
The issue is basically how long AbbVie can extend the legal challenges to Humira's intellectual property to lengthen its exclusivity period in the U.S. and abroad. AbbVie has said that 2022 is a likely cut-off point, but there have already been some setbacks on the legal front that suggest a biosimilar threat could materialize by 2019 to 2020.
If we take EvaluatePharma's outlook, AbbVie's shares would appear be trading at around 3.2 to 3.4 times its 2022 revenue. This estimate also assumes that the company's pipeline delivers on at least two of these four experimental drugs, which appears likely, given that its hep C combo of glecaprevir/pibrentasvir is already under FDA review, and its next-generation anti-inflammatory drug, upadacitinib, is producing stellar results in its late-stage program.
In sum, this bullish case implies that AbbVie's top line can continue to grow at a healthy compound annual growth rate of around 5% from 2016 to 2022. If this line holds, AbbVie would be in the upper tier of large-cap biotech stocks in terms of revenue growth. Equally as important, though, this level of growth should be sufficient to at least maintain its outstanding dividend program at current levels.
The bear case
If you're a pessimist, you probably still have to bake in the revenue from both glecaprevir/pibrentasvir and upadacitinib, based on their likelihood of approval. But if Amgen's Amjevita breaks into the market by 2020, AbbVie's 2022 annual revenue could drop off by perhaps $4.7 billion relative to the more bullish outlook.
So if Amjevita or other Humira biosimilars were to enter the market in 2020, AbbVie's shares would be trading right now at around 3.8 to 4 times its 2022 revenue. That's fairly good news, as AbbVie's shares are basically trading at this level right now.
The bad news is that AbbVie's top-notch dividend might not be safe if its top line stagnates. A big reason the company has such a promising pipeline, after all, is that AbbVie's management has aggressively used debt financing to bring in new blood. The net result is that the company has leveraged its balance sheet out to worrying levels -- meaning debt is going to play a substantial role in its capital allocation strategy moving forward.
The drugmaker's 12-month trailing payout ratio of 60.88 implies that it can increase its dividend even further. However, this metric might be grossly misleading in light of its jaw-dropping debt-to-equity ratio of 746. In other words, AbbVie must continue to grow its free cash flow at a respectable clip to both service its debt obligations and raise its dividend at the same time.
Investing takeaway
AbbVie's shares may look cheap at the moment in comparison with other high-flying biopharmas. But a deeper dive shows that the company simply can't afford any setbacks in its legal defense to Humira. If Amgen's Amjevita or other biosimilar threats materialize earlier than 2022, for example, AbbVie may struggle to grow its dividend in light of its massive debt load. And its shares may turn out to be fairly valued at best if a biosimilar does come into play in 2020.
Bottom line: AbbVie's clinical pipeline and longer-term growth prospects may look great on paper, but its unsightly debt load will almost certainly compound any headwinds arising from a slowdown in Humira's double-digit sales trajectory. So if you're a long-term-oriented investor, this stock's risks might outweigh its rewards.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Bottom line: AbbVie's clinical pipeline and longer-term growth prospects may look great on paper, but its unsightly debt load will almost certainly compound any headwinds arising from a slowdown in Humira's double-digit sales trajectory. According to a recent report from EvaluatePharma, AbbVie (NYSE: ABBV) has the most valuable late-stage clinical pipeline among the major drug manufacturers. Of course, AbbVie's management has been trying to convey this positive message for months now, but it's been largely drowned out by the concerns over Humira's patent expiration. | With this theme in mind, let's consider if AbbVie's positives outweigh the risks presented by the biosimilar threat to Humira. In sum, this bullish case implies that AbbVie's top line can continue to grow at a healthy compound annual growth rate of around 5% from 2016 to 2022. That's fairly good news, as AbbVie's shares are basically trading at this level right now. | So if Amjevita or other Humira biosimilars were to enter the market in 2020, AbbVie's shares would be trading right now at around 3.8 to 4 times its 2022 revenue. If Amgen's Amjevita or other biosimilar threats materialize earlier than 2022, for example, AbbVie may struggle to grow its dividend in light of its massive debt load. According to a recent report from EvaluatePharma, AbbVie (NYSE: ABBV) has the most valuable late-stage clinical pipeline among the major drug manufacturers. | In sum, this bullish case implies that AbbVie's top line can continue to grow at a healthy compound annual growth rate of around 5% from 2016 to 2022. That's fairly good news, as AbbVie's shares are basically trading at this level right now. If Amgen's Amjevita or other biosimilar threats materialize earlier than 2022, for example, AbbVie may struggle to grow its dividend in light of its massive debt load. |
26112.0 | 2017-06-27 00:00:00 UTC | Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti | ABBV | https://www.nasdaq.com/articles/bristol-myers-reports-data-on-immuno-oncology-drug-empliciti-2017-06-27 | nan | nan | Bristol-Myers Squibb CompanyBMY announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti during the 22nd Congress of the European Hematology Association in Madrid, Spain.
The results from the trial showed that Empliciti plus lenalidomide/dexamethasone (ELd) continued to demonstrate efficacy in patients with relapsed/refractory multiple myeloma (RRMM), compared with patients treated with lenalidomide/dexamethasone (Ld) alone.
The trial randomized 646 patients with RRMM who had one to three prior therapies to receive either ELd (321 patients) or Ld (325 patients) in 28-day cycles until their disease progressed or they withdrew consent.
ELd therapy maintained a reduction in the risk of disease progression or death of 29%. At four-years, ELd therapy continued to demonstrate a clinically meaningful and sustained relative improvement of 50% in progression-free survival (PFS) rate, 21% compared to Ld therapy, 14% (95% CI: 12.1,17.3). Patients receiving ELd therapy also demonstrated an overall response rate (ORR) of 79% among patients receiving Ld therapy alone.
We note that Empliciti is already approved in the U.S. in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. It gained EU approval in May 2016.
The long-term efficacy data for Empliciti in patients with advanced multiple myeloma shows the combination of Empliciti with standard lenalidomide/dexamethasone treatment can improve patient outcome.
The company's key oncology products include Opdivo, Sprycel, Yervoy and Empliciti. Bristol-Myers Squibb and AbbVie ABBV are co-developing Empliciti with the former being solely responsible for commercial activities.
Meanwhile, Bristol-Myers' shares declined 21.0% in the last 12 months, the Zacks classified Large Cap Pharmaceuticals industry gained 7.7%. The company suffered a setback in Jan 2017 when it decided not to pursue accelerated regulatory pathway for Opdivo plus Yervoy in first-line lung cancer in the U.S. based on a review of available data. The share price of the company declined significantly on the news. Opdivo is facing stiff competition in the U.S. With the FDA approving Merck's MRK Keytruda, for the first-line treatment of metastatic nonsquamous NSCLC, the company is expected to suffer further loss of market share.
Zacks Rank & Key Pick
Bristol-Myers currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the health care sector is VIVUS, Inc. VVUS which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
VIVUS' loss per share estimates have narrowed from 50 cents to 39 cents for 2017 in the last 60 days. The company delivered positive earnings surprises in the four trailing quarters, with an average beat of 233.69%.
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These are sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
See today's Zacks "Strong Sells" absolutely free >>.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
VIVUS, Inc. (VVUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Bristol-Myers Squibb and AbbVie ABBV are co-developing Empliciti with the former being solely responsible for commercial activities. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers Squibb CompanyBMY announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti during the 22nd Congress of the European Hematology Association in Madrid, Spain. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers Squibb and AbbVie ABBV are co-developing Empliciti with the former being solely responsible for commercial activities. The results from the trial showed that Empliciti plus lenalidomide/dexamethasone (ELd) continued to demonstrate efficacy in patients with relapsed/refractory multiple myeloma (RRMM), compared with patients treated with lenalidomide/dexamethasone (Ld) alone. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers Squibb and AbbVie ABBV are co-developing Empliciti with the former being solely responsible for commercial activities. The trial randomized 646 patients with RRMM who had one to three prior therapies to receive either ELd (321 patients) or Ld (325 patients) in 28-day cycles until their disease progressed or they withdrew consent. | Bristol-Myers Squibb and AbbVie ABBV are co-developing Empliciti with the former being solely responsible for commercial activities. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report To read this article on Zacks.com click here. You can see the complete list of today's Zacks #1 Rank stocks here . |
26113.0 | 2017-06-27 00:00:00 UTC | Health Care Select Sector SPDR Fund Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/health-care-select-sector-spdr-fund-experiences-big-inflow-2017-06-27 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $297.4 million dollar inflow -- that's a 1.7% increase week over week in outstanding units (from 214,415,324 to 218,115,324). Among the largest underlying components of XLV, in trading today Amgen Inc (Symbol: AMGN) is down about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.1%, and Celgene Corp. (Symbol: CELG) is lower by about 0.5%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $65.96 per share, with $81.08 as the 52 week high point - that compares with a last trade of $80.28. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Amgen Inc (Symbol: AMGN) is down about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.1%, and Celgene Corp. (Symbol: CELG) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $297.4 million dollar inflow -- that's a 1.7% increase week over week in outstanding units (from 214,415,324 to 218,115,324). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Amgen Inc (Symbol: AMGN) is down about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.1%, and Celgene Corp. (Symbol: CELG) is lower by about 0.5%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $65.96 per share, with $81.08 as the 52 week high point - that compares with a last trade of $80.28. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of XLV, in trading today Amgen Inc (Symbol: AMGN) is down about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.1%, and Celgene Corp. (Symbol: CELG) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $297.4 million dollar inflow -- that's a 1.7% increase week over week in outstanding units (from 214,415,324 to 218,115,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $65.96 per share, with $81.08 as the 52 week high point - that compares with a last trade of $80.28. | Among the largest underlying components of XLV, in trading today Amgen Inc (Symbol: AMGN) is down about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.1%, and Celgene Corp. (Symbol: CELG) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $297.4 million dollar inflow -- that's a 1.7% increase week over week in outstanding units (from 214,415,324 to 218,115,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $65.96 per share, with $81.08 as the 52 week high point - that compares with a last trade of $80.28. |
26114.0 | 2017-06-27 00:00:00 UTC | Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU | ABBV | https://www.nasdaq.com/articles/sanofi-regenerons-kevzara-gets-marketing-approval-in-eu-2017-06-27 | nan | nan | SanofiSNY and partner Regeneron Pharmaceuticals, Inc. REGN announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.
The IL-6R antibody has been approved for the treatment of adult patients in combination with methotrexate (MTX) with moderate-to-severely active RA, who have had an inadequate response or intolerance to one or more biologic or non-biologic disease-modifying anti-rheumatic drugs (DMARDs) such as MTX.
So far this year, Sanofi's shares are up 22.8%, better than a 15% increase for the Zacks classified Large-Cap Pharma industry.
We remind investors that the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) had granted a positive opinion recommending marketing approval of Kevzara in the EU in April this year.
The marketing approval in the EU was based on results from seven phase III trials in the global SARIL-RA clinical development program conducted in more than 3,300 adults with moderate-to-severely active RA who had an inadequate response to previous treatment regimens. Kevzara demonstrated statistically significant, clinically-meaningful improvements in combination with conventional DMARDs, including MTX in two pivotal phase III studies.
While Kevzara has blockbuster potential, the RA market is highly crowded given the presence of treatments like AbbVie, Inc.'s ABBV Humira and Pfizer, Inc.'s PFE Xeljanz among others. Moreover, the patient population is huge with many patients spending years on different treatments without achieving their treatment goals. With RA affecting about 2.9 million people in Europe, Kevzara represents a new treatment option for patients.
Sanofi currently has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here .
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These are sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
See today's Zacks ""Strong Sells"" absolutely free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY): Free Stock Analysis Report
Pfizer, Inc. (PFE): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | While Kevzara has blockbuster potential, the RA market is highly crowded given the presence of treatments like AbbVie, Inc.'s ABBV Humira and Pfizer, Inc.'s PFE Xeljanz among others. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report To read this article on Zacks.com click here. SanofiSNY and partner Regeneron Pharmaceuticals, Inc. REGN announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara. | Click to get this free report Sanofi (SNY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report To read this article on Zacks.com click here. While Kevzara has blockbuster potential, the RA market is highly crowded given the presence of treatments like AbbVie, Inc.'s ABBV Humira and Pfizer, Inc.'s PFE Xeljanz among others. The IL-6R antibody has been approved for the treatment of adult patients in combination with methotrexate (MTX) with moderate-to-severely active RA, who have had an inadequate response or intolerance to one or more biologic or non-biologic disease-modifying anti-rheumatic drugs (DMARDs) such as MTX. | Click to get this free report Sanofi (SNY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report To read this article on Zacks.com click here. While Kevzara has blockbuster potential, the RA market is highly crowded given the presence of treatments like AbbVie, Inc.'s ABBV Humira and Pfizer, Inc.'s PFE Xeljanz among others. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here . | While Kevzara has blockbuster potential, the RA market is highly crowded given the presence of treatments like AbbVie, Inc.'s ABBV Humira and Pfizer, Inc.'s PFE Xeljanz among others. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report To read this article on Zacks.com click here. The IL-6R antibody has been approved for the treatment of adult patients in combination with methotrexate (MTX) with moderate-to-severely active RA, who have had an inadequate response or intolerance to one or more biologic or non-biologic disease-modifying anti-rheumatic drugs (DMARDs) such as MTX. |
26115.0 | 2017-06-27 00:00:00 UTC | Gilead's (GILD) HCV Drug Application Accepted in the EU | ABBV | https://www.nasdaq.com/articles/gileads-gild-hcv-drug-application-accepted-in-the-eu-2017-06-27 | nan | nan | Gilead Sciences, Inc.GILD announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the company's Marketing Authorization Application (MAA) for Vosevi following an accelerated assessment procedure.
Vosevi is an experimental once-daily, single tablet regimen of Sovaldi, velpatasvir 100 mg, and voxilaprevir 100 mg (SOF/VEL/VOX) which is being evaluated for the treatment of chronic hepatitis C virus (HCV)-infected patients.
The data included in the application support the use of SOF/VEL/VOX in patients with or without compensated cirrhosis, with all genotypes (GT1-6) of HCV infection regardless of prior therapy. It includes eight weeks of treatment for HCV direct-acting antiviral (DAA)-naïve patients without cirrhosis, as well as 12 weeks of treatment for patients who have previously failed therapy with a DAA-containing regimen.
The recommendation will now be reviewed by the European Commission. The EMA generally takes into account CHMP's opinion while reviewing a drug but is not bound by it.
The MAA was filed based on positive data from four phase III studies. We remind investors that Sovaldi was approved in the EU in Jan 2014 for use in combination with other agents while the single tablet regimen of Sovaldi and ledipasvir (90 mg) received marketing authorization in the European Union in Nov 2014 under the trade name Harvoni. On the other hand, the single tablet regimen of Sovaldi and velpatasvir (100 mg) received marketing authorization in the EU in Jul 2016, under the trade name Epclusa..
Meanwhile, Gilead has also submitted a regulatory application for SOF/VEL/VOX in the U.S. as well. The FDA has set a target action date under the Prescription Drug User Fee Act of Aug 8, 2017.
If approved, the combination would be the first once-daily STR available as a salvage therapy for patients infected with HCV genotype 1-6 who have failed prior treatment with DAA regimens including NS5A inhibitors.
Gilead's HCV franchise is under pressure due to intense competition and pricing issues. HCV product sales were weaker than expected mainly due to fewer new patient starts for Harvoni and lower revenues per patient. Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, Bristol-Myers' BMY Daklinza and Johnson & Johnson's JNJ Olysio.
The company expects that the persistent decline in HCV patient starts will be the primary factor behind the year-over-year decrease in revenues in 2017 along with increased competition which will impact patient share and pricing.
Shares of Gilead have underperformed the Zacks classified Medical-Biomedical and Genetics industry in the last one year, with the stock losing 13.4% during this period, against the industry's gain of 8.2%.
Nevertheless, the HIV franchise of Gilead is performing well and is expected to help the company combat the persistent decline in HCV franchise.
Gilead currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank stocks here .
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500. See today's Zacks "Strong Sells" absolutely free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, Bristol-Myers' BMY Daklinza and Johnson & Johnson's JNJ Olysio. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Gilead Sciences, Inc.GILD announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the company's Marketing Authorization Application (MAA) for Vosevi following an accelerated assessment procedure. | Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, Bristol-Myers' BMY Daklinza and Johnson & Johnson's JNJ Olysio. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. If approved, the combination would be the first once-daily STR available as a salvage therapy for patients infected with HCV genotype 1-6 who have failed prior treatment with DAA regimens including NS5A inhibitors. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, Bristol-Myers' BMY Daklinza and Johnson & Johnson's JNJ Olysio. Gilead Sciences, Inc.GILD announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the company's Marketing Authorization Application (MAA) for Vosevi following an accelerated assessment procedure. | Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, Bristol-Myers' BMY Daklinza and Johnson & Johnson's JNJ Olysio. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Gilead Sciences, Inc.GILD announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the company's Marketing Authorization Application (MAA) for Vosevi following an accelerated assessment procedure. |
26116.0 | 2017-06-27 00:00:00 UTC | AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU | ABBV | https://www.nasdaq.com/articles/abbvies-hcv-combo-drug-gets-positive-chmp-opinion-in-eu-2017-06-27 | nan | nan | AbbVie Inc.ABBV announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing approval of its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).
The combination medicine is currently under accelerated assessment in the EU and priority review in the U.S. and Japan for the treatment of all major chronic hepatitis C virus (HCV) genotypes (genotypes 1-6) with commercialization expected this year.
The candidate will be marketed by the trade name of Maviret. A decision from the European Commission is expected in the third quarter of 2017.
If approved, the G/P regimen will provide patients with a shorter-duration eight week, once-daily, ribavirin-free treatment option.
So far this year, AbbVie's share price has increased 16.1%, comparing favorably with a gain of 15% recorded by the Zacks classified Large-Cap Pharma industry.
Coming back to the latest news, Glecaprevir (GLE) is a potent protease inhibitor while pibrentasvir (PIB) is a new NS5A inhibitor. Glecaprevir was discovered under a collaboration agreement between AbbVie and Enanta Pharmaceuticals ENTA for HCV protease inhibitors.
The Marketing Authorization Application (MAA) in the EU was backed by data from eight registration studies in AbbVie's G/P clinical development program. The clinical studies were conducted on more than 2,300 patients across major HCV genotypes and special populations in 27 countries. Data from the studies showed that eight weeks of treatment with G/P achieved high SVR12 rates across all major genotypes of chronic HCV.
We remind investors that Gilead Sciences, Inc. GILD launched Epclusa, the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 HCV infection, in the U.S. and EU last year. This could pose strong competition to AbbVie's next-generation HCV combo therapy, if approved.
Meanwhile, Merck & Co., Inc. MRK is also evaluating an all-oral triple combination therapy MK-3682B, a combination of MK-3682, grazoprevir and ruzasvir1, for the treatment of chronic HCV genotype (GT) infection. The candidate has also resulted in high SVR12 rates in GT1, GT2 and GT3-infected patients, who received the combination therapy for 12 or 16 weeks.
AbbVie carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These are sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
See today's Zacks ""Strong Sells"" absolutely free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Enanta Pharmaceuticals, Inc. (ENTA): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | So far this year, AbbVie's share price has increased 16.1%, comparing favorably with a gain of 15% recorded by the Zacks classified Large-Cap Pharma industry. The Marketing Authorization Application (MAA) in the EU was backed by data from eight registration studies in AbbVie's G/P clinical development program. AbbVie Inc.ABBV announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing approval of its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). | Glecaprevir was discovered under a collaboration agreement between AbbVie and Enanta Pharmaceuticals ENTA for HCV protease inhibitors. Click to get this free report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Enanta Pharmaceuticals, Inc. (ENTA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing approval of its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). | Click to get this free report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Enanta Pharmaceuticals, Inc. (ENTA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing approval of its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). So far this year, AbbVie's share price has increased 16.1%, comparing favorably with a gain of 15% recorded by the Zacks classified Large-Cap Pharma industry. | AbbVie Inc.ABBV announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing approval of its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). So far this year, AbbVie's share price has increased 16.1%, comparing favorably with a gain of 15% recorded by the Zacks classified Large-Cap Pharma industry. Glecaprevir was discovered under a collaboration agreement between AbbVie and Enanta Pharmaceuticals ENTA for HCV protease inhibitors. |
26117.0 | 2017-06-26 00:00:00 UTC | Better Buy: Merck & Co. Inc. vs. AbbVie Inc. | ABBV | https://www.nasdaq.com/articles/better-buy-merck-co-inc-vs-abbvie-inc-2017-06-26 | nan | nan | Similarities between Merck & Co. Inc. (NYSE: MRK) and AbbVie Inc. (NYSE: ABBV) are easy to find. Both are big pharma companies with promising cancer drugs on the market. Both face some challenges with current products. Both pay attractive dividends.
For most of 2017, Merck stock outperformed AbbVie. However, AbbVie now claims higher year-to-date gains after a recent surge. Which of these drug stocks is the better pick for investors over the long run? Here are the arguments for Merck and for AbbVie.
The case for Merck
There's no better argument for buying Merck than the potential for Keytruda. Merck won approval from the U.S. Food and Drug Administration (FDA) for the drug in treating melanoma in September 2014, followed by approval in 2015 as a second-line treatment for non-small cell lung cancer (NSCLC). The drug continued to rack up approvals for other indications, perhaps most importantly getting a green light from the FDA in October 2016 as a first-line treatment for NSCLC and just last month for treating any solid tumor with a specific genetic feature known as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
Wall Street analysts are so enthused about Keytruda's prospects that several of them peg the peak sales opportunity for the drug at close to $8 billion. This estimate assumes that late-stage clinical trials for Keytruda in treating other types of cancer go well.
Merck awaits approval for several drugs, most notably diabetes drug ertugliflozin as a stand-alone treatment and as part of two combinations. The company also has 11 late-stage programs in addition to Keytruda.
The bad news for Merck is that sales are falling for several of its current products. In the first quarter of 2017, the drugmaker reported lower revenue from 20 of its top 33 drugs, with the biggest decline for cardiovascular drug Zetia.
Despite these headwinds, analysts think Merck will grow earnings by an average of 6% annually over the next few years, thanks primarily to Keytruda. Investors also should like Merck's dividend, which currently yields 2.91%.
The case for AbbVie
AbbVie continues enjoy solid growth from its top-selling product Humira. Last year, Humira generated revenue of $16 billion, representing nearly 63% of the company's total revenue -- up 15% from the prior year.
Another drug is coming on strong, though. Sales for cancer drug Imbruvica soared 45% year over year to $551 million in the first quarter of 2017. AbbVie expects the drug to generate $5 billion annually by 2020.
The company also has great expectations for another approved drug, Venclexta, which gained approval for treating chronic lymphocytic leukemia with 17p deletion in April 2016. Analysts have projected peak annual sales of up to $2 billion if the drug also wins approval for two other targeted indications, multiple myeloma and acute myeloid leukemia.
AbbVie is counting on its pipeline to deliver more blockbusters. On the immunology front, the company has two promising late-stage candidates in ABT-494 and risankizumab. In oncology, AbbVie should have big winners with Rova-T and veliparib.
With sustained momentum for Humira and Imbruvica combined with great potential for Venclexta and pipeline candidates, Wall Street analysts think that AbbVie can grow earnings by more than 14% annually on average over the next few years. Shareholders also benefit from the company's attractive dividend yield of 3.59%.
Better buy
There are problematic areas for both of these companies. Merck's declining sales for several of its products put a lot of pressure on Keytruda to deliver as expected. Some potential safety issues in clinical studies evaluating the drug in treating multiple myeloma are concerning.
AbbVie's primary challenge is the potential for biosimilar competition to Humira. Amgen won FDA approval for its Humira biosimilar last year but hasn't launched the drug yet due to a lawsuit filed by AbbVie.
So which of these two drug stocks is the better pick? I'd go with AbbVie. I think the company will be able to hold off biosimilar rivals in the U.S. for at least four more years. That gives time for Imbruvica and Venclexta to fully ramp up and for new drugs from the pipeline to reach the market. AbbVie has some risks, but I like the stock's prospects over the new few years.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With sustained momentum for Humira and Imbruvica combined with great potential for Venclexta and pipeline candidates, Wall Street analysts think that AbbVie can grow earnings by more than 14% annually on average over the next few years. Similarities between Merck & Co. Inc. (NYSE: MRK) and AbbVie Inc. (NYSE: ABBV) are easy to find. For most of 2017, Merck stock outperformed AbbVie. | AbbVie expects the drug to generate $5 billion annually by 2020. With sustained momentum for Humira and Imbruvica combined with great potential for Venclexta and pipeline candidates, Wall Street analysts think that AbbVie can grow earnings by more than 14% annually on average over the next few years. Similarities between Merck & Co. Inc. (NYSE: MRK) and AbbVie Inc. (NYSE: ABBV) are easy to find. | Amgen won FDA approval for its Humira biosimilar last year but hasn't launched the drug yet due to a lawsuit filed by AbbVie. Similarities between Merck & Co. Inc. (NYSE: MRK) and AbbVie Inc. (NYSE: ABBV) are easy to find. For most of 2017, Merck stock outperformed AbbVie. | I'd go with AbbVie. Similarities between Merck & Co. Inc. (NYSE: MRK) and AbbVie Inc. (NYSE: ABBV) are easy to find. For most of 2017, Merck stock outperformed AbbVie. |
26118.0 | 2017-06-24 00:00:00 UTC | 2 Top Biotech Stocks to Buy on Sale | ABBV | https://www.nasdaq.com/articles/2-top-biotech-stocks-buy-sale-2017-06-24 | nan | nan | Biotech stocks have been soaring over the last few years due to an uptick in innovation and a growing demand for healthcare services across the board. As a result, valuations across this high-flying space have ballooned -- making it increasingly difficult to suss out attractive bargains.
Having said that, the top biotechs Celgene Corp. (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD) are the rare exceptions to this general trend. Read on to find out why these two biotech titans might be compelling buys right now.
Celgene's cellar-dwelling valuation might be a once-in a lifetime buying opportunity
Celgene's industry-leading sales growth has apparently fallen on deaf ears of late. The company's shares, after all, are trading at a 16% discount relative to the Street's consensus 12-month price target, and some bolder analysts -- such as those at Leerink Swann -- even think the biotech's shares could be presently undervalued by as much as 25%. Put simply, Celgene might be one of the cheapest large cap biotechs available right now.
So why is Celgene trading at such an attractive valuation? The core factors at play are the real world capability of Celgene's internal and external pipelines to drive long-term growth, the fate of President Trump's corporate tax reforms, and the specifics regarding Trump's plan to lower prescription drug prices.
Digging into the details, some industry insiders are concerned that Celgene's experimental relapsing multiple sclerosis (RMS) treatment called ozanimod might not have the efficacy profile required to penetrate all that deeply into an already crowded field. That's an immensely important issue because this drug is forecast to eventually become one of Celgene's top sellers, with its peak sales ranging from $4 to $6 billion within the next decade.
Compounding matters, the company has also fallen behind some of its biggest rivals in the hotly contested immuno-oncology race -- highlighted by the clinical setbacks in its adoptive cell therapy partnership with Juno Therapeutics .
These two headwinds -- ozanimod's unclear commercial future and Celgene's unenviable position in the immuno-oncology race -- are key because corporate tax reform doesn't appear likely in this political climate. More to the point, Celgene may remain hesitant to repatriate any of its unremitted foreign profits to pursue additional pipeline opportunities, or to buy new sources of revenue via M&A in the event of further unexpected setbacks. And of course, the fact that drug prices have been under heavy scrutiny lately has only added to investors' concerns about Celgene's long-term growth potential.
On the bright side, there are a number of analysts that believe that the concerns over ozanimod are largely overblown, and that Celgene's shotgun approach to immuno-oncology will eventually pay big dividends. And another reassuring factor is that the more drastic price control measures that were being floated during the presidential campaign last year -- such as the importation of cheaper drugs from abroad -- now appear to be off the table altogether. So there's no overwhelmingly good reason to believe that Celgene's profitability is going to tank under the current administration.
The bottom line is that Celgene's robust and extremely deep clinical pipeline -- which was validated most recently by ozanimod's success in RMS -- can almost certainly keep the company's top-line headed in the right direction. In other words, Celgene will continue to grow at a respectable clip regardless of these headwinds -- the only question is by how much.
Gilead Sciences seems to have hit bottom
From 2013 to 2015, Gilead's top line was growing at an absolutely explosive rate thanks to its next-generation hepatitis drug franchise, consisting initially of the megablockbusters Sovaldi and Harvoni. Due to the launch of rival hep C therapies and a steep decline in demand, though, Gilead's hep C revenues have since fallen in an almost equally dramatic fashion.
What's left, for the most part, is a biotech with a staggering amount of cash and cash equivalents: approximately $72 billion when including Gilead's unremitted foreign earnings, which may become available if corporate tax reform becomes reality. Backing up this assertion, Gilead's HIV franchise is also under threat from both generics and forthcoming experimental-stage drugs, and its clinical pipeline has yet to produce another franchise-level drug capable of restarting the biotech's faltering growth engine. The net result is a company that has lost over a third of its value over just the past 18 months.
Now, the bright side is that Gilead's stock appears to have finally stabilized, as shown by its shares trading sideways in the last four weeks (down only 0.7% at the time of writing), and its short interest declining markedly from the beginning of the year.
GILD Short Interest data by YCharts
The key issue is that Gilead may no longer have the luxury of waiting for either corporate tax reform or for valuations to come to down to more reasonable levels in order to begin to engage in M&A.
AbbVie , after all, is likely to bring a new pan-genotypic hep C drug to market soon, which would be the biggest competitive threat to Sovaldi and Harvoni so far. So with its core franchises in hep C and HIV under siege from all sides, Gilead's hand is going to be forced on the matter -- and short-sellers appear to be preparing for this growing possibility.
Which therapeutic area might Gilead pursue via acquisition? The oncology space is the logical fit because of the field's projected 12.7% compound annual growth rate over the next five years running, combined with the biotech's known interest in building out a cancer drug franchise.
To go this route, though, Gilead may indeed have trouble locating deals at a reasonable price tag based on the staggering premiums being paid by other suitors for attractive oncology targets, which has been a sticking point for management according to public comments on the matter. At this critical juncture, though, Gilead has more than enough cash to get its top-line turned around, and the pressure is undoubtedly mounting on management to get a deal done soon, regardless of the cost.
In all, Gilead is a large cap biotech that's flush with cash, and primed to be a major player in the next wave of M&A as a result. Eventually the dam is going to burst and Gilead will add new sources of revenue through one or perhaps several acquisitions. And once this pivotal event occurs, Gilead will probably look like an absolute steal in hindsight.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
George Budwell has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Celgene and Gilead Sciences. The Motley Fool recommends Juno Therapeutics. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie , after all, is likely to bring a new pan-genotypic hep C drug to market soon, which would be the biggest competitive threat to Sovaldi and Harvoni so far. Digging into the details, some industry insiders are concerned that Celgene's experimental relapsing multiple sclerosis (RMS) treatment called ozanimod might not have the efficacy profile required to penetrate all that deeply into an already crowded field. Now, the bright side is that Gilead's stock appears to have finally stabilized, as shown by its shares trading sideways in the last four weeks (down only 0.7% at the time of writing), and its short interest declining markedly from the beginning of the year. | AbbVie , after all, is likely to bring a new pan-genotypic hep C drug to market soon, which would be the biggest competitive threat to Sovaldi and Harvoni so far. Having said that, the top biotechs Celgene Corp. (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD) are the rare exceptions to this general trend. These two headwinds -- ozanimod's unclear commercial future and Celgene's unenviable position in the immuno-oncology race -- are key because corporate tax reform doesn't appear likely in this political climate. | AbbVie , after all, is likely to bring a new pan-genotypic hep C drug to market soon, which would be the biggest competitive threat to Sovaldi and Harvoni so far. Having said that, the top biotechs Celgene Corp. (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD) are the rare exceptions to this general trend. Gilead Sciences seems to have hit bottom From 2013 to 2015, Gilead's top line was growing at an absolutely explosive rate thanks to its next-generation hepatitis drug franchise, consisting initially of the megablockbusters Sovaldi and Harvoni. | AbbVie , after all, is likely to bring a new pan-genotypic hep C drug to market soon, which would be the biggest competitive threat to Sovaldi and Harvoni so far. So why is Celgene trading at such an attractive valuation? Gilead Sciences seems to have hit bottom From 2013 to 2015, Gilead's top line was growing at an absolutely explosive rate thanks to its next-generation hepatitis drug franchise, consisting initially of the megablockbusters Sovaldi and Harvoni. |
26119.0 | 2017-06-24 00:00:00 UTC | 3 Dividend Stocks Perfect for Retirement | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-perfect-retirement-2017-06-24 | nan | nan | Dividend stocks can be a great source of extra income during retirement, but you can't just buy any dividend-paying stock for your golden years. That's because some dividends can be risky, so you need to ensure that the stocks you own are paying out dividends that are not only growing but are also stable and reliable. Three such perfect dividend stocks for retirement are biotech company AbbVie (NYSE: ABBV) , coatings company RPM International (NYSE: RPM) , and clothing retailer The Gap (NYSE: GPS) .
AbbVie is a proven commodity in the world of dividend stocks
George Budwell (AbbVie): The Dividend Aristocrat AbbVie is arguably a great stock for retirees because of its ability to continually deliver top-notch revenue growth and regular increases to its payout. Since being spun off from Abbott Laboratories in 2013, for example, Abbvie has raised its dividend by a healthy 60% and has been, quite literally, the fastest-growing large-cap biopharma from a revenue standpoint.
Like any stock, though, AbbVie is not risk-free. Right now, the company is building a bridge from its core revenue driver -- the anti-inflammatory megablockbuster Humira -- to its next generation of products, headlined by the blood-cancer drug Imbruvica. Long story short, Humira has now lost exclusivity in the United States and is close to doing so in the European Union, as well. Therefore, Humira is expected to hit its commercial zenith as early as next year, and then begin to decline as copycat drugs, known as biosimilars, enter the market.
The good news is that AbbVie has a particularly strong clinical pipeline of both oncology drug candidates -- such as late-stage solid tumor candidate rovalpituzumab tesirine (Rova-T), and a possible replacement product for Humira known as upadacitinib (ABT-494). While upadacitinib isn't forecast to come anywhere close to Humira's commercial peak, this single drug still has the opportunity to haul in sales in excess of $3.5 billion per year, according to analysts.
All in all, AbbVie offers a proven track record on the dividend side of the equation, and a promising clinical pipeline that should more than offset any erosion in Humira's overwhelming market share going forward.
This boring dividend stock offers exactly what you need
Neha Chamaria(RPM International) : I don't blame you if you haven't heard about RPM International -- a business as boring as coatings, sealants, and specialty chemicals doesn't make it to coffee-table conversations, after all. But what if I tell you that this lesser-known dividend stock packs a punch -- so much so that it would make a perfect dividend stock to invest in for retirement.
Consider that RPM has increased its dividend for 43 consecutive years, including the housing bubble and recessionary periods. Not that those increases haven't been sizable: RPM's hike last year was a good 9%. As RPM's dividends grew, so did it's share price. Or wait: On a total-return basis (dividend plus share-price appreciation), RPM has turned a nine-bagger since the beginning of the decade.
RPM Dividend data by YCharts.
Incredible, isn't it? And you thought boring isn't beautiful.
One factor that has worked in RPM's favor is that, over the years, it has branched out into products that are primarily used for maintenance and repairs, demand for which is less cyclical than that of, say, paints and coatings, which is driven by new construction. In fact, RPM estimates that maintenance and repairs are bringing in almost 70% of its total sales. Last year, the company generated sales worth $4.8 billion.
I can't say for sure whether RPM will be a multi-bagger in coming years, but go ahead and consider adding RPM to your retirement portfolio. From what I see, you can count on its dividends, given the company's incredible record, and a portfolio of products that look capable of withstanding the test of time.
(Don't) mind The Gap... the Gap is just fine.
Rich Smith(The Gap): If you ask me, some of the best stocks to own in retirement are the very same stocks most investors would like to own any other time. I'm talking about stocks that pay a nice dividend and have the ability to grow that dividend over time. And of course, the most important attribute of all -- stocks that don't cost too much.
Stocks like The Gap.
Priced at just 13.4 times earnings today, The Gap stock is cheap enough for any investor to own. Right now, the average stock selling on the S&P 500 index of companies costs 25.8 times earnings. So there's a pretty big "gap" between how expensive most stocks are today and how cheap The Gap is selling for. And this gap grows into a gulf when you consider how much cheaper The Gap stock is when valued on free cash flow.
Over the past year, The Gap has generated $1.1 billion in cash profits from its business -- 66% higher than its reported net income calculated according to, of course, " GAAP " accounting principles.
The Gap generates so much cash these days, in fact, that it's built up a $268 million net cash position on its balance sheet. Subtracted from its $9.3 billion market capitalization, that leaves The Gap stock selling for an enterprise value of only $9 billion -- and an enterprise-value-to-free-cash-flow ratio of just 8.2.
With the Gap's Old Navy chain showing 8% same-store-sales growth in its most recent quarter , The Gap is in the midst of a turnaround that analysts predict will see its profits grow a respectable 7% annually over the next five years. This earnings growth, combined with the stock's modest 53% payout ratio for dividends currently, creates plenty of room for The Gap to grow its already generous 3.9% dividend yield over time.
At its current price, and with its current prospects for growing an already sizable dividend, I think The Gap is a pretty perfect stock to own in retirement.
10 stocks we like better than Gap
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gap wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
George Budwell has no position in any stocks mentioned. Neha Chamaria has no position in any stocks mentioned. Rich Smith has no position in any stocks mentioned. The Motley Fool recommends RPM International. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | All in all, AbbVie offers a proven track record on the dividend side of the equation, and a promising clinical pipeline that should more than offset any erosion in Humira's overwhelming market share going forward. Three such perfect dividend stocks for retirement are biotech company AbbVie (NYSE: ABBV) , coatings company RPM International (NYSE: RPM) , and clothing retailer The Gap (NYSE: GPS) . AbbVie is a proven commodity in the world of dividend stocks George Budwell (AbbVie): The Dividend Aristocrat AbbVie is arguably a great stock for retirees because of its ability to continually deliver top-notch revenue growth and regular increases to its payout. | Three such perfect dividend stocks for retirement are biotech company AbbVie (NYSE: ABBV) , coatings company RPM International (NYSE: RPM) , and clothing retailer The Gap (NYSE: GPS) . AbbVie is a proven commodity in the world of dividend stocks George Budwell (AbbVie): The Dividend Aristocrat AbbVie is arguably a great stock for retirees because of its ability to continually deliver top-notch revenue growth and regular increases to its payout. Since being spun off from Abbott Laboratories in 2013, for example, Abbvie has raised its dividend by a healthy 60% and has been, quite literally, the fastest-growing large-cap biopharma from a revenue standpoint. | Three such perfect dividend stocks for retirement are biotech company AbbVie (NYSE: ABBV) , coatings company RPM International (NYSE: RPM) , and clothing retailer The Gap (NYSE: GPS) . AbbVie is a proven commodity in the world of dividend stocks George Budwell (AbbVie): The Dividend Aristocrat AbbVie is arguably a great stock for retirees because of its ability to continually deliver top-notch revenue growth and regular increases to its payout. Since being spun off from Abbott Laboratories in 2013, for example, Abbvie has raised its dividend by a healthy 60% and has been, quite literally, the fastest-growing large-cap biopharma from a revenue standpoint. | AbbVie is a proven commodity in the world of dividend stocks George Budwell (AbbVie): The Dividend Aristocrat AbbVie is arguably a great stock for retirees because of its ability to continually deliver top-notch revenue growth and regular increases to its payout. Three such perfect dividend stocks for retirement are biotech company AbbVie (NYSE: ABBV) , coatings company RPM International (NYSE: RPM) , and clothing retailer The Gap (NYSE: GPS) . Since being spun off from Abbott Laboratories in 2013, for example, Abbvie has raised its dividend by a healthy 60% and has been, quite literally, the fastest-growing large-cap biopharma from a revenue standpoint. |
26120.0 | 2017-06-23 00:00:00 UTC | AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know | ABBV | https://www.nasdaq.com/articles/abbvies-eagerly-anticipated-followup-humira-coming-what-you-need-know-2017-06-23 | nan | nan | For years, AbbVie 's (NYSE: ABBV) powerhouse product Humira has held the top-dog position of best-selling drug in the world. In 2016, this anti-inflammatory drug brought in over $16 billion in global sales and is expected to remain the world's top-selling drug out to 2020. However, being lead husky means the competition is always nipping at your heels, and competitors are itching to knock Humira off its perch. Luckily, AbbVie may have an ace up its sleeve -- namely, it's developing a sequel to Humira. Here's what you need to know.
A "JAK" of all trades
AbbVie's sequel to Humira is a drug called upadacitinib. Unlike Humira, which belongs to class of drug called "anti-TNF's," upadacitinib is what's known as a "JAK" inhibitor. While the science is a little heavy, you can think of JAK (short for janus kinase) as an enzyme that activates the cell's immune/inflammatory response. By inhibiting the activation of JAK, drugs like upadacitinib are able to lower the body's immune response.
Why lower the body's immune response you might ask? This function is very useful in autoimmune diseases, or diseases in which the body's immune system mistakenly identifies its own host as a foreign invader and attacks. Humira has already been approved for a laundry list of autoimmune indications including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and Crohn's disease. Upadacitinib is currently being studied as a potential treatment for many similar indications.
Phase 3 data
Earlier this month, AbbVie release positive top-line data from a phase 3 study of upadacitinib as a treatment for rheumatoid arthritis (RA). In this study, which compared upadacitinib vs placebo in RA patients who had already failed on conventional therapy, upadacitinib met its primary endpoint of a 20% improvement in patient symptoms as measured by what's known as an "ACR20" score.
Furthermore, upadacitinib also hit key secondary endpoints, including higher ACR scores (indicating more patient improvement) and around 30% of trial patients achieved clinical remission. The safety profile for upadacitinib was also encouraging, with no deaths reported and an adverse event profile consistent with earlier phase 2 trials.
Will it be enough?
While the phase 3 data for upadacitinib is encouraging, it is unlikely that this drug will ever come close to matching Humira in sales. For one, once Humira loses its patent protection (which the company estimates will be in 2022), payors will likely require potential patients to first fail on the cheaper biosimilar version of Humira prior to approving payment for upadacitinib.
In addition, upadacitinib will not the first JAK inihibitor approved for the treatment of autoimmune conditions. Should upadacitinib achieve FDA approval, the drug would face stiff competition from the likes of Pfizer 's Xeljanz as well as other next-generation autoimmune therapies.
AbbVie's future
With Humira's patent expiration looming, AbbVie has not been one to sit on its haunches. In addition to upadacitinib, AbbVie sports an incredibly rich pipeline with 12 pivotal trials reading out in 2017 alone. Keep an eye on future readouts from risankizumab in psoriasis as well as phase 3 data from Venclexta's MURANO trials in relapsed/refractory chronic lymphocytic leukemia.
In addition, while future sales of upadacitinib may never touch those of Humira, analysts have projected upwards of $3.5 billion in peak sales for this product. With AbbVie's background, distribution network, and proven brand within the autoimmune space, I believe this number may even be an underestimate.
While I wouldn't recommend buying AbbVie on the potential of upadacitinib alone, this company is definitely one I'm keeping my eye on.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
David Liang has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For years, AbbVie 's (NYSE: ABBV) powerhouse product Humira has held the top-dog position of best-selling drug in the world. Luckily, AbbVie may have an ace up its sleeve -- namely, it's developing a sequel to Humira. A "JAK" of all trades AbbVie's sequel to Humira is a drug called upadacitinib. | Phase 3 data Earlier this month, AbbVie release positive top-line data from a phase 3 study of upadacitinib as a treatment for rheumatoid arthritis (RA). For years, AbbVie 's (NYSE: ABBV) powerhouse product Humira has held the top-dog position of best-selling drug in the world. Luckily, AbbVie may have an ace up its sleeve -- namely, it's developing a sequel to Humira. | A "JAK" of all trades AbbVie's sequel to Humira is a drug called upadacitinib. Phase 3 data Earlier this month, AbbVie release positive top-line data from a phase 3 study of upadacitinib as a treatment for rheumatoid arthritis (RA). For years, AbbVie 's (NYSE: ABBV) powerhouse product Humira has held the top-dog position of best-selling drug in the world. | A "JAK" of all trades AbbVie's sequel to Humira is a drug called upadacitinib. For years, AbbVie 's (NYSE: ABBV) powerhouse product Humira has held the top-dog position of best-selling drug in the world. Luckily, AbbVie may have an ace up its sleeve -- namely, it's developing a sequel to Humira. |
26121.0 | 2017-06-23 00:00:00 UTC | Too Late To Catch Biotech Rally As Trump Fears Subside? | ABBV | https://www.nasdaq.com/articles/too-late-catch-biotech-rally-trump-fears-subside-2017-06-23 | nan | nan | With names like AbbVie ( ABBV ) and Celgene ( CELG ) on a tear the past week, many biotech sector ETFs hit 52-week or longer highs.
On Friday, they took a breather but retained the bulk of their big weekly gains. Most biotech funds are extended from their buy points , but several are still in or have pulled back into their respective buy zones.
For instance, iShares Nasdaq Biotechnology ( IBB ), which rose as much as 6.5% from its 303.84 entry, eased Friday and is near the top of its buy range. The $9.4 billion fund has rallied 19% this year through June 21, according to Morningstar Inc. That's well above the S&P 500's slight one-week decline and 10% YTD return for the same period.
BioShares Biotechnology Clinical Trials ( BBC ), up 31% YTD, is in buy range from a 24.31 cup-base entry. The $24.5 million fund is thinly traded with an average daily volume of about 12,000 shares.
VanEck Vectors Biotech ( BBH ), up nearly 20% for the year, was waffling near the top of the 5% buy zone from 123.25 entry. The 5-year-old fund has attracted $702.3 million in assets.
Analysts attributed the rally to subsiding drug-price concerns . Could there be further growth ahead?
"CFRA is positive fundamentally on the biotech industry and sees strong revenue growth in 2017 aided by a robust pipeline," Todd Rosenbluth, Director of ETF & Mutual Fund Research at CFRA, told IBD via email. "We have buy recommendations on ABBV, Amgen (AMGN), Biogen (BIIB), BioMarin Pharmaceutical (BMRN), CELG and Gilead Sciences (GILD)."
Those stocks all fall in the big-cap category, with market caps north of $16 billion.
"We are more favorable on larger-cap biotechs and as such think IBB offers the best exposure to these stocks," he said. "(Some) other ETFs offer more stock diversification and smaller cap exposure, which provides potential rewards, but also additional risk."
Leveraged ETFs, which try to magnify returns by doubling or tripling their benchmark index each day, posted double-digit gains in the week ended June 21. For instance, Direxion Daily S&P Biotech Bull 3X (LABU), which seeks investment results triple the performance of the S&P Biotechnology Select Industry Index, led with a 26% return, bringing its year-to-date haul to 113.9%.
ProShares UltraPro Nasdaq Biotechnology (UBIO), which aims for three times the Nasdaq Biotechnology Index's daily performance, rallied 20.8% on the week for a 60.4% YTD return. ProShares Ultra Nasdaq Biotechnology (BIB) scored a 13.7% gain for a 17.9% YTD return.
All three are well extended. While such leveraged plays can make for big gains when the going is good, they tend to carry higher risk than most traditional biotech sector funds.
On the other end of the spectrum are inverse ETFs, which are designed to give the opposite performance of the index they track. These funds provide a result similar to shorting the stocks in the index. The four shown in the accompanying chart have seen losses as biotechs have rallied. But they'd likely outperform if the sector heads south.
"We don't have a view on leveraged and inverse ETFs other than that investors can easily get hurt if they hold on to them too long," Rosenbluth said. "The risks are compounded much faster than investors can appreciate."
RELATED:
Can Biotech Stocks Keep Their New Lead?
This Top Biotech Stock Remains Just Within Buy Range
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With names like AbbVie ( ABBV ) and Celgene ( CELG ) on a tear the past week, many biotech sector ETFs hit 52-week or longer highs. "We have buy recommendations on ABBV, Amgen (AMGN), Biogen (BIIB), BioMarin Pharmaceutical (BMRN), CELG and Gilead Sciences (GILD)." Leveraged ETFs, which try to magnify returns by doubling or tripling their benchmark index each day, posted double-digit gains in the week ended June 21. | With names like AbbVie ( ABBV ) and Celgene ( CELG ) on a tear the past week, many biotech sector ETFs hit 52-week or longer highs. "We have buy recommendations on ABBV, Amgen (AMGN), Biogen (BIIB), BioMarin Pharmaceutical (BMRN), CELG and Gilead Sciences (GILD)." ProShares UltraPro Nasdaq Biotechnology (UBIO), which aims for three times the Nasdaq Biotechnology Index's daily performance, rallied 20.8% on the week for a 60.4% YTD return. | With names like AbbVie ( ABBV ) and Celgene ( CELG ) on a tear the past week, many biotech sector ETFs hit 52-week or longer highs. "We have buy recommendations on ABBV, Amgen (AMGN), Biogen (BIIB), BioMarin Pharmaceutical (BMRN), CELG and Gilead Sciences (GILD)." Most biotech funds are extended from their buy points , but several are still in or have pulled back into their respective buy zones. | With names like AbbVie ( ABBV ) and Celgene ( CELG ) on a tear the past week, many biotech sector ETFs hit 52-week or longer highs. "We have buy recommendations on ABBV, Amgen (AMGN), Biogen (BIIB), BioMarin Pharmaceutical (BMRN), CELG and Gilead Sciences (GILD)." For instance, iShares Nasdaq Biotechnology ( IBB ), which rose as much as 6.5% from its 303.84 entry, eased Friday and is near the top of its buy range. |
26122.0 | 2017-06-23 00:00:00 UTC | Daily Dividend Report: MDT, ABBV, DTE, XRAY, UDR, SNX, BBBY, CHS | ABBV | https://www.nasdaq.com/articles/daily-dividend-report-mdt-abbv-dte-xray-udr-snx-bbby-chs-2017-06-23 | nan | nan | Medtronic ( MDT ) approved a 7 percent increase in its quarterly cash dividend, raising the quarterly amount to $0.46 per ordinary share. The dividend is payable on July 26, 2017, to shareholders of record at the close of business on July 7, 2017.
AbbVie ( ABBV ) declared a quarterly cash dividend of $0.64 per share. The cash dividend is payable Aug. 15, 2017 to stockholders of record at the close of business on July 14, 2017.
DTE Energy declared a $0.825 per share dividend on its common stock payable Oct. 15, 2017, to shareholders of record at the close of business Sept. 18, 2017.
DENTSPLY SIRONA ( XRAY ) declared a quarterly cash dividend of $0.0875 per share of common stock, an indicated annual rate of $0.35 per share. The dividend is payable on July 14, 2017 to holders of record on June 30, 2017.
UDR ( UDR ) declared a regular quarterly dividend on its common stock for the second quarter of 2017 in the amount of $0.31 per share, payable in cash, on July 31, 2017 to UDR common stock shareholders of record as of July 10, 2017.
SYNNEX has declared a quarterly cash dividend of $0.25 per common share. The dividend will be payable on July 28, 2017 to stockholders of record as of the close of business on July 14, 2017.
Bed Bath & Beyond has declared a quarterly dividend of $.15 per share, to be paid on October 17, 2017 to shareholders of record at the close of business on September 15, 2017.
Chico's FAS ( CHS ) declared a quarterly cash dividend of $0.0825 per share of its common stock, a 3.1% increase over the dividend rate from September 2016. The dividend is payable on September 25, 2017 to Chico's FAS shareholders of record at the close of business on September 11, 2017.
VIDEO: Daily Dividend Report: MDT, ABBV, DTE, XRAY, UDR, SNX, BBBY, CHS
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | VIDEO: Daily Dividend Report: MDT, ABBV, DTE, XRAY, UDR, SNX, BBBY, CHS The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AbbVie ( ABBV ) declared a quarterly cash dividend of $0.64 per share. DTE Energy declared a $0.825 per share dividend on its common stock payable Oct. 15, 2017, to shareholders of record at the close of business Sept. 18, 2017. | VIDEO: Daily Dividend Report: MDT, ABBV, DTE, XRAY, UDR, SNX, BBBY, CHS The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AbbVie ( ABBV ) declared a quarterly cash dividend of $0.64 per share. UDR ( UDR ) declared a regular quarterly dividend on its common stock for the second quarter of 2017 in the amount of $0.31 per share, payable in cash, on July 31, 2017 to UDR common stock shareholders of record as of July 10, 2017. | AbbVie ( ABBV ) declared a quarterly cash dividend of $0.64 per share. VIDEO: Daily Dividend Report: MDT, ABBV, DTE, XRAY, UDR, SNX, BBBY, CHS The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. DTE Energy declared a $0.825 per share dividend on its common stock payable Oct. 15, 2017, to shareholders of record at the close of business Sept. 18, 2017. | AbbVie ( ABBV ) declared a quarterly cash dividend of $0.64 per share. VIDEO: Daily Dividend Report: MDT, ABBV, DTE, XRAY, UDR, SNX, BBBY, CHS The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. DTE Energy declared a $0.825 per share dividend on its common stock payable Oct. 15, 2017, to shareholders of record at the close of business Sept. 18, 2017. |
26123.0 | 2017-06-22 00:00:00 UTC | Noteworthy Thursday Option Activity: COST, ABBV, AET | ABBV | https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-cost-abbv-aet-2017-06-22 | nan | nan | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Costco Wholesale Corp (Symbol: COST), where a total of 67,940 contracts have traded so far, representing approximately 6.8 million underlying shares. That amounts to about 164.5% of COST's average daily trading volume over the past month of 4.1 million shares. Particularly high volume was seen for the $120 strike put option expiring January 18, 2019 , with 5,000 contracts trading so far today, representing approximately 500,000 underlying shares of COST. Below is a chart showing COST's trailing twelve month trading history, with the $120 strike highlighted in orange:
AbbVie Inc (Symbol: ABBV) options are showing a volume of 29,233 contracts thus far today. That number of contracts represents approximately 2.9 million underlying shares, working out to a sizeable 50.7% of ABBV's average daily trading volume over the past month, of 5.8 million shares. Especially high volume was seen for the $75 strike call option expiring January 19, 2018 , with 5,222 contracts trading so far today, representing approximately 522,200 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $75 strike highlighted in orange:
And Aetna Inc. (Symbol: AET) saw options trading volume of 8,416 contracts, representing approximately 841,600 underlying shares or approximately 42.9% of AET's average daily trading volume over the past month, of 2.0 million shares. Especially high volume was seen for the $125 strike call option expiring July 21, 2017 , with 2,500 contracts trading so far today, representing approximately 250,000 underlying shares of AET. Below is a chart showing AET's trailing twelve month trading history, with the $125 strike highlighted in orange:
For the various different available expirations for COST options , ABBV options , or AET options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $75 strike call option expiring January 19, 2018 , with 5,222 contracts trading so far today, representing approximately 522,200 underlying shares of ABBV. Below is a chart showing COST's trailing twelve month trading history, with the $120 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 29,233 contracts thus far today. That number of contracts represents approximately 2.9 million underlying shares, working out to a sizeable 50.7% of ABBV's average daily trading volume over the past month, of 5.8 million shares. | Below is a chart showing COST's trailing twelve month trading history, with the $120 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 29,233 contracts thus far today. Below is a chart showing ABBV's trailing twelve month trading history, with the $75 strike highlighted in orange: And Aetna Inc. (Symbol: AET) saw options trading volume of 8,416 contracts, representing approximately 841,600 underlying shares or approximately 42.9% of AET's average daily trading volume over the past month, of 2.0 million shares. That number of contracts represents approximately 2.9 million underlying shares, working out to a sizeable 50.7% of ABBV's average daily trading volume over the past month, of 5.8 million shares. | Especially high volume was seen for the $75 strike call option expiring January 19, 2018 , with 5,222 contracts trading so far today, representing approximately 522,200 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $75 strike highlighted in orange: And Aetna Inc. (Symbol: AET) saw options trading volume of 8,416 contracts, representing approximately 841,600 underlying shares or approximately 42.9% of AET's average daily trading volume over the past month, of 2.0 million shares. Below is a chart showing COST's trailing twelve month trading history, with the $120 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 29,233 contracts thus far today. | Especially high volume was seen for the $75 strike call option expiring January 19, 2018 , with 5,222 contracts trading so far today, representing approximately 522,200 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $75 strike highlighted in orange: And Aetna Inc. (Symbol: AET) saw options trading volume of 8,416 contracts, representing approximately 841,600 underlying shares or approximately 42.9% of AET's average daily trading volume over the past month, of 2.0 million shares. Below is a chart showing COST's trailing twelve month trading history, with the $120 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 29,233 contracts thus far today. |
26124.0 | 2017-06-20 00:00:00 UTC | J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study | ABBV | https://www.nasdaq.com/articles/jj-abbvies-imbruvica-positive-in-follow-up-lymphoma-study-2017-06-20 | nan | nan | Johnson & JohnsonJNJ announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica (ibrutinib) against Pfizer Inc.'s PFE Torisel (temsirolimus) for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).
Notably, Imbruvica is jointly developed and marketed by J&J subsidiary Janssen Biotech and Pharmacyclics LLC, a subsidiary of AbbVie Inc. ABBV .
Imbruvica is currently approved in the U.S. for treating patients with mantle cell lymphoma or MCL, who have received at least one therapy earlier and for CLL patients with deletion 17p. It is also approved in the EU for treatment of MCL. Significantly in Jan 2017, Imbruvica was approved for patients with marginal zone lymphoma (MZL), requiring a systemic therapy and having received at least one prior anti-CD20 based therapy.
Shares of J&J have outperformed the Zacks classified Large Cap Pharma industry so far this year. The stock has climbed 16.4% with the broader industry's increase of 12.1% during the period.
Data from the phase III RAY study showed that the progression-free survival (PFS) of patients when treated with Imbruvica is four times more (25.4 months) compared with Torisel (6.2 months) at first relapse after one prior line of therapy. Patients who had received over one prior line of therapy, their median PFS significantly increased when treated with Imbruvica in comparison to Torisel (15.6 months vs 6.2 months). The study was conducted on a total of 280 patients. Data showed a median overall survival (OS) with Imbruvica after one prior line of therapy of 42.1 months against 27.0 months with Torisel.
Data from the study was presented at the International Conference on Malignant Lymphoma (ICML).
J&J is presently exploring the potential to expand Imbruvica's label into solid tumors and autoimmune diseases.
Importantly, Imbruvica has one of the most robust clinical oncology development programs in the industry with nearly 30 company-sponsored trials underway. Of these, 14 are in phase III development. The drug is being evaluated in a number of cancer indications and has a multi-billion dollar potential. Another 100 investigator-sponsored trials and external collaborations for Imbruvica are underway around the world.
Per the company's press release, MCL is a rare disease that accounts for 5-10% of all non-Hodgkin's lymphomas. Besides, one in two lakh people in Europe suffer from the disease. Thus, there is a huge market potential for the drug to cater to the unmet needs of patients affected with the disease.
Johnson & Johnson Price
Johnson & Johnson Price | Johnson & Johnson Quote
Zacks Rank & Key Picks
J&J currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the healthcare sector is Regeneron Pharmaceuticals, Inc. REGN , which carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Regeneron's earnings per share estimates increased from $10.16 to $10.52 for 2017 and from $10.90 to $12.10, over the last 60 days. The company has delivered positive earnings surprises in two of the four trailing quarters with an average beat of 0.45%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer, Inc. (PFE): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Notably, Imbruvica is jointly developed and marketed by J&J subsidiary Janssen Biotech and Pharmacyclics LLC, a subsidiary of AbbVie Inc. ABBV . Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report To read this article on Zacks.com click here. Johnson & JohnsonJNJ announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica (ibrutinib) against Pfizer Inc.'s PFE Torisel (temsirolimus) for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL). | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, Imbruvica is jointly developed and marketed by J&J subsidiary Janssen Biotech and Pharmacyclics LLC, a subsidiary of AbbVie Inc. ABBV . Johnson & JohnsonJNJ announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica (ibrutinib) against Pfizer Inc.'s PFE Torisel (temsirolimus) for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL). | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, Imbruvica is jointly developed and marketed by J&J subsidiary Janssen Biotech and Pharmacyclics LLC, a subsidiary of AbbVie Inc. ABBV . Johnson & JohnsonJNJ announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica (ibrutinib) against Pfizer Inc.'s PFE Torisel (temsirolimus) for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL). | Notably, Imbruvica is jointly developed and marketed by J&J subsidiary Janssen Biotech and Pharmacyclics LLC, a subsidiary of AbbVie Inc. ABBV . Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report To read this article on Zacks.com click here. Johnson & JohnsonJNJ announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica (ibrutinib) against Pfizer Inc.'s PFE Torisel (temsirolimus) for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL). |
26125.0 | 2017-06-20 00:00:00 UTC | Better Buy: Pfizer Inc. vs. AbbVie Inc. | ABBV | https://www.nasdaq.com/articles/better-buy-pfizer-inc-vs-abbvie-inc-2017-06-20 | nan | nan | When it comes to drugmaker dividends, Pfizer Inc. (NYSE: PFE) and AbbVie Inc. (NYSE: ABBV) stand out with higher-than-average yields. Of course, when shopping for pharmaceutical stocks, it pays to treat above-average yields with suspicion.
To see which of these big pharma stocks is the better pick right now, we'll look beyond their dividends. Major revenue streams for both are under threat for various reasons, but they also have exciting new drugs that could more than offset the imminent losses. Let's look at some of the different moving pieces to see which one comes out on top.
The shifting sands beneath Pfizer Inc.
The worst patent losses are in the rear view, but the threat of generic competition continues to hound the company. Pfizer's second-largest revenue stream, Lyrica, will probably begin to dry up after its basic U.S. patent expires next year. Sales of the nerve pain reliever accounted for about 10% of total revenue in the first quarter.
Pfizer's best-selling product at the moment has become a victim of its own success. It seems the population of older adults the Prevnar vaccine was aimed at has reached a saturation point. The pneumonia-preventing vaccine was still the company's best-selling drug in the first quarter, but sales slid about 8% lower than the same period last year to an annualized run rate of $5.6 billion.
Luckily for Pfizer, a couple recently launched cancer therapies could offset the losses. Ibrance has quickly become a popular breast cancer treatment since its launch in early 2015. First-quarter sales of the oral therapy jumped 58% over the prior-year period to a $2.7 billion run rate, and are poised to keep climbing. This March, the Food and Drug Administration confirmed its previous conditional approval and expanded the range of anti-hormonal treatments oncologists can use in concert with the drug.
More recently, Pfizer became the fourth company with an approved anti-PD(L)1 cancer immunotherapy. Marketed in partnership with Germany's Merck KGaA , Bavencio inhibits cancer cells from exploiting the same immune attack shutoff switch as Keytruda and Opdivo. Both immunotherapies quickly crossed the $1 billion annual sales threshold, and Bavencio is widely expected to follow in their footsteps.
AbbVie Inc.'s ticking time bomb
Pfizer's Lyrica headache pales in comparison to AbbVie's exclusivity issues. In the first quarter, Humira sales of about $4.1 billion comprised 63% of total revenue for the period. AbbVie insists its stack of Humira-related patents should prevent copycat versions from pressuring U.S. sales until 2022, but investors have plenty of reasons to be nervous. Last year, the FDA approved Amgen 's biosimilar version of the aging anti-inflammatory treatment, and more recently Coherus BioSciences received a favorable verdict that could help it shorten the timeline for its version of the world's best-selling drug.
If AbbVie's intellectual property portfolio indeed allows Humira sales to remain stable for another five years, its shareholders will have plenty to smile about. The company has used the massive cash flows Humira generates to bulk up its product offerings and clinical development pipeline.
In 2015, the company snapped up rights to roughly half of Imbruvica sales, which rose 45% to a $2.2 billion run rate based on first-quarter sales. The oral blood-cancer treatment is the first chemo-free option for the most common form of leukemia, and AbbVie's share of its annual sales could reach the $5 billion mark.
Further ahead, AbbVie has an anti-inflammatory candidate that could also go a long way toward offsetting impending Humira losses. Upadacitinib, formerly ABT-494, is an orally administered Janus kinase blocker of the same class as baricitinib from Eli Lilly and Incyte . The experimental therapy recently beat the pants off a placebo as a treatment for rheumatoid arthritis, and the company intends to submit applications for its approval next year. Following the FDA's recent rejection of baricitinib, annual upadacitinib sales are expected to top out at around $3.5 billion.
Running the numbers
Recently, AbbVie and Pfizer have been trading at 12.7 and 12.9 times this year's earnings estimates, respectively. That's far below the average stock in the benchmark S&P 500 Index , which currently trades at 19.0 times forward earnings estimates.
Both dividend-paying big pharma stocks also offer above-average yields. At recent prices, Pfizer shares offer 3.9%, which is a bit higher than the 3.6% you'd see from AbbVie.
Pfizer's dividend also has a leg up on AbbVie's in terms of sustainability. Pfizer used about 54% of free cash flow to make the past four quarterly payments, which was about 4% less than AbbVie needed. Add these slight advantages to Pfizer's more diversified revenue stream and it looks like the bigger pharma is the better buy right now.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
Cory Renauer has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The oral blood-cancer treatment is the first chemo-free option for the most common form of leukemia, and AbbVie's share of its annual sales could reach the $5 billion mark. When it comes to drugmaker dividends, Pfizer Inc. (NYSE: PFE) and AbbVie Inc. (NYSE: ABBV) stand out with higher-than-average yields. AbbVie Inc.'s ticking time bomb Pfizer's Lyrica headache pales in comparison to AbbVie's exclusivity issues. | Running the numbers Recently, AbbVie and Pfizer have been trading at 12.7 and 12.9 times this year's earnings estimates, respectively. When it comes to drugmaker dividends, Pfizer Inc. (NYSE: PFE) and AbbVie Inc. (NYSE: ABBV) stand out with higher-than-average yields. AbbVie Inc.'s ticking time bomb Pfizer's Lyrica headache pales in comparison to AbbVie's exclusivity issues. | Running the numbers Recently, AbbVie and Pfizer have been trading at 12.7 and 12.9 times this year's earnings estimates, respectively. When it comes to drugmaker dividends, Pfizer Inc. (NYSE: PFE) and AbbVie Inc. (NYSE: ABBV) stand out with higher-than-average yields. AbbVie Inc.'s ticking time bomb Pfizer's Lyrica headache pales in comparison to AbbVie's exclusivity issues. | When it comes to drugmaker dividends, Pfizer Inc. (NYSE: PFE) and AbbVie Inc. (NYSE: ABBV) stand out with higher-than-average yields. AbbVie Inc.'s ticking time bomb Pfizer's Lyrica headache pales in comparison to AbbVie's exclusivity issues. AbbVie insists its stack of Humira-related patents should prevent copycat versions from pressuring U.S. sales until 2022, but investors have plenty of reasons to be nervous. |
26126.0 | 2017-06-19 00:00:00 UTC | Health Care Select Sector SPDR Fund Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/health-care-select-sector-spdr-fund-experiences-big-inflow-2017-06-19 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $170.9 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from 212,215,324 to 214,415,324). Among the largest underlying components of XLV, in trading today Amgen Inc (Symbol: AMGN) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is up about 0.6%, and Celgene Corp. (Symbol: CELG) is up by about 1.5%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $65.96 per share, with $78.23 as the 52 week high point - that compares with a last trade of $78.21. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Amgen Inc (Symbol: AMGN) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is up about 0.6%, and Celgene Corp. (Symbol: CELG) is up by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $170.9 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from 212,215,324 to 214,415,324). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Amgen Inc (Symbol: AMGN) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is up about 0.6%, and Celgene Corp. (Symbol: CELG) is up by about 1.5%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $65.96 per share, with $78.23 as the 52 week high point - that compares with a last trade of $78.21. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of XLV, in trading today Amgen Inc (Symbol: AMGN) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is up about 0.6%, and Celgene Corp. (Symbol: CELG) is up by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $170.9 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from 212,215,324 to 214,415,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $65.96 per share, with $78.23 as the 52 week high point - that compares with a last trade of $78.21. | Among the largest underlying components of XLV, in trading today Amgen Inc (Symbol: AMGN) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is up about 0.6%, and Celgene Corp. (Symbol: CELG) is up by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $170.9 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from 212,215,324 to 214,415,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $65.96 per share, with $78.23 as the 52 week high point - that compares with a last trade of $78.21. |
26127.0 | 2017-06-19 00:00:00 UTC | AbbVie (ABBV) Stock Hits 52-Week High: More Room to Run? | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-hits-52-week-high%3A-more-room-to-run-2017-06-19 | nan | nan | AbbVie Inc.ABBV shares hit a 52-week high of $71.12 on Friday before eventually closing at $71.05. In fact, shares of the company are up 13.4% since the beginning of this year, outperforming the Zacks classified Large Cap Pharmaceuticals industry, which increased 11.4% in the same period.
Factors at Play
The company's flagship rheumatoid arthritis drug Humira accounted for almost 63% of total revenue in the first quarter of 2017, registering growth of nearly 15% year over year. The drug is the main driver of AbbVie's revenues, currently approved for several indications. The company is also conducting studies to expand its label into other indications. The company expects Humira to bring in total sales of more than $18 billion in 2020.
However, quite a few companies are working on bringing Humira biosimilars to the market.
A biosimilar from Amgen Inc. AMGN was approved by the FDA in 2016. However, the drug has not yet been launched due to ongoing litigation. In May 2017, AbbVie lost a lawsuit to Coherus Biosciences, Inc. CHRS regarding the dosing patent '135 for Humira. However, shares weren't affected much as the investment community believes that AbbVie has a robust intellectual property (IP) portfolio beyond the '135 patent, which should preclude biosimilars from the U.S. market until 2022. Sales should continue to remain strong until then.
Although Humira generates most of its revenues, the company has diversified its revenue stream with the addition of Imbruvica to its portfolio. Imbruvica sales increased 44.6% from the year-ago quarter to $551 million in the first quarter of 2017. The company expects Imbruvica peak sales of more than $7 billion and revenues of about $5 billion in 2020. Imbruvica, currently approved for quite a few indications, has multi-billion dollar potential. AbbVie intends to expand Imbruvica's label into solid tumors and autoimmune diseases. AbbVie co-owns the drug with Johnson & Johnson JNJ .
With expected growth in Humira and Imbruvica sales over the next few years, the company's top line should see an upside. Moreover, AbbVie also has a strong pipeline with several late-stage candidates. The company is developing risankizumab for psoriasis and Crohn's disease while ABT-494 is being developed for treating rheumatoid arthritis (RA).
In the last couple of months, AbbVie announced positive top-line results from a phase III study on upadacitinib (ABT-494) for RAas well as a phase II study for Crohn's disease. These played an important role in driving up the share price. Meanwhile, AbbVie's RBV-free once-daily pan-genotypic combinationregimen, glecaprevir/pibrentasvir (G/P),is under accelerated assessment in the EU and priority review in the U.S. and Japan with commercialization expected this year.Also, the company announced some label updates for both Imbruvica and Humira.
Venetoclax, an oncology pipeline candidate was approved by the FDA in 2016 for chronic lymphocytic leukemia (CLL) and is being studied in other indications as well.
Investors are focused on the performance of AbbVie's HCV portfolio as the segment is facing competition from Gilead's Sovaldi and Harvoni along with increasing pricing pressure. Viekira suffered a year-over-year drop of 36.5% in its sales in the first quarter of 2017 to $263 million. The weak performance is expected to continue this year with sales expected to decline to $1 billion in 2017 from $1.5 billion in 2016.
Despite these pressures, AbbVie looks well poised to deliver strong earnings and sales growth through the rest of this year backed by its key drugs Imbruvica and Humira. Meanwhile, investor focus will remain on the stock with several late-stage data-readouts expected in the second half as well.
Attractive Numbers
The stock trades at an attractive valuation as evident from its favorable P/E F12M (forward twelve months), which stands at 11.84 and trades at a discount to large cap pharmaceuticals industry's P/E F12M of 15.91. Moreover, earnings are expected to increase 14.62% in 2017 and 18.59% in 2018. The numbers indicate that the stock has the potential to rise further.
AbbVie Inc. Price
AbbVie Inc. Price | AbbVie Inc. Quote
Zacks Rank
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Coherus BioSciences, Inc. (CHRS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, shares weren't affected much as the investment community believes that AbbVie has a robust intellectual property (IP) portfolio beyond the '135 patent, which should preclude biosimilars from the U.S. market until 2022. Meanwhile, AbbVie's RBV-free once-daily pan-genotypic combinationregimen, glecaprevir/pibrentasvir (G/P),is under accelerated assessment in the EU and priority review in the U.S. and Japan with commercialization expected this year.Also, the company announced some label updates for both Imbruvica and Humira. Investors are focused on the performance of AbbVie's HCV portfolio as the segment is facing competition from Gilead's Sovaldi and Harvoni along with increasing pricing pressure. | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Coherus BioSciences, Inc. (CHRS): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV shares hit a 52-week high of $71.12 on Friday before eventually closing at $71.05. | Despite these pressures, AbbVie looks well poised to deliver strong earnings and sales growth through the rest of this year backed by its key drugs Imbruvica and Humira. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Coherus BioSciences, Inc. (CHRS): Free Stock Analysis Report To read this article on Zacks.com click here. | AbbVie Inc.ABBV shares hit a 52-week high of $71.12 on Friday before eventually closing at $71.05. The drug is the main driver of AbbVie's revenues, currently approved for several indications. In May 2017, AbbVie lost a lawsuit to Coherus Biosciences, Inc. CHRS regarding the dosing patent '135 for Humira. |
26128.0 | 2017-06-18 00:00:00 UTC | AbbVie Stock Just Hit a 52-Week High: Here's Why It Should Go Even Higher | ABBV | https://www.nasdaq.com/articles/abbvie-stock-just-hit-52-week-high-heres-why-it-should-go-even-higher-2017-06-18 | nan | nan | AbbVie (NYSE: ABBV) stock has been on a roll. The biotech's share price recently hit a 52-week high and is within striking distance of breaking its all-time record high.
Will AbbVie's momentum continue? It's possible that the stock will soon run out of steam. However, I think there's a compelling reason to think that AbbVie should go even higher.
Simple logic
Why will AbbVie stock go higher? The logic is simple and based on two assumptions. The first assumption is that the biotech's earnings will increase significantly. The second assumption is that AbbVie's valuation isn't likely to go much lower than it is now. When you put these two assumptions together, you have a stock that is headed higher.
I'll delve more into why AbbVie's earnings will increase significantly later. For now, know this: I'm not the only one who thinks this will happen. The company itself forecasts adjusted earnings growth of 13% to 15% for 2017. The consensus among Wall Street analysts is that AbbVie will grow earnings by an average annual rate of over 14% during the next five years.
As for the second assumption, consider that AbbVie stock currently trades at less than 11 times expected earnings. That's cheaper than plenty of other drugmakers with much lower growth prospects than AbbVie has. If earnings are solid, I seriously doubt that the stock's valuation will deteriorate.
But what about Humira?
The most important objection that could be made to these two assumptions is that Humira is in danger. Amgen (NASDAQ: AMGN) has already won approval of a biosimilar to Humira. Coherus Biosciences (NASDAQ: CHRS) recently won a ruling from the U.S. Patent and Trademark Office that invalidated one of the patents for Humira.
Around 63% of AbbVie's total revenue stems from the drug. If Humira sales fall, AbbVie's earnings will fall. And if that happens, both of the stated assumptions would be blown out of the water.
But how much danger does Humira really face right now? Yes, Amgen won FDA approval for Amjevita, the first Humira biosimilar to be approved in the U.S. However, Amjevita isn't on the market yet. AbbVie is fighting Amgen in the legal system, alleging infringement of 61 patents that are still in force for Humira. The trial doesn't even begin until November 2019.
And while Coherus succeeded in its effort to have one of Humira's patents invalidated, AbbVie will employ the same legal strategy against the company that it did with Amgen. Coherus might state publicly that it intends to launch a Humira biosimilar in 2018, but the reality is that the biotech will almost certainly be bogged down in court for a few years.
AbbVie thinks that it will be able to fend off biosimilar rivals to Humira until 2022 . Wall Street analysts don't think any biosimilar to the drug will launch in the U.S. prior to 2021. That's at least four or five years of continued revenue and earnings for AbbVie from its top-selling drug.
More revenue and earnings coming
Although AbbVie depends on Humira for most of its revenue now, that should be about to change. The company has multiple opportunities for revenue and earnings growth.
Put Imbruvica at the top of the list. The cancer drug generated sales of more than $1.8 billion last year for AbbVie. AbbVie thinks that Imbruvica could reach peak annual sales of $7 billion. Even if it doesn't hit that mark, there's plenty of revenue and earnings growth ahead from the drug.
Venclexta won approval in 2016 for treating chronic lymphocytic leukemia (CLL). Several other indications could be on the way if clinical studies go well. The cancer drug could reach peak annual sales of $3.5 billion.
AbbVie claims other pipeline candidates with similar or even greater potential. Experimental cancer drug Rova-T could make as much as $5 billion annually at peak if approved. Psoriasis drug risankizumab has the potential to generate annual revenue of $4 billion per year. Rheumatoid arthritis treatment upadacitinib could make AbbVie $3.5 billion annually in the future.
Going higher
Again, the logic is simple. If AbbVie's earnings keep rising, so will the stock. I don't see why the biotech's earnings won't continue to increase, therefore I predict AbbVie's momentum isn't about to end.
Of course, it's possible that the overall market will undergo a major correction. In that event, AbbVie stock will likely fall like most other stocks. When biosimilars to Humira hit the market, AbbVie could be in trouble if Imbruvica, Venclexta, and its pipeline candidates don't produce as expected. That's a few years off, though. As of right now, all signs appear to point to AbbVie stock keeping the good times rolling.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And while Coherus succeeded in its effort to have one of Humira's patents invalidated, AbbVie will employ the same legal strategy against the company that it did with Amgen. When biosimilars to Humira hit the market, AbbVie could be in trouble if Imbruvica, Venclexta, and its pipeline candidates don't produce as expected. AbbVie (NYSE: ABBV) stock has been on a roll. | If Humira sales fall, AbbVie's earnings will fall. AbbVie thinks that Imbruvica could reach peak annual sales of $7 billion. AbbVie (NYSE: ABBV) stock has been on a roll. | As for the second assumption, consider that AbbVie stock currently trades at less than 11 times expected earnings. I don't see why the biotech's earnings won't continue to increase, therefore I predict AbbVie's momentum isn't about to end. In that event, AbbVie stock will likely fall like most other stocks. | In that event, AbbVie stock will likely fall like most other stocks. When biosimilars to Humira hit the market, AbbVie could be in trouble if Imbruvica, Venclexta, and its pipeline candidates don't produce as expected. AbbVie (NYSE: ABBV) stock has been on a roll. |
26129.0 | 2017-06-16 00:00:00 UTC | 3 Stocks That Could Double Your Money | ABBV | https://www.nasdaq.com/articles/3-stocks-could-double-your-money-2017-06-16 | nan | nan | It would be silly for us to promise that any stock could double over any given time frame. There are thousands of variables that play a role in a stock's price, and many of them aren't predictable.
That being said, by focusing on a few variables that are both easy to verify and indicative of positive business momentum, we can narrow down the field of companies that are ripe for doubling. Small cap stocks with a history of -- or potential to -- drastically increase sales are good targets for such investments.
Below, our analysts tell you why they believe Coherus BioSciences (NASDAQ: CHRS) , CalAmp (NASDAQ: CAMP) , and Axon Enterprises (NASDAQ: AAXN) are three such candidates.
Down, but not out
Brian Feroldi (Coherus BioSciences):Biosimilar drugs hold a lot of promise to help reverse the skyrocketing cost of medicine. That's why I've had my eye on Coherus BioSciences for quite some time. This small-cap biotech offers investors a pure-play way to buy into this potential $20 billion market.
Coherus is researching copycat versions of a handful of multi-billion dollar drugs, including Amgen 's Neulasta and Enbrel as well as AbbVie 's Humira. If Coherus succeeds at bringing one of these drugs to market and can steal even a small amount of market share then it could be a financial bonanza for the business.
Unfortuantly, we recently learned that Coherus whiffed with its first shot on goal. The FDA just rejected its application for a biosimilar version of Amgen's Neulasta. The agency said it needed to take a closer look at existing data and get more information on the company's manufacturing processes before it could give the thumbs up. Predictably, this news didn't sit well with investors.
While I understand the market's reaction, it is worth pointing out that the FDA isn't requiring any additional clinical testing. That could mean that Coherus could have this drug back in the FDA's hands within a matter of months. If that happens, my guess is that the company will have much better luck the second time around. What's more, it's important to remember that Coherus still has two other drug candidates in development that should be sent off to regulators in the U.S. and E.U. later this year. I think that it is fair to say that Coherus learned a lot from this fiasco and will be much more careful with future filings.
In total, Coherus is down, but it is certainly not out. If the company successfully addresses its issue with its next regulatory filing, it wouldn't surprise me to see shares double from here.
This small-cap winner is only getting stronger
Steve Symington (CalAmp): I think CalAmp can (at least) double investors' money in the coming years. CalAmp's revenue last quarter climbed a solid 21.6% year over year to $86.1 million, but would have increased 46% had it not been for CalAmp shuttering its satellite business in late 2016.
Meanwhile, revenue from international customers climbed 90% last fiscal year to $91 million, but still only represented just 26% of total sales. And recurring revenue climbed 39% last year to $59.4 million, adding a modest measure of stability to CalAmp's often volatile results in these early stages.
Last quarter CalAmp also completed the integration of vehicle recovery solutions company LoJack, which it acquired for $134 million early last year. In doing so, CalAmp can now hone its focus on entering new multibillion-dollar markets by leveraging LoJack's products on a global scale.
Better yet, CalAmp management told investors last quarter that it expects the business to "strengthen as the year progresses." If CalAmp delivers on that prediction when it reports earnings later this month -- even with shares trading near a fresh 52-week high -- I think investors have every right to be excited for what's to come.
Making policing safe for everyone
Brian Stoffel (Axon): This company has a simple mission: "To protect life." For most of the company's history -- it was formerly known as TASER International -- it accomplished that goal by offering non-lethal weapons to law enforcement. But over the last two years, the focus has changed drastically to include equipping America's police with body cameras and a platform to store and analyze all of that data.
Earlier this year, the company made the bold move of offering up a free body camera and one-year subscription to its Evidence.com platform -- among other things -- to every law enforcement officer in America. While that means the company will definitely take a hit in the short-term, it introduces enormous potential moving forward.
Even before the announcement, the company announced that the Axon side of its business -- including body cameras and Evidence.com -- saw revenue climb 122% while the sale of Tasers grew a solid 26%.
Perhaps most important, the number of seats occupied on the Evidence.com platform -- which is very sticky due to enormously high switching costs -- grew 12% to 148,000. With a market cap of just $1.3 billion, I don't think it's a stretch to say that Axon could double your money in just a few years.
10 stocks we like better than Axon Enterprise
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Axon Enterprise wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
Brian Feroldi has no position in any stocks mentioned. Brian Stoffel owns shares of Axon Enterprise. Steve Symington has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Axon Enterprise. The Motley Fool recommends CalAmp. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Coherus is researching copycat versions of a handful of multi-billion dollar drugs, including Amgen 's Neulasta and Enbrel as well as AbbVie 's Humira. But over the last two years, the focus has changed drastically to include equipping America's police with body cameras and a platform to store and analyze all of that data. Earlier this year, the company made the bold move of offering up a free body camera and one-year subscription to its Evidence.com platform -- among other things -- to every law enforcement officer in America. | Coherus is researching copycat versions of a handful of multi-billion dollar drugs, including Amgen 's Neulasta and Enbrel as well as AbbVie 's Humira. Below, our analysts tell you why they believe Coherus BioSciences (NASDAQ: CHRS) , CalAmp (NASDAQ: CAMP) , and Axon Enterprises (NASDAQ: AAXN) are three such candidates. Down, but not out Brian Feroldi (Coherus BioSciences):Biosimilar drugs hold a lot of promise to help reverse the skyrocketing cost of medicine. | Coherus is researching copycat versions of a handful of multi-billion dollar drugs, including Amgen 's Neulasta and Enbrel as well as AbbVie 's Humira. Below, our analysts tell you why they believe Coherus BioSciences (NASDAQ: CHRS) , CalAmp (NASDAQ: CAMP) , and Axon Enterprises (NASDAQ: AAXN) are three such candidates. This small-cap winner is only getting stronger Steve Symington (CalAmp): I think CalAmp can (at least) double investors' money in the coming years. | Coherus is researching copycat versions of a handful of multi-billion dollar drugs, including Amgen 's Neulasta and Enbrel as well as AbbVie 's Humira. later this year. With a market cap of just $1.3 billion, I don't think it's a stretch to say that Axon could double your money in just a few years. |
26130.0 | 2017-06-16 00:00:00 UTC | 3 Dividend Stocks in Healthcare | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-healthcare-2017-06-16 | nan | nan | The healthcare sector can be an enormously profitable area to hunt for dividend stocks . Top healthcare companies, after all, often sport ginormous free cash flows, and sustainable levels of growth.
Based on this insight, we turned to our contributors to ask them which healthcare dividend stocks might be exceptional buys right now. They suggested Bristol-Myers Squibb (NYSE: BMY) , Teva Pharmaceutical Industries (NYSE: TEVA) , and AbbVie (NYSE: ABBV) . Here's why.
Growth and sustainability
George Budwell (Bristol-Myers Squibb): Since 2009, Bristol has been on a mission to both become a prominent player in the emerging immuno-oncology space and vastly increase the efficiency of its operations worldwide. The result of these concerted efforts has been the development of the drugmaker's new flagship checkpoint inhibitor Opdivo, which is now approved for a whopping 11 indications in the U.S. across six tumor types and is on track to break $4 billion in sales in 2017. Opdivo is also in numerous clinical trials that may establish it as a key backbone therapy across a wide swath of hard-to-treat malignancies.
Opdivo's stunning commercial success has been a primary reason this big pharma has been producing industry-leading levels of growth of late. In 2016, for instance, Bristol's top-line exploded higher by 17%, and its bottom-line performed even better with a staggering 41% increase over 2015.
The one chink in Bristol's turnaround story, though, is perhaps the disappointing growth within its dividend program since 2009. At present, this big pharma stock pays a below average yield of 2.97%, and the company has only grown its dividend by 25.8% in the past eight years. That's fairly weak compared to industry leaders like AbbVie that sport yields of 3.72% and have grown their dividends at a record pace over the past few years.
Bristol's cautious approach to its dividend program, however, isn't without reason. Instead of allocating capital to shareholder rewards, the company has been racking up value-creating acquisitions -- such as its billion dollar plus expenditures to acquire both Padlock Therapeutics and Cormorant Pharmaceuticals last year. As a result, Bristol now sports one of the deepest and most promising clinical pipelines among even the most elite drugmakers, which should eventually translate into sustainable growth and richer dividend payouts down the road.
There's nothing generic about this dividend stock
Sean Williams (Teva Pharmaceutical Industries): Though it's been about as unpopular a stock as you can get in the healthcare industry of late, a top healthcare dividend that this Fool has been nibbling on for weeks is branded and generic drug developer Teva Pharmaceutical Industries.
Without question, Teva is going through a rough patch. It's buried under $33.7 billion in net debt after an acquisition spree that included generic drugmaker Actavis. Its CEO and CFO have stepped down following the company's admission and settlement of bribery charges in three foreign countries. And the company's lead branded drug, Copaxone, an injectable treatment for multiple sclerosis, could soon lose a decent chunk of its sales to generic competition.
Yet this Fool keeps buying!
To begin with, Teva appears set to benefit greatly from the addition of Actavis. The buyout makes Teva the largest producer of generic drugs in the world, which should increase its pricing power with insurers and pharmacies and also boost its margins by allowing the company to eliminate redundant operations. Some $1.5 billion in net synergies are expected to be realized by year's end, based on Teva's Q1 earnings report.
Secondly, unlike other drugmakers (ahem, Valeant Pharmaceuticals ) that have struggled mightily with debt, Teva has plenty of levers it can pull to reduce its burden. The company has already announced its intent to put its Women's Health and European oncology and pain operations on the chopping block for the right bidder. I believe these operations could generate in the neighborhood of $3 billion , combined, if both sell. More importantly, though, Teva had more than $1 billion in organic paydown of its debt during Q1. Don't forget that this is a company that can generate around $5 billion in free cash flow annually.
Even Teva's efforts to protect Copaxone from generic competition have been admirable. Teva has used the legal system masterfully to keep generics off pharmacy shelves long enough to bring a reformulated version to market that only needs to be injected three times a week as opposed to daily. Even when generic competition does hit the market, Teva may be able to protect more of its branded sales than Wall Street realizes.
Considering its beat-up share price, Teva's dividend yield is now up to 4%. However, given the factors described above, I believe its payout to be pretty safe, making it among the most attractive healthcare dividend stocks you can consider buying.
Betting on the pipeline
Brian Feroldi (AbbVie): Sporting a dividend yield of 3.7%, AbbVie is one of the highest-yielding big pharma stocks out there. What's more, shares are trading around 11 times next year's earnings estimates, which is quite cheap when compared to the S&P 500 in general. What gives?
Investors are likely assigning AbbVie a below-market multiple right now because they are concerned that the company's cash-cow drug Humira could soon face some serious competition. Between biosimilars and recent competitive launches , several companies are actively fighting for a slice of Humira's sales. That aggressiveness makes sense since Humira rang up more than $16 billion in total sales last year, making it the best-selling drug in the world. If competitors succeed, AbbVie could be in for a world of hurt since Humira is responsible for more than 60% of the company's total sales.
For what it's worth, AbbVie's management team is very confident that Humira will be able to hold its own for years to come -- the company believes that its patents will protect it from competition for some time. That's why they were willing to go on record and predict that Humira's sales will top $18 billion by 2020, which, if true, represents slow but steady growth from here.
Beyond Humira, AbbVie is also counting on other drugs to help move its top-line forward from here. That growth is expected to be powered by its fast-growing cancer drug Imbruvica and more than 20 new products or indications that are currently in its development.
Will the company's pipeline pick up the slack left when Humira's sales eventually decline? That's the multi-billion dollar question that investors want to know. If you believe that the answer is yes, then buying AbbVie for its cheap valuation and high-dividend yield today probably makes sense.
10 stocks we like better than Teva Pharmaceutical Industries
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Teva Pharmaceutical Industries wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
Brian Feroldi has no position in any stocks mentioned. George Budwell has no position in any stocks mentioned. Sean Williams owns shares of Teva Pharmaceutical Industries. The Motley Fool owns shares of and recommends Valeant Pharmaceuticals. The Motley Fool recommends Teva Pharmaceutical Industries. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | They suggested Bristol-Myers Squibb (NYSE: BMY) , Teva Pharmaceutical Industries (NYSE: TEVA) , and AbbVie (NYSE: ABBV) . That's fairly weak compared to industry leaders like AbbVie that sport yields of 3.72% and have grown their dividends at a record pace over the past few years. Betting on the pipeline Brian Feroldi (AbbVie): Sporting a dividend yield of 3.7%, AbbVie is one of the highest-yielding big pharma stocks out there. | They suggested Bristol-Myers Squibb (NYSE: BMY) , Teva Pharmaceutical Industries (NYSE: TEVA) , and AbbVie (NYSE: ABBV) . Betting on the pipeline Brian Feroldi (AbbVie): Sporting a dividend yield of 3.7%, AbbVie is one of the highest-yielding big pharma stocks out there. That's fairly weak compared to industry leaders like AbbVie that sport yields of 3.72% and have grown their dividends at a record pace over the past few years. | They suggested Bristol-Myers Squibb (NYSE: BMY) , Teva Pharmaceutical Industries (NYSE: TEVA) , and AbbVie (NYSE: ABBV) . That's fairly weak compared to industry leaders like AbbVie that sport yields of 3.72% and have grown their dividends at a record pace over the past few years. Betting on the pipeline Brian Feroldi (AbbVie): Sporting a dividend yield of 3.7%, AbbVie is one of the highest-yielding big pharma stocks out there. | They suggested Bristol-Myers Squibb (NYSE: BMY) , Teva Pharmaceutical Industries (NYSE: TEVA) , and AbbVie (NYSE: ABBV) . That's fairly weak compared to industry leaders like AbbVie that sport yields of 3.72% and have grown their dividends at a record pace over the past few years. Betting on the pipeline Brian Feroldi (AbbVie): Sporting a dividend yield of 3.7%, AbbVie is one of the highest-yielding big pharma stocks out there. |
26131.0 | 2017-06-15 00:00:00 UTC | AbbVie a Top Socially Responsible Dividend Stock With 3.6% Yield (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-top-socially-responsible-dividend-stock-36-yield-abbv-2017-06-15 | nan | nan | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-average ''DividendRank'' statistics including a strong 3.6% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. Environmental criteria include considerations like the environmental impact of the company's products and services, as well as the company's efficiency in terms of its use of energy and resources. Social criteria include elements such as human rights, child labor, corporate diversity, and the company's impact on society - for instance, taken into consideration would be business activities tied to weapons, gambling, tobacco, and alcohol.
According to the ETF Finder at ETF Channel , AbbVie Inc is a member of the iShares MSCI USA ESG Select Social Index Fund ETF ( KLD ), making up 0.16% of the underlying holdings of the fund, which owns $894,192 worth of ABBV shares.
The annualized dividend paid by AbbVie Inc is $2.56/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 04/11/2017. Below is a long-term dividend history chart for ABBV, which the DividendRank report stressed as being of key importance. Indeed, studying a company's past dividend history can be of good help in judging whether the most recent dividend is likely to continue.
ABBV operates in the Drugs & Pharmaceuticals sector, among companies like Johnson & Johnson ( JNJ ), and Novartis ( NVS ).
Top 25 Socially Responsible Dividend Stocks - Income To Feel Good About »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-average ''DividendRank'' statistics including a strong 3.6% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. Below is a long-term dividend history chart for ABBV, which the DividendRank report stressed as being of key importance. According to the ETF Finder at ETF Channel , AbbVie Inc is a member of the iShares MSCI USA ESG Select Social Index Fund ETF ( KLD ), making up 0.16% of the underlying holdings of the fund, which owns $894,192 worth of ABBV shares. | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-average ''DividendRank'' statistics including a strong 3.6% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. According to the ETF Finder at ETF Channel , AbbVie Inc is a member of the iShares MSCI USA ESG Select Social Index Fund ETF ( KLD ), making up 0.16% of the underlying holdings of the fund, which owns $894,192 worth of ABBV shares. The annualized dividend paid by AbbVie Inc is $2.56/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 04/11/2017. | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-average ''DividendRank'' statistics including a strong 3.6% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. According to the ETF Finder at ETF Channel , AbbVie Inc is a member of the iShares MSCI USA ESG Select Social Index Fund ETF ( KLD ), making up 0.16% of the underlying holdings of the fund, which owns $894,192 worth of ABBV shares. The annualized dividend paid by AbbVie Inc is $2.56/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 04/11/2017. | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-average ''DividendRank'' statistics including a strong 3.6% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. According to the ETF Finder at ETF Channel , AbbVie Inc is a member of the iShares MSCI USA ESG Select Social Index Fund ETF ( KLD ), making up 0.16% of the underlying holdings of the fund, which owns $894,192 worth of ABBV shares. The annualized dividend paid by AbbVie Inc is $2.56/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 04/11/2017. |
26132.0 | 2017-06-15 00:00:00 UTC | Can Celgene Corporation Be a Value Stock? | ABBV | https://www.nasdaq.com/articles/can-celgene-corporation-be-value-stock-2017-06-15 | nan | nan | Call me crazy, but I don't think Celgene Corporation (NASDAQ: CELG) is quite as expensive as it looks on the surface. Sure, the biotech stock is trading at a price-to-earnings multiple nearly twice that of the average stock in the benchmark S&P 500 index , but the oncology giant's growth spurt is far from over.
To see if Celgene truly is an unlikely value stock, we'll need to look at the drugs and new drug candidates that have pushed the stock price up to nosebleed valuations recently. Let's begin with its flagship therapy, Revlimid.
A first-place contender
It's been 12 years since the FDA approved Revlimid capsules for the treatment of multiple myeloma, an increasingly common blood-based cancer. Sales of the drug continue to soar despite years of availability because Celgene has successfully expanded Revlimid's addressable patient population to include newly diagnosed multiple myeloma patients and people with related blood cancers.
Those label expansions helped first quarter Revlimid sales surge 20% over the same period last year, and the company expects full-year revenue from the therapy to reach between $8.0 billion and $8.3 billion for the full year. That could be enough to make it the second best-selling drug on the planet, behind AbbVie 's Humira.
While Revlimid might not top the $16.1 billion in sales Humira generated last year, incoming biosimilar competition for AbbVie's blockbuster gives Celgene's therapy a shot at the top spot in the years ahead.
Staying on top
Revlimid will most likely begin losing ground to generic competition in 2022, but a therapy in development could keep the company on top of the multiple myeloma indication. Celgene's has collaboration agreements in place with over a dozen industry peers, and one with bluebird bio gives the company access to bb2121.
This experimental therapy involves re-engineering a patient's own immune cells to fight multiple myeloma. In a group that had been so heavily pretreated any responders would be impressive, bb2121 produced breathtaking results. All 15 patients showed a response, and the experimental therapy drove the disease into remission for 27% of this group, which had run out of treatment options after multiple relapses.
Beyond oncology
Celgene may have cut its teeth in the oncology space, but it's already proved its ability to expand into the autoimmune-disorder arena. In 2014, the company launched Otezla for the treatment of psoriasis, and the oral treatment is already on pace to reach the $1 billion dollar mark this year. First-quarter Otezla sales rose 23.5% over the same period last year to $242 million.
Further ahead, the company could make a big splash in two more autoimmune indications with another conveniently administered oral therapy. Ozanimod is in late-stage clinical trials that could support applications for the treatment of multiple sclerosis (MS) and ulcerative colitis.
Earlier this year, Celgene presented some results from an MS trial that showed ozanimod significantly outperformed a popular therapy on two important measurements of efficacy, reducing relapse frequency and the appearance of new or enlarged brain lesions. The company intends to submit an application for the MS indication by the end of the year. If approved, the drug could generate more than $4 billion in annual sales from the MS indication alone.
In the numbers
With a product lineup firing on all cylinders now, and a pipeline chock-full of potential blockbusters, Celgene's bottom line is expected to grow at a 20.7% annual rate over the next five years. That's a bit slower than the 24.9% growth rate the company achieved over the past five years, but it's still fast enough to make this stock look like a bargain.
At recent prices, Celgene stock is trading at about 44.9 times trailing earnings. That's well above the average stock in the S&P 500, which currently trades at about 24.2 times trailing earnings, but you need to look forward to see why this is one of the best value stocks you can buy right now.
The average stock in the same benchmark index currently trades at around 19 times this year's earnings estimates. That means on a forward basis, Celgene is cheaper than average. With late-stage hopefuls such as ozanimod and bb2121 in its pipeline, though, this company's growth story should be anything but ordinary in the years ahead.
10 stocks we like better than Celgene
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Celgene wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
Cory Renauer has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Bluebird Bio and Celgene. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | That could be enough to make it the second best-selling drug on the planet, behind AbbVie 's Humira. While Revlimid might not top the $16.1 billion in sales Humira generated last year, incoming biosimilar competition for AbbVie's blockbuster gives Celgene's therapy a shot at the top spot in the years ahead. All 15 patients showed a response, and the experimental therapy drove the disease into remission for 27% of this group, which had run out of treatment options after multiple relapses. | While Revlimid might not top the $16.1 billion in sales Humira generated last year, incoming biosimilar competition for AbbVie's blockbuster gives Celgene's therapy a shot at the top spot in the years ahead. That could be enough to make it the second best-selling drug on the planet, behind AbbVie 's Humira. If approved, the drug could generate more than $4 billion in annual sales from the MS indication alone. | While Revlimid might not top the $16.1 billion in sales Humira generated last year, incoming biosimilar competition for AbbVie's blockbuster gives Celgene's therapy a shot at the top spot in the years ahead. That could be enough to make it the second best-selling drug on the planet, behind AbbVie 's Humira. Sales of the drug continue to soar despite years of availability because Celgene has successfully expanded Revlimid's addressable patient population to include newly diagnosed multiple myeloma patients and people with related blood cancers. | That could be enough to make it the second best-selling drug on the planet, behind AbbVie 's Humira. While Revlimid might not top the $16.1 billion in sales Humira generated last year, incoming biosimilar competition for AbbVie's blockbuster gives Celgene's therapy a shot at the top spot in the years ahead. Sure, the biotech stock is trading at a price-to-earnings multiple nearly twice that of the average stock in the benchmark S&P 500 index , but the oncology giant's growth spurt is far from over. |
26133.0 | 2017-06-15 00:00:00 UTC | Novartis (NVS) Announced Positive Data on Psoriasis Cosentyx | ABBV | https://www.nasdaq.com/articles/novartis-nvs-announced-positive-data-on-psoriasis-cosentyx-2017-06-15 | nan | nan | Novartis AGNVS announced positive data on arthritis drug Cosentyx from two phase III studies at the Annual European Congress of Rheumatology (EULAR 2017), in Madrid.
Cosentyx, fully human monoclonal antibody, is already approved in the U.S. and EU for the treatment of moderate-to-severe plaque psoriasis. The drug is also approved in the EU for the treatment of adults with ankylosing spondylitis (AS) who have responded inadequately to conventional therapy, such as non-steroidal anti-inflammatory drugs. The drug is also instrumental for the treatment of active psoriatic arthritis (PsA) in adults when the response to disease modifying anti-rheumatic drug therapy is unsatisfactory.
In Jan 2016, Cosentyx obtained the FDA approval for the treatment of adults with active ankylosing spondylitis and for the treatment of adults with active psoriatic arthritis.
The data shows sustained improvement in the signs and symptoms for active AS at three years. The new data also revealed that Cosentyx provides rapid and sustained pain relief in patients with PsA out to 2 years.
Data from the phase III study, MEASURE 1 extension study, showed 80% of AS patients consistently achieved an ASAS 20 response at 3 years, in tandem with previous findings from the FUTURE 1 study on Cosentyx for active PsA. Additionally, a 2-year post-hoc analysis of the FUTURE 2 study evaluated Cosentyx in PsA, where 99% patients reported moderate-to-extreme pain or discomfort before initiating treatment. At week 3, half of the treated with Cosentyx reported clinically meaningful improvements in pain of over 20%, as measured by Visual Analogue Scale.
Meanwhile, patient recruitment is underway for the new head-to-head clinical trial, EXCEED, to evaluate the superiority of Cosentyx versus AbbVie's ABBV Humira in PsA.
Novartis' has outperformed the Zacks classified industry over the last six months. The stock has rallied 12.2% compared with the Large Cap Pharmaceuticals industry's gain of 4.5%.
The uptake of Cosentyx has been strong and the company has grabbed market shares from rivals, Humira and Amgen's AMGN Enbrel. Cosentyx achieved blockbuster status in 2016 recording over $1 billion of sales.
Zacks Rank & Key Pick
Novartis currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in healthcare sector include VIVUS, Inc. VVUS which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
VIVUS's loss per share estimates lessened from 50 cents to 39 cents for 2017 in the last 30 days. The company posted positive earnings surprises in all four trailing quarters with average beat of 233.69%.
3 Stocks to Ride a 588% Revenue Explosion
At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold.
By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. See Zacks' Top 3 Stocks to Ride This Space >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
VIVUS, Inc. (VVUS): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meanwhile, patient recruitment is underway for the new head-to-head clinical trial, EXCEED, to evaluate the superiority of Cosentyx versus AbbVie's ABBV Humira in PsA. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis AGNVS announced positive data on arthritis drug Cosentyx from two phase III studies at the Annual European Congress of Rheumatology (EULAR 2017), in Madrid. | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, patient recruitment is underway for the new head-to-head clinical trial, EXCEED, to evaluate the superiority of Cosentyx versus AbbVie's ABBV Humira in PsA. In Jan 2016, Cosentyx obtained the FDA approval for the treatment of adults with active ankylosing spondylitis and for the treatment of adults with active psoriatic arthritis. | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, patient recruitment is underway for the new head-to-head clinical trial, EXCEED, to evaluate the superiority of Cosentyx versus AbbVie's ABBV Humira in PsA. In Jan 2016, Cosentyx obtained the FDA approval for the treatment of adults with active ankylosing spondylitis and for the treatment of adults with active psoriatic arthritis. | Meanwhile, patient recruitment is underway for the new head-to-head clinical trial, EXCEED, to evaluate the superiority of Cosentyx versus AbbVie's ABBV Humira in PsA. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Data from the phase III study, MEASURE 1 extension study, showed 80% of AS patients consistently achieved an ASAS 20 response at 3 years, in tandem with previous findings from the FUTURE 1 study on Cosentyx for active PsA. |
26134.0 | 2017-06-15 00:00:00 UTC | Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug | ABBV | https://www.nasdaq.com/articles/biotech-stock-roundup-management-changes-biogen-alexion-gild-files-hiv-drug-2017-06-15 | nan | nan | Biogen BIIB and Alexion ALXN were both in the headlines this week with the companies announcing management changes -- while Biogen's shares were down on the news, Alexion's shares soared. Meanwhile, Gilead GILD continues to work on strengthening its HIV franchise with the company now seeking FDA approval for a once-daily single tablet regimen.
Recap of the Week's Most Important Stories
Biogen Loses, Alexion Gains on Management Shakeup: Biogen's long-standing CFO, Paul Clancy, will be leaving the company at the end of the second quarter to join as CFO of Alexion. Biogen has seen quite a few top position exits over the last few quarters with this being the latest. Biogen's shares were down 3.1% while Alexion's investors reacted positively to the news with shares gaining 9.3% (Read more: Biogen Loses Top Executive Again, CFO Clancy to Join Alexion ).
Year-to-date (YTD), Biogen has underperformed the Zacks-categorized Medical-Biomedical/Genetics industry with the company losing 10.7% while the industry is up 2.6%.
Celgene Lupus Drug Looks Promising: Celgene's CELG investigational, oral immunomodulatory compound fared well in a mid-stage study in lupus with a trend toward greater improvement being observed. With treatment options for lupus remaining limited, there is significant demand for new treatments.
Meanwhile, Celgene entered into a five-year strategic collaboration with Dragonfly Therapeutics, which uses its novel TriNKET technology to harness the body's innate immune system to bring breakthrough cancer treatments to patients.
Under the collaboration, Celgene will get exclusive options to in-license up to four of Dragonfly's pipeline candidates focused on high-value targets in hematological malignancies including acute myeloid leukemia and multiple myeloma. Celgene will shell out $33 million upfront and make milestone as well as royalty payments.
AbbVie ABBV has also signed up with Principia Biopharma, a private, clinical-stage company, for the development of oral immunoproteasome inhibitors. The companies will work on developing first-in-class oral therapies that bring the power of proteasome inhibition safely into the field of immunology. Both Celgene and AbbVie are Zacks Rank #3 (Hold) stocks -- you can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Acceleron Drops Dalantercept Development: Clinical-stage company, Acceleron XLRN , has decided to shelve the development of dalantercept after it failed in a mid-stage study in advanced renal cell carcinoma (RCC). The company, which is working on developing treatments for serious and rare diseases, has now decided to focus on lead pipeline candidate, luspatercept, which is in several mid- and late-stage studies. Luspatercept is being developed for different types of blood cancer in partnership with Celgene (Read more: Acceleron Kidney Cancer Candidate Fails in Phase II ).
CRL for Neulasta Biosimilar: Amgen AMGN got a bit of a breather with the FDA issuing a complete response letter (CRL) to Coherus for its biosimilar version of Amgen's blockbuster drug Neulasta. While the FDA has not asked for a clinical study, the agency has requested a reanalysis of a subset of subject samples with a revised immunogenicity assay and has also asked for certain additional manufacturing related process information. Neulasta is a key product in Amgen's portfolio with 2016 sales coming in at $4.6 billion including $3.9 billion in the U.S. Coherus intends to work with the FDA to determine the path forward. On its first quarter call, Amgen had said that it could start facing biosimilar completion for Neulasta as early as the fourth quarter of the year.
Gilead Seeks FDA Nod for HIV Regimen: Gilead submitted a regulatory application in the U.S. seeking FDA approval for a once-daily single tablet regimen which has the potential to advance triple-therapy treatment (BIC/FTC/TAF) for a wide range of HIV patients. Gilead enjoys a strong presence in the HIV market and is working on launching new products. With the hepatitis C virus (HCV) franchise under pressure, Gilead is looking towards its HIV segment to drive results (Read more: Gilead Submits NDA for HIV Combination Therapy Regimen ). The company expects to file for EU approval of the regimen in the third quarter.
Performance
Medical - Biomedical and Genetics Industry 5YR % Return
Medical - Biomedical and Genetics Industry 5YR % Return
The NASDAQ Biotechnology Index gained 1% over the last five trading sessions. Among major biotech stocks, Alexion gained 17.8% while Regeneron lost 1.1%. Over the last six months, Vertex was up 59.2% while Gilead was down 14.2%.
What's Next in the Biotech World?
Watch out for the usual pipeline updates and data presentations from biotech companies.
3 Stocks to Ride a 588% Revenue Explosion
At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...
By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. See Zacks' Top 3 Stocks to Ride This Space >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
Acceleron Pharma Inc. (XLRN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie ABBV has also signed up with Principia Biopharma, a private, clinical-stage company, for the development of oral immunoproteasome inhibitors. Both Celgene and AbbVie are Zacks Rank #3 (Hold) stocks -- you can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Acceleron Pharma Inc. (XLRN): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Acceleron Pharma Inc. (XLRN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV has also signed up with Principia Biopharma, a private, clinical-stage company, for the development of oral immunoproteasome inhibitors. Both Celgene and AbbVie are Zacks Rank #3 (Hold) stocks -- you can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Acceleron Pharma Inc. (XLRN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV has also signed up with Principia Biopharma, a private, clinical-stage company, for the development of oral immunoproteasome inhibitors. Both Celgene and AbbVie are Zacks Rank #3 (Hold) stocks -- you can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . | Both Celgene and AbbVie are Zacks Rank #3 (Hold) stocks -- you can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . AbbVie ABBV has also signed up with Principia Biopharma, a private, clinical-stage company, for the development of oral immunoproteasome inhibitors. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Acceleron Pharma Inc. (XLRN): Free Stock Analysis Report To read this article on Zacks.com click here. |
26135.0 | 2017-06-15 00:00:00 UTC | New Data Shows TG Therapeutics Could Be Onto Something Big | ABBV | https://www.nasdaq.com/articles/new-data-shows-tg-therapeutics-could-be-something-big-2017-06-15 | nan | nan | TG Therapeutics (NASDAQ: TGTX) shares have been on a roll since positive data from cancer trials was presented at the annual American Society of Clinical Oncology (ASCO) conference earlier this month. This week, the company's adding to its good news with updated data for a triplet cancer regimen being presented at the International Conference on Malignant Lymphoma.
Producing precision medicine
At ASCO, TG Therapeutics said that adding its TG-1101, or ublituximab, to AbbVie Inc. 's (NYSE: ABBV) top-selling Imbruvica resulted in an objective response rate (ORR) of 78% in patients with high-risk chronic lymphocytic leukemia. The complete response rate to the two-drug combination was 7%.
Those results match up favorably with Imbruvica monotherapy. In the trial, the ORR and complete response rates for Imbruvica on its own were 45% and 0%, respectively.
Ublituximab is a monoclonal antibody designed to inhibit CD-20, and that makes it one of many drugs being developed by biotech companies eager to improve patient outcomes by focusing on specific genetic or molecular characteristics.
CD-20 is a type of protein that's found on a type of white blood cell called B-cells. It plays a role in optimizing a patient's immune response, and it can be highly expressed in patients with certain forms of lymphoma and leukemia.
Inhibiting CD-20 activity has already been proven to help patients with blood cancers. For example, it's the target of the top-selling cancer drug Rituxan. However, ublituximab is different from these drugs because it targets a specific and unique CD-20 molecule that's found on mature B-cells.
In cancer patients with high-risk mutations, such as 17p deletion, 11q deletion, and p53 mutation, the use of TG-1101 alongside Imbruvica, which targets a different protein, appears to be quite effective.
Another win
At the International Conference on Malignant Lymphoma, TG Therapeutics is rolling out data showing that a three-drug combination of ublituximab with its drug TGR-1202 and the chemotherapy drug bendamustine may improve outcomes in patients with non-Hodgkin lymphoma.
In a small group of patients with relapsing diffuse large B-cell lymphoma (DLBCL), the three-drug mash-up delivered an ORR of 100%. The ORR among DLBCL patients with chemorefractory and/or SCT-refractory DLBCL was 50%. And it was 88% in patients with relapsing or refractory follicular lymphoma.
What's intriguing is that TGR-1202 is a PI3K delta inhibitor like Gilead Sciences ' (NASDAQ: GILD) Zydelig, yet safety concerns that have derailed Zydelig's commercial sales might not be a problem for TGR-1202 -- at least not yet. TG Therapeutics says that in this trial, the three-drug combination "was very well tolerated, with a low incidence of Grade 3 or greater adverse events, particularly those that have been associated with the PI3K-delta class."
If efficacy and safety stay this good in a planned registrational study, then TGR-1202 could eventually generate sales in nine figures. For perspective, despite safety concerns, Zydelig's first-quarter sales were still $35 million.
Looking ahead
TG Therapeutics still has more work to do before it can present any data to regulators for an eventual approval of these drugs, but the results are encouraging, and the company's focus on late-line, precision therapies where there's an important need for new treatments could give it an edge in securing an accelerated review from the U.S. Food and Drug Administration.
If so, then the market potential could be significant enough to support further upside. TG Therapeutics thinks ublituximab's market potential exceeds $200 million annually, and that its opportunity in DLBCL could be $1 billion plus. Given that the company's market cap values it at less than $750 million right now, an argument can be made that there's still running room for its shares to go higher.
10 stocks we like better than TG Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and TG Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
Todd Campbell owns shares of Gilead Sciences. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has the following options: short June 2017 $70 calls on Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Producing precision medicine At ASCO, TG Therapeutics said that adding its TG-1101, or ublituximab, to AbbVie Inc. 's (NYSE: ABBV) top-selling Imbruvica resulted in an objective response rate (ORR) of 78% in patients with high-risk chronic lymphocytic leukemia. TG Therapeutics (NASDAQ: TGTX) shares have been on a roll since positive data from cancer trials was presented at the annual American Society of Clinical Oncology (ASCO) conference earlier this month. Ublituximab is a monoclonal antibody designed to inhibit CD-20, and that makes it one of many drugs being developed by biotech companies eager to improve patient outcomes by focusing on specific genetic or molecular characteristics. | Producing precision medicine At ASCO, TG Therapeutics said that adding its TG-1101, or ublituximab, to AbbVie Inc. 's (NYSE: ABBV) top-selling Imbruvica resulted in an objective response rate (ORR) of 78% in patients with high-risk chronic lymphocytic leukemia. Another win At the International Conference on Malignant Lymphoma, TG Therapeutics is rolling out data showing that a three-drug combination of ublituximab with its drug TGR-1202 and the chemotherapy drug bendamustine may improve outcomes in patients with non-Hodgkin lymphoma. TG Therapeutics thinks ublituximab's market potential exceeds $200 million annually, and that its opportunity in DLBCL could be $1 billion plus. | Producing precision medicine At ASCO, TG Therapeutics said that adding its TG-1101, or ublituximab, to AbbVie Inc. 's (NYSE: ABBV) top-selling Imbruvica resulted in an objective response rate (ORR) of 78% in patients with high-risk chronic lymphocytic leukemia. Another win At the International Conference on Malignant Lymphoma, TG Therapeutics is rolling out data showing that a three-drug combination of ublituximab with its drug TGR-1202 and the chemotherapy drug bendamustine may improve outcomes in patients with non-Hodgkin lymphoma. Looking ahead TG Therapeutics still has more work to do before it can present any data to regulators for an eventual approval of these drugs, but the results are encouraging, and the company's focus on late-line, precision therapies where there's an important need for new treatments could give it an edge in securing an accelerated review from the U.S. Food and Drug Administration. | Producing precision medicine At ASCO, TG Therapeutics said that adding its TG-1101, or ublituximab, to AbbVie Inc. 's (NYSE: ABBV) top-selling Imbruvica resulted in an objective response rate (ORR) of 78% in patients with high-risk chronic lymphocytic leukemia. Another win At the International Conference on Malignant Lymphoma, TG Therapeutics is rolling out data showing that a three-drug combination of ublituximab with its drug TGR-1202 and the chemotherapy drug bendamustine may improve outcomes in patients with non-Hodgkin lymphoma. TG Therapeutics thinks ublituximab's market potential exceeds $200 million annually, and that its opportunity in DLBCL could be $1 billion plus. |
26136.0 | 2017-06-15 00:00:00 UTC | Hike Just Too Predictable to Move the Market | ABBV | https://www.nasdaq.com/articles/hike-just-too-predictable-move-market-2017-06-15 | nan | nan | As has been said previously, the only real shock to the market today would have been if the Fed didn't raise rates. But they did...for the third time in the last 18 months. They also shed some light on the plan to unwind their massive balance sheet. Given how expected this quarter-point rate hike was, it was almost a non-event and allowed the major indices to go their separate ways on Wednesday.
The Dow reached another new high in the session with a gain of 0.22% to 21374.6, but the S&P declined 0.10% to 2437.9. At one point, the recently-beleaguered NASDAQ had slipped by about 1%, but a late-day surge helped reduce the loss to only 0.41% to 6194.9. "Quite frankly, I'm not bothered by today's modest red arrows in some of the indices. Especially the S&P as it gave them a chance to fill in a gap that was left on the chart after yesterday's higher open,", said Kevin in Options Trader, which made two buys today (see below).
In addition to OT, there were also buys from Reitmeister Trading Alert and Momentum Trader , as the portfolios were more active today than on Tuesday. Give it all a look below:
Today's Portfolio Highlights:
Reitmeister Trading Alert: Shares of Anixter Int'l (AXE) jumped as high as $88 after the positive earnings surprise in its most recent quarterly report...but shares have since pulled back. Steve sees a "ripe buying opportunity" with this leading cable and connector supplier, so he added it to RTA on Wednesday with a 7% allocation. In addition to the value aspect, AXE is also a Zacks Rank #1 with a Zacks VGM Score of A. The editor believes this company could get up to $90-$100 if the PE cooperates. Read the complete commentary for a lot more on this new addition.
Momentum Trader: Dave has been looking to take advantage of the recent tech selloff, but didn't want to buy any chips since the portfolio already has enough exposure to the space. His solution was to pick up QIWI (QIWI) on Wednesday, which is a next gen payment provider with an integrated payment network in Russia across various channels. The editor says this stock has been "absolutely en fuego", as it breaks out to new highs on strong momentum. The full write-up has more on this new pick.
Options Trader: Biotech is a very explosive space that can be fantastically lucrative when its up and a catastrophe when its down. Kevin is betting that we're in one of those fantastic times with S&P Biotech ETF (XBI), which is in a very well defined bullish ascending triangle pattern. The editor thinks the fund is in the midst of a breakout, so he bought to open a Sept 73.00 Call in XBI.
AbbVie (ABBV) is actually a part of XBI, but Kevin thought it was a standout that deserved special attention. Therefore, he also bought to open a Nov 70.00 Call in this global research-based biopharma company. This stock is in a bullish ascending triangle pattern as well. Plus, its options are inexpensive. Get more specifics on both of these moves in the complete commentary.
Surprise Trader:"And as largely expected, the Fed raised interest rates again, putting the benchmark Fed funds rate to a range of 1%-1.25%. The Fed also put out some initially commentary regarding how it will wind down its massive balance sheet. According to Business Insider , the Fed looks to start the process with a 'roll off' of assets by not reinvesting the proceeds. They will start with $6 billion in Treasury bonds and $4 billion in MBS on a monthly basis, eventually expanding to $30 billion for Treasury bonds and $20 billion for MBS.
"The Fed remains light on the specifics when it comes to timing, and some investors are starting to question the Fed's commitment to future rate hikes. Sure, unemployment is low, but there has been no pressure at all on the inflation front and wage growth remains non-existent. We are now over 50% for the CME Fed Watch for December when it comes to bets that the Fed will stay at this level, so most aren't buying that a hike will come in the near-term. I think most will want to see some inflation first before adjusting this prediction! -- Eric Dutram
All the Best,
Jim Giaquinto Recommendations from Zacks' Private Portfolios:
Believe it or not, this article is not available on the Zacks.com website. The commentary is a partial overview of the daily activity from Zacks' private recommendation services. If you would like to follow our Buy and Sell signals in real time, we've made a special arrangement for readers of this website. Starting today you can see all the recommendations from all of Zacks' portfolios absolutely free for 7 days. Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises (which we've predicted with an astonishing 80%+ accuracy). Click here to "test drive" Zacks Ultimate for FREE >>
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (ABBV) is actually a part of XBI, but Kevin thought it was a standout that deserved special attention. Especially the S&P as it gave them a chance to fill in a gap that was left on the chart after yesterday's higher open,", said Kevin in Options Trader, which made two buys today (see below). Steve sees a "ripe buying opportunity" with this leading cable and connector supplier, so he added it to RTA on Wednesday with a 7% allocation. | AbbVie (ABBV) is actually a part of XBI, but Kevin thought it was a standout that deserved special attention. In addition to OT, there were also buys from Reitmeister Trading Alert and Momentum Trader , as the portfolios were more active today than on Tuesday. Surprise Trader:"And as largely expected, the Fed raised interest rates again, putting the benchmark Fed funds rate to a range of 1%-1.25%. | AbbVie (ABBV) is actually a part of XBI, but Kevin thought it was a standout that deserved special attention. Surprise Trader:"And as largely expected, the Fed raised interest rates again, putting the benchmark Fed funds rate to a range of 1%-1.25%. "The Fed remains light on the specifics when it comes to timing, and some investors are starting to question the Fed's commitment to future rate hikes. | AbbVie (ABBV) is actually a part of XBI, but Kevin thought it was a standout that deserved special attention. In addition to OT, there were also buys from Reitmeister Trading Alert and Momentum Trader , as the portfolios were more active today than on Tuesday. "The Fed remains light on the specifics when it comes to timing, and some investors are starting to question the Fed's commitment to future rate hikes. |
26137.0 | 2017-06-15 00:00:00 UTC | Want Market-Beating Dividends? These 2 ETFs Own Buffett Stocks | ABBV | https://www.nasdaq.com/articles/want-market-beating-dividends-these-2-etfs-own-buffett-stocks-2017-06-15 | nan | nan | Two exchange traded funds that offer market-beating dividends are in new high ground and firmly in a buy zone.
SPDR S&P Dividend ( SDY ) broke out past an 89.92 flat-base buy point June 9, but remains in buy range from the entry. It first climbed above the buy point intraday June 2, then pulled back ahead of its breakout, which occurred the following week. The three-month pattern began forming two weeks after a February breakout from a flat base. It advanced 2% between the two bases.
[ibd-display-video id=449449 width=50 float=left] The $15.8 billion fund tracks the S&P High Yield Dividend Aristocrats Index, which comprises companies that have raised their dividends for at least 20 straight years.
SDY is underperforming the broader market this year with a 6.6% return through June 14 vs. the S&P 500's 9.9% gain, according to Morningstar Inc. The ETF's five-year average annual return is 15.2%, almost in step with the S&P 500's 15.3%. But over a 10-year period, SDY has returned an average of 7.95%, slightly ahead of the S&P 500's 7.1%.
[ibdchart symbol="SDY" type="daily" size="threequarter" position="leftchart" ]The ETF's annualized dividend yield is 2.4%, ahead of the benchmark index's 1.9% payout. Top holdings in the fund include AT&T ( T ), Target ( TGT ) and AbbVie ( ABBV ). The three companies offer annualized dividend yields of 5.1%, 4.3% and 3.6%, respectively. Also making SDY's top 10 is a longtime Warren Buffett favorite, Coca-Cola ( KO ), which is paying out an annualized 3.3%.
Coca-Cola has formed a long saucer-with-handle base with a 46.16 buy point. The start of the pattern dates back to April 2016.
SDY's top three sector weightings were financial services, consumer defensive and industrials at about 16% each. Consumer cyclicals accounted for roughly 12% of assets, followed by utilities at just under 10%. SDY's net expense ratio is 0.35%.
WisdomTree LargeCap Dividend (DLN), which tracks the index of the same name, also owns Coca-Cola. It holds several other Buffett stocks such as Apple (AAPL), Johnson & Johnson (JNJ) and Procter & Gamble (PG). The underlying index is made up of large-cap stocks that are weighted by the value of the dividend the company is projected to pay the next year.
Top holding Apple has come under pressure recently. The stock has been trading below its 50-day moving average the past week, following a 4% drop June 9 amid a news report that Apple's upcoming iPhone 8 series handsets will have slower data download speeds vs. rival devices on the market. It also got hit with several analyst downgrades. Shares are still well extended from a 118.12 cup-with-handle entry cleared in January.
Apple and Coca-Cola were two of the top five holdings in Buffett's Berkshire Hathaway (BRKA) portfolio in Q1. Apple's annualized dividend yield is 1.7%. Johnson & Johnson offers a 2.5% payout, while Procter & Gamble yields 3.1%.
DLN, launched in June 2006, has attracted nearly $2 billion in assets. It has slightly underperformed the S&P 500 index with YTD, five-year and 10-year average annual returns of 7.3%, 13.65% and 6.31%, respectively. DLN's annualized yield is 2.4%. Its net expense ratio is 0.28%.
[ibdchart symbol="DLN" type="daily" size="threequarter" position="leftchart" ]Shares climbed past an 84.59 flat-base entry on June 2, but eased below the buy point in the following sessions. It broke out again on June 9 and remains slightly above the entry. The ETF gained 4% from its prior flat-base breakout in February to the start of the current pattern in March.
Consumer defensive names accounted for nearly 16% of DLN's total assets and technology, about 15%. Health care and financial services stocks made up 13% apiece, followed by industrials at 11%.
RELATED:
Apple Dives Nearly 4%, Finds Support At 50-Day Moving Average
Strategist's 3 Best Picks Include These Bond, Emerging-Market ETFs
Big Caps, Robotics Outperform; What's The Outlook For China?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top holdings in the fund include AT&T ( T ), Target ( TGT ) and AbbVie ( ABBV ). The stock has been trading below its 50-day moving average the past week, following a 4% drop June 9 amid a news report that Apple's upcoming iPhone 8 series handsets will have slower data download speeds vs. rival devices on the market. [ibdchart symbol="DLN" type="daily" size="threequarter" position="leftchart" ]Shares climbed past an 84.59 flat-base entry on June 2, but eased below the buy point in the following sessions. | Top holdings in the fund include AT&T ( T ), Target ( TGT ) and AbbVie ( ABBV ). SPDR S&P Dividend ( SDY ) broke out past an 89.92 flat-base buy point June 9, but remains in buy range from the entry. [ibdchart symbol="SDY" type="daily" size="threequarter" position="leftchart" ]The ETF's annualized dividend yield is 2.4%, ahead of the benchmark index's 1.9% payout. | Top holdings in the fund include AT&T ( T ), Target ( TGT ) and AbbVie ( ABBV ). SPDR S&P Dividend ( SDY ) broke out past an 89.92 flat-base buy point June 9, but remains in buy range from the entry. [ibdchart symbol="SDY" type="daily" size="threequarter" position="leftchart" ]The ETF's annualized dividend yield is 2.4%, ahead of the benchmark index's 1.9% payout. | Top holdings in the fund include AT&T ( T ), Target ( TGT ) and AbbVie ( ABBV ). The ETF's five-year average annual return is 15.2%, almost in step with the S&P 500's 15.3%. Apple's annualized dividend yield is 1.7%. |
26138.0 | 2017-06-09 00:00:00 UTC | PowerShares Dynamic Pharmaceuticals Portfolio Experiences Big Outflow | ABBV | https://www.nasdaq.com/articles/powershares-dynamic-pharmaceuticals-portfolio-experiences-big-outflow-2017-06-09 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the PowerShares Dynamic Pharmaceuticals Portfolio (Symbol: PJP) where we have detected an approximate $113.8 million dollar outflow -- that's a 13.5% decrease week over week (from 14,050,000 to 12,150,000). Among the largest underlying components of PJP, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.7%, Lilly (Eli) & Co (Symbol: LLY) is up about 0.7%, and Bristol-Myers Squibb Co. (Symbol: BMY) is up by about 1.2%. For a complete list of holdings, visit the PJP Holdings page » The chart below shows the one year price performance of PJP, versus its 200 day moving average:
Looking at the chart above, PJP's low point in its 52 week range is $53.55 per share, with $69.24 as the 52 week high point - that compares with a last trade of $59.89. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of PJP, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.7%, Lilly (Eli) & Co (Symbol: LLY) is up about 0.7%, and Bristol-Myers Squibb Co. (Symbol: BMY) is up by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the PowerShares Dynamic Pharmaceuticals Portfolio (Symbol: PJP) where we have detected an approximate $113.8 million dollar outflow -- that's a 13.5% decrease week over week (from 14,050,000 to 12,150,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of PJP, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.7%, Lilly (Eli) & Co (Symbol: LLY) is up about 0.7%, and Bristol-Myers Squibb Co. (Symbol: BMY) is up by about 1.2%. For a complete list of holdings, visit the PJP Holdings page » The chart below shows the one year price performance of PJP, versus its 200 day moving average: Looking at the chart above, PJP's low point in its 52 week range is $53.55 per share, with $69.24 as the 52 week high point - that compares with a last trade of $59.89. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of PJP, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.7%, Lilly (Eli) & Co (Symbol: LLY) is up about 0.7%, and Bristol-Myers Squibb Co. (Symbol: BMY) is up by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the PowerShares Dynamic Pharmaceuticals Portfolio (Symbol: PJP) where we have detected an approximate $113.8 million dollar outflow -- that's a 13.5% decrease week over week (from 14,050,000 to 12,150,000). For a complete list of holdings, visit the PJP Holdings page » The chart below shows the one year price performance of PJP, versus its 200 day moving average: Looking at the chart above, PJP's low point in its 52 week range is $53.55 per share, with $69.24 as the 52 week high point - that compares with a last trade of $59.89. | Among the largest underlying components of PJP, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.7%, Lilly (Eli) & Co (Symbol: LLY) is up about 0.7%, and Bristol-Myers Squibb Co. (Symbol: BMY) is up by about 1.2%. For a complete list of holdings, visit the PJP Holdings page » The chart below shows the one year price performance of PJP, versus its 200 day moving average: Looking at the chart above, PJP's low point in its 52 week range is $53.55 per share, with $69.24 as the 52 week high point - that compares with a last trade of $59.89. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
26139.0 | 2017-06-09 00:00:00 UTC | 3 Dividend Stock Winners | ABBV | https://www.nasdaq.com/articles/3-dividend-stock-winners-2017-06-09 | nan | nan | Nearly everybody loves a winner. From the Rocky movies to sports heroes, people cheer on winners. That's true for investing also.
With this in mind, we asked three Motley Fool contributors to pick dividend stocks that they think are winners. They chose General Motors (NYSE: GM) , Enbridge (NYSE: ENB) , and AbbVie (NYSE: ABBV) . Here's why these are three dividend stock winners that could make you a winner over the long run also.
A lot to like
Tim Green (General Motors) : Shares of GM haven't done much over the past few years, other than fluctuate around the same level. This has frustrated some investors, most notably hedge fund manager David Einhorn, who has been pushing a convoluted dual-class stock proposal to unlock value. Shareholders easily shot that idea down , deciding that financial engineering wasn't the answer.
GM stock may not be a winner at the moment, but the company certainly is. Adjusted earnings per share jumped 22% in 2016, and GM expects to maintain or even grow earnings this year despite stagnating U.S. auto sales. GM has also exited some less profitable international markets , including India and Europe. While the company is giving up sales, the bottom line should benefit.
GM's dividend currently yields 4.4%, the result of a beaten-down stock price. The payout ratio, based on 2016 adjusted earnings, is just 25%. Earnings could fall if demand in the U.S. declines significantly in the coming years, so GM is playing it safe and making sure the likelihood of a dividend cut down the road is close to nil. With the stock trading for less than 6 times earnings, share buybacks are a better use of cash anyways.
GM stock may not reflect its true value until the company proves that it can thrive during periods of weaker demand. For dividend investors, getting paid 4.4% to hold a value stock that has the potential to be a big winner over the next few years seems like a good deal to me.
An illustrious past and an even brighter future
Matt DiLallo (Enbridge) : North American energy infrastructure giant Enbridge has been an excellent stock for dividend investors over the years. The company has paid a dividend for 64 straight years, including increasing the payout for the last 22. Further, over the last two decades, it has grown the payout by a remarkable 11.2% compound annual rate. That growth has created meaningful value for investors, evidenced by the fact that Enbridge has generated an 18% compound annual total return over the past decade, outperforming the market and its peers by a wide margin.
That said, the company's best dividend growth days might still be ahead of it . That's because the company expects to increase the payout by 15% this year and 10% to 12% annually from 2018 through 2024. Backing that outlook is the fact that Enbridge has the largest backlog of growth capital projects in the energy infrastructure sector.
Further supporting the company's forecast is its conservative financial profile. The foundation of which is its predictable cash flow since 96% comes from fee-based and regulated assets. The next support of its strong financial foundation is its investment-grade balance sheet. While the company's leverage ratio was elevated last year at 6.2 times debt-to-EBITDA, that was due to a slew of growth projects it currently has under construction. As those projects enter service and start generating cash flow, leverage should drop to a much more comfortable 4.3 times by 2019, which is well below its 5.0 times target. The final piece of its conservative financial plan is the fact the company expects to achieve its peer-leading dividend growth while maintaining a conservative payout ratio of 50% to 60% of cash flow.
With a visible growth forecast backed by rock-solid financials, Enbridge appears poised to continue its winning ways for income investors.
A dividend stock that has it all
Keith Speights (AbbVie) : The best winning dividend stocks have it all. They, of course, pay great dividends. They consistently generate solid gains for shareholders. And they somehow manage to remain attractively priced. AbbVie is definitely a dividend stock that has it all.
This big biotech pays a dividend that currently yields 3.81%. AbbVie has increased its dividend 60% since being spun off in 2013 from its parent, Abbott Laboratories . It's also a Dividend Aristocrat , including the time that it was part of Abbott, with annual dividend increases for 45 consecutive years. With AbbVie using only 61% of its earnings to fund dividend payouts, the company appears to be in good position to keep the dividend hikes coming.
AbbVie's stock price has nearly doubled in the last five years. That's something many dividend stocks can't claim. The company also should be poised for solid growth in the future. AbbVie's pipeline is loaded with promising candidates, including experimental autoimmune drugs ABT-494 and risankizumab and cancer drugs veliparib and Rova-T. Wall Street analysts think that the biotech's new drugs combined with its current product lineup could help deliver annual earnings growth of more than 14%.
Despite having a strong dividend and great growth prospects, AbbVie's shares trade at only 10 times expected earnings. The stock's valuation appears even more attractive considering the company's growth prospects. Probably the biggest risk for AbbVie is that its top-selling drug Humira could come under pressure from biosimilars. However, AbbVie thinks it can hold off U.S. competitors until 2022, which should allow it to roll out some of its potential winners currently in the pipeline.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
Keith Speights owns shares of AbbVie. Matt DiLallo has no position in any stocks mentioned. Timothy Green owns shares of General Motors. The Motley Fool owns shares of and recommends Enbridge. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | They chose General Motors (NYSE: GM) , Enbridge (NYSE: ENB) , and AbbVie (NYSE: ABBV) . A dividend stock that has it all Keith Speights (AbbVie) : The best winning dividend stocks have it all. AbbVie is definitely a dividend stock that has it all. | They chose General Motors (NYSE: GM) , Enbridge (NYSE: ENB) , and AbbVie (NYSE: ABBV) . Despite having a strong dividend and great growth prospects, AbbVie's shares trade at only 10 times expected earnings. *Stock Advisor returns as of June 5, 2017 Keith Speights owns shares of AbbVie. | A dividend stock that has it all Keith Speights (AbbVie) : The best winning dividend stocks have it all. With AbbVie using only 61% of its earnings to fund dividend payouts, the company appears to be in good position to keep the dividend hikes coming. They chose General Motors (NYSE: GM) , Enbridge (NYSE: ENB) , and AbbVie (NYSE: ABBV) . | A dividend stock that has it all Keith Speights (AbbVie) : The best winning dividend stocks have it all. AbbVie is definitely a dividend stock that has it all. Despite having a strong dividend and great growth prospects, AbbVie's shares trade at only 10 times expected earnings. |
26140.0 | 2017-06-09 00:00:00 UTC | 7 Reasons Why Prescription Drug Prices Are Extremely Expensive | ABBV | https://www.nasdaq.com/articles/7-reasons-why-prescription-drug-prices-are-extremely-expensive-2017-06-09 | nan | nan | Spending on prescription drugs increased by 3.8% in 2016, according to pharmacy benefit manager Express Scripts . While that's slower growth than the 5.2% year-over-year increase experienced in 2015, spending is still headed in the wrong direction. Using data from 2014, America's Health Insurance Plans (AHIP) -- the trade group for health insurers -- estimates that over 22% of health insurance premium goes to paying for prescription drugs.
Here are seven reasons why prescription drugs are so expensive.
1. High research and development costs
Researching drugs isn't cheap, but it's the development costs once a drug candidate is discovered that really rack up the bills. The Food and Drug Administration generally requires companies to run at least one phase 1 and phase 2 trial, and then requires at least two independent phase 3 trials (except in cases where the drug treats a disease with a high unmet need).
For many diseases where drugs are making modest improvements, companies have to run many large phase 3 trials to demonstrate efficacy and safety in different types of patients. For example, AbbVie 's (NYSE: ABBV) phase 3 program for its rheumatoid arthritis drug upadacitinib is testing the drug in more than 4,000 patients.
Equally important, the drugs that work have to indirectly pay for all the drug candidates that fail to show an effect or have side effects that keep them from being approvable. Companies will only invest in development if they know the potential rewards justify the sunk costs if the drug fails.
2. Marketing
Unlike most countries, the U.S. allows drugmakers to market directly to consumers. Nielsen estimates that drugmakers spent a whopping $5.6 billion hawking their drugs to patients in 2016, a 9% increase over the previous year. Pfizer (NYSE: PFE) was the biggest spender, shelling out $1.19 billion. Bristol-Myers Squibb (NYSE: BMY) , AbbVie (NYSE: ABBV) , and Eli Lilly (NYSE: LLY) rounded out the top four with spending of $458 million, $433 million, and $414 million, respectively.
Those marketing costs are recouped by -- you guessed it -- higher drug prices.
The marketing also results in increased use of the drugs, which can allow companies to increase prices through the standard economic principle of supply and demand.
3. Exclusivity
Generic drugs can reduce drug costs dramatically through increased competition, but most drugs gain regulatory approval with a decade or more left on their patents. And companies can extend their exclusivity by an additional six months for running clinical trials to see if their drugs work on children.
Once patents expire, the speed at which the FDA approves generic competitors greatly affects the price. An FDA study found that when a drug has three generic manufacturers, the average price was 44% of the branded drug price, but that drops to 23% when there are seven manufacturers and all the way down to 6% of the branded price if there are 19 generic manufacturers.
Exclusivity can also be broken when other branded drugs are approved with essentially the same efficacy and safety profiles. We've seen this recently with insulin and hepatitis C drugs, where insurers have been able to demand lower prices for them to stay on the insurers' lists of preferred drugs.
5. Small markets
Drugmakers try to earn a certain amount of revenue from each drug. For mass-market drugs, such as statins that lower cholesterol, companies can offer reasonable prices and make up for it with volume. Conversely, when drugmakers develop drugs that treat orphan diseases that affect a relatively small number of Americans, they have to charge more to generate the same revenue from the drug.
BioMarin Pharmaceuticals (NASDAQ: BMRN) , for example, priced its recently approved drug Brineura, which treats Batten disease, an ultra-rare pediatric brain disorder, at $702,000 per year. BioMarin estimates that about 20 infants are born with the disease each year.
Because a small number of patients are affected, insurers can afford to pay the high price, which is ultimately shared by all the insured members. And government programs, such as Medicaid, typically get substantial discounts off the list price. In the case of BioMarin's Brineura, the price drops to a-still-quite-staggering $486,000 per year.
6. Insurance companies accept it
Insurers try to negotiate lower costs to reduce member premiums as they compete with each other, but unless an insurer wants to refuse to cover a drug, it has limited negotiating power. When there aren't equivalent drugs on the market, drugmakers can offer a price and say: take it or leave it.
And the price of prescription drugs doesn't actually matter for health insurance companies' profits since they're really just middlemen that are agnostic to the price. They add up all the expected costs for their members, tack on a little for profit, and divide the cost by the members to get the premium they charge. The high price of drugs is just passed on to members.
7. We're subsidizing other parts of the world
Other countries have lower costs for prescription drugs because their governments institute price controls or because they have single-payer systems that refuse to pay for medications that they believe aren't worth the costs. For the most part, drugmakers are still willing to sell their drugs in those countries at the lower costs because some revenue is better than no revenue at all.
But imagine an alternative universe where patients in every country paid the same amount for any given drug; U.S. patients could pay less, others could pay more, and drugmakers would generate the same revenue. Since decisions about whether to develop a drug or not are based on expected revenue, the same drugs would be developed in this alternate universe with the rest of the world picking up their fair share.
10 stocks we like better than Wal-Mart
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Wal-Mart wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
The author(s) may have a position in any stocks mentioned.
Brian Orelli has no position in any stocks mentioned. The Motley Fool owns shares of Express Scripts. The Motley Fool recommends BioMarin Pharmaceutical. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For example, AbbVie 's (NYSE: ABBV) phase 3 program for its rheumatoid arthritis drug upadacitinib is testing the drug in more than 4,000 patients. Bristol-Myers Squibb (NYSE: BMY) , AbbVie (NYSE: ABBV) , and Eli Lilly (NYSE: LLY) rounded out the top four with spending of $458 million, $433 million, and $414 million, respectively. For many diseases where drugs are making modest improvements, companies have to run many large phase 3 trials to demonstrate efficacy and safety in different types of patients. | For example, AbbVie 's (NYSE: ABBV) phase 3 program for its rheumatoid arthritis drug upadacitinib is testing the drug in more than 4,000 patients. Bristol-Myers Squibb (NYSE: BMY) , AbbVie (NYSE: ABBV) , and Eli Lilly (NYSE: LLY) rounded out the top four with spending of $458 million, $433 million, and $414 million, respectively. High research and development costs Researching drugs isn't cheap, but it's the development costs once a drug candidate is discovered that really rack up the bills. | For example, AbbVie 's (NYSE: ABBV) phase 3 program for its rheumatoid arthritis drug upadacitinib is testing the drug in more than 4,000 patients. Bristol-Myers Squibb (NYSE: BMY) , AbbVie (NYSE: ABBV) , and Eli Lilly (NYSE: LLY) rounded out the top four with spending of $458 million, $433 million, and $414 million, respectively. Exclusivity Generic drugs can reduce drug costs dramatically through increased competition, but most drugs gain regulatory approval with a decade or more left on their patents. | For example, AbbVie 's (NYSE: ABBV) phase 3 program for its rheumatoid arthritis drug upadacitinib is testing the drug in more than 4,000 patients. Bristol-Myers Squibb (NYSE: BMY) , AbbVie (NYSE: ABBV) , and Eli Lilly (NYSE: LLY) rounded out the top four with spending of $458 million, $433 million, and $414 million, respectively. For many diseases where drugs are making modest improvements, companies have to run many large phase 3 trials to demonstrate efficacy and safety in different types of patients. |
26141.0 | 2017-06-08 00:00:00 UTC | AbbVie (ABBV) Announced Positive Phase III RA Candidate Data | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-announced-positive-phase-iii-ra-candidate-data-2017-06-08 | nan | nan | AbbVie Inc.ABBV announced positive top-line results from a phase III study on rheumatoid arthritis candidate, upadacitinib (ABT-494). Upadacitinib is an investigational oral JAK1-selective inhibitor being studied as a once-a-day oral therapy.
AbbVie's shares have rallied 13.2% in the past one year, outperforming the Zacks classified Large Cap Pharmaceuticals industry's 1.7% rise.
The study met its primary endpoint and all secondary endpoints with highly statistically significant and clinically meaningful results for both the doses compared to placebo.
The results showed that 64% of patients, receiving 15 mg and 66% of patients, administered 30 mg dose once daily, achieved ACR20 responses after 12 weeks of treatment compared to 36% of patients receiving placebo. Low disease activity was achieved by 48% of the patients receiving either dose of upadacitinib compared to 17% for placebo.
Upadacitinib is also being investigated in a pivotal study for psoriatic arthritis. Other studies are also ongoing for the treatment of Crohn's disease, ulcerative colitis and atopic dermatitis.
AbbVie's flagship RA drug Humira brought in sales of $4.1 billion. However, the RA market is extremely crowded including drugs like Johnson & Johnson's Simponi and UCB's Cimzia among others.
We note that upadacitinib is a JAK1 inhibitor as second-line treatment for RA patients where drugs like Humira have inadequate response. However, Eli Lilly and Company's LLY JAK inhibitor, Olumiant was recently approved in the EU and Pfizer Inc.'s PFE Xeljanz is marketed in the U.S. for treating RA by inhibiting JAK enzyme.
Meanwhile, Amgen Inc. AMGN has already received approval to market a Humira biosimilar but the drug has not been launched due to ongoing litigation. If upadacitinib is approved, it may reduce the potential negative impact of Humira generics on the company's top line.
AbbVie Inc. Price
AbbVie Inc. Price | AbbVie Inc. Quote
Zacks Rank
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here .
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer, Inc. (PFE): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie's shares have rallied 13.2% in the past one year, outperforming the Zacks classified Large Cap Pharmaceuticals industry's 1.7% rise. AbbVie Inc.ABBV announced positive top-line results from a phase III study on rheumatoid arthritis candidate, upadacitinib (ABT-494). AbbVie's flagship RA drug Humira brought in sales of $4.1 billion. | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV announced positive top-line results from a phase III study on rheumatoid arthritis candidate, upadacitinib (ABT-494). | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV announced positive top-line results from a phase III study on rheumatoid arthritis candidate, upadacitinib (ABT-494). | AbbVie's flagship RA drug Humira brought in sales of $4.1 billion. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). AbbVie Inc.ABBV announced positive top-line results from a phase III study on rheumatoid arthritis candidate, upadacitinib (ABT-494). |
26142.0 | 2017-06-08 00:00:00 UTC | The Best Hep C Drug Stock to Buy in 2017 | ABBV | https://www.nasdaq.com/articles/best-hep-c-drug-stock-buy-2017-2017-06-08 | nan | nan | These days, investing in hepatitis C drug stocks is challenging since sales of drugs that treat the infection are expected to decrease dramatically. Gilead Sciences, for instance, sold $14.8 billion worth of hepatitis C drugs in 2016, but management forecasts sales will drop to between $7.5 billion and $9 billion in 2017. Differentiating value stocks from value traps in this kind of environment is difficult, and investors' best move is likely to look at the different characteristics of the companies when deciding which hepatitis C drug stock to buy.
Data sources: Company websites.
Best opportunity to buy growth
Gilead Sciences wins this category hands down with $34 billion in the bank at the end of the first quarter. While the big biotech's revenue takes a major blow from lower hepatitis C sales due to fewer patients starting medication and lower prices as competition increases, Gilead has an opportunity to buy growth through a large acquisition.
When an acquisition will occur is anyone's guess , but its nest egg keeps getting larger as its hepatitis C franchise continues to throw off a ton of free cash.
Best opportunity outside of hepatitis C
Merck fits the bill here with its cancer drug Keytruda. Sales of the drug, which spurs the immune system to attack cancer cells, jumped to $584 million in the first quarter, up 134% year over year.
And there's plenty of additional sales growth ahead with recent U.S. approvals to market the drug as a treatment for Hodgkin lymphoma, non-small cell lung cancer, and urothelial carcinoma. Last month, Merck secured a first-of-its-kind approval to treat patients with tumors with specific genetic mutations regardless of which tissue the tumor originated from. In the EU, Keytruda was recently approved to treat non-small cell lung cancer and for Hodgkin lymphoma.
Best opportunity to capture more market share
AbbVie has had a hard time competing with Gilead's franchise, especially in the U.S., where sales of Viekira amounted to just $38 million in the first quarter. The company doesn't even bother breaking out sales of its other two hepatitis C drugs.
Fortunately the pharma has a new medication -- a combination of glecaprevir and pibrentasvir -- that's under review by regulators in the U.S. and EU. Unlike Viekira, AbbVie has data for glecaprevir/pibrentasvir in all six of the major hepatitis C genotypes, many of which can be cured with just eight weeks of treatment, making it easier to compete against Gilead.
AbbVie is shooting for launching glecaprevir/pibrentasvir this year, assuming it's approved by the FDA, so it won't be long before investors know how much additional market share AbbVie can take.
Best play on a hepatitis C sales rebound (or maybe even a stabilization)
Unlike the other drugmakers, Enanta Pharmaceuticals derives all of its revenue from hepatitis C drugs, specifically from royalties on AbbVie's drugs through its contribution of paritaprevir, which is a component of Viekira, Technivie, and Viekirax. A turnaround in the hepatitis C market would have a major effect on Enanta's revenue.
Even a stabilization of the market could be a major boost to Enanta since the company helped develop the glecaprevir half of AbbVie's aforementioned regimen that's under regulatory review. Because glecaprevir makes up half of the new regimen, Enanta's deal with Abbvie calls for a double-digit royalty on 50% of net sales of the new medication, compared to 30% of net sales of Viekira.
Best overall winner
While each of these hepatitis C drugmakers has opportunities, Merck looks like the best investment because of its clear ability to benefit from Keytruda sales growth in addition to a potential opportunity in the hepatitis C market.
10 stocks we like better than Merck & Co.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now...and Merck & Co. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017.
Brian Orelli has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has the following options: short June 2017 $70 calls on Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Best opportunity to capture more market share AbbVie has had a hard time competing with Gilead's franchise, especially in the U.S., where sales of Viekira amounted to just $38 million in the first quarter. Even a stabilization of the market could be a major boost to Enanta since the company helped develop the glecaprevir half of AbbVie's aforementioned regimen that's under regulatory review. Unlike Viekira, AbbVie has data for glecaprevir/pibrentasvir in all six of the major hepatitis C genotypes, many of which can be cured with just eight weeks of treatment, making it easier to compete against Gilead. | Because glecaprevir makes up half of the new regimen, Enanta's deal with Abbvie calls for a double-digit royalty on 50% of net sales of the new medication, compared to 30% of net sales of Viekira. Best opportunity to capture more market share AbbVie has had a hard time competing with Gilead's franchise, especially in the U.S., where sales of Viekira amounted to just $38 million in the first quarter. Unlike Viekira, AbbVie has data for glecaprevir/pibrentasvir in all six of the major hepatitis C genotypes, many of which can be cured with just eight weeks of treatment, making it easier to compete against Gilead. | Best play on a hepatitis C sales rebound (or maybe even a stabilization) Unlike the other drugmakers, Enanta Pharmaceuticals derives all of its revenue from hepatitis C drugs, specifically from royalties on AbbVie's drugs through its contribution of paritaprevir, which is a component of Viekira, Technivie, and Viekirax. Best opportunity to capture more market share AbbVie has had a hard time competing with Gilead's franchise, especially in the U.S., where sales of Viekira amounted to just $38 million in the first quarter. Unlike Viekira, AbbVie has data for glecaprevir/pibrentasvir in all six of the major hepatitis C genotypes, many of which can be cured with just eight weeks of treatment, making it easier to compete against Gilead. | Best opportunity to capture more market share AbbVie has had a hard time competing with Gilead's franchise, especially in the U.S., where sales of Viekira amounted to just $38 million in the first quarter. Unlike Viekira, AbbVie has data for glecaprevir/pibrentasvir in all six of the major hepatitis C genotypes, many of which can be cured with just eight weeks of treatment, making it easier to compete against Gilead. AbbVie is shooting for launching glecaprevir/pibrentasvir this year, assuming it's approved by the FDA, so it won't be long before investors know how much additional market share AbbVie can take. |
26143.0 | 2017-06-07 00:00:00 UTC | 3 Cheap Stocks You Can Buy Today | ABBV | https://www.nasdaq.com/articles/3-cheap-stocks-you-can-buy-today-2017-06-07 | nan | nan | With market indexes hitting all-time highs, some investors might be worried that stock valuations have become too frothy. But while it's true that many stocks are priced expensively right now, there are still some bargains to be found.
AbbVie (NYSE: ABBV) , Cisco Systems (NASDAQ: CSCO) , and Citigroup (NYSE: C) are three stocks that especially look cheap. All three also claim solid businesses with good growth prospects. Here's why AbbVie, Cisco, and Citigroup are cheap stocks you can buy today.
AbbVie
AbbVie stock trades at a little over 10 times expected earnings. That would be an attractive valuation even if the biotech didn't have solid sources for future growth. But AbbVie does have plenty of growth drivers. So why is the stock so cheap right now?
The biggest issue relates to fears over the possibility that the company's top-selling drug Humira could face competition from biosimilars . However, AbbVie thinks it can fend off U.S. competition until 2022 by defending its intellectual property rights to the drug. That doesn't seem overly optimistic, considering that the company has 61 patents for Humira and the first court date doesn't happen until November 2019.
In the meantime, Humira keeps on generating billions of dollars in revenue and sales continue to grow. AbbVie's fastest-growing current product, though, is Imbruvica. Sales for the cancer drug soared nearly 45% year over year in the first quarter of 2017.
AbbVie's pipeline includes several strong candidates as well. The company could launch two new products next year with blockbuster potential -- endometriosis drug elagolix and cancer drug Rova-T. Two prospective successors to Humira, ABT-494 and risankizumab, could hit the market in 2019 if all goes well in clinical studies. On top of its solid growth potential, AbbVie rewards investors with a nice dividend, which currently yields 3.81%.
Cisco Systems
Cisco Systems stock trades at less than 13 times expected earnings. The technology giant took a beating in May after providing disappointing guidance for its fiscal fourth-quarter revenue . Should this weak outlook scare investors away? I don't think so. Instead, Cisco now looks like an even better bargain than before.
The company gave three key reasons for expecting lower revenue in the fourth quarter. Up to half of the revenue decline will come from Cisco transitioning to a subscription model. While this move will produce short-term pain, it should provide long-term gain with higher recurring revenue. The other two reasons for the lower revenue -- weak orders from service providers and in emerging markets and weakness in the public-sector market -- should only be temporary issues.
Over the longer term, Cisco should be in position to perform relatively well. Over the past five years, the company grew earnings by an average annual rate of a little over 5%. During that same period, Cisco stock nearly doubled. Wall Street analysts project the company will grow earnings by more than 10% over the next five years.
Even if Cisco doesn't quite hit that level of earnings growth, investors should still profit handsomely from owning the stock. Cisco's dividend yield currently stands at 3.63%. The company appears to be in great shape to keep increasing its dividend in the future.
Citigroup
Citigroup stock trades at just over 10 times expected earnings and below the book value of the company. After a big drop in its share price in early 2016, the global financial-services firm has rebounded nicely. So why is Citigroup still so inexpensive?
The company has seen lower mortgage revenue in the U.S. Citigroup derives a significant chunk of its total revenue from Europe. Uncertainty in Europe, especially the U.K. withdrawal from the European Union, isn't good for the company. However, these aren't enough to outweigh the positives for Citigroup, in my view.
While higher interest rates in the U.S. could cause mortgage applications to fall, Citigroup should be helped by higher earnings resulting from increased rates. Analysts think Citigroup's future over the next five years looks reasonably good, with a consensus projection of earnings growth of 9.5%.
Unfortunately for investors, Citigroup's dividend isn't as attractive as AbbVie's or Cisco's. Citigroup's dividend currently yields only 1.05%. However, the company's dividend has improved a lot since the financial crisis of 2008 and 2009. Citigroup appears to be in good shape for future dividend hikes.
10 stocks we like better than Citigroup
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Citigroup wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
Keith Speights owns shares of AbbVie. The Motley Fool recommends Cisco Systems. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) , Cisco Systems (NASDAQ: CSCO) , and Citigroup (NYSE: C) are three stocks that especially look cheap. Here's why AbbVie, Cisco, and Citigroup are cheap stocks you can buy today. AbbVie AbbVie stock trades at a little over 10 times expected earnings. | On top of its solid growth potential, AbbVie rewards investors with a nice dividend, which currently yields 3.81%. AbbVie (NYSE: ABBV) , Cisco Systems (NASDAQ: CSCO) , and Citigroup (NYSE: C) are three stocks that especially look cheap. Here's why AbbVie, Cisco, and Citigroup are cheap stocks you can buy today. | AbbVie (NYSE: ABBV) , Cisco Systems (NASDAQ: CSCO) , and Citigroup (NYSE: C) are three stocks that especially look cheap. Unfortunately for investors, Citigroup's dividend isn't as attractive as AbbVie's or Cisco's. Here's why AbbVie, Cisco, and Citigroup are cheap stocks you can buy today. | AbbVie AbbVie stock trades at a little over 10 times expected earnings. Unfortunately for investors, Citigroup's dividend isn't as attractive as AbbVie's or Cisco's. AbbVie (NYSE: ABBV) , Cisco Systems (NASDAQ: CSCO) , and Citigroup (NYSE: C) are three stocks that especially look cheap. |
26144.0 | 2017-06-06 00:00:00 UTC | Want Market-Beating Dividends? These 2 ETFs Own Buffett Stocks | ABBV | https://www.nasdaq.com/articles/want-market-beating-dividends-these-2-etfs-own-buffett-stocks-2017-06-06 | nan | nan | Two exchange traded funds that offer market-beating dividends are in new high ground and hovering near their buy points.
SPDR S&P Dividend ( SDY ) climbed past a 90.02 flat-base buy point intraday Friday, before settling just below the entry. On Monday, it closed fractionally lower. The current three-month pattern began forming two weeks after a February breakout from a flat base. It advanced 2% between the two bases.
[ibd-display-video id=449449 width=50 float=left] The $15.6 billion fund tracks the S&P High Yield Dividend Aristocrats Index, which comprises companies that have raised their dividends for at least 20 consecutive years.
SDY is underperforming the broader market this year with a 5.5% return through June 2 vs. the S&P 500's 9.9% gain, according to Morningstar Inc. The ETF's five-year average annual return is 15.8%, closer to the S&P 500's 16.3%. But over a 10-year period, SDY has returned an average of 7.6%, just ahead of the S&P 500's 7%.
[ibdchart symbol="SDY" type="daily" size="threequarter" position="leftchart" ]The ETF's annualized dividend yield is 2.5%, ahead of the benchmark index's 1.9% payout. Top holdings in the fund include AT&T ( T ), Target ( TGT ) and AbbVie ( ABBV ). The three companies offer annualized dividend yields of 5%, 4.3% and 3.8% respectively. Also making SDY's top 10 is a longtime Warren Buffett favorite, Coca-Cola ( KO ), which is paying out an annualized 3.2% of its Friday stock price.
WisdomTree LargeCap Dividend (DLN), which tracks the index of the same name, also owns Coca-Cola. It holds several other Buffett stocks such as Apple (AAPL), Johnson & Johnson (JNJ) and Procter & Gamble (PG). The underlying index is made up of large-cap stocks that are weighted by the value of the dividend the company is projected to pay the next year.
The fund, launched in June 2006, has attracted $1.95 billion in assets. It's slightly underperformed the S&P 500 index with YTD, five-year and 10-year average annual returns of 6.9%, 14.5% and 6.15%, respectively. DLN's annualized yield is 2.4%.
[ibdchart symbol="DLN" type="daily" size="threequarter" position="leftchart" ]Shares cleared an 84.59 flat-base entry on Friday and closed Monday a penny below the buy point. The ETF gained 4% from its prior flat-base breakout in February to the start of the current pattern in March.
Checking in on Monday's ETF picks, the four India-focused funds closed largely unchanged to remain in buy range from recent rebounds off their respective 50-day lines. They are: iShares MSCI India (INDA), PowerShares India Portfolio (PIN), VanEck Vectors India Small-Cap (SCIF) and WisdomTree India Earnings Fund (EPI).
RELATED:
These 4 Plays Offer Chances To Ride India's Stock Market Rally
Miss Thursday's Breakouts? 2 Fresh Ideas As Market Hits Highs
2 ETFs On Breakout Watch Hold Buffett Dividend Stocks
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top holdings in the fund include AT&T ( T ), Target ( TGT ) and AbbVie ( ABBV ). Also making SDY's top 10 is a longtime Warren Buffett favorite, Coca-Cola ( KO ), which is paying out an annualized 3.2% of its Friday stock price. [ibdchart symbol="DLN" type="daily" size="threequarter" position="leftchart" ]Shares cleared an 84.59 flat-base entry on Friday and closed Monday a penny below the buy point. | Top holdings in the fund include AT&T ( T ), Target ( TGT ) and AbbVie ( ABBV ). [ibdchart symbol="SDY" type="daily" size="threequarter" position="leftchart" ]The ETF's annualized dividend yield is 2.5%, ahead of the benchmark index's 1.9% payout. [ibdchart symbol="DLN" type="daily" size="threequarter" position="leftchart" ]Shares cleared an 84.59 flat-base entry on Friday and closed Monday a penny below the buy point. | Top holdings in the fund include AT&T ( T ), Target ( TGT ) and AbbVie ( ABBV ). [ibd-display-video id=449449 width=50 float=left] The $15.6 billion fund tracks the S&P High Yield Dividend Aristocrats Index, which comprises companies that have raised their dividends for at least 20 consecutive years. [ibdchart symbol="SDY" type="daily" size="threequarter" position="leftchart" ]The ETF's annualized dividend yield is 2.5%, ahead of the benchmark index's 1.9% payout. | Top holdings in the fund include AT&T ( T ), Target ( TGT ) and AbbVie ( ABBV ). [ibd-display-video id=449449 width=50 float=left] The $15.6 billion fund tracks the S&P High Yield Dividend Aristocrats Index, which comprises companies that have raised their dividends for at least 20 consecutive years. [ibdchart symbol="DLN" type="daily" size="threequarter" position="leftchart" ]Shares cleared an 84.59 flat-base entry on Friday and closed Monday a penny below the buy point. |
26145.0 | 2017-06-02 00:00:00 UTC | 3 Dividend Aristocrats That Deserve the Title … and 2 Pretenders | ABBV | https://www.nasdaq.com/articles/3-dividend-aristocrats-that-deserve-the-title-...-and-2-pretenders-2017-06-02 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Investors looking for the surest path to dividend growth typically look to the S&P 500 Dividend Aristocrats. These are the supposedly "elite" dividend stocks within the S&P 500 that have not just paid but hiked their regular distributions at least once a year for a minimum of 25 consecutive years.
It's not a crowded clubhouse, with just 52 members at the moment, but don't be fooled - just like most groups of stocks, there are winners and losers, like the group of five Dividend Aristocrats I'll be breaking down for you today.
You'd think that decades of dividend growth would be a sure indication of stock quality, and thus outperformance. And if you look at the performance of the S&P 500 Dividend Aristocrats Index since inception in May 2005, you'd be right - from inception through 2016, it outperformed by about 200% to 125%.
Not bad at all.
However, over the past three years, the ProShares S&P 500 Dividend Aristocrats ETF (BATS: NOBL ) is barely outdoing the S&P 500, and is actually underperforming some broad dividend funds such as the iShares Select Dividend ETF (NYSEARCA: DVY ).
The Dividend Aristocrats Look Awfully Pedestrian
What gives?
It could just be a period of relative weakness for the NOBL. But it's also the same thing that plagues many other simple index funds - the losers hold back the winners.
I like a few Dividend Aristocrats because, after all, dividend growth is one of the most important elements of any retirement portfolio . But a few Aristocrats give the index a bad name, and should be explicitly avoided.
The Top 10 S&P 500 Dividend Stocks to Buy Now
Today, we'll discuss three Dividend Aristocrats that are the real deal, and two that are just pretenders to the throne.
Johnson & Johnson (JNJ)
Dividend Yield: 2.7%
How many times have you heard someone say that Johnson & Johnson (NYSE: JNJ ) is dead money? Because it happens all the time.
Sometimes it's amid certain disaster, such as in 1982 after several people died from taking potassium cyanide-laced Tylenol, or even last year as the company was forced to pay out nearly $200 million in lawsuits over deaths related to its baby powder and talc products.
And yet the 131-year-old company's stock sits near all-time highs.
JNJ is consistently buoyed by its large consumer products brands such as Band-Aid, Neutrogena and Acuvue, as well as its deep roster of pharmaceuticals products such as blood thinner Xarelto, blood cancer drug Imbruvica and multiple myeloma treatment Darzalex.
Johnson & Johnson just hiked its dividend another 5%, yet its payout is less than half next year's projected earnings. Those profit forecasts, by the way, are for an 8% jump to $7.67 in 2018 - on decent 5% top-line growth, no less. If you are going to buy JNJ, I would merely recommend doing so on a dip to squeeze out a bit more yield.
Old Johnson & Johnson (JNJ) Still Has Some Bite
VF Corp (VFC)
Dividend Yield: 3.1%
We've recently discussed how retail is taking it on the chin , and VF Corp (NYSE: VFC) isn't immune.
You probably don't know the VF Corp name, but you surely know its various brands that include Timberland, The North Face, Lee and Wrangler jeans, Nautica, Jansport and Vans.
Now, VF Corp is trying to build out its direct-to-consumer business, which makes up just less than a third of the company's revenues right now. That's important to the company's long-term survival … because the brick-and-mortar businesses that help peddle VF Corp's wares, such as J C Penney Company Inc (NYSE: JCP ), Macy's Inc (NYSE: M ) and Sears Holdings Corp (NASDAQ: SHLD ) are getting crushed.
As a result, VFC shares are off about 30% in the past couple years while the top and bottom lines have plateaued. This year, earnings and revenues alike are actually expected to contract.
Despite this, VFC trades at 17 times earnings and at a PEG of 2 (where anything over 1 is considered overbought).
7 Top Dividend Stocks to Buy for Every Kind of Investor
Retail is home to a few battered bargains, but VFC isn't one of them.
VF Corp (VFC) Is Singin' the Retail Blues
Consolidated Edison, Inc. (ED)
Dividend Yield: 3.3%
Slow and steady wins the race - as long-term Consolidated Edison, Inc. (NYSE: ED ) investors are happy to attest.
When it comes to utility investing, you know what to expect - stable revenues, slow but consistent profit growth and dividends that steadily melt higher.
That's what you get out of Consolidated Edison.
New York City continues to swell, reaching over 8.5 million people this year, and that means more clients for ConEd to serve. Profits hit new heights last year, which in turn has propelled the stock to fresh all-time highs. And analysts expect the utility to keep oozing out more growth this year and next.
Edison ticked the dividend another 3% higher earlier this year, and they can expect much of the same going forward. It's not exciting, but that's OK. We like our utilities to be boring.
Consolidated Edison (ED): Sweet, Boring Profits
The Coca-Cola Co (KO)
Dividend Yield: 3.3%
The Coca-Cola Co (NYSE: KO ) was once a can't-miss investment not just for its income and dividend hikes, but for its outsize growth. Coca-Cola and Diet Coke were a 1-2 punch that PepsiCo, Inc. (NYSE: PEP ) couldn't unseat, but the company kept expanding thanks to older acquisitions such as Minute Maid juices back in the '60s, as well as relatively newer offerings such as Dasani water and Powerade sports drinks.
Those days are long gone.
Coca-Cola recently suffered its eighth consecutive quarter of revenue declines as sugary drink consumption continues to circle the drain. The company's woes have cost CEO Muhtar Kent his job, too, with prior COO James Quincey taking the reins beginning in May.
KO also announced earlier this year that it would be laying off 1,200 people to save $800 million - in addition to the $3 billion in cost cuts the company was already seeking out.
10 Dividend Aristocrats That Are Ready to Rally
The only thing growing at Coca-Cola is its dividend, and that's by modest mid-single digits. KO isn't dead by a long shot, but it won't quench your thirst for total returns.
Coca-Cola (KO) Is Running Out of Caffeine
AbbVie Inc (ABBV)
Dividend Yield: 3.9%
Last but certainly not least is AbbVie Inc (NYSE: ABBV ), the pharmaceutical arm of the Abbott Laboratories (NYSE: ABT ) business that was spun off back in 2013.
AbbVie currently is home to a number of big-name drugs, such as arthritis/Crohn's disease/psoriasis treatment Humira, testosterone replacement therapy treatment AndroGel and the aforementioned Imbruvica, which was formed in a partnership between JNJ and Pharmacyclics, which AbbVie bought up in 2015.
These drugs have powered a constant forward march on the top and bottom lines, and should really propel growth over the next couple years. Analysts are projecting high-single-digit sales growth this year and next, and overall profit expansion of 35% between now and the end of 2018.
But what really matters going forward for AbbVie is the pipeline, and investors should be assured on that front thanks to about a dozen indications that are currently in Phase 3 trials.
AbbVie's last dividend hike was a 12% whopper that brought the payout to 64 cents per share, and investors can expect robust improvements going forward. This is an aristocrat that lives up to its name.
AbbVie's (ABBV) Dividend Hit the Ground Running After the Split
The Retirement Portfolio You NEVER Have to Touch!
I love Dividend Aristocrats because they emphasize one of the most important aspects of the retirement investing game: dividend growth. But most of them lack another vital quality - big headline yield .
High yield, dividend growth and the potential for capital gains are the three pillars a retiree needs to lean on in retirement - and you'll find the kinds of "triple threat" stocks that offer all three in my "No Withdrawal" retirement portfolio .
The path to this ultimate basket of retirement stocks wasn't easy. My research led to dead end after dead end as I had to weed out yield traps and value traps alike. But the effort was worth it - after months delving into high-income assets like REITs, BDCs and other stocks, I've finally compiled a can't-miss portfolio featuring:
An average yield of 8% … which includes a few double-digit beauties
The potential for 7% to 15% in annual capital gains
Generous dividend growth that will keep up with (and beat) inflation
It's not greedy to go after all three of these qualities - in fact, it's the only way to retire the way you've always planned. That's because high yield, dividend growth and the potential for high capital gains will allow you to live off income … and actually grow your nest egg at the same time!
Many recommended blue-chip stocks only yield 3%, maybe 4% if you're lucky. But do the math! Even if you've saved up $500,000 for retirement, 4% annually is just $20,000 a year. You and I both know that even with Social Security tucked in there, you won't be able to afford the retirement you've been working toward.
The 10 Best Growth Stocks for Retirement
The 8% average yield on my "No Withdrawal" portfolio - as well as the dividend growth that will yield to double-digit yields on cost over time - will ensure you have all the income you need to pay the bills (and then some). Meanwhile, the growth potential of these picks will help grow your nest egg in retirement, which is essential should you ever need to pay for a big one-time expense, whether it's an emergency or just buying a vacation home.
This all-star portfolio features the very best of several high-income assets, from preferred stocks to REITs to closed-end funds and more. That means diversification and continued payouts regardless of how volatile or bearish the stock market becomes.
Don't let mediocre yields from uninspired, lazy stock picks ruin the retirement you've worked so hard to build. You deserve substantial, regular dividend checks that will let you see the world and live in comfort for the rest of your post-career life.
Let me show you the path to a no-worry retirement. Click here and I'll provide you with THREE special reports that show you the path to building a "No Withdrawal" portfolio. You'll get the names, tickers, buy prices and full analysis of their wealth-building potential - and it's absolutely risk FREE!
The post 3 Dividend Aristocrats That Deserve the Title … and 2 Pretenders appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Coca-Cola (KO) Is Running Out of Caffeine AbbVie Inc (ABBV) Dividend Yield: 3.9% Last but certainly not least is AbbVie Inc (NYSE: ABBV ), the pharmaceutical arm of the Abbott Laboratories (NYSE: ABT ) business that was spun off back in 2013. AbbVie currently is home to a number of big-name drugs, such as arthritis/Crohn's disease/psoriasis treatment Humira, testosterone replacement therapy treatment AndroGel and the aforementioned Imbruvica, which was formed in a partnership between JNJ and Pharmacyclics, which AbbVie bought up in 2015. But what really matters going forward for AbbVie is the pipeline, and investors should be assured on that front thanks to about a dozen indications that are currently in Phase 3 trials. | Coca-Cola (KO) Is Running Out of Caffeine AbbVie Inc (ABBV) Dividend Yield: 3.9% Last but certainly not least is AbbVie Inc (NYSE: ABBV ), the pharmaceutical arm of the Abbott Laboratories (NYSE: ABT ) business that was spun off back in 2013. AbbVie currently is home to a number of big-name drugs, such as arthritis/Crohn's disease/psoriasis treatment Humira, testosterone replacement therapy treatment AndroGel and the aforementioned Imbruvica, which was formed in a partnership between JNJ and Pharmacyclics, which AbbVie bought up in 2015. But what really matters going forward for AbbVie is the pipeline, and investors should be assured on that front thanks to about a dozen indications that are currently in Phase 3 trials. | Coca-Cola (KO) Is Running Out of Caffeine AbbVie Inc (ABBV) Dividend Yield: 3.9% Last but certainly not least is AbbVie Inc (NYSE: ABBV ), the pharmaceutical arm of the Abbott Laboratories (NYSE: ABT ) business that was spun off back in 2013. AbbVie currently is home to a number of big-name drugs, such as arthritis/Crohn's disease/psoriasis treatment Humira, testosterone replacement therapy treatment AndroGel and the aforementioned Imbruvica, which was formed in a partnership between JNJ and Pharmacyclics, which AbbVie bought up in 2015. But what really matters going forward for AbbVie is the pipeline, and investors should be assured on that front thanks to about a dozen indications that are currently in Phase 3 trials. | Coca-Cola (KO) Is Running Out of Caffeine AbbVie Inc (ABBV) Dividend Yield: 3.9% Last but certainly not least is AbbVie Inc (NYSE: ABBV ), the pharmaceutical arm of the Abbott Laboratories (NYSE: ABT ) business that was spun off back in 2013. AbbVie currently is home to a number of big-name drugs, such as arthritis/Crohn's disease/psoriasis treatment Humira, testosterone replacement therapy treatment AndroGel and the aforementioned Imbruvica, which was formed in a partnership between JNJ and Pharmacyclics, which AbbVie bought up in 2015. But what really matters going forward for AbbVie is the pipeline, and investors should be assured on that front thanks to about a dozen indications that are currently in Phase 3 trials. |
26146.0 | 2017-06-02 00:00:00 UTC | Why TG Therapeutics Inc Jumped Higher Today | ABBV | https://www.nasdaq.com/articles/why-tg-therapeutics-inc-jumped-higher-today-2017-06-02 | nan | nan | What happened
TG Therapeutics (NASDAQ: TGTX) ended Friday up 17% in anticipation of presentations at the American Society of Clinical Oncology (ASCO) meeting tomorrow and Monday. A blog post by Richard Pazdur, the director of the Food and Drug Administration's (FDA) Oncology Center of Excellence, about the use of surrogate endpoints for measuring clinical benefit, also may have helped boost the share price today.
So what
The most important data will come tomorrow when TG Therapeutics presents the results of the phase 3 GENUINE trial testing ublituximab in combination with Imbruvica, sold by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) . The top-line data for the trial, which was released back in March, showed an 80% overall response rate for high-risk chronic lymphocytic leukemia patients who received ublituximab plus Imbruvica compared to a 47% overall response rate in patients who only received Imbruvica.
But the devil is often in the details, which will be presented at ASCO. The meeting will also give investors a sense of how the drug will be received by the doctors who will prescribe the medication if ublituximab is approved by the Food and Drug Administration.
TG Therapeutics also has a pair of presentations on Monday testing a second drug, TGR-1202, either in combination with ublituximab and Imbruvica, or on its own. The results aren't as important for TG Therapeutics' near-term valuation because they were earlier-stage trials.
Now what
Pazdur's blog post pointing to the use of surrogate endpoints, such as TG Therapeutics' overall response rate, supports the approval of TG Therapeutics, but this idea isn't all that new for the oncology division of the FDA. TG Therapeutics' data is so strong, it would be kind of a shock if the FDA didn't approve it based on overall response rate.
A 17% jump ahead of the presentation seems a bit overdone, but the price is still lower than where it was when it peaked in March after the top-line data was released, so today's move may be caused by investors buying back in after taking profits a few months ago.
10 stocks we like better than TG Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and TG Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
Brian Orelli has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | So what The most important data will come tomorrow when TG Therapeutics presents the results of the phase 3 GENUINE trial testing ublituximab in combination with Imbruvica, sold by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) . What happened TG Therapeutics (NASDAQ: TGTX) ended Friday up 17% in anticipation of presentations at the American Society of Clinical Oncology (ASCO) meeting tomorrow and Monday. A blog post by Richard Pazdur, the director of the Food and Drug Administration's (FDA) Oncology Center of Excellence, about the use of surrogate endpoints for measuring clinical benefit, also may have helped boost the share price today. | So what The most important data will come tomorrow when TG Therapeutics presents the results of the phase 3 GENUINE trial testing ublituximab in combination with Imbruvica, sold by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) . What happened TG Therapeutics (NASDAQ: TGTX) ended Friday up 17% in anticipation of presentations at the American Society of Clinical Oncology (ASCO) meeting tomorrow and Monday. Now what Pazdur's blog post pointing to the use of surrogate endpoints, such as TG Therapeutics' overall response rate, supports the approval of TG Therapeutics, but this idea isn't all that new for the oncology division of the FDA. | So what The most important data will come tomorrow when TG Therapeutics presents the results of the phase 3 GENUINE trial testing ublituximab in combination with Imbruvica, sold by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) . Now what Pazdur's blog post pointing to the use of surrogate endpoints, such as TG Therapeutics' overall response rate, supports the approval of TG Therapeutics, but this idea isn't all that new for the oncology division of the FDA. 10 stocks we like better than TG Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | So what The most important data will come tomorrow when TG Therapeutics presents the results of the phase 3 GENUINE trial testing ublituximab in combination with Imbruvica, sold by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) . The top-line data for the trial, which was released back in March, showed an 80% overall response rate for high-risk chronic lymphocytic leukemia patients who received ublituximab plus Imbruvica compared to a 47% overall response rate in patients who only received Imbruvica. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and TG Therapeutics wasn't one of them! |
26147.0 | 2017-06-02 00:00:00 UTC | Is This Dividend Aristocrat Ridiculously Undervalued? | ABBV | https://www.nasdaq.com/articles/dividend-aristocrat-ridiculously-undervalued-2017-06-02 | nan | nan | Despite sporting industry-leading levels of growth and raising its dividend by a whopping 60% since its inception in 2013, the dividend aristocrat AbbVie (NYSE: ABBV) is without question a hotly contested battleground stock. (To be clear: AbbVie is considered a dividend aristocrat because it was spun-off from dividend aristocrat Abbott Labs in 2013.)
The basic issue under debate is AbbVie's ability to continue to deliver top notch revenue growth and free cash flow following the loss of exclusivity for its anti-inflammatory drug Humira inside the United States. Humira, after all, made up an unsightly 63% of the drugmaker's total revenues last year.
AbbVie's value proposition could change drastically if Amgen 's FDA-approved biosimilar Amjevita -- or any other forthcoming biosimilar -- for Humira is able to enter the market sooner than expected. At present, the most likely scenario has Amjevita hitting pharmacy shelves somewhere between 2019 to 2020 at the earliest -- but several would-be competitors are attempting to undermine AbbVie's legal defenses in an effort to break into this multi-billion dollar market sooner.
The net result is that AbbVie's shares are only trading at around 10 times the company's forward-looking earnings at the moment, which is one of the lowest valuations among either its dividend aristocrat or blue-chip biotech peer groups. With this in mind, let's dig deeper to find out if AbbVie really is undervalued, or if investors are right to be worried about the company's growth prospects moving forward.
AbbVie's future hinges on its clinical efforts in oncology
As part of its broader efforts to prepare for Humira's eventual zenith, AbbVie has been investing heavily in its oncology product portfolio and pipeline. AbbVie now owns the blood cancer drugs Empliciti, Imbruvica, and Venclexta, the late-stage solid tumor candidate rovalpituzumab tesirine (Rova-T), and the experimental PARP inhibitor veliparib, which is being assessed in a variety of solid tumors as well.
The key takeaway is that AbbVie is attempting to become a top player in the high-growth cancer drug market by rolling out multiple new drugs, and line extensions for products already on the market over the next few years. Even so, the market apparently isn't convinced that AbbVie's pivot to oncology will work out as planned for a couple of reasons.
First off, the drugmaker arguably grossly overpaid to gain access to only a share of Imbruvica's revenue stream. Johnson & Johnson , after all, owns 50% of this key oncology product, which has been growing its market share by leaps and bounds of late. Most importantly, AbbVie limited its future M&A opportunities by leveraging its balance sheet to the max partly as a result of this deal -- evinced by its current jaw-dropping debt to equity ratio of 746%.
Next up, AbbVie's attempt to grab the lion's share of the emerging PARP inhibitor market with veliparib hit a major snag recently when the drug flamed out in late-stage trials for both non-small cell lung cancer and triple negative breast cancer. These failures don't necessarily mean that veliparib's other putative indications are going to turn out to be a bust as well, but it does put a sizable dent in AbbVie's ability to offset any unexpected dips in Humira's sales in the near-term.
Is AbbVie under, over, or fairly valued right now?
To be honest, the biosimilar threat to Humira probably won't start to materialize until at least 2019. So this top biotech definitely has some time left on the clock to build upon its already substantial efforts in oncology in order to stave off an eventual dip in Humira's global sales. But the real question is: Will these efforts be enough to keep AbbVie's top line moving in the right direction?
Unfortunately, the answer to this question is anything but clear-cut. As currently constructed, AbbVie's oncology pipeline could pick up the slack if everything goes according to plan -- but as veliparib's late-stage hiccups demonstrate, experimental cancer drugs are never a sure thing.
Cutting to the chase, AbbVie probably is fairly valued in light of the looming biosimilar threat to its most important product, and the risks associated with clinical-stage oncology drugs -- despite management's repeated suggestions otherwise during the company's quarterly conference calls. No one knows for sure, after all, how deeply biosimilars will cut into Humira's market share, or even when this threat will materialize.
So while AbbVie still comes across as an outstanding growth, value, and dividend stock based on its projected fundamentals over the next year, this dividend aristocrat's longer-term value proposition is murky, to say the least.
The good news is that AbbVie is barreling toward a plethora of late-stage readouts in the second half of 2017 that should provide some much-needed clarity regarding its future growth prospects. Until then, though, bargain-hunters may want to think twice before diving headfirst into what could very well turn out to be a classic value trap.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
George Budwell has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The basic issue under debate is AbbVie's ability to continue to deliver top notch revenue growth and free cash flow following the loss of exclusivity for its anti-inflammatory drug Humira inside the United States. At present, the most likely scenario has Amjevita hitting pharmacy shelves somewhere between 2019 to 2020 at the earliest -- but several would-be competitors are attempting to undermine AbbVie's legal defenses in an effort to break into this multi-billion dollar market sooner. Cutting to the chase, AbbVie probably is fairly valued in light of the looming biosimilar threat to its most important product, and the risks associated with clinical-stage oncology drugs -- despite management's repeated suggestions otherwise during the company's quarterly conference calls. | AbbVie's future hinges on its clinical efforts in oncology As part of its broader efforts to prepare for Humira's eventual zenith, AbbVie has been investing heavily in its oncology product portfolio and pipeline. AbbVie now owns the blood cancer drugs Empliciti, Imbruvica, and Venclexta, the late-stage solid tumor candidate rovalpituzumab tesirine (Rova-T), and the experimental PARP inhibitor veliparib, which is being assessed in a variety of solid tumors as well. Despite sporting industry-leading levels of growth and raising its dividend by a whopping 60% since its inception in 2013, the dividend aristocrat AbbVie (NYSE: ABBV) is without question a hotly contested battleground stock. | AbbVie's future hinges on its clinical efforts in oncology As part of its broader efforts to prepare for Humira's eventual zenith, AbbVie has been investing heavily in its oncology product portfolio and pipeline. The key takeaway is that AbbVie is attempting to become a top player in the high-growth cancer drug market by rolling out multiple new drugs, and line extensions for products already on the market over the next few years. Next up, AbbVie's attempt to grab the lion's share of the emerging PARP inhibitor market with veliparib hit a major snag recently when the drug flamed out in late-stage trials for both non-small cell lung cancer and triple negative breast cancer. | But the real question is: Will these efforts be enough to keep AbbVie's top line moving in the right direction? As currently constructed, AbbVie's oncology pipeline could pick up the slack if everything goes according to plan -- but as veliparib's late-stage hiccups demonstrate, experimental cancer drugs are never a sure thing. Despite sporting industry-leading levels of growth and raising its dividend by a whopping 60% since its inception in 2013, the dividend aristocrat AbbVie (NYSE: ABBV) is without question a hotly contested battleground stock. |
26148.0 | 2017-06-01 00:00:00 UTC | Notable ETF Inflow Detected - VOO, BRK.B, V, ABBV | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-voo-brkb-v-abbv-2017-06-01 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard S&P 500 ETF (Symbol: VOO) where we have detected an approximate $465.2 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 307,931,633 to 310,029,958). Among the largest underlying components of VOO, in trading today Berkshire Hathaway Inc (Symbol: BRK.B) is off about 0.1%, Visa Inc (Symbol: V) is down about 0.6%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.5%. For a complete list of holdings, visit the VOO Holdings page » The chart below shows the one year price performance of VOO, versus its 200 day moving average:
Looking at the chart above, VOO's low point in its 52 week range is $182.27 per share, with $222.27 as the 52 week high point - that compares with a last trade of $222.10. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VOO, in trading today Berkshire Hathaway Inc (Symbol: BRK.B) is off about 0.1%, Visa Inc (Symbol: V) is down about 0.6%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.5%. For a complete list of holdings, visit the VOO Holdings page » The chart below shows the one year price performance of VOO, versus its 200 day moving average: Looking at the chart above, VOO's low point in its 52 week range is $182.27 per share, with $222.27 as the 52 week high point - that compares with a last trade of $222.10. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VOO, in trading today Berkshire Hathaway Inc (Symbol: BRK.B) is off about 0.1%, Visa Inc (Symbol: V) is down about 0.6%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.5%. For a complete list of holdings, visit the VOO Holdings page » The chart below shows the one year price performance of VOO, versus its 200 day moving average: Looking at the chart above, VOO's low point in its 52 week range is $182.27 per share, with $222.27 as the 52 week high point - that compares with a last trade of $222.10. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VOO, in trading today Berkshire Hathaway Inc (Symbol: BRK.B) is off about 0.1%, Visa Inc (Symbol: V) is down about 0.6%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard S&P 500 ETF (Symbol: VOO) where we have detected an approximate $465.2 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 307,931,633 to 310,029,958). For a complete list of holdings, visit the VOO Holdings page » The chart below shows the one year price performance of VOO, versus its 200 day moving average: Looking at the chart above, VOO's low point in its 52 week range is $182.27 per share, with $222.27 as the 52 week high point - that compares with a last trade of $222.10. | Among the largest underlying components of VOO, in trading today Berkshire Hathaway Inc (Symbol: BRK.B) is off about 0.1%, Visa Inc (Symbol: V) is down about 0.6%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard S&P 500 ETF (Symbol: VOO) where we have detected an approximate $465.2 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 307,931,633 to 310,029,958). For a complete list of holdings, visit the VOO Holdings page » The chart below shows the one year price performance of VOO, versus its 200 day moving average: Looking at the chart above, VOO's low point in its 52 week range is $182.27 per share, with $222.27 as the 52 week high point - that compares with a last trade of $222.10. |
26149.0 | 2017-05-31 00:00:00 UTC | Novartis Biosimilar Pipeline, 2018 Growth Plans on Track | ABBV | https://www.nasdaq.com/articles/novartis-biosimilar-pipeline-2018-growth-plans-on-track-2017-05-31 | nan | nan | Novartis AGNVS announced that the European Medicines Agency (EMA) has accepted the company's Marketing Authorization Applications for biosimilar versions of AbbVie's ABBV Humira (adalimumab) and Johnson & Johnson's JNJ Remicade (infliximab) for review.
Sandoz is seeking approval for use in all indications for which the drugs are approved. Sandoz currently markets three biosimilars - Omnitrope, a human growth hormone; Binocrit, an erythropoiesis-stimulating agent; and Zarxio - in the U.S. In addition, Sandoz has a strong pipeline of biosimilars including Roche's RHHBY Rituxan.
In Apr 2017, the CHMP gave positive opinion on biosimilar versions of Rituxan and Enbrel. Hence, Novartis is on track to launch five biosimilars of major oncology and immunology biologics by 2020.
Concurrently, Novartis shed light on its long-term plans as well. The company expects the next growth phase to begin in 2018 driven by Cosentyx (in all three indications psoriasis, psoriatic arthritis and ankylosing spondylitis (AS)) Entresto, and Kisqali and a deep pipeline with candidates like CTL019, BAF312, AMG 334, RTH258. We note that Cosentyx attained the blockbuster status in 2016.
The company is, however, facing significant pricing pressures in the U.S. in its Sandoz division and the impact of the delayed launch of Glatopa 40mg are likely to impact the second-quarter results.
Meanwhile, Novartis is conducting a strategic review of the Alcon Division and exploring all options to maximize value for shareholders. The company stated that the review is on track and will provide a status update for the same toward the end of 2017.
So far in the year, Novartis has outperformed the Zacks classified industry. The stock has rallied 12.3% compared with the Large Cap Pharmaceuticals industry's gain of 9%.
Zacks Rank
Novartis currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here .
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Novartis AGNVS announced that the European Medicines Agency (EMA) has accepted the company's Marketing Authorization Applications for biosimilar versions of AbbVie's ABBV Humira (adalimumab) and Johnson & Johnson's JNJ Remicade (infliximab) for review. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Sandoz currently markets three biosimilars - Omnitrope, a human growth hormone; Binocrit, an erythropoiesis-stimulating agent; and Zarxio - in the U.S. | Novartis AGNVS announced that the European Medicines Agency (EMA) has accepted the company's Marketing Authorization Applications for biosimilar versions of AbbVie's ABBV Humira (adalimumab) and Johnson & Johnson's JNJ Remicade (infliximab) for review. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Novartis AGNVS announced that the European Medicines Agency (EMA) has accepted the company's Marketing Authorization Applications for biosimilar versions of AbbVie's ABBV Humira (adalimumab) and Johnson & Johnson's JNJ Remicade (infliximab) for review. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis AGNVS announced that the European Medicines Agency (EMA) has accepted the company's Marketing Authorization Applications for biosimilar versions of AbbVie's ABBV Humira (adalimumab) and Johnson & Johnson's JNJ Remicade (infliximab) for review. The company stated that the review is on track and will provide a status update for the same toward the end of 2017. |
26150.0 | 2017-05-30 00:00:00 UTC | Biotech Stock Roundup: Puma Soars on Advisory Panel Vote, Priority Review for Kite Drug | ABBV | https://www.nasdaq.com/articles/biotech-stock-roundup-puma-soars-advisory-panel-vote-priority-review-kite-drug-2017-05-30 | nan | nan | While Puma's PBYI shares soared on a positive recommendation from an FDA advisory panel for the company's breast cancer treatment, neratinib, companies like Inovio INO and BioCryst BCRX also saw their shares gaining on positive data.
Recap of the Week's Most Important Stories
Puma Hits 52-Week High on Favorable FDA Panel Vote: Puma's shares touched a 52-week high last week with the company gaining the support of an FDA advisory panel for its experimental breast cancer treatment, neratinib. The FDA's Oncologic Drugs Advisory Committee voted 12 - 4 in favor of approving neratinib for the extended adjuvant treatment of HER2-positive early stage breast cancer based on a favorable risk-benefit profile (Read more: Puma Soaring After Neratinib FDA Panel Win, Time to Buy? ).
Puma's shares are up 159.8% year-to-date (YTD) with a major part of this gain (96.4%) being recorded over the past one month. Puma is a Zacks Rank #2 (Buy) stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Full Marketing Approval for Biogen's Fampyra in the EU: Biogen BIIB got full marketing approval from the European Commission (EC) for Fampyra, which is indicated for walking improvement in people with multiple sclerosis (MS). Fampyra was initially given conditional marketing authorization in 2011. Fampyra is marketed in the U.S. by Acorda under the trade name Ampyra (Read more: Biogen's Fampyra Conditional Approval Converted to Standard ).
Kite Drug Gets Priority Review: Kite KITE gained priority review for its regulatory application for its lead pipeline candidate, axicabtagene ciloleucel, with the FDA expected to respond on the approval status of the CAR-T treatment by Nov 29, 2017. Kite is looking to get axicabtagene ciloleucel approved for use in patients with refractory aggressive non-Hodgkin lymphoma (NHL). There is urgent medical need for this patient population with these patients facing only a 50% chance of surviving six months. The European marketing application for axicabtagene ciloleucel is slated for submission in the third quarter (Read more: Kite Pharma Cancer Drug BLA Gets Priority Review Status ).
Inovio Up on HIV Data: Inovio's HIV vaccine, Pennvax-GP, showed promising results in a study with the investigational vaccine achieving almost 100% immune response rates. This is amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine. Inovio's shares shot up 21.7% on the data.
BioCryst HAE Drug Impresses in Second Interim Analysis: BioCryst's shares were also up on results from a second interim analysis of the company's phase II study on BCX7353 for hereditary angioedema (HAE). The company said that a once-daily 125 mg dose of BCX7353 showed a high level of efficacy with an improved tolerability profile compared to the 350 mg dose observed in the first interim analysis. BioCryst is now looking to complete Part 3 of the study and select suitable doses for its pivotal program.
FDA Panel Supports Pfizer's Biosimilar Version of Amgen's Epogen: Pfizer, which is making a biosimilar version of J&J's Procrit and Amgen's Epogen (epoetin alfa), got a favorable vote from the FDA's Oncologic Drugs Advisory Committee (ODAC) across all indications. This is the first time a biosimilar erythropoiesis-stimulating agent (ESA) has been recommended for approval by an FDA advisory panel. While the FDA is not required to do so, it usually follows the recommendation of its advisory panels. Although Epogen sales have been declining, it contributed $1.3 billion to Amgen's total revenues in 2016.
YTD, Amgen has performed better than the Zacks-categorized Medical-Biomedical/Genetics industry with the company gaining 6% while the industry is down 0.3%.
Performance
Medical - Biomedical and Genetics Industry 5YR % Return
Medical - Biomedical and Genetics Industry 5YR % Return
The NASDAQ Biotechnology Index declined 1% over the last four trading sessions. Among major biotech stocks, Amgen gained 1.3% while Alexion lost 15.4%. Over the last six months, Vertex was up 36.6% while Biogen and Alexion were down 17.8% (See the last biotech stock roundup here: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data ).
What's Next in the Biotech World?
Companies like Amgen, Celgene CELG and AbbVie ABBV will all be at the annual meeting of the American Society of Clinical Oncology (ASCO) showcasing data on approved and pipeline candidates targeting cancer.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
Inovio Pharmaceuticals, Inc. (INO): Free Stock Analysis Report
Kite Pharma, Inc. (KITE): Free Stock Analysis Report
Puma Biotechnology Inc (PBYI): Free Stock Analysis Report
BioCryst Pharmaceuticals, Inc. (BCRX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Companies like Amgen, Celgene CELG and AbbVie ABBV will all be at the annual meeting of the American Society of Clinical Oncology (ASCO) showcasing data on approved and pipeline candidates targeting cancer. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Inovio Pharmaceuticals, Inc. (INO): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report Puma Biotechnology Inc (PBYI): Free Stock Analysis Report BioCryst Pharmaceuticals, Inc. (BCRX): Free Stock Analysis Report To read this article on Zacks.com click here. The European marketing application for axicabtagene ciloleucel is slated for submission in the third quarter (Read more: Kite Pharma Cancer Drug BLA Gets Priority Review Status ). | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Inovio Pharmaceuticals, Inc. (INO): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report Puma Biotechnology Inc (PBYI): Free Stock Analysis Report BioCryst Pharmaceuticals, Inc. (BCRX): Free Stock Analysis Report To read this article on Zacks.com click here. Companies like Amgen, Celgene CELG and AbbVie ABBV will all be at the annual meeting of the American Society of Clinical Oncology (ASCO) showcasing data on approved and pipeline candidates targeting cancer. While Puma's PBYI shares soared on a positive recommendation from an FDA advisory panel for the company's breast cancer treatment, neratinib, companies like Inovio INO and BioCryst BCRX also saw their shares gaining on positive data. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Inovio Pharmaceuticals, Inc. (INO): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report Puma Biotechnology Inc (PBYI): Free Stock Analysis Report BioCryst Pharmaceuticals, Inc. (BCRX): Free Stock Analysis Report To read this article on Zacks.com click here. Companies like Amgen, Celgene CELG and AbbVie ABBV will all be at the annual meeting of the American Society of Clinical Oncology (ASCO) showcasing data on approved and pipeline candidates targeting cancer. While Puma's PBYI shares soared on a positive recommendation from an FDA advisory panel for the company's breast cancer treatment, neratinib, companies like Inovio INO and BioCryst BCRX also saw their shares gaining on positive data. | Companies like Amgen, Celgene CELG and AbbVie ABBV will all be at the annual meeting of the American Society of Clinical Oncology (ASCO) showcasing data on approved and pipeline candidates targeting cancer. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Inovio Pharmaceuticals, Inc. (INO): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report Puma Biotechnology Inc (PBYI): Free Stock Analysis Report BioCryst Pharmaceuticals, Inc. (BCRX): Free Stock Analysis Report To read this article on Zacks.com click here. While Puma's PBYI shares soared on a positive recommendation from an FDA advisory panel for the company's breast cancer treatment, neratinib, companies like Inovio INO and BioCryst BCRX also saw their shares gaining on positive data. |
26151.0 | 2017-05-29 00:00:00 UTC | Meet the Cancer Therapy that Could Become the Second Best-Selling Drug in the World by Year's End | ABBV | https://www.nasdaq.com/articles/meet-cancer-therapy-could-become-second-best-selling-drug-world-years-end-2017-05-29 | nan | nan | The pharmaceutical industry is big business. According to the International Trade Administration's Top Markets Report on pharmaceuticals last year, the global drug market is expected to grow from about $1 trillion in sales in 2015 to $1.3 trillion by 2020, representing about 5% annual growth. And at the center of that growth trend is the U.S. market.
U.S. drugmakers are thriving
The U.S. is an optimal target for drug developers for a variety of reasons . To begin with, the U.S. lacks a universal healthcare system, meaning Congress has no true ability to cap or limit drug pricing. The Food and Drug Administration also grants exceptionally long patent protection periods for novel therapies, which prevent the entrance of cheaper generic medicines. Additionally, insurers have a tendency to accept rather than fight drugmakers' pricing for fear of losing members by excluding a popular drug. And, of course, who can forget that demand for pharmaceuticals is higher in the U.S. than any other country in the world. This laundry list of catalysts makes the U.S. an optimal market for drugmakers to thrive -- and thrive they have.
Last year, AbbVie 's (NYSE: ABBV) anti-inflammatory drug Humira, the best-selling drug in the world, tallied $16.08 billion in sales. A little more than $10.4 billion of this was recognized in the United States, with strong pricing power helping to push sales of its leading therapeutic up 24% year-over-year domestically.
Another major success story was Gilead Sciences (NASDAQ: GILD) with its hepatitis C drug Harvoni. Even though sales of Harvoni, which has a list price of $94,500 for a standard 12-week treatment, dipped in 2016 as a result of Gilead having hit the "low-hanging fruit" and treating the sickest HCV patients in 2014 and 2015, the drug still generated $9.08 billion in full-year sales. Nearly $5 billion of that came from the U.S.
In fact, five drugs in total managed to eclipse the $8.5 billion annual sales mark in 2016. After Humira and Harvoni were Amgen 's (NASDAQ: AMGN) and Pfizer 's (NYSE: PFE) anti-inflammatory drug Enbrel, Roche 's (NASDAQOTH: RHHBY) and Biogen 's cancer drug Rituxan, and Johnson & Johnson 's (NYSE: JNJ) and Merck 's anti-inflammatory therapy Remicade.
Big changes are in the offing for the world's top-selling drugs
However, we appear to be on the verge of seeing some major shifts atop the best-selling drug leaderboard. For example, Remicade is dealing with the entrance of Inflectra, a biosimilar drug (essentially a copycat version of a biologic drug) that's priced at a 15% discount to its list price and is being marketed by Pfizer. Sales of Remicade dipped by more than 10% in 2016, largely driven by weakness in Europe. Without pricing power, Remicade sales are liable to fall again in 2017.
Likewise, increased competition in the anti-inflammatory space and the signing of new supply contracts has put the kibosh on Enbrel's pricing power. Amgen has been regularly using hefty price increases on Enbrel to drive growth, but that came to a crashing halt in the first quarter. Sales of Amgen's former lead drug dropped by 15% in Q1. Roughly 12% of this decline came from a reduction in sales volume, while about 2% came from a decrease in Enbrel's price.
Even Gilead's Harvoni could see further pressure in 2017. Increasing competition in the HCV space from the likes of Merck, which priced its HCV drug Zepatier nearly $40,000 below Harvoni for a standard 12-week treatment, have Gilead forecasting $7.5 billion to $9 billion in full-year hepatitis C sales. Mind you, this includes sales from Sovaldi and Epclusa, its respective first and newest HCV drugs, not just Harvoni.
The one exception this year, other than Humira, which is leaving its competition in the dust on an annual sales basis, is Rituxan. Roche reported a 4% increase in sales of the drug during the first quarter. Nonetheless, biosimilars of Rituxan may be ready to hit pharmacy shelves sooner than investors realize, and Rituxan's patents won't last that much longer either. Even Rituxan could see its sales reverse sooner rather than later.
This cancer drug could ascend to the No. 2 spot in 2017
With some of the top-selling drugs potentially seeing their sales decline in the quarters and years that lie ahead, it looks as if Celgene 's (NASDAQ: CELG) multiple myeloma blockbuster Revlimid has an outside chance of claiming the No. 2 spot among best-selling therapies in 2017. Celgene stuck by a forecast for $8 billon to $8.3 billion in full-year Revlimid sales, although it's been notoriously conservative with its sales estimates throughout the years.
Revlimid's success has been based on a confluence of factors. To begin with, demand for Revlimid is on the rise. An increase in multiple myeloma diagnoses, which is a result of an increase in population and earlier detection of the disease, has lifted demand for a go-to drug used as a first- and second-line therapy.
Celgene also has exceptional pricing power with its lead drug. Though list prices of cancer drugs are often a well-kept secret, Celgene has had little trouble passing along higher price points to insurers and patients. Considering its exceptional market share in treating multiple myeloma, Revlimid shouldn't face much in the way of pricing pressure short of federal legislation that caps drug prices (which is unlikely).
Celgene also notes that duration-of-use for its key therapy has helped its sales growth. Improvements in the multiple myeloma treatment process have allowed patients to remain on Revlimid for a longer period of time, ultimately boosting sales for Celgene.
Lastly, Revlimid has multiple label expansion opportunities beyond multiple myeloma. These include first-line follicular lymphoma, relapsed/refractory indolent lymphoma, and first-line ABC-subtype diffuse large B-cell lymphoma. These aren't major money indications for Celgene like multiple myeloma, but they provide a channel to nicely increase sales.
This is what sets Revlimid apart from the rest of its peers
However, there's an additional factor that sets Revlimid apart from the group . In Dec. 2015, Celgene worked out a settlement with a number of generic-drug manufacturers over Revlimid. One manufacturer will be allowed to introduce a limited generic supply of the drug beginning in March 2022 and extending through 2025. By Jan. 31, 2026, a flood of generic Revlimid can finally enter the market. In effect, Celgene cleared a decade-long runway for its lead drug to keep growing.
On the other hand, we're seeing a clear decline in sales of Harvoni, Enbrel, and Remicade, and Rituxan and even AbbVie's Humira are just a few years away from losing sales due to patent expirations. In other words, Revlimid may have a path to not only generate $10 billion-plus in annual sales -- it could become the best-selling drug in the world by the early 2020s.
There's obviously a lot that could happen between now and the early 2020s, including new competition in multiple myeloma, as well as the introduction of a new therapy that ramps up quicker than Revlimid. An example would be Biogen's experimental Alzheimer's disease drug aducanumab. If successful in late-stage trials and approved by the Food and Drug Administration, it could have $10 billion in peak annual sales potential, if not more.
Nevertheless, Revlimid has a clear path to higher sales for at least the next couple of years, and if things go Celgene's way it could become the second best-selling drug in the world by the end of this year.
10 stocks we like better than Celgene
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Celgene wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
Sean Williams has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Biogen, Celgene, Gilead Sciences, and Johnson & Johnson. The Motley Fool has the following options: short June 2017 $70 calls on Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last year, AbbVie 's (NYSE: ABBV) anti-inflammatory drug Humira, the best-selling drug in the world, tallied $16.08 billion in sales. On the other hand, we're seeing a clear decline in sales of Harvoni, Enbrel, and Remicade, and Rituxan and even AbbVie's Humira are just a few years away from losing sales due to patent expirations. The Food and Drug Administration also grants exceptionally long patent protection periods for novel therapies, which prevent the entrance of cheaper generic medicines. | Last year, AbbVie 's (NYSE: ABBV) anti-inflammatory drug Humira, the best-selling drug in the world, tallied $16.08 billion in sales. On the other hand, we're seeing a clear decline in sales of Harvoni, Enbrel, and Remicade, and Rituxan and even AbbVie's Humira are just a few years away from losing sales due to patent expirations. After Humira and Harvoni were Amgen 's (NASDAQ: AMGN) and Pfizer 's (NYSE: PFE) anti-inflammatory drug Enbrel, Roche 's (NASDAQOTH: RHHBY) and Biogen 's cancer drug Rituxan, and Johnson & Johnson 's (NYSE: JNJ) and Merck 's anti-inflammatory therapy Remicade. | Last year, AbbVie 's (NYSE: ABBV) anti-inflammatory drug Humira, the best-selling drug in the world, tallied $16.08 billion in sales. On the other hand, we're seeing a clear decline in sales of Harvoni, Enbrel, and Remicade, and Rituxan and even AbbVie's Humira are just a few years away from losing sales due to patent expirations. Even though sales of Harvoni, which has a list price of $94,500 for a standard 12-week treatment, dipped in 2016 as a result of Gilead having hit the "low-hanging fruit" and treating the sickest HCV patients in 2014 and 2015, the drug still generated $9.08 billion in full-year sales. | Last year, AbbVie 's (NYSE: ABBV) anti-inflammatory drug Humira, the best-selling drug in the world, tallied $16.08 billion in sales. On the other hand, we're seeing a clear decline in sales of Harvoni, Enbrel, and Remicade, and Rituxan and even AbbVie's Humira are just a few years away from losing sales due to patent expirations. Even though sales of Harvoni, which has a list price of $94,500 for a standard 12-week treatment, dipped in 2016 as a result of Gilead having hit the "low-hanging fruit" and treating the sickest HCV patients in 2014 and 2015, the drug still generated $9.08 billion in full-year sales. |
26152.0 | 2017-05-27 00:00:00 UTC | The 2 Best Dividend Stocks in Marijuana | ABBV | https://www.nasdaq.com/articles/2-best-dividend-stocks-marijuana-2017-05-27 | nan | nan | Marijuana stocks that pay dividends? That might seem like an oxymoron. For one thing, profitability is usually a prerequisite for paying out dividends, and there aren't too many profitable marijuana stocks out there.
If you're really wanting to find marijuana stocks that pay a dividend, though, there are two that stand out -- AbbVie (NYSE: ABBV) and The Scotts Miracle-Gro Company (NYSE: SMG) . Admittedly, there's a bit of a stretch required to truly call these marijuana stocks, but both do have solid marijuana connections. Here's why AbbVie and Scotts Miracle-Gro are the best (and perhaps only) dividend stocks in marijuana.
Image source: Getty Images.
An early marijuana drug and a sky-high dividend yield
AbbVie markets Marinol for managing the loss of appetite associated with AIDS treatment and for nausea and vomiting associated with cancer chemotherapy. Marinol holds the distinction as the first cannabinoid approved in the U.S., with the Food and Drug Administration (FDA) granting approval of the drug back in 1985.
Marinol's active ingredient is dronabinol, a synthetic delta-9-tetrahydrocannabinol (THC), which is the psychoactive component of marijuana. The drug was first made by Unimed. Solvay Pharmaceuticals acquired Unimed in 1999, and Abbott Laboratories purchased Solvay Pharmaceuticals in 2010. Three years later, Abbott spun off AbbVie as a separate entity, with the new company taking Marinol with it.
Does Marinol generate a lot of money for AbbVie? Um, no. In fact, the company doesn't even mention the drug in its financial reports. Still, AbbVie continues to market Marinol, which qualifies it as a marijuana stock (at least in the broadest sense of the term). More importantly for our discussion, the company pays out a tremendous dividend.
AbbVie's dividend yield currently stands at 3.9%. AbbVie also ranks as one of the stocks with the fastest-growing dividends on the market. The company appears to be in a good position to keep the dividend checks flowing, with growing earnings and a strong cash flow.
The go-to source for marijuana growers
Scotts Miracle-Gro doesn't sell any products that contain marijuana. But the company is intertwined with the marijuana-growing industry. Scotts Miracle-Gro has become the go-to source for marijuana cultivators for supplies, including fertilizers, lighting, and hydroponic products.
Over the past few years, Scotts Miracle-Gro has completed several acquisitions that bolstered its position as a primary supplier for marijuana growers. In 2015, the company acquired the assets of General Hydroponics and Vermicrop, both of which are leading producers of liquid plant food products and accessories for hydroponic gardening. Last year, Scotts bought Gravita, a Netherlands-based maker of indoor lighting used in the greenhouse and hydroponic markets. The company also purchased American Agritech, a producer of plant nutrients, plant supplements, and growing systems used for hydroponic gardening.
Scotts Miracle-Gro doesn't provide details on how much of its revenue stems from sales to marijuana growers. However, it's clearly an important market to the company. CEO James Hagedorn has stated that the company intends to be a major supplier for both recreational and professional marijuana growers.
Dividend-seeking investors have something to like with Scotts Miracle-Gro. The dividend currently yields 2.26%. Scotts has increased its dividend payments for seven consecutive years. With a payout ratio of 58% and growing earnings, the company appears to have plenty of room for future dividend hikes.
More possibilities in the future?
Could there be more dividend stocks for investors to choose from down the road? It's possible. However, I wouldn't count on any surge in alternatives anytime soon.
As mentioned earlier, most marijuana stocks aren't profitable yet. Even some of the ones that are profitable right now aren't yet able to sustain those profits. Although expected growth in the marijuana industry could change that relatively soon, there's still no guarantee that companies will choose to return profits to investors in the form of dividends.
My hunch is that it will be years before there are plenty of marijuana stocks offering dividends. For now, AbbVie and Scotts Miracle-Gro appear to be the only choices. At least they're good ones.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | An early marijuana drug and a sky-high dividend yield AbbVie markets Marinol for managing the loss of appetite associated with AIDS treatment and for nausea and vomiting associated with cancer chemotherapy. If you're really wanting to find marijuana stocks that pay a dividend, though, there are two that stand out -- AbbVie (NYSE: ABBV) and The Scotts Miracle-Gro Company (NYSE: SMG) . Here's why AbbVie and Scotts Miracle-Gro are the best (and perhaps only) dividend stocks in marijuana. | An early marijuana drug and a sky-high dividend yield AbbVie markets Marinol for managing the loss of appetite associated with AIDS treatment and for nausea and vomiting associated with cancer chemotherapy. If you're really wanting to find marijuana stocks that pay a dividend, though, there are two that stand out -- AbbVie (NYSE: ABBV) and The Scotts Miracle-Gro Company (NYSE: SMG) . Here's why AbbVie and Scotts Miracle-Gro are the best (and perhaps only) dividend stocks in marijuana. | If you're really wanting to find marijuana stocks that pay a dividend, though, there are two that stand out -- AbbVie (NYSE: ABBV) and The Scotts Miracle-Gro Company (NYSE: SMG) . Here's why AbbVie and Scotts Miracle-Gro are the best (and perhaps only) dividend stocks in marijuana. An early marijuana drug and a sky-high dividend yield AbbVie markets Marinol for managing the loss of appetite associated with AIDS treatment and for nausea and vomiting associated with cancer chemotherapy. | Here's why AbbVie and Scotts Miracle-Gro are the best (and perhaps only) dividend stocks in marijuana. If you're really wanting to find marijuana stocks that pay a dividend, though, there are two that stand out -- AbbVie (NYSE: ABBV) and The Scotts Miracle-Gro Company (NYSE: SMG) . An early marijuana drug and a sky-high dividend yield AbbVie markets Marinol for managing the loss of appetite associated with AIDS treatment and for nausea and vomiting associated with cancer chemotherapy. |
26153.0 | 2017-05-26 00:00:00 UTC | Johnson & Johnson's Analyst Day Was Overshadowed by This Worrisome Data | ABBV | https://www.nasdaq.com/articles/johnson-johnsons-analyst-day-was-overshadowed-worrisome-data-2017-05-26 | nan | nan | Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is a common holding in long-term investors' portfolios for one reason: its consistency.
Johnson & Johnson's consistency derives from its business structure. Although J&J reports as a single entity, it consists of more than 250 subsidiaries, which makes it easy for the company to acquire or remove puzzle pieces with relative ease from time to time.
It also has three reporting segments -- pharmaceuticals, medical devices, and consumer-health products -- that each serve a purpose. Pharma provides the backbone of its margin and growth, medical devices are a long-term growth play on an aging global population, and consumer health provides a bounty of inelastic products with strong pricing power and predictable cash flow.
Johnson & Johnson showcases a bountiful pipeline
Last week, Johnson & Johnson added to its allure with its annual analyst day meeting, which primarily focused on its pharmaceutical pipeline. Much as it called for two years ago, J&J provided an outlook that calls for at least 10 blockbuster drug filings between now and 2021.
The company has two promising novel molecular entities that have already been filed with the Food and Drug Administration (FDA) and should be launched later this year, assuming approval. These currently experimental drugs are guselkumab for psoriasis and sirukumab for rheumatoid arthritis.
Guselkumab is of particular interest because it targets the interleukein-23 protein that's known for its specificity in terms of immune response for skin disorders. In phase 3 clinical studies, it not only left the placebo in the dust at the 16-week and 48-week marks, but it also mopped the floor with AbbVie 's (NYSE: ABBV) Humira, the best-selling drug in the world, with regard to near-complete skin clearance at weeks 16 and 48.
Looking ahead, J&J listed nine other compounds in development with an expectation of a regulatory approval filing between 2017 and 2021. These are (as taken directly from J&J's press release):
apalutamide (ARN-509) for pre-metastatic prostate cancer.
esketamine for treatment-resistant depression.
talacotuzumab (CSL362) for acute myeloid leukemia.
erdafitinib (FGFR inhibitor) for solid tumors.
niraparib for prostate cancer.
imetelstat for myelofibrosis.
pimodivir (JNJ-3872) for influenza A.
lumicitabine (JNJ-1575) for respiratory syncytial virus (RSV) infection.
JNJ-7922 (orexin-2 agonist) for adjunctive treatment for major depressive disorder.
Imetelstat is an exciting first-of-its-kind compound. What attracted J&J to Geron (NASDAQ: GERN) , the developer of imetelstat, was its success in phase 1 studies. No prior therapy had led to a partial or complete response in myelofibrosis patients, which is exactly what imetelstat did. In fact, the only FDA-approved drug on the market right now for myelofibrosis focuses on its symptoms (enlarged spleen and anemia) but does nothing to slow disease progression . With interim data on imetelstat looking promising for the higher 9.4 mg/kg dose, Geron and J&J have to be excited about its potential.
Analysts walking away from J&J's investor presentation, along with shareholders, have to be pleased with the progress the company is making.
This clinical data overshadowed what was otherwise a solid forecast
However, this outlook was marred by the release of clinical data just a few days prior.
According to data from two recently completed clinical studies, J&J's SGLT-2 inhibitor to treat type 2 diabetes, Invokana, was found to have led to a higher risk of foot and leg amputations compared to the placebo. In the first study, the risk of amputation in patients treated with Invokana was 5.9 out of every 1,000 patients over the course of a year, compared to 2.8 out of every 1,000 patients given the placebo. The second trial demonstrated the equivalent of 7.5 out of every 1,000 patients for the Invokana arm, compared with 4.2 out of every 1,000 patients given the placebo.
So, what's this mean for J&J's blockbuster type 2 diabetes drug? According to the FDA, J&J will now have to place a boxed warning on Invokana regarding an increased risk of foot and leg amputations.
What makes the addition of this warning so worrisome for J&J is that Invokana's sales tumbled in the U.S. during the first quarter by 17% to $247 million. It's unclear what caused this rapid backtrack in sales (i.e., was it competition or an inventory issue?), but it occurred well before the release of this long-term safety data. Now that this safety data has been released, it could provide a catalyst for physicians and consumers to make the switch to Eli Lilly 's (NYSE: LLY) and Boehringer Ingelheim's Jardiance, another SGLT-2 inhibitor.
For those who may not recall, Eli Lilly and Boehringer reported that Jardiance provided a statistically significant reduction in cardiovascular events and risk of death relative to the placebo in the EMPA-REG OUTCOME long-term study. J&J's long-term study on Invokana isn't due out until later this year. This means the new data release plus the EMPA-REG study gives Jardiance two clear positives over Invokana.
Understandably, Johnson & Johnson's product portfolio can overcome weakness from a single drug, and as you saw above, it has a healthy pipeline. However, J&J appears to be running into issues with what should be a foundational therapy over the next five-to-10 years - and that's not good news.
At this point, it's probably not worth altering your investment thesis in J&J if you're a shareholder or prospective investor, but it may be worth toning down your growth expectations for the company's diabetes segment in the interim.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
Sean Williams has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In phase 3 clinical studies, it not only left the placebo in the dust at the 16-week and 48-week marks, but it also mopped the floor with AbbVie 's (NYSE: ABBV) Humira, the best-selling drug in the world, with regard to near-complete skin clearance at weeks 16 and 48. According to data from two recently completed clinical studies, J&J's SGLT-2 inhibitor to treat type 2 diabetes, Invokana, was found to have led to a higher risk of foot and leg amputations compared to the placebo. For those who may not recall, Eli Lilly and Boehringer reported that Jardiance provided a statistically significant reduction in cardiovascular events and risk of death relative to the placebo in the EMPA-REG OUTCOME long-term study. | In phase 3 clinical studies, it not only left the placebo in the dust at the 16-week and 48-week marks, but it also mopped the floor with AbbVie 's (NYSE: ABBV) Humira, the best-selling drug in the world, with regard to near-complete skin clearance at weeks 16 and 48. It also has three reporting segments -- pharmaceuticals, medical devices, and consumer-health products -- that each serve a purpose. Johnson & Johnson showcases a bountiful pipeline Last week, Johnson & Johnson added to its allure with its annual analyst day meeting, which primarily focused on its pharmaceutical pipeline. | In phase 3 clinical studies, it not only left the placebo in the dust at the 16-week and 48-week marks, but it also mopped the floor with AbbVie 's (NYSE: ABBV) Humira, the best-selling drug in the world, with regard to near-complete skin clearance at weeks 16 and 48. Johnson & Johnson showcases a bountiful pipeline Last week, Johnson & Johnson added to its allure with its annual analyst day meeting, which primarily focused on its pharmaceutical pipeline. According to data from two recently completed clinical studies, J&J's SGLT-2 inhibitor to treat type 2 diabetes, Invokana, was found to have led to a higher risk of foot and leg amputations compared to the placebo. | In phase 3 clinical studies, it not only left the placebo in the dust at the 16-week and 48-week marks, but it also mopped the floor with AbbVie 's (NYSE: ABBV) Humira, the best-selling drug in the world, with regard to near-complete skin clearance at weeks 16 and 48. imetelstat for myelofibrosis. According to data from two recently completed clinical studies, J&J's SGLT-2 inhibitor to treat type 2 diabetes, Invokana, was found to have led to a higher risk of foot and leg amputations compared to the placebo. |
26154.0 | 2017-05-25 00:00:00 UTC | Biogen's Fampyra Conditional Approval Converted to Standard | ABBV | https://www.nasdaq.com/articles/biogens-fampyra-conditional-approval-converted-to-standard-2017-05-25 | nan | nan | Biogen Inc.BIIB announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval.
As part of the conditional approval received in 2011, Biogen was required to provide additional data on the long-term safety and benefits of Fampyra, especially on the drug's benefits beyond an improvement in walking speed.
The standard approval was based on positive results of the phase III ENHANCE study, which was conducted to evaluate the long-term safety and efficacy of Fampyra in patients with both relapsing and progressive forms of MS. The study confirmed the clinically meaningful benefits and safety of Fampyra over the long term.
Fampyra is available in the U.S. under the trade name Ampyra where it is marketed by Acorda Therapeutics, Inc. ACOR . Biogen acquired ex-U.S. rights to Fampyra from Acorda in Jul 2009
Biogen has a strong position in the MS market with a wide range of products including Avonex, Tysabri, Tecfidera and Plegridy. Biogen has another MS product, Zinbryta, in its portfolio in partnership with AbbVie, Inc. ABBV . However, increasing competition and a slowdown in the overall MS market is hurting sales of it MS drugs lately. Importantly, Roche's Ocrevus (ocrelizumab) was approved for the treatment of relapsing MS (RMS) and primary progressive MS (PPMS) in Mar 2017, which will pose strong competition to Biogen's MS drugs. However, on Wednesday, Reuters reported that a progressive multifocal leukoencephalopathy (PML) case has been disclosed in a MS patient in Germany who had recently switched to Ocrevus from Tysabri.
Shares of Biogen were up 2% on Wednesday. This year, Biogen's shares have declined 10.6% so far while the Zacks classified Biomed-Genetics industry has gained 0.3%.
Biogen is looking to strengthen its Alzheimer's disease (AD) and other neurodegenerative disorders pipeline. Biogen's AD pipeline comprises candidates with different mechanisms of action including anti-tau (BMS-986168) and anti-amyloid (aducanumab) candidates as well as a BACE inhibitor (elenbecestat) program. The Dec 2016 FDA approval of Biogen and partner Ionis Pharmaceuticals, Inc.'s IONS spinal muscular atrophy (SMA) treatment, Spinraza (nusinersen), consolidated its position in the neurological disease market with the drug being the first and only treatment to be approved in the U.S. for SMA.
Biogen carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Biogen has another MS product, Zinbryta, in its portfolio in partnership with AbbVie, Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. The standard approval was based on positive results of the phase III ENHANCE study, which was conducted to evaluate the long-term safety and efficacy of Fampyra in patients with both relapsing and progressive forms of MS. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen has another MS product, Zinbryta, in its portfolio in partnership with AbbVie, Inc. ABBV . Biogen Inc.BIIB announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen has another MS product, Zinbryta, in its portfolio in partnership with AbbVie, Inc. ABBV . Biogen acquired ex-U.S. rights to Fampyra from Acorda in Jul 2009 Biogen has a strong position in the MS market with a wide range of products including Avonex, Tysabri, Tecfidera and Plegridy. | Biogen has another MS product, Zinbryta, in its portfolio in partnership with AbbVie, Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen Inc.BIIB announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval. |
26155.0 | 2017-05-24 00:00:00 UTC | 3 Dividend Stocks to Buy for 12 Months of Retirement Income | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-to-buy-for-12-months-of-retirement-income-2017-05-24 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
If there is one driving force when it comes to retirement, it has to be the search for income. Turning your nest egg into a source of reliable income is paramount to enjoying your golden years without worry. Because of this, dividend stocks are increasingly becoming the well from which investors draw their retirement income. There's just one problem with dividend stocks - waiting to cash your checks.
Source: Shutterstock
Most dividend stocks hand out their payouts every three months. Typically in March, June, September and December, as the quarter ends. That poses a bit of a conundrum for those in the throes of retirement: I don't know about you, but I wouldn't want my income stream to dry up for months at a time waiting on dividends to clear the bank.
But it's not a total loss, there are plenty of dividend stocks to buy that offer income in the off months. Yes, that means you're getting a full 12 months of dividend payouts.
10 Best Mutual Funds for Retirement
If that sounds like a retirement plan you can get behind, we review three dividend stocks that will ensure a steady, full year's worth of payouts.
Dividend Stocks to Buy: Cisco Systems (CSCO)
Source: Shutterstock
Dividend Yield: 3.7%
Dividend Schedule: January, April, July and October
Want to find the best dividend stocks? The investors should look toward tech. Thanks to high-profit margins and low operating cost, tech stocks have quickly become some of the best dividend-paying firms in the world. Case in point Cisco Systems, Inc. (NASDAQ: CSCO ).
The former dot-com darling is still going strong. Wireless routing and networking still rule the roost at CSCO. However, the firm has expanded beyond just switching equipment and routers. It's now a software and services giant with its tentacles in everything from cloud computing and cyber security to the Internet of Things and renewable energy software.
The real beauty is that these sorts of areas come with much higher growth rates and profit margins. Even more so when it's able to bundle its services with its networking expertise. That provides customers with a comprehensive solution to build and secure their network in one fell swoop.
All of this has been great for dividend investors. Cisco has become a cash-minting machine! Cash, mind you, that makes its way back into shareholders pocket. Since 2011, when it initiated a dividend, CSCO stock has grown its payout by a whopping 385%. Today, Cisco yields 3.7% and investors should expect that yield to grow further based on its cash-generating powers.
Dividend Stocks to Buy: AbbVie (ABBV)
Source: Black Stripe via Wikimedia (Modified)
Dividend Yield: 3.9%
Dividend Schedule: February, May, August, November
Biotech firms aren't normally a favorite stomping ground for those investors looking for dividend stocks. However, some of the sector's elder statesmen are amazing when it comes cash flows and producing big-time dividends. Case in point, biotech giant AbbVie Inc (NASDAQ: ABBV ).
Spun off from Abbott Laboratories (NYSE: ABT ) back in 2013, ABBV has become a monster in the world of dividends thanks to one source - Humira. The autoimmune disease medication is currently the best-selling drug on the planet, funneling more than $16.3 billion in revenues back to ABBV last year. That's about 63% of its total revenues.
What's great is that, despite reaching the patent cliff for the drug, Humira sales continue to increase as doctors use it for more than its original purpose. During the last quarter, revenues for the drug actually jumped more than 15%. That's because ABBV has been able to kick the can on some of these other uses when it comes to patents.
5 of the Best-Managed Mutual Funds on Wall Street
Adding to the appeal of AbbVie is its robust pipeline of drugs entering late-stage critical trials. When these finally hit the ground running, ABBV should continue to see robust cash-flow growth. With a dividend yield of nearly 4%, investors looking for a strong healthcare dividend should prescribe AbbVie for their portfolios.
Dividend Stocks to Buy: Cummins (CMI)
Source: Jon Olav Eikenes Via Flickr
Dividend Yield: 2.7%
Dividend Schedule: March, June, September and December
The only time people ever really think about Cummins Inc . (NYSE: CMI ) is when they recognize the logo on the back of a truck. In reality, the company is a powerhouse in the world of engines and industrial generators. The fact that it's underloved leads to a wonderful opportunity for dividend investors.
Today, CMI controls around 40% of the large heavy-duty engine market in North America and around 70% of the medium-duty engine market. Those engines find their way into everything from passenger trucks to utility-scale generators and mega-sized construction equipment. Increasingly, CMI has turned to emerging markets to fuel its growth and as such, earnings and revenues at the firm have continued to rise. During the last quarter, international sales improved by 17% - driven primarily by China, India and other developing markets.
And CMI should grow further thanks to a recent joint venture with Eaton Corporation, PLC Ordinary Shares (NYSE: ETN ). The new J.V. will create new automated transmissions for heavy-duty and medium-duty commercial vehicles that are deigned to save energy while keeping power steady. That's a vital cross-selling and market dominating partnership that will pull in more customers across CMI's operating spectrum.
What all this really means is dividends. Over the past ten years, CMI has gotten serious about rewarding shareholders and increased its total payout by 720%. With more growth on the horizon, CMI's current yield of 2.6% is really just a drop in the bucket for this dividend stock.
As of this writing, Aaron Levitt did not hold a position in any of the aforementioned securities.
The post 3 Dividend Stocks to Buy for 12 Months of Retirement Income appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The autoimmune disease medication is currently the best-selling drug on the planet, funneling more than $16.3 billion in revenues back to ABBV last year. 5 of the Best-Managed Mutual Funds on Wall Street Adding to the appeal of AbbVie is its robust pipeline of drugs entering late-stage critical trials. Dividend Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield: 3.9% Dividend Schedule: February, May, August, November Biotech firms aren't normally a favorite stomping ground for those investors looking for dividend stocks. | Case in point, biotech giant AbbVie Inc (NASDAQ: ABBV ). Dividend Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield: 3.9% Dividend Schedule: February, May, August, November Biotech firms aren't normally a favorite stomping ground for those investors looking for dividend stocks. Spun off from Abbott Laboratories (NYSE: ABT ) back in 2013, ABBV has become a monster in the world of dividends thanks to one source - Humira. | Dividend Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield: 3.9% Dividend Schedule: February, May, August, November Biotech firms aren't normally a favorite stomping ground for those investors looking for dividend stocks. Case in point, biotech giant AbbVie Inc (NASDAQ: ABBV ). Spun off from Abbott Laboratories (NYSE: ABT ) back in 2013, ABBV has become a monster in the world of dividends thanks to one source - Humira. | Dividend Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield: 3.9% Dividend Schedule: February, May, August, November Biotech firms aren't normally a favorite stomping ground for those investors looking for dividend stocks. Case in point, biotech giant AbbVie Inc (NASDAQ: ABBV ). Spun off from Abbott Laboratories (NYSE: ABT ) back in 2013, ABBV has become a monster in the world of dividends thanks to one source - Humira. |
26156.0 | 2017-05-22 00:00:00 UTC | The 3 Best Dividend Stocks in Arthritis Medication | ABBV | https://www.nasdaq.com/articles/3-best-dividend-stocks-arthritis-medication-2017-05-22 | nan | nan | Theglobal marketfor rheumatoid-arthritis drugs is expected to top $19 billion by 2020. Three of the 10 best-selling drugs in the world are arthritis medications. Pharmaceutical companies that market arthritis medications are making a lot of money -- and, as a result, some rank among the top dividend stocks around.
AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Johnson & Johnson (NYSE: JNJ) appear to be the best dividend stocks among arthritis drugmakers. Here's why.
AbbVie: Best-selling arthritis drug and a strong dividend
AbbVie's Humira is the world's best-selling rheumatoid-arthritis drug and best-selling prescription drug overall, raking in $16 billion in sales last year. Thanks in large part to the success of Humira, AbbVie's dividend currently yields 3.84%, one of the highest among biopharmaceutical companies.
What's even better is that AbbVie has raised its dividend 60% since being spun off from parent Abbott Labs in 2013. The company appears to be in excellent position to continue dividend increases in the future, with a dividend payout ratio of less than 61% and growing earnings.
AbbVie depends on Humira for 63% of its total revenue, but the biotech has another rising star in cancer drug Imbruvica. In addition, AbbVie's pipeline includes several potential blockbusters, with cancer drug Rova-T and autoimmune-disease drugs ABT-494 and risankizumab at the top of the list.
Some might worry about threats from biosimilars to Humira. Amgen (NASDAQ: AMGN) won U.S. regulatory approval for its Humira biosimilar last year. However, AbbVie thinks it will be able to fend off U.S. rivals through 2022 by defending its array of patents for Humira.
Pfizer: High yield and great long-term prospects
Pfizer markets Enbrel along with partner Amgen. The drug ranked as the No. 2 rheumatoid arthritis drug in sales and the No. 3 prescription drug overall. Pfizer's portion of revenue generated by Enbrel in 2016 totaled $2.9 billion. (Amgen made nearly $6 billion from the drug.)
Enbrel was one of four megablockbuster drugs in Pfizer's product lineup last year. These big moneymakers helped Pfizer pay out a very attractive dividend, which currently yields 3.88%.
Although Pfizer's growth has been sluggish in recent years, the company should be in good shape for better performance in the future . Pfizer could become one of the biggest success stories in the cancer drug market, with soaring sales for Ibrance, the addition of Xtandi with its acquisition of Medivation last year, and a promising new drug, Bavencio.
Pfizer also should generate nice growth outside the oncology arena. Atopic dermatitis drug Eucrisa could reach peak annual sales of around $2 billion. Sales are also growing strongly for anticoagulant Eliquis, which Pfizer co-markets with Bristol-Myers Squibb .
Johnson & Johnson: A stellar track record and loaded pipeline
Johnson & Johnson's Remicade stood as the world's third highest-selling arthritis drug last year. It also held the spot as the No. 5 prescription drug in overall sales. However, the position for Remicade could be in jeopardy in the near future as Pfizer cranks up its efforts in marketing its biosimilar, Inflectra.
J&J's dividend yield currently stands at 2.65%. That's lower than a few arthritis-drug stocks that aren't on this list, notably including both Amgen and Bristol-Myers Squibb (which markets Orencia). So why did J&J leapfrog these other stocks?
It comes down to history. Johnson & Johnson boasts one of the most stellar track records of any dividend stock. The company has increased its dividend for 54 consecutive years. That track record gives J&J a distinct advantage in attracting dividend-seeking investors.
The company's reliable cash flow should allow Johnson & Johnson to keep its streak of dividend increases going for a long time to come. J&J also has what I consider to be among the strongest pipelines of any major drugmaker . The company has 30 late-stage clinical programs and will add even more once its acquisition of Actelion closes.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
Keith Speights owns shares of AbbVie and Pfizer. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie depends on Humira for 63% of its total revenue, but the biotech has another rising star in cancer drug Imbruvica. AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Johnson & Johnson (NYSE: JNJ) appear to be the best dividend stocks among arthritis drugmakers. AbbVie: Best-selling arthritis drug and a strong dividend AbbVie's Humira is the world's best-selling rheumatoid-arthritis drug and best-selling prescription drug overall, raking in $16 billion in sales last year. | AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Johnson & Johnson (NYSE: JNJ) appear to be the best dividend stocks among arthritis drugmakers. AbbVie: Best-selling arthritis drug and a strong dividend AbbVie's Humira is the world's best-selling rheumatoid-arthritis drug and best-selling prescription drug overall, raking in $16 billion in sales last year. Thanks in large part to the success of Humira, AbbVie's dividend currently yields 3.84%, one of the highest among biopharmaceutical companies. | AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Johnson & Johnson (NYSE: JNJ) appear to be the best dividend stocks among arthritis drugmakers. AbbVie: Best-selling arthritis drug and a strong dividend AbbVie's Humira is the world's best-selling rheumatoid-arthritis drug and best-selling prescription drug overall, raking in $16 billion in sales last year. Thanks in large part to the success of Humira, AbbVie's dividend currently yields 3.84%, one of the highest among biopharmaceutical companies. | AbbVie: Best-selling arthritis drug and a strong dividend AbbVie's Humira is the world's best-selling rheumatoid-arthritis drug and best-selling prescription drug overall, raking in $16 billion in sales last year. AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Johnson & Johnson (NYSE: JNJ) appear to be the best dividend stocks among arthritis drugmakers. Thanks in large part to the success of Humira, AbbVie's dividend currently yields 3.84%, one of the highest among biopharmaceutical companies. |
26157.0 | 2017-05-22 00:00:00 UTC | Woodford Investment Management LLP Buys Gilead Sciences Inc, Bioverativ Inc, Biogen Inc, Sells ... | ABBV | https://www.nasdaq.com/articles/woodford-investment-management-llp-buys-gilead-sciences-inc-bioverativ-inc-biogen-inc | nan | nan | Woodford Investment Management LLP
Added Positions: GILD , PRTA , BIVV , BIIB, TBPH,
Reduced Positions:ABBV,
Sold Out:NWBO,
For the details of Woodford Investment Management LLP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Woodford+Investment+Management+LLP
These are the top 5 holdings of Woodford Investment Management LLP
AbbVie Inc ( ABBV ) - 10,917,258 shares, 29.45% of the total portfolio. Shares reduced by 2.81%
Prothena Corp PLC ( PRTA ) - 11,106,211 shares, 25.64% of the total portfolio. Shares added by 7.72%
Alkermes PLC ( ALKS ) - 7,470,528 shares, 18.09% of the total portfolio. Shares added by 0.26%
Theravance Biopharma Inc ( TBPH ) - 10,705,108 shares, 16.31% of the total portfolio. Shares added by 1.88%
Gilead Sciences Inc ( GILD ) - 1,588,100 shares, 4.47% of the total portfolio. Shares added by 158.52%
Added: Gilead Sciences Inc ( GILD )
Woodford Investment Management LLP added to the holdings in Gilead Sciences Inc by 158.52%. The purchase prices were between $65.59 and $76.38, with an estimated average price of $70.32. The stock is now traded at around $64.36. The impact to the portfolio due to this purchase was 2.74%. The holdings were 1,588,100 shares as of 2017-03-31.
Added: Bioverativ Inc (BIVV)
Woodford Investment Management LLP added to the holdings in Bioverativ Inc by 536.76%. The purchase prices were between $41.82 and $54.46, with an estimated average price of $47.97. The stock is now traded at around $54.69. The impact to the portfolio due to this purchase was 1.5%. The holdings were 791,264 shares as of 2017-03-31.
Added: Biogen Inc (BIIB)
Woodford Investment Management LLP added to the holdings in Biogen Inc by 51.61%. The purchase prices were between $251.68 and $297.85, with an estimated average price of $275.15. The stock is now traded at around $250.04. The impact to the portfolio due to this purchase was 1.45%. The holdings were 376,788 shares as of 2017-03-31.
Sold Out: Northwest Biotherapeutics Inc (NWBO)
Woodford Investment Management LLP sold out the holdings in Northwest Biotherapeutics Inc. The sale prices were between $0.23 and $0.48, with an estimated average price of $0.37.
GILD 15-Year Financial Data
The intrinsic value of GILD
Peter Lynch Chart of GILD
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Woodford Investment Management LLP Added Positions: GILD , PRTA , BIVV , BIIB, TBPH, Reduced Positions:ABBV, Sold Out:NWBO, For the details of Woodford Investment Management LLP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Woodford+Investment+Management+LLP These are the top 5 holdings of Woodford Investment Management LLP AbbVie Inc ( ABBV ) - 10,917,258 shares, 29.45% of the total portfolio. Added: Bioverativ Inc (BIVV) Woodford Investment Management LLP added to the holdings in Bioverativ Inc by 536.76%. Sold Out: Northwest Biotherapeutics Inc (NWBO) Woodford Investment Management LLP sold out the holdings in Northwest Biotherapeutics Inc. | Woodford Investment Management LLP Added Positions: GILD , PRTA , BIVV , BIIB, TBPH, Reduced Positions:ABBV, Sold Out:NWBO, For the details of Woodford Investment Management LLP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Woodford+Investment+Management+LLP These are the top 5 holdings of Woodford Investment Management LLP AbbVie Inc ( ABBV ) - 10,917,258 shares, 29.45% of the total portfolio. Shares added by 158.52% Added: Gilead Sciences Inc ( GILD ) Woodford Investment Management LLP added to the holdings in Gilead Sciences Inc by 158.52%. Sold Out: Northwest Biotherapeutics Inc (NWBO) Woodford Investment Management LLP sold out the holdings in Northwest Biotherapeutics Inc. | Woodford Investment Management LLP Added Positions: GILD , PRTA , BIVV , BIIB, TBPH, Reduced Positions:ABBV, Sold Out:NWBO, For the details of Woodford Investment Management LLP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Woodford+Investment+Management+LLP These are the top 5 holdings of Woodford Investment Management LLP AbbVie Inc ( ABBV ) - 10,917,258 shares, 29.45% of the total portfolio. Shares added by 1.88% Gilead Sciences Inc ( GILD ) - 1,588,100 shares, 4.47% of the total portfolio. Shares added by 158.52% Added: Gilead Sciences Inc ( GILD ) Woodford Investment Management LLP added to the holdings in Gilead Sciences Inc by 158.52%. | Woodford Investment Management LLP Added Positions: GILD , PRTA , BIVV , BIIB, TBPH, Reduced Positions:ABBV, Sold Out:NWBO, For the details of Woodford Investment Management LLP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Woodford+Investment+Management+LLP These are the top 5 holdings of Woodford Investment Management LLP AbbVie Inc ( ABBV ) - 10,917,258 shares, 29.45% of the total portfolio. Shares added by 1.88% Gilead Sciences Inc ( GILD ) - 1,588,100 shares, 4.47% of the total portfolio. Shares added by 158.52% Added: Gilead Sciences Inc ( GILD ) Woodford Investment Management LLP added to the holdings in Gilead Sciences Inc by 158.52%. |
26158.0 | 2017-05-19 00:00:00 UTC | The Zacks Analyst Blog Highlights: Boeing, AbbVie, UnitedHealth, Consolidated Edison and Cisco | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-boeing-abbvie-unitedhealth-consolidated-edison-and | nan | nan | For Immediate Release
Chicago, IL - May 19, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Boeing (NYSE: BA- Free Report ), AbbVie (NYSE: ABBV- Free Report ), UnitedHealth (NYSE: UNH- Free Report ), Consolidated Edison (NYSE: ED- Free Report ) and Cisco (NASDAQ: CSCO- Free Report ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Thursday's Analyst Blog:
New Stock Research Reports for Today: BA, ABBV, UNH & More
Today's Research Daily features new research reports on 16 major stocks, including Boeing (NYSE: BA- Free Report ), AbbVie (NYSE: ABBV- Free Report ) and UnitedHealth (NYSE: UNH- Free Report ). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today's research reports here >>>
Boeing shares have surged +39.6% over the past one-year, outperforming the Zacks Aerospace & Defense sector, which gained +20.9% during the same time period. The Zacks analyst stresses that rising demand for its commercial airplanes on the back of steady improvement in passenger and freight traffic is the major factor behind the surge in Boeing shares. These developments reflect the company's latest expansion on the international front, apart from its strong presence in the domestic aviation market. The improving outlook for defense spending under the Trump administration is another long-term positive in the Boeing story. However, challenges including uncertain fate of high-cost programs, risks related to key project executions, order cancellations as well as stiff competition might have a negative impact on the company. (You can read the full research report on Boeing here>>> )
AbbVieshares have gained +10.2% over the last one year, outperforming the large cap pharma industry, which has gained +4.4% over the same period. The stock as well as the industry has lagged the broader market, however, on continued macro uncertainty related to drug pricing. AbbVie reported better-than-expected results in the first quarter, surpassing expectations for both earnings and sales. The Zacks analyst likes its key drug Humira's performance. Sales should continue to be driven by growing awareness, favorable clinical data, additional indications and expansion into new markets. Moreover, products like Viekira and Imbruvica have diversified AbbVie's revenue base. AbbVie has a deep and promising pipeline and is also working on expanding its portfolio though additional deals. On the flip side, the Zacks analyst points out that Viekira faces intense pricing pressure and competition in the HCV market. Additionally, quite a few companies are working on bringing Humira biosimilars to the market. (You can read the full research report on AbbVie here>>> )
UnitedHealth shares have lagged the peer group lately, with the stock up +5.5% in the year-to-date period vs. the Zacks HMO industry's +10.5% gain. A big reason for the stock's recent underperformance are questions about the company's Medicare Advantage policies in recent years following a whistleblower accusations. The company's decision to reduce its exposure to the troubled public exchange business is a likely another issue. Though this move will shield it from losses in this business, the company's premium revenues will be affected. These challenges notwithstanding, the Zacks analyst likes the company's strong fundamentals and diversified operations which should help it counter these headwinds. The company raised its 2017 guidance on the back of its solid first-quarter earnings. UnitedHealth has also witnessed an upward revision in earnings estimates for 2017 over the last 30 days. (You can read the full research report on UnitedHealth here>>> )
Other noteworthy reports we are featuring today include Consolidated Edison (NYSE: ED- Free Report ) and Cisco (NASDAQ: CSCO- Free Report ).
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
See today's Zacks "Strong Sells" absolutely free >> .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free .
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Get the full Report on BA - FREE
Get the full Report on ABBV - FREE
Get the full Report on UNH - FREE
Get the full Report on ED - FREE
Get the full Report on CSCO - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.
This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boeing Company (The) (BA): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report
Consolidated Edison Inc (ED): Free Stock Analysis Report
Cisco Systems, Inc. (CSCO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (You can read the full research report on AbbVie here>>> ) UnitedHealth shares have lagged the peer group lately, with the stock up +5.5% in the year-to-date period vs. the Zacks HMO industry's +10.5% gain. Stocks recently featured in the blog include Boeing (NYSE: BA- Free Report ), AbbVie (NYSE: ABBV- Free Report ), UnitedHealth (NYSE: UNH- Free Report ), Consolidated Edison (NYSE: ED- Free Report ) and Cisco (NASDAQ: CSCO- Free Report ). Here are highlights from Thursday's Analyst Blog: New Stock Research Reports for Today: BA, ABBV, UNH & More Today's Research Daily features new research reports on 16 major stocks, including Boeing (NYSE: BA- Free Report ), AbbVie (NYSE: ABBV- Free Report ) and UnitedHealth (NYSE: UNH- Free Report ). | Stocks recently featured in the blog include Boeing (NYSE: BA- Free Report ), AbbVie (NYSE: ABBV- Free Report ), UnitedHealth (NYSE: UNH- Free Report ), Consolidated Edison (NYSE: ED- Free Report ) and Cisco (NASDAQ: CSCO- Free Report ). Here are highlights from Thursday's Analyst Blog: New Stock Research Reports for Today: BA, ABBV, UNH & More Today's Research Daily features new research reports on 16 major stocks, including Boeing (NYSE: BA- Free Report ), AbbVie (NYSE: ABBV- Free Report ) and UnitedHealth (NYSE: UNH- Free Report ). Click to get this free report Boeing Company (The) (BA): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Consolidated Edison Inc (ED): Free Stock Analysis Report Cisco Systems, Inc. (CSCO): Free Stock Analysis Report To read this article on Zacks.com click here. | Here are highlights from Thursday's Analyst Blog: New Stock Research Reports for Today: BA, ABBV, UNH & More Today's Research Daily features new research reports on 16 major stocks, including Boeing (NYSE: BA- Free Report ), AbbVie (NYSE: ABBV- Free Report ) and UnitedHealth (NYSE: UNH- Free Report ). Get the full Report on BA - FREE Get the full Report on ABBV - FREE Get the full Report on UNH - FREE Get the full Report on ED - FREE Get the full Report on CSCO - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report Boeing Company (The) (BA): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Consolidated Edison Inc (ED): Free Stock Analysis Report Cisco Systems, Inc. (CSCO): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include Boeing (NYSE: BA- Free Report ), AbbVie (NYSE: ABBV- Free Report ), UnitedHealth (NYSE: UNH- Free Report ), Consolidated Edison (NYSE: ED- Free Report ) and Cisco (NASDAQ: CSCO- Free Report ). Here are highlights from Thursday's Analyst Blog: New Stock Research Reports for Today: BA, ABBV, UNH & More Today's Research Daily features new research reports on 16 major stocks, including Boeing (NYSE: BA- Free Report ), AbbVie (NYSE: ABBV- Free Report ) and UnitedHealth (NYSE: UNH- Free Report ). (You can read the full research report on Boeing here>>> ) AbbVieshares have gained +10.2% over the last one year, outperforming the large cap pharma industry, which has gained +4.4% over the same period. |
26159.0 | 2017-05-18 00:00:00 UTC | AbbVie Down on Humira Patent Loss: Is More Damage in Store? | ABBV | https://www.nasdaq.com/articles/abbvie-down-on-humira-patent-loss%3A-is-more-damage-in-store-2017-05-18 | nan | nan | AbbVie Inc. 's ABBV shares declined more than 2% on Wednesday after it lost a lawsuit related to a patent protecting its key rheumatoid arthritis drug, Humira to small biotech Coherus BioSciences, Inc. CHRS .
So far this year, AbbVie's share price has increased 4.4%, comparing unfavorably with a gain of 9.4% recorded by the Zacks classified Large-Cap Pharma industry.
Coherus is looking to get approval for a biosimilar version of Humira. Its shares shot up almost 8% on Wednesday.
Patent '135, which expires in Jun 2022, faces two additional IPR challenges from Boehringer Ingelheim, with rulings expected by early July.
The PTAB ruling did not come as a surprise as it was broadly expected. The investment community generally believes that AbbVie has a robust intellectual property (IP) portfolio beyond the '135 patent, which should preclude biosimilars from the U.S. market until 2022. Sales should continue to remain strong until then.
However, another group of investors comment that though the PTAB ruling was a minor hit for AbbVie, it still increases the chance of a biosimilar Humira launch earlier than expected.
Humira is key driver of Amgen's revenues, accounting for more than 60% of its total sales. The product continues to see strong growth in the dermatology and gastroenterology markets. Growing awareness, favorable clinical data, additional indications and expansion into new markets like China and Japan is helping the product contribute consistently to AbbVie's top line. The company expects Humira to bring in total sales of more than $18 billion in 2020.
However, several companies including Amgen, Inc. AMGN /Allergan plc AGN and Samsung Bioepis are working on biosimilar versions of Humira. Amgen's biosimilar version of Humira, Amjevita, was approved by the FDA in Sep 2016 and in the EU (trade name: Amgevita) in Mar 2017 for the same indications as Humira. However, Amgen is not expected to launch the drug at-risk amid litigation.
The entry of biosimilars will have a huge impact on the company's financials.
AbbVie carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Allergan PLC. (AGN): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Coherus BioSciences, Inc. (CHRS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. 's ABBV shares declined more than 2% on Wednesday after it lost a lawsuit related to a patent protecting its key rheumatoid arthritis drug, Humira to small biotech Coherus BioSciences, Inc. CHRS . However, another group of investors comment that though the PTAB ruling was a minor hit for AbbVie, it still increases the chance of a biosimilar Humira launch earlier than expected. Growing awareness, favorable clinical data, additional indications and expansion into new markets like China and Japan is helping the product contribute consistently to AbbVie's top line. | So far this year, AbbVie's share price has increased 4.4%, comparing unfavorably with a gain of 9.4% recorded by the Zacks classified Large-Cap Pharma industry. (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Coherus BioSciences, Inc. (CHRS): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. 's ABBV shares declined more than 2% on Wednesday after it lost a lawsuit related to a patent protecting its key rheumatoid arthritis drug, Humira to small biotech Coherus BioSciences, Inc. CHRS . | AbbVie Inc. 's ABBV shares declined more than 2% on Wednesday after it lost a lawsuit related to a patent protecting its key rheumatoid arthritis drug, Humira to small biotech Coherus BioSciences, Inc. CHRS . However, another group of investors comment that though the PTAB ruling was a minor hit for AbbVie, it still increases the chance of a biosimilar Humira launch earlier than expected. (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Coherus BioSciences, Inc. (CHRS): Free Stock Analysis Report To read this article on Zacks.com click here. | AbbVie Inc. 's ABBV shares declined more than 2% on Wednesday after it lost a lawsuit related to a patent protecting its key rheumatoid arthritis drug, Humira to small biotech Coherus BioSciences, Inc. CHRS . So far this year, AbbVie's share price has increased 4.4%, comparing unfavorably with a gain of 9.4% recorded by the Zacks classified Large-Cap Pharma industry. The investment community generally believes that AbbVie has a robust intellectual property (IP) portfolio beyond the '135 patent, which should preclude biosimilars from the U.S. market until 2022. |
26160.0 | 2017-05-18 00:00:00 UTC | SPHD's Holdings Imply 10% Gain Potential | ABBV | https://www.nasdaq.com/articles/sphds-holdings-imply-10-gain-potential-2017-05-18 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the PowerShares S&P 500 High Dividend Low Volatility Portfolio ETF (Symbol: SPHD), we found that the implied analyst target price for the ETF based upon its underlying holdings is $43.39 per unit.
With SPHD trading at a recent price near $39.32 per unit, that means that analysts see 10.35% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of SPHD's underlying holdings with notable upside to their analyst target prices are Realty Income Corp (Symbol: O), AbbVie Inc (Symbol: ABBV), and AT&T Inc (Symbol: T). Although O has traded at a recent price of $53.76/share, the average analyst target is 15.49% higher at $62.09/share. Similarly, ABBV has 15.01% upside from the recent share price of $65.37 if the average analyst target price of $75.18/share is reached, and analysts on average are expecting T to reach a target price of $43.05/share, which is 14.94% above the recent price of $37.46. Below is a twelve month price history chart comparing the stock performance of O, ABBV, and T:
Combined, O, ABBV, and T represent 6.14% of the PowerShares S&P 500 High Dividend Low Volatility Portfolio ETF. Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a twelve month price history chart comparing the stock performance of O, ABBV, and T: Combined, O, ABBV, and T represent 6.14% of the PowerShares S&P 500 High Dividend Low Volatility Portfolio ETF. Three of SPHD's underlying holdings with notable upside to their analyst target prices are Realty Income Corp (Symbol: O), AbbVie Inc (Symbol: ABBV), and AT&T Inc (Symbol: T). Similarly, ABBV has 15.01% upside from the recent share price of $65.37 if the average analyst target price of $75.18/share is reached, and analysts on average are expecting T to reach a target price of $43.05/share, which is 14.94% above the recent price of $37.46. | Similarly, ABBV has 15.01% upside from the recent share price of $65.37 if the average analyst target price of $75.18/share is reached, and analysts on average are expecting T to reach a target price of $43.05/share, which is 14.94% above the recent price of $37.46. Three of SPHD's underlying holdings with notable upside to their analyst target prices are Realty Income Corp (Symbol: O), AbbVie Inc (Symbol: ABBV), and AT&T Inc (Symbol: T). Below is a twelve month price history chart comparing the stock performance of O, ABBV, and T: Combined, O, ABBV, and T represent 6.14% of the PowerShares S&P 500 High Dividend Low Volatility Portfolio ETF. | Similarly, ABBV has 15.01% upside from the recent share price of $65.37 if the average analyst target price of $75.18/share is reached, and analysts on average are expecting T to reach a target price of $43.05/share, which is 14.94% above the recent price of $37.46. Three of SPHD's underlying holdings with notable upside to their analyst target prices are Realty Income Corp (Symbol: O), AbbVie Inc (Symbol: ABBV), and AT&T Inc (Symbol: T). Below is a twelve month price history chart comparing the stock performance of O, ABBV, and T: Combined, O, ABBV, and T represent 6.14% of the PowerShares S&P 500 High Dividend Low Volatility Portfolio ETF. | Three of SPHD's underlying holdings with notable upside to their analyst target prices are Realty Income Corp (Symbol: O), AbbVie Inc (Symbol: ABBV), and AT&T Inc (Symbol: T). Similarly, ABBV has 15.01% upside from the recent share price of $65.37 if the average analyst target price of $75.18/share is reached, and analysts on average are expecting T to reach a target price of $43.05/share, which is 14.94% above the recent price of $37.46. Below is a twelve month price history chart comparing the stock performance of O, ABBV, and T: Combined, O, ABBV, and T represent 6.14% of the PowerShares S&P 500 High Dividend Low Volatility Portfolio ETF. |
26161.0 | 2017-05-18 00:00:00 UTC | AbbVie's Humira Loses Patent in Coherus’ Petitions | ABBV | https://www.nasdaq.com/articles/abbvies-humira-loses-patent-coherus-petitions-2017-05-18 | nan | nan | It seems that the decision of the U.S. Patent and Trademark Office's Patent Trial and Appeal Board to rule "in favor of Coherus' petitions for Inter Partes Review ("IPR") of AbbVie's U.S. Patent 8,889,135 (the 135 Patent)" as reported by Coherus Biosciences ( CHRS ) through its Web site, is not weighing so much on AbbVie Inc. ( ABBV ) whose shares have - in contrast - resumed their uptrending and are $65.40 each, up 3 cents or plus 6% from the previous trading day.
The decision of the Patent Trial and Appeal Board, reports Coherus Biosciences, to invalidate "all claims of the patent that were directed to a method for treating rheumatoid arthritis by administering 40 mg of HUMIRA( R ) subcutaneously every 13 to 15 days," opens the door to the launch on the market of Coherus Biosciences' CHS-1420 as a biosimilar of Humira, the trade name under which AbbVie markets adalimumab, a drug used to treat patients affected with rheumatoid arthritis.
But before Coherus Biosciences' CHS-1420 starts to erode the market share of Humira from which sale AbbVie makes approximately 60% of its total revenue, it can take years. This is for two reasons:
First, because revenues of Humira are protected by a wide range of patents that cover the drug. Many of these patents have not been disputed yet.
Second, because Coherus' CHS is a biosimilar to Humira and not an interchangeable product, it is not identical to AbbVie's product to treat the rheumatoid arthritis - in primis - in terms of clinical results and side effects, bringing for patients a risk of developing side effects and/or obtain clinical results that are "similar" but not identical to the reference product (Humira). This will lead the doctors who have of course knowledge of the matter to be very careful at the beginning prescribing any biosimilar to AbbVie's adalimumab, and as a consequence, there will be, at least initially, fewer sales of Humira's product competitors.
Global sales of Humira were $4.118 billion, up 15.1% year over year, approximately 63% of the company's total revenue for the first quarter. For the next quarter analysts forecast Abbvie's revenue will come in at $6.92 billion, a 7.70% increase from the same item of one year ago and at $27.77 billion for fiscal year 2017, an 8.70% increase on a year-over-year basis.
Concerning earnings, analysts expect that AbbVie will generate an EPS of $1.4 in the second quarter versus an EPS of $1.26 generated in the comparable quarter of 2016 and an EPS of $5.53 in 2017 versus an EPS of $4.82 generated by the company in 2016.
As of the most recent quarter, AbbVie had approximately $6.25 billion in cash and securities. The total debt amounted to $37.3 billion.
The long-term debt-equity ratio is 730.81 versus an industry average ratio of 9.04, according to Reuters. This suggests the company is highly indebted, but the interest coverage ratio is 7.19, which means AbbVie can easily pay the interest expenses on its outstanding debt.
AbbVie has 1.59 billion shares outstanding, of which almost 100% is float. The percentage of shares held by insiders is 0.10% and by institutions is 73.60%.
AbbVie has a market capitalization of $104.17 billion and an enterprise value of $136.19 billion. The pharmaceutical company is trading at 20.84 times the book value and at 12.22 times the EBITDA.
The 52-week range is between $55.06 per share and $68.12 per share. The forward price-earnings (P/E) ratio is 10.13.
In the first quarter, Richard Pzena increased his position in AbbVie by 19.97% to a total volume of shares held of 4,170 as of March 31.
Leucadia National and NWQ Managers established a position in AbbVie, buying 8,008 and 4,232 shares.
Joel Greenblatt , David Dreman, Mario Gabelli and Ken Fisher decreased their positions in AbbVie by 33.88% to 618,480 shares, 2.41% to 22,356 shares, 3.49% to 19,376 shares and 1.96% to 682,915 shares as of March 31, 2016.
AbbVie distributes an annual dividend of $2.56 to its shareholders, through quarterly payments of 64 cents, for a dividend yield of 3.83%.
Disclosure: I have no positions in any stock mentioned in this article.
Start a free seven-day trial of Premium Membership to GuruFocus.
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The decision of the Patent Trial and Appeal Board, reports Coherus Biosciences, to invalidate "all claims of the patent that were directed to a method for treating rheumatoid arthritis by administering 40 mg of HUMIRA( R ) subcutaneously every 13 to 15 days," opens the door to the launch on the market of Coherus Biosciences' CHS-1420 as a biosimilar of Humira, the trade name under which AbbVie markets adalimumab, a drug used to treat patients affected with rheumatoid arthritis. But before Coherus Biosciences' CHS-1420 starts to erode the market share of Humira from which sale AbbVie makes approximately 60% of its total revenue, it can take years. This will lead the doctors who have of course knowledge of the matter to be very careful at the beginning prescribing any biosimilar to AbbVie's adalimumab, and as a consequence, there will be, at least initially, fewer sales of Humira's product competitors. | The decision of the Patent Trial and Appeal Board, reports Coherus Biosciences, to invalidate "all claims of the patent that were directed to a method for treating rheumatoid arthritis by administering 40 mg of HUMIRA( R ) subcutaneously every 13 to 15 days," opens the door to the launch on the market of Coherus Biosciences' CHS-1420 as a biosimilar of Humira, the trade name under which AbbVie markets adalimumab, a drug used to treat patients affected with rheumatoid arthritis. But before Coherus Biosciences' CHS-1420 starts to erode the market share of Humira from which sale AbbVie makes approximately 60% of its total revenue, it can take years. It seems that the decision of the U.S. Patent and Trademark Office's Patent Trial and Appeal Board to rule "in favor of Coherus' petitions for Inter Partes Review ("IPR") of AbbVie's U.S. Patent 8,889,135 (the 135 Patent)" as reported by Coherus Biosciences ( CHRS ) through its Web site, is not weighing so much on AbbVie Inc. ( ABBV ) whose shares have - in contrast - resumed their uptrending and are $65.40 each, up 3 cents or plus 6% from the previous trading day. | It seems that the decision of the U.S. Patent and Trademark Office's Patent Trial and Appeal Board to rule "in favor of Coherus' petitions for Inter Partes Review ("IPR") of AbbVie's U.S. Patent 8,889,135 (the 135 Patent)" as reported by Coherus Biosciences ( CHRS ) through its Web site, is not weighing so much on AbbVie Inc. ( ABBV ) whose shares have - in contrast - resumed their uptrending and are $65.40 each, up 3 cents or plus 6% from the previous trading day. The decision of the Patent Trial and Appeal Board, reports Coherus Biosciences, to invalidate "all claims of the patent that were directed to a method for treating rheumatoid arthritis by administering 40 mg of HUMIRA( R ) subcutaneously every 13 to 15 days," opens the door to the launch on the market of Coherus Biosciences' CHS-1420 as a biosimilar of Humira, the trade name under which AbbVie markets adalimumab, a drug used to treat patients affected with rheumatoid arthritis. Joel Greenblatt , David Dreman, Mario Gabelli and Ken Fisher decreased their positions in AbbVie by 33.88% to 618,480 shares, 2.41% to 22,356 shares, 3.49% to 19,376 shares and 1.96% to 682,915 shares as of March 31, 2016. | But before Coherus Biosciences' CHS-1420 starts to erode the market share of Humira from which sale AbbVie makes approximately 60% of its total revenue, it can take years. In the first quarter, Richard Pzena increased his position in AbbVie by 19.97% to a total volume of shares held of 4,170 as of March 31. It seems that the decision of the U.S. Patent and Trademark Office's Patent Trial and Appeal Board to rule "in favor of Coherus' petitions for Inter Partes Review ("IPR") of AbbVie's U.S. Patent 8,889,135 (the 135 Patent)" as reported by Coherus Biosciences ( CHRS ) through its Web site, is not weighing so much on AbbVie Inc. ( ABBV ) whose shares have - in contrast - resumed their uptrending and are $65.40 each, up 3 cents or plus 6% from the previous trading day. |
26162.0 | 2017-05-18 00:00:00 UTC | AbbVie Inc (ABBV) Stock STILL Has Much More Room to Run Higher | ABBV | https://www.nasdaq.com/articles/abbvie-inc-abbv-stock-still-has-much-more-room-to-run-higher-2017-05-18 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie Inc (NYSE: ABBV ) is the maker of the world's best selling pharmaceutical, Humira. In late 2012, Abbott Laboratories (NYSE: ABT ) spun off AbbVie with one drug and a lot of its accumulated debt. At the time, it looked like ABBV stock was being set up to fail so ABT could offload a lot of debt.
Source: Black Stripe via Wikimedia (Modified)
But now it looks like ABT might have some spinoff remorse now that the drug AbbVie was left with is doing about $16 billion a year in revenue.
Instead of getting sucked into the black hole of all the debt, ABBV stock has become a shining star in the biotech world.
Now that it has been averaging about 25% growth a year some analysts are throwing up caution signs because Humira's patent ran out in 2016. They talk about the nearly three dozen cheap generics and biosimlars that are ready to eat its lunch.
Why ABBV Stock Still Has Strength
AbbVie relies heavily on Humira revenue and anything that significantly eats into that revenue is cause for concern. But one of the strength of ABBV stock is the fact that it's backed by a company that is not only fighting hard to keep the would-be competitors out of its markets using legal tactics, it's also showing analysts that Humira still has some good years left.
It has raised the price of the drug by 8% and yet, according to its own numbers, saw sales growth in the U.S. of nearly 23% in the past quarter compared to the same quarter a year ago. International sales were up 15%.
7 Stocks to Buy Now for BIG Summer Outperformance
Speaking of Q1 numbers, revenue and earnings beat estimates handily. These are strong signals that AbbVie is not going down quickly. The company currently estimates it has about three years until Humira revenue starts dropping off. Part of what's keeping Humira alive is the fact that ABBV is also expanding its uses for the drug and it expects to bring in $20 billion on Humira in 2020.
But the biggest ace AbbVie has up its sleeve is its late-stage drug pipeline. The company estimates that eight of its drugs that are either in the market now or will be in the next year or two will bring in another $25 to $30 billion annually by 2020.
Spinraza for spinal muscular atrophy was just approved. There are two others in the phase 3 trials for Alzheimer's and 11 other drugs in phase 2 trials. The point is, ABBV stock is more than a one-trick pony.
The other nice component that AbbVie offers is a solid dividend. Even trading near its 52-week highs, the stock is still delivering an impressive 3.8% dividend. Coupled with the stock's near-5% rise year-to-date, that's a solid return for 2017.
The stock looks to be taking a breather right now and the bulls and bears are both tugging at it. This is a good time to get in on ABBV stock while neither side has the advantage and it is trading at a very reasonable price.
Richard Band'sProfitable Investing advisory service helps retirement savers outperform the market without losing a minute of sleep along the way. His straightforward style and low-risk value approach has won seven Best Financial Advisory awards from the Newsletter and Electronic Publishers Foundation.
More From InvestorPlace
7 Stocks That Will Get Crushed in the Next Crash
7 Stocks to Buy on the Next Big Market Dip
7 Stocks to Sell Thanks to TERRIBLE Seasonality
The post AbbVie Inc (ABBV) Stock STILL Has Much More Room to Run Higher appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Source: Black Stripe via Wikimedia (Modified) But now it looks like ABT might have some spinoff remorse now that the drug AbbVie was left with is doing about $16 billion a year in revenue. But one of the strength of ABBV stock is the fact that it's backed by a company that is not only fighting hard to keep the would-be competitors out of its markets using legal tactics, it's also showing analysts that Humira still has some good years left. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) is the maker of the world's best selling pharmaceutical, Humira. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) is the maker of the world's best selling pharmaceutical, Humira. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In late 2012, Abbott Laboratories (NYSE: ABT ) spun off AbbVie with one drug and a lot of its accumulated debt. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) is the maker of the world's best selling pharmaceutical, Humira. Why ABBV Stock Still Has Strength AbbVie relies heavily on Humira revenue and anything that significantly eats into that revenue is cause for concern. More From InvestorPlace 7 Stocks That Will Get Crushed in the Next Crash 7 Stocks to Buy on the Next Big Market Dip 7 Stocks to Sell Thanks to TERRIBLE Seasonality The post AbbVie Inc (ABBV) Stock STILL Has Much More Room to Run Higher appeared first on InvestorPlace . | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) is the maker of the world's best selling pharmaceutical, Humira. But one of the strength of ABBV stock is the fact that it's backed by a company that is not only fighting hard to keep the would-be competitors out of its markets using legal tactics, it's also showing analysts that Humira still has some good years left. In late 2012, Abbott Laboratories (NYSE: ABT ) spun off AbbVie with one drug and a lot of its accumulated debt. |
26163.0 | 2017-05-18 00:00:00 UTC | Notable Thursday Option Activity: ABBV, LB, GPS | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity-abbv-lb-gps-2017-05-18 | nan | nan | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 37,126 contracts have traded so far, representing approximately 3.7 million underlying shares. That amounts to about 60.5% of ABBV's average daily trading volume over the past month of 6.1 million shares. Especially high volume was seen for the $65 strike call option expiring May 19, 2017 , with 5,677 contracts trading so far today, representing approximately 567,700 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $65 strike highlighted in orange:
L Brands, Inc (Symbol: LB) saw options trading volume of 23,116 contracts, representing approximately 2.3 million underlying shares or approximately 54.3% of LB's average daily trading volume over the past month, of 4.3 million shares. Especially high volume was seen for the $50 strike call option expiring May 19, 2017 , with 9,430 contracts trading so far today, representing approximately 943,000 underlying shares of LB. Below is a chart showing LB's trailing twelve month trading history, with the $50 strike highlighted in orange:
And The Gap Inc (Symbol: GPS) options are showing a volume of 24,683 contracts thus far today. That number of contracts represents approximately 2.5 million underlying shares, working out to a sizeable 47.2% of GPS's average daily trading volume over the past month, of 5.2 million shares. Particularly high volume was seen for the $23 strike put option expiring May 19, 2017 , with 7,048 contracts trading so far today, representing approximately 704,800 underlying shares of GPS. Below is a chart showing GPS's trailing twelve month trading history, with the $23 strike highlighted in orange:
For the various different available expirations for ABBV options , LB options , or GPS options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $65 strike call option expiring May 19, 2017 , with 5,677 contracts trading so far today, representing approximately 567,700 underlying shares of ABBV. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 37,126 contracts have traded so far, representing approximately 3.7 million underlying shares. That amounts to about 60.5% of ABBV's average daily trading volume over the past month of 6.1 million shares. | Below is a chart showing ABBV's trailing twelve month trading history, with the $65 strike highlighted in orange: L Brands, Inc (Symbol: LB) saw options trading volume of 23,116 contracts, representing approximately 2.3 million underlying shares or approximately 54.3% of LB's average daily trading volume over the past month, of 4.3 million shares. Below is a chart showing GPS's trailing twelve month trading history, with the $23 strike highlighted in orange: For the various different available expirations for ABBV options , LB options , or GPS options , visit StockOptionsChannel.com. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 37,126 contracts have traded so far, representing approximately 3.7 million underlying shares. | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 37,126 contracts have traded so far, representing approximately 3.7 million underlying shares. Especially high volume was seen for the $65 strike call option expiring May 19, 2017 , with 5,677 contracts trading so far today, representing approximately 567,700 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $65 strike highlighted in orange: L Brands, Inc (Symbol: LB) saw options trading volume of 23,116 contracts, representing approximately 2.3 million underlying shares or approximately 54.3% of LB's average daily trading volume over the past month, of 4.3 million shares. | Below is a chart showing ABBV's trailing twelve month trading history, with the $65 strike highlighted in orange: L Brands, Inc (Symbol: LB) saw options trading volume of 23,116 contracts, representing approximately 2.3 million underlying shares or approximately 54.3% of LB's average daily trading volume over the past month, of 4.3 million shares. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 37,126 contracts have traded so far, representing approximately 3.7 million underlying shares. That amounts to about 60.5% of ABBV's average daily trading volume over the past month of 6.1 million shares. |
26164.0 | 2017-05-17 00:00:00 UTC | Look Out! Dow Drops More Than 200 Points; VIX Spikes 21% | ABBV | https://www.nasdaq.com/articles/look-out-dow-drops-more-200-points-vix-spikes-21-2017-05-17 | nan | nan | The market is getting nervous. The Dow dropped more than 280 points, and the U.S. dollar is falling, while the so-called fear gauge spiked as political drama continues to surround President Trump and the White House.
Agence France-Presse/Getty Images
The Dow Jones Industrial Average lost 282 points, or 1.3%, to 20,696, while the S&P 500 fell 30 points, or 1.25% to 2,370. The Nasdaq Composite lost 106 points, or 1.7% to 6,063.
Even tech stocks didn't weather the storm. The Technology Select Sector SPDR ETF (XLK) fell 1.4% to $55.35 a share, with Advanced Micro Devices (ADM) falling more than a 6%.
The CBOE Volatility Index (VIX) spiked 21.3% to 12.92. The index, which is based on options contracts on the S&P 500 index 30 days in the future, fell into the double digits earlier this month, hitting a 24-year low.
Not all stocks suffered alike. Coherus BioSciences (CHRS) rose 8.5% on a patent victory over AbbVie (ABBV). Abbvie shares, however, fell 2.2%.
Target (TGT) jumped 3.7% after posting better-than-feared fiscal first quarter financial results. Meanwhile, off-price retail chain TJX (TJX) climbed 1.7% on an upgrade by Morgan Stanley. And Colgate (CL) climbed 2.5% after the New York Post reported that t CEO Ian Cook is reportedly willing to sell the company for $100 per share.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Coherus BioSciences (CHRS) rose 8.5% on a patent victory over AbbVie (ABBV). Abbvie shares, however, fell 2.2%. The Dow dropped more than 280 points, and the U.S. dollar is falling, while the so-called fear gauge spiked as political drama continues to surround President Trump and the White House. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Coherus BioSciences (CHRS) rose 8.5% on a patent victory over AbbVie (ABBV). Abbvie shares, however, fell 2.2%. | Coherus BioSciences (CHRS) rose 8.5% on a patent victory over AbbVie (ABBV). Abbvie shares, however, fell 2.2%. Agence France-Presse/Getty Images The Dow Jones Industrial Average lost 282 points, or 1.3%, to 20,696, while the S&P 500 fell 30 points, or 1.25% to 2,370. | Abbvie shares, however, fell 2.2%. Coherus BioSciences (CHRS) rose 8.5% on a patent victory over AbbVie (ABBV). The market is getting nervous. |
26165.0 | 2017-05-16 00:00:00 UTC | Celgene's (CELG) Revlimid Looks Solid on Label Expansion | ABBV | https://www.nasdaq.com/articles/celgenes-celg-revlimid-looks-solid-on-label-expansion-2017-05-16 | nan | nan | We issued an updated research report on Celgene CorporationCELG on May 15, 2017.
Celgene is a biopharmaceutical company focused on the discovery, development and commercialization of drugs targeting cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetic, immunology and neuro-inflammation.
Celgene's key growth engine is Revlimid. Revlimid, an oral immunomodulatory drug, is currently approved for several indications including MM, myelodysplastic syndromes (MDS) and mantle cell lymphoma (MCL). The drug performed well in the first quarter and combated the deterrents of uneven buying patterns and coverage gap challenges. Continued momentum in the core indication, label expansion and global launches are likely to help the product to boost the top line.
Market share gains in key markets and longer treatment duration are contributing to the drug's growth. Meanwhile, Celgene is working on expanding Revlimid's label further. Revlimid received FDA approval for use as a maintenance treatment in NDMM patients after they receive an autologous stem-cell transplant. The drug was also approved in the EU for the same. NDMM market share continues to grow outside of the U.S., with a positive uptake both in the EU and in Japan.
Celgene's share price movement shows that the stock outperformed the Zacks classified Medical-Biomedical and Genetics industry in the past year. Specifically, the stock gained 18.7.% during this period, compared with a decline of 4.4% for the industry.
Celgene is also currently working on label expansion of drugs like Pomalyst/Imnovid, Abraxane and Otezla among others, which is encouraging. Pomalyst/Imnovid is being evaluated in multiple combination studies in relapsed/refractory MM.
Meanwhile, Celgene has a robust pipeline. Interesting candidates include GED-0301 (phase III - Crohn's disease, phase II - UC), CC-486 (phase III - high-risk MDS, phase II - NSCLC), enasidenib (phase III - relapsed/refractory AML - regulatory application filed in the U.S.) and luspatercept (phase III - lower-risk MDS and beta-thalassemia).
Successful development and subsequent approval of these candidates will be a huge boost for the company. The NDA for Idhifa was granted Priority Review with a Prescription Drug User Fee Act (PDUFA) action date of Aug 30.
While Revlimid sales continue to be impressive, we are concerned about the company's dependence on the product for growth. Lower-than-expected sales of the drug could adversely impact the company's growth prospects. On the other hand, Otezla sales in the first quarter were impacted by managed care dynamics that drove lower total marketplace prescriptions for psoriasis therapies in the first quarter.
Higher gross to net adjustment related to new contracts with several large payers that were implemented in January and a modest decline in inventory levels also impacted sales. Moreover, the hematology, oncology, inflammation and immunology markets are dominated by several major players like AbbVie ABBV and Amgen AMGN , among others.
Zacks Rank & Key Pick
Celgene currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the healthcare sector is VIVUS, Inc. VVUS which currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
VIVUS' loss per share estimates narrowed from 502 cents to 39 cents for 2017 over the last 60 days. The company posted positive earnings surprises in all of the four trailing quarters, with an average beat of 233.69%.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
VIVUS, Inc. (VVUS): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Moreover, the hematology, oncology, inflammation and immunology markets are dominated by several major players like AbbVie ABBV and Amgen AMGN , among others. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Celgene is a biopharmaceutical company focused on the discovery, development and commercialization of drugs targeting cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetic, immunology and neuro-inflammation. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, the hematology, oncology, inflammation and immunology markets are dominated by several major players like AbbVie ABBV and Amgen AMGN , among others. Market share gains in key markets and longer treatment duration are contributing to the drug's growth. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, the hematology, oncology, inflammation and immunology markets are dominated by several major players like AbbVie ABBV and Amgen AMGN , among others. Interesting candidates include GED-0301 (phase III - Crohn's disease, phase II - UC), CC-486 (phase III - high-risk MDS, phase II - NSCLC), enasidenib (phase III - relapsed/refractory AML - regulatory application filed in the U.S.) and luspatercept (phase III - lower-risk MDS and beta-thalassemia). | Moreover, the hematology, oncology, inflammation and immunology markets are dominated by several major players like AbbVie ABBV and Amgen AMGN , among others. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The drug was also approved in the EU for the same. |
26166.0 | 2017-05-15 00:00:00 UTC | Gyroscope Capital Management Group, LLC Buys Carnival Corp, General Electric Co, Leucadia ... | ABBV | https://www.nasdaq.com/articles/gyroscope-capital-management-group-llc-buys-carnival-corp-general-electric-co-leucadia | nan | nan | Gyroscope Capital Management Group, LLC
New Purchases: CCL , GE , LUK , PGR, ACN, TLT, BLV, XLF, XLV, XLY,
Added Positions:ABBV, T, AAPL, QCOM, CAH, CVX, ABC, XLK, MET, NEE,
Reduced Positions:TGT, PM, TEL, WLTW, XOM, AMP, CSCO, SHW, STZ, ACWV,
Sold Out:COH, LNC, SPY, INCY, MUB, LM, PEP, IJT, STJ, D,
For the details of Gyroscope Capital Management Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Gyroscope+Capital+Management+Group%2C+LLC
These are the top 5 holdings of Gyroscope Capital Management Group, LLC
AbbVie Inc ( ABBV ) - 89,825 shares, 3.53% of the total portfolio. Shares added by 27.98%
UnitedHealth Group Inc ( UNH ) - 34,822 shares, 3.45% of the total portfolio. Shares reduced by 0.34%
Sherwin-Williams Co ( SHW ) - 17,851 shares, 3.34% of the total portfolio. Shares reduced by 1.87%
AT&T Inc ( T ) - 130,262 shares, 3.27% of the total portfolio. Shares added by 28.56%
Carnival Corp ( CCL ) - 91,569 shares, 3.26% of the total portfolio. New Position
New Purchase: Carnival Corp ( CCL )
Gyroscope Capital Management Group, LLC initiated holdings in Carnival Corp. The purchase prices were between $52.14 and $59.29, with an estimated average price of $55.92. The stock is now traded at around $61.19. The impact to the portfolio due to this purchase was 3.26%. The holdings were 91,569 shares as of 2017-03-31.
New Purchase: General Electric Co (GE)
Gyroscope Capital Management Group, LLC initiated holdings in General Electric Co. The purchase prices were between $29.39 and $31.7, with an estimated average price of $30.2. The stock is now traded at around $28.27. The impact to the portfolio due to this purchase was 3.12%. The holdings were 173,258 shares as of 2017-03-31.
New Purchase: Leucadia National Corp (LUK)
Gyroscope Capital Management Group, LLC initiated holdings in Leucadia National Corp. The purchase prices were between $22.85 and $27.2, with an estimated average price of $24.98. The stock is now traded at around $25.30. The impact to the portfolio due to this purchase was 1.38%. The holdings were 88,010 shares as of 2017-03-31.
New Purchase: Progressive Corp (PGR)
Gyroscope Capital Management Group, LLC initiated holdings in Progressive Corp. The purchase prices were between $35.53 and $40.31, with an estimated average price of $38.16. The stock is now traded at around $39.98. The impact to the portfolio due to this purchase was 1.28%. The holdings were 54,136 shares as of 2017-03-31.
New Purchase: Accenture PLC (ACN)
Gyroscope Capital Management Group, LLC initiated holdings in Accenture PLC. The purchase prices were between $113.21 and $126.48, with an estimated average price of $119.39. The stock is now traded at around $120.96. The impact to the portfolio due to this purchase was 1.19%. The holdings were 16,398 shares as of 2017-03-31.
New Purchase: iShares 20+ Year Treasury Bond ETF (TLT)
Gyroscope Capital Management Group, LLC initiated holdings in iShares 20+ Year Treasury Bond ETF. The purchase prices were between $116.51 and $122.58, with an estimated average price of $120. The stock is now traded at around $121.39. The impact to the portfolio due to this purchase was 0.77%. The holdings were 10,549 shares as of 2017-03-31.
Added: AbbVie Inc ( ABBV )
Gyroscope Capital Management Group, LLC added to the holdings in AbbVie Inc by 27.98%. The purchase prices were between $60 and $66.55, with an estimated average price of $62.87. The stock is now traded at around $66.06. The impact to the portfolio due to this purchase was 0.77%. The holdings were 89,825 shares as of 2017-03-31.
Added: AT&T Inc ( T )
Gyroscope Capital Management Group, LLC added to the holdings in AT&T Inc by 28.56%. The purchase prices were between $40.61 and $43.02, with an estimated average price of $41.67. The stock is now traded at around $38.49. The impact to the portfolio due to this purchase was 0.73%. The holdings were 130,262 shares as of 2017-03-31.
Added: Apple Inc (AAPL)
Gyroscope Capital Management Group, LLC added to the holdings in Apple Inc by 236.58%. The purchase prices were between $115.82 and $144.12, with an estimated average price of $131.33. The stock is now traded at around $156.10. The impact to the portfolio due to this purchase was 0.7%. The holdings were 11,521 shares as of 2017-03-31.
Added: Cardinal Health Inc (CAH)
Gyroscope Capital Management Group, LLC added to the holdings in Cardinal Health Inc by 23.29%. The purchase prices were between $72.47 and $83.8, with an estimated average price of $78.71. The stock is now traded at around $72.90. The impact to the portfolio due to this purchase was 0.58%. The holdings were 61,916 shares as of 2017-03-31.
Added: Qualcomm Inc (QCOM)
Gyroscope Capital Management Group, LLC added to the holdings in Qualcomm Inc by 22.52%. The purchase prices were between $52.66 and $66.88, with an estimated average price of $58.02. The stock is now traded at around $55.32. The impact to the portfolio due to this purchase was 0.58%. The holdings were 90,668 shares as of 2017-03-31.
Added: SPDR Select Sector Fund - Technology (XLK)
Gyroscope Capital Management Group, LLC added to the holdings in SPDR Select Sector Fund - Technology by 221.12%. The purchase prices were between $48.36 and $53.43, with an estimated average price of $51.51. The stock is now traded at around $55.56. The impact to the portfolio due to this purchase was 0.34%. The holdings were 15,324 shares as of 2017-03-31.
Sold Out: Coach Inc (COH)
Gyroscope Capital Management Group, LLC sold out the holdings in Coach Inc. The sale prices were between $34.99 and $41.69, with an estimated average price of $37.68.
Sold Out: Lincoln National Corp (LNC)
Gyroscope Capital Management Group, LLC sold out the holdings in Lincoln National Corp. The sale prices were between $63.34 and $73.08, with an estimated average price of $68.38.
Sold Out: SPDR S&P 500 (SPY)
Gyroscope Capital Management Group, LLC sold out the holdings in SPDR S&P 500. The sale prices were between $223.53 and $239.78, with an estimated average price of $232.29.
Sold Out: Incyte Corp (INCY)
Gyroscope Capital Management Group, LLC sold out the holdings in Incyte Corp. The sale prices were between $102.32 and $152.66, with an estimated average price of $127.32.
Sold Out: iShares National Muni Bond (MUB)
Gyroscope Capital Management Group, LLC sold out the holdings in iShares National Muni Bond. The sale prices were between $107.63 and $109.26, with an estimated average price of $108.41.
Sold Out: Legg Mason Inc (LM)
Gyroscope Capital Management Group, LLC sold out the holdings in Legg Mason Inc. The sale prices were between $30.7 and $37.72, with an estimated average price of $34.65.
Warning! GuruFocus has detected 4 Warning Sign with ABBV. Click here to check it out.
ABBV 15-Year Financial Data
The intrinsic value of ABBV
Peter Lynch Chart of ABBV
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Gyroscope Capital Management Group, LLC New Purchases: CCL , GE , LUK , PGR, ACN, TLT, BLV, XLF, XLV, XLY, Added Positions:ABBV, T, AAPL, QCOM, CAH, CVX, ABC, XLK, MET, NEE, Reduced Positions:TGT, PM, TEL, WLTW, XOM, AMP, CSCO, SHW, STZ, ACWV, Sold Out:COH, LNC, SPY, INCY, MUB, LM, PEP, IJT, STJ, D, For the details of Gyroscope Capital Management Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Gyroscope+Capital+Management+Group%2C+LLC These are the top 5 holdings of Gyroscope Capital Management Group, LLC AbbVie Inc ( ABBV ) - 89,825 shares, 3.53% of the total portfolio. Added: AbbVie Inc ( ABBV ) Gyroscope Capital Management Group, LLC added to the holdings in AbbVie Inc by 27.98%. GuruFocus has detected 4 Warning Sign with ABBV. | Gyroscope Capital Management Group, LLC New Purchases: CCL , GE , LUK , PGR, ACN, TLT, BLV, XLF, XLV, XLY, Added Positions:ABBV, T, AAPL, QCOM, CAH, CVX, ABC, XLK, MET, NEE, Reduced Positions:TGT, PM, TEL, WLTW, XOM, AMP, CSCO, SHW, STZ, ACWV, Sold Out:COH, LNC, SPY, INCY, MUB, LM, PEP, IJT, STJ, D, For the details of Gyroscope Capital Management Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Gyroscope+Capital+Management+Group%2C+LLC These are the top 5 holdings of Gyroscope Capital Management Group, LLC AbbVie Inc ( ABBV ) - 89,825 shares, 3.53% of the total portfolio. Added: AbbVie Inc ( ABBV ) Gyroscope Capital Management Group, LLC added to the holdings in AbbVie Inc by 27.98%. GuruFocus has detected 4 Warning Sign with ABBV. | Gyroscope Capital Management Group, LLC New Purchases: CCL , GE , LUK , PGR, ACN, TLT, BLV, XLF, XLV, XLY, Added Positions:ABBV, T, AAPL, QCOM, CAH, CVX, ABC, XLK, MET, NEE, Reduced Positions:TGT, PM, TEL, WLTW, XOM, AMP, CSCO, SHW, STZ, ACWV, Sold Out:COH, LNC, SPY, INCY, MUB, LM, PEP, IJT, STJ, D, For the details of Gyroscope Capital Management Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Gyroscope+Capital+Management+Group%2C+LLC These are the top 5 holdings of Gyroscope Capital Management Group, LLC AbbVie Inc ( ABBV ) - 89,825 shares, 3.53% of the total portfolio. Added: AbbVie Inc ( ABBV ) Gyroscope Capital Management Group, LLC added to the holdings in AbbVie Inc by 27.98%. GuruFocus has detected 4 Warning Sign with ABBV. | Gyroscope Capital Management Group, LLC New Purchases: CCL , GE , LUK , PGR, ACN, TLT, BLV, XLF, XLV, XLY, Added Positions:ABBV, T, AAPL, QCOM, CAH, CVX, ABC, XLK, MET, NEE, Reduced Positions:TGT, PM, TEL, WLTW, XOM, AMP, CSCO, SHW, STZ, ACWV, Sold Out:COH, LNC, SPY, INCY, MUB, LM, PEP, IJT, STJ, D, For the details of Gyroscope Capital Management Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Gyroscope+Capital+Management+Group%2C+LLC These are the top 5 holdings of Gyroscope Capital Management Group, LLC AbbVie Inc ( ABBV ) - 89,825 shares, 3.53% of the total portfolio. Added: AbbVie Inc ( ABBV ) Gyroscope Capital Management Group, LLC added to the holdings in AbbVie Inc by 27.98%. GuruFocus has detected 4 Warning Sign with ABBV. |
26167.0 | 2017-05-15 00:00:00 UTC | AbbVie and J&J Present Positive Imbruvica Leukemia Data | ABBV | https://www.nasdaq.com/articles/abbvie-and-jj-present-positive-imbruvica-leukemia-data-2017-05-15 | nan | nan | AbbVie Inc.ABBV recently announced positive data from a pooled analysis of three phase III studies evaluating its cancer drug, Imbruvica (ibrutinib). The drug is to be used for the treatment of patients with high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Imbruvica is currently approved in the U.S. for the treatment of patients with mantle cell lymphoma or CLL, who have received at least one therapy earlier and for CLL patients with deletion 17p. It is also approved for the treatment of Waldenstrom's macroglobulinemia. Please note that in Jan 2017, Imbruvica was approved for patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20 based therapy.
Analysis of the data from the three phase III studies (RESONATE, RESONATE-2 and HELIOS) showed that CLL/SLL patients with genomic abnormalities, when treated with Imbruvica, achieved higher complete response (CR) rates and overall response rates (ORR) as well as longer progression free survival (PFS) at 24 months and overall survival (OS) at 30 months versus patients treated with comparator-treated patients. CLL/SLL patients with genomic abnormalities are usually the ones who are at high risk for poor outcomes.
Data were presented at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL).
We note that Imbruvica became part of AbbVie's portfolio following its acquisition of Pharmacyclics in May 2015. Imbruvica is jointly marketed by AbbVie and Janssen Biotech, a subsidiary of Johnson & Johnson JNJ .
Shares of AbbVie have underperformed the Zacks classified Large Cap Pharma industry so far this year. The stock has gained 5.5% during the period, while the broader industry witnessed an increase of 8.6%.
AbbVie is presently exploring the potential to expand Imbruvica's label into solid tumors (in phase III for diffuse large B-cell lymphoma and follicular lymphoma) and autoimmune diseases.
Notably, Imbruvica has one of the most robust clinical oncology development programs in the industry with nearly 30 company-sponsored trials underway. Of these, 14 are in phase III. The drug is approved for a number of indications and has multi-billion dollar potential. Moreover, another 100 investigator-sponsored trials and external collaborations for Imbruvica are underway around the world.
According to the company, more than 25,000 CLL patients have been treated in the U.S. alone with Imbruvica since approval in 2014. Per the company's press release, nearly 19,000 patients are diagnosed with CLL every year in the U.S. Thus, there is a huge market potential for the drug to cater the unmet needs of patients in the nation.
AbbVie Inc. Price
AbbVie Inc. Price | AbbVie Inc. Quote
Zacks Rank & Key Picks
AbbVie currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Galena Biopharma, Inc. GALE and VIVUS, Inc. VVUS . While Galena carries a Zacks Rank #2 (Buy), VIVUS sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Galena's loss per share estimates narrowed from $2.03 to 58 cents for 2017, over the last 60 days. The company posted positive earnings surprises in two of the four trailing quarters with an average beat of 53.83%.
VIVUS's loss per share estimates narrowed from 50 cents to 39 cents for 2017, over the last 30 days. The company posted positive earnings surprises in all of the four trailing quarters with an average beat of 233.69%.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
VIVUS, Inc. (VVUS): Free Stock Analysis Report
Galena Biopharma, Inc. (GALE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc.ABBV recently announced positive data from a pooled analysis of three phase III studies evaluating its cancer drug, Imbruvica (ibrutinib). We note that Imbruvica became part of AbbVie's portfolio following its acquisition of Pharmacyclics in May 2015. Imbruvica is jointly marketed by AbbVie and Janssen Biotech, a subsidiary of Johnson & Johnson JNJ . | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report Galena Biopharma, Inc. (GALE): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV recently announced positive data from a pooled analysis of three phase III studies evaluating its cancer drug, Imbruvica (ibrutinib). | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report Galena Biopharma, Inc. (GALE): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV recently announced positive data from a pooled analysis of three phase III studies evaluating its cancer drug, Imbruvica (ibrutinib). | AbbVie Inc.ABBV recently announced positive data from a pooled analysis of three phase III studies evaluating its cancer drug, Imbruvica (ibrutinib). We note that Imbruvica became part of AbbVie's portfolio following its acquisition of Pharmacyclics in May 2015. Imbruvica is jointly marketed by AbbVie and Janssen Biotech, a subsidiary of Johnson & Johnson JNJ . |
26168.0 | 2017-05-12 00:00:00 UTC | Noteworthy ETF Inflows: DGRO, ABBV, MCD, MDT | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows-dgro-abbv-mcd-mdt-2017-05-12 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $80.1 million dollar inflow -- that's a 5.2% increase week over week in outstanding units (from 50,100,000 to 52,700,000). Among the largest underlying components of DGRO, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.1%, McDonald's Corp (Symbol: MCD) is up about 0.7%, and Medtronic PLC (Symbol: MDT) is higher by about 0.5%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average:
Looking at the chart above, DGRO's low point in its 52 week range is $25.87 per share, with $31.09 as the 52 week high point - that compares with a last trade of $30.70. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of DGRO, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.1%, McDonald's Corp (Symbol: MCD) is up about 0.7%, and Medtronic PLC (Symbol: MDT) is higher by about 0.5%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average: Looking at the chart above, DGRO's low point in its 52 week range is $25.87 per share, with $31.09 as the 52 week high point - that compares with a last trade of $30.70. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of DGRO, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.1%, McDonald's Corp (Symbol: MCD) is up about 0.7%, and Medtronic PLC (Symbol: MDT) is higher by about 0.5%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average: Looking at the chart above, DGRO's low point in its 52 week range is $25.87 per share, with $31.09 as the 52 week high point - that compares with a last trade of $30.70. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of DGRO, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.1%, McDonald's Corp (Symbol: MCD) is up about 0.7%, and Medtronic PLC (Symbol: MDT) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $80.1 million dollar inflow -- that's a 5.2% increase week over week in outstanding units (from 50,100,000 to 52,700,000). For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average: Looking at the chart above, DGRO's low point in its 52 week range is $25.87 per share, with $31.09 as the 52 week high point - that compares with a last trade of $30.70. | Among the largest underlying components of DGRO, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.1%, McDonald's Corp (Symbol: MCD) is up about 0.7%, and Medtronic PLC (Symbol: MDT) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $80.1 million dollar inflow -- that's a 5.2% increase week over week in outstanding units (from 50,100,000 to 52,700,000). For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average: Looking at the chart above, DGRO's low point in its 52 week range is $25.87 per share, with $31.09 as the 52 week high point - that compares with a last trade of $30.70. |
26169.0 | 2017-05-10 00:00:00 UTC | Infinity (INFI) Reports Narrower-than-Expected Loss in Q1 | ABBV | https://www.nasdaq.com/articles/infinity-infi-reports-narrower-than-expected-loss-in-q1-2017-05-10 | nan | nan | Infinity Pharmaceuticals, Inc.INFI reported a loss of 21 cents per share in first-quarter 2017, narrower than the Zacks Consensus Estimate loss of 22 cents. Also, the company had reported loss of 82 cents in the year-ago quarter.
Since Infinity does not have any approved product in its portfolio, the company earns revenues in the form of royalties, license and milestone payments as well as research and development (R&D) support fees paid by its partners.
Infinity did not record any revenue during first-quarter 2017. But it had recorded collaboration revenue of $9.3 million in the year-ago quarter, related to Infinity's previous collaboration agreement with AbbVie Inc. ABBV .
Infinity's share price has increased 36.3% year to date, while the Zacks classified Medical-Drugs industry gained 3.3%.
Quarter in Detail
In the reported quarter, Research and Development (R&D) expenses plummeted 89.7% to $4.03 million. The decline was mainly related to a decrease in clinical development expenses for duvelisib in addition to the company's 2016 restructuring activities.
General and administrative (G&A) expenses were $6.44 million for the reported quarter, down 40.6% year over year. The decrease was mainly due to the company's 2016 restructuring activities.
Currently, Infinity is evaluating IPI-549 as a monotherapy and in combination with Opdivo (nivolumab) in a phase I study in patients with advanced solid tumors.
The company anticipates completing the monotherapy dose-escalation phase of the study in the first half of 2017. Also, it expects to initiate patient enrolment in the monotherapy expansion cohort in the second half of 2017. In addition, it plans to complete the dose-escalation phase evaluating IPI-549 in combination with Opdivo in the same period, and initiate multiple combination expansion cohorts as well.
2017 Outlook
In 2017, Infinity expects net loss to be in the range of $40 million to $50 million. The Zacks Consensus Estimate is pegged at a loss of $1.03 per share. Moreover, the company anticipates ending 2017 with year-end cash and cash equivalents and available-for-sale securities balance in $40 million to $50 million band.
Infinity Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Infinity Pharmaceuticals, Inc. Price, Consensus and EPS Surprise | Infinity Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Infinity currently holds a Zacks Rank #2 (Buy). Other favorable ranked stocks in the health care sector include Galena Biopharma, Inc. GALE and BioTime, Inc. BTX . While Galena sports a Zacks Rank #1 (Strong Buy), BioTime carries a Zacks Rank #2 (Buy) .You can see the complete list of today's Zacks #1 Rank stocks here .
Galena's loss per share estimates narrowed from $2.03 to 58 cents for 2017 over the last 60 days. The company posted positive earnings surprises in two of the four trailing quarters, with an average beat of 53.83%.
BioTime's loss per share estimates narrowed 60.9% to 18 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in two of the four trailing quarters with an average beat of 12.32%.
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Galena Biopharma, Inc. (GALE): Free Stock Analysis Report
BioTime, Inc. (BTX): Free Stock Analysis Report
Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But it had recorded collaboration revenue of $9.3 million in the year-ago quarter, related to Infinity's previous collaboration agreement with AbbVie Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Galena Biopharma, Inc. (GALE): Free Stock Analysis Report BioTime, Inc. (BTX): Free Stock Analysis Report Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. Since Infinity does not have any approved product in its portfolio, the company earns revenues in the form of royalties, license and milestone payments as well as research and development (R&D) support fees paid by its partners. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Galena Biopharma, Inc. (GALE): Free Stock Analysis Report BioTime, Inc. (BTX): Free Stock Analysis Report Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. But it had recorded collaboration revenue of $9.3 million in the year-ago quarter, related to Infinity's previous collaboration agreement with AbbVie Inc. ABBV . Infinity Pharmaceuticals, Inc. Price, Consensus and EPS Surprise Infinity Pharmaceuticals, Inc. Price, Consensus and EPS Surprise | Infinity Pharmaceuticals, Inc. Quote Zacks Rank & Stocks to Consider Infinity currently holds a Zacks Rank #2 (Buy). | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Galena Biopharma, Inc. (GALE): Free Stock Analysis Report BioTime, Inc. (BTX): Free Stock Analysis Report Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. But it had recorded collaboration revenue of $9.3 million in the year-ago quarter, related to Infinity's previous collaboration agreement with AbbVie Inc. ABBV . Infinity Pharmaceuticals, Inc. Price, Consensus and EPS Surprise Infinity Pharmaceuticals, Inc. Price, Consensus and EPS Surprise | Infinity Pharmaceuticals, Inc. Quote Zacks Rank & Stocks to Consider Infinity currently holds a Zacks Rank #2 (Buy). | But it had recorded collaboration revenue of $9.3 million in the year-ago quarter, related to Infinity's previous collaboration agreement with AbbVie Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Galena Biopharma, Inc. (GALE): Free Stock Analysis Report BioTime, Inc. (BTX): Free Stock Analysis Report Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. Infinity Pharmaceuticals, Inc.INFI reported a loss of 21 cents per share in first-quarter 2017, narrower than the Zacks Consensus Estimate loss of 22 cents. |
26170.0 | 2017-05-10 00:00:00 UTC | Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death | ABBV | https://www.nasdaq.com/articles/biotech-stock-roundup-regeneron-biomarin-report-q1-kite-down-patient-death-2017-05-10 | nan | nan | Kite Pharma's KITE announcement regarding a patient death related to its lead pipeline candidate was the big news in the biotech sector with the company's shares taking a hit. Meanwhile, major players like Regeneron REGN and BioMarin BMRN reported 1Q results -- while Regeneron posted a mixed quarter (Read more: Regeneron Q1 Earnings Miss, Revenues Beat Estimates ), BioMarin surpassed expectations (Read more: BioMarin Posts Earnings in Q1, Sales Top, Stock Up ).
Recap of the Week's Most Important Stories
Kite Hit By Patient Death: Kite Pharma's 1Q17 results were totally overshadowed by the company's revelation about a cerebral edema-related death in a safety expansion cohort evaluating its lead pipeline candidate, CAR-T therapy, KTE-C19 (axicabtagene ciloleucel). Although Kite said that patient recruitment in ongoing studies was not paused or put on hold, investors got spooked by the update sending the shares down 13.2% (Read more: Here's Why Kite Pharma Stock Is Plummeting Today ). While the news has left investors jittery, the general view is that the news will not dent the candidate's chances of gaining FDA approval later this year.
Regeneron in Immuno-Oncology (I-O) Clinical Study Deals: Regeneron is tying up with Inovio for a clinical study deal that will see the companies evaluating Regeneron's PD-1 inhibitor, REGN2810 in combination with Inovio's INO-5401 T cell activating immunotherapy encoding multiple antigens and INO-9012, an immune activator encoding IL-12 for newly-diagnosed glioblastoma multiforme (GBM).
A phase Ib/IIa immuno-oncology study is slated to commence later this year with safety and tolerability being the primary endpoints. Immunological impact, progression-free survival and overall survival will also be evaluated.
GBM is the most common and aggressive type of brain cancer with an extremely poor prognosis even though a limited number of new therapies was approved over the last ten years. While the median overall survival for patients on standard of care therapy is about 15 months, the average five-year survival rate is less than 3%.
Regeneron has also signed up with South Korean biotech company SillaJen for a phase Ib dose-escalation study in renal cell carcinoma (RCC) or kidney cancer. This agreement will see REGN2810 being evaluated in combination with SillaJen's oncolytic vaccinia virus, Pexa-Vec, in patients with previously treated metastatic or unresectable kidney cancer. The study will commence later this year.
Regeneron is a Zacks Rank #2 (Buy) stock -- you can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Year-to-date, the company has performed better than the Zacks-categorized Medical-Biomedical/Genetics industry with shares gaining 16.3% compared to the industry gain of 7.5%.
Amgen Ties Up with Feldan and Elasmogen for Intracellular Biologics: Biotech major Amgen is teaming up with Elasmogen Ltd and Feldan Therapeutics for the development and delivery of novel intracellular biologics. Feldan's Shuttle platform and Elasmogen's soloMER technology will be used under the deal for two undisclosed intracellular targets.
Promising Mid-Stage Data on AbbVie Crohn's Drug: AbbVie ABBV presented promising results from a mid-stage study on its investigational oral JAK1-selective inhibitor, upadacitinib (ABT-494), for the treatment of adult patients with moderately to severely active Crohn's disease. The company said that the results support the advancement of the candidate into late-stage studies for the indication -- a phase III program is scheduled to commence later this year. Upadacitinib is one of the key candidates in the company's immunology pipeline and is in a mid-stage study for atopic dermatitis while another study for ulcerative colitis is scheduled to start shortly. Meanwhile, data from the first of six late-stage studies for rheumatoid arthritis should be out in the coming months.
Array Reports Positive Melanoma Data, Signs Deal with Merck: Array ARRY announced positive top-line results from Part 2 of a late-stage study evaluating binimetinib, a MEK inhibitor, and encorafenib, a BRAF inhibitor, in patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The median progression-free survival (PFS) for patients on binimetinib plus encorafenib was 12.9 months compared to 9.2 months for patients on encorafenib. Array plans to file for FDA approval in June or July this year. According to information provided by Array, currently marketed MEK/BRAF combination agents have a run rate approaching $1 billion in annual worldwide sales.
Array also entered into a clinical trial collaboration agreement with Merck under which a combination of binimetinib and Merck's Keytruda (anti-PD-1 therapy) will be evaluated in colorectal cancer patients with microsatellite stable tumors. The study is scheduled to commence in the second half of the year.
Novartis Opts in for Conatus Drug: Conatus' CNAT partner Novartis has decided to exercise its option to an exclusive license for the global development and commercialization of emricasan, a first-in-class, orally-active pan-caspase inhibitor being developed for chronic liver disease including nonalcoholic steatohepatitis (NASH) cirrhosis. Emricasan is in a phase IIb study in patients with decompensated liver cirrhosis caused by NASH.
Conatus stands to receive a $7 million option exercise payment in mid-2017. So far, the company has received a $50 million upfront payment plus $15 million in exchange for a convertible promissory note issued to Novartis under the Dec 2016 agreement.
NASH is an increasingly common, progressive form of fatty-liver disease which is becoming a significant and growing health issue given the rising obesity epidemic. With no treatments currently approved for this disease, the market opportunity is significant. Several companies are working on developing treatments for NASH -- the market could be worth billions of dollars and many companies are hoping to cash in on this opportunity.
Data readouts from the emricasan phase IIb clinical development program are expected in the first half of 2018.
Performance
Medical - Biomedical and Genetics Industry 5YR % Return
Medical - Biomedical and Genetics Industry 5YR % Return
The NASDAQ Biotechnology Index declined 1.8% over the last five trading sessions. Among major biotech stocks, Alexion ALXN declined 6.5% while Regeneron gained 6.3% with the Dupixent launch looking strong. Over the last six months, Vertex was up 25.6% while Biogen was down 18.3% (See the last biotech stock roundup here: Amgen, Gilead, Celgene Q1 Earnings, Sunesis Down on Vosaroxin Update ).
What's Next in the Biotech World?
Watch out for earnings results from several small biotech companies in the coming days.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Conatus Pharmaceuticals Inc. (CNAT): Free Stock Analysis Report
Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report
Kite Pharma, Inc. (KITE): Free Stock Analysis Report
Array BioPharma Inc. (ARRY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Promising Mid-Stage Data on AbbVie Crohn's Drug: AbbVie ABBV presented promising results from a mid-stage study on its investigational oral JAK1-selective inhibitor, upadacitinib (ABT-494), for the treatment of adult patients with moderately to severely active Crohn's disease. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Conatus Pharmaceuticals Inc. (CNAT): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report Array BioPharma Inc. (ARRY): Free Stock Analysis Report To read this article on Zacks.com click here. GBM is the most common and aggressive type of brain cancer with an extremely poor prognosis even though a limited number of new therapies was approved over the last ten years. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Conatus Pharmaceuticals Inc. (CNAT): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report Array BioPharma Inc. (ARRY): Free Stock Analysis Report To read this article on Zacks.com click here. Promising Mid-Stage Data on AbbVie Crohn's Drug: AbbVie ABBV presented promising results from a mid-stage study on its investigational oral JAK1-selective inhibitor, upadacitinib (ABT-494), for the treatment of adult patients with moderately to severely active Crohn's disease. Array Reports Positive Melanoma Data, Signs Deal with Merck: Array ARRY announced positive top-line results from Part 2 of a late-stage study evaluating binimetinib, a MEK inhibitor, and encorafenib, a BRAF inhibitor, in patients with BRAF-mutant advanced, unresectable or metastatic melanoma. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Conatus Pharmaceuticals Inc. (CNAT): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report Array BioPharma Inc. (ARRY): Free Stock Analysis Report To read this article on Zacks.com click here. Promising Mid-Stage Data on AbbVie Crohn's Drug: AbbVie ABBV presented promising results from a mid-stage study on its investigational oral JAK1-selective inhibitor, upadacitinib (ABT-494), for the treatment of adult patients with moderately to severely active Crohn's disease. Regeneron in Immuno-Oncology (I-O) Clinical Study Deals: Regeneron is tying up with Inovio for a clinical study deal that will see the companies evaluating Regeneron's PD-1 inhibitor, REGN2810 in combination with Inovio's INO-5401 T cell activating immunotherapy encoding multiple antigens and INO-9012, an immune activator encoding IL-12 for newly-diagnosed glioblastoma multiforme (GBM). | Promising Mid-Stage Data on AbbVie Crohn's Drug: AbbVie ABBV presented promising results from a mid-stage study on its investigational oral JAK1-selective inhibitor, upadacitinib (ABT-494), for the treatment of adult patients with moderately to severely active Crohn's disease. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Conatus Pharmaceuticals Inc. (CNAT): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report Array BioPharma Inc. (ARRY): Free Stock Analysis Report To read this article on Zacks.com click here. Array Reports Positive Melanoma Data, Signs Deal with Merck: Array ARRY announced positive top-line results from Part 2 of a late-stage study evaluating binimetinib, a MEK inhibitor, and encorafenib, a BRAF inhibitor, in patients with BRAF-mutant advanced, unresectable or metastatic melanoma. |
26171.0 | 2017-05-10 00:00:00 UTC | Why Gilead Sciences Stock Lagged Behind Other Biotechs in April | ABBV | https://www.nasdaq.com/articles/why-gilead-sciences-stock-lagged-behind-other-biotechs-april-2017-05-10 | nan | nan | What happened
According to data from S&P Global Market Intelligence , Gilead Sciences (NASDAQ: GILD) stock gained only 0.98% in April, despite the rest of the industry having yet another fairly strong month. The iShares Nasdaq Biotechnology Index (NASDAQ: IBB) , for instance, gained 2.29% last month.
So what
Gilead's stock has so far failed to take part in the broader biotech rally this year due to a continually worsening outlook for its hepatitis C franchise. In the first quarter of this year, for example, the company missed consensus estimates on revenue by $126 million because of its plummeting hepatitis C product sales both domestically and abroad. As a result, Gilead's stock has now lost over 7% this year, while the iShares Nasdaq Biotechnology Index has rallied by more than 10%:
GILD data by YCharts .
Now what
Unfortunately, Gilead's hepatitis C revenue could take another major hit later this year if AbbVie 's (NYSE: ABBV) new once-daily pan-genotype hepatitis C therapy gets a green light from the FDA. The short version of the story is that AbbVie's glecaprevir/pibrentasvir, or G/P for short, is currently under priority review with the FDA, meaning that it could hit the market before year's end.
Unlike the slew of other would-be competitors in the past, this experimental drug is actually significant threat to Gilead's hepatitis C trio of Harvoni, Sovaldi, and Epclusa because it offers shorter treatment times across a range of genotypes. And besides lowering the average treatment duration, AbbVie's G/P could also trigger another round of discounts across the spectrum of next-generation hepatitis C drugs at the behest of payers.
Bottom line: Gilead's going to remain under significant pressure until it fixes its top line via an acquisition. And until that day comes, this stock will almost certainly continue to diverge from the rest of the surging biotech industry.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
George Budwell owns shares of iShares NASDAQ Biotechnology Index. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has the following options: short June 2017 $70 calls on Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Now what Unfortunately, Gilead's hepatitis C revenue could take another major hit later this year if AbbVie 's (NYSE: ABBV) new once-daily pan-genotype hepatitis C therapy gets a green light from the FDA. The short version of the story is that AbbVie's glecaprevir/pibrentasvir, or G/P for short, is currently under priority review with the FDA, meaning that it could hit the market before year's end. And besides lowering the average treatment duration, AbbVie's G/P could also trigger another round of discounts across the spectrum of next-generation hepatitis C drugs at the behest of payers. | Now what Unfortunately, Gilead's hepatitis C revenue could take another major hit later this year if AbbVie 's (NYSE: ABBV) new once-daily pan-genotype hepatitis C therapy gets a green light from the FDA. The short version of the story is that AbbVie's glecaprevir/pibrentasvir, or G/P for short, is currently under priority review with the FDA, meaning that it could hit the market before year's end. And besides lowering the average treatment duration, AbbVie's G/P could also trigger another round of discounts across the spectrum of next-generation hepatitis C drugs at the behest of payers. | Now what Unfortunately, Gilead's hepatitis C revenue could take another major hit later this year if AbbVie 's (NYSE: ABBV) new once-daily pan-genotype hepatitis C therapy gets a green light from the FDA. The short version of the story is that AbbVie's glecaprevir/pibrentasvir, or G/P for short, is currently under priority review with the FDA, meaning that it could hit the market before year's end. And besides lowering the average treatment duration, AbbVie's G/P could also trigger another round of discounts across the spectrum of next-generation hepatitis C drugs at the behest of payers. | Now what Unfortunately, Gilead's hepatitis C revenue could take another major hit later this year if AbbVie 's (NYSE: ABBV) new once-daily pan-genotype hepatitis C therapy gets a green light from the FDA. The short version of the story is that AbbVie's glecaprevir/pibrentasvir, or G/P for short, is currently under priority review with the FDA, meaning that it could hit the market before year's end. And besides lowering the average treatment duration, AbbVie's G/P could also trigger another round of discounts across the spectrum of next-generation hepatitis C drugs at the behest of payers. |
26172.0 | 2017-05-10 00:00:00 UTC | Investors Are Betting Big Against Marijuana Stock Insys Therapeutics -- Why They're Wrong | ABBV | https://www.nasdaq.com/articles/investors-are-betting-big-against-marijuana-stock-insys-therapeutics-why-theyre-wrong-2017 | nan | nan | As of April 13, 2017, more than 10.4 million shares of Insys Therapeutics (NASDAQ: INSY) were sold short . That's 44% of the marijuana stock's float . Investors have clearly bet big against Insys, anticipating that the stock will sink.
However, that pessimism could be very short-sighted (pun fully intended). Here's why investors betting against Insys are wrong about the marijuana stock's prospects.
Potential end in sight for federal Subsys probe
Some short-sellers might have been counting on federal and state probes into Insys' sales and marketing practices related to opioid breakthrough cancer pain drug Subsys. Insys is being investigated for marketing and selling the drug beyond what its label allows.
It's possible, though, that the most significant of these investigations, the U.S. Department of Justice probe, could be over in the foreseeable future. New Insys CEO Saeed Motahari said on the company's first-quarter earnings conference call on Tuesday that Insys is working closely with the Justice Department to resolve the probe and improve its compliance with all applicable laws. Motahari said that Insys "remains highly committed to resolving these matters."
No smoking gun with internal review
Insys' long-awaited scheduling of cannabinoid drug Syndros by the U.S. Drug Enforcement Agency in March was overshadowed somewhat by an internal review that caused the company to delay filing its annual report for 2016 with the Securities and Exchange Commission. Some short-sellers likely hoped for a smoking gun to be found in that review. That didn't happen.
The annual report for 2016 was filed a few weeks after Insys announced the delay. As for the internal review, it focused on processes related to estimation of, and increases to, certain sales allowances recorded during 2016. The company's audit committee determined there were some miscalculations of rebate obligation on government payer and managed care contracts. Insys also found that some stock option expenses recorded in the first quarter of 2016 should be applied to the fourth quarter of 2015. As a result, Insys restated financial statements for several quarters in 2015 and 2016.
But that was all there was to the story. Insys' board of directors didn't report any more serious concerns. It appears that this issue has now been put to rest.
Great prospects for Syndros
I wouldn't expect Insys' issues with Subsys to disappear entirely. Concerns over the national epidemic of opioid abuse seem likely to continue impacting sales of the breakthrough pain drug. However, Insys saw some signs of stabilization in prescriptions for Subsys in the first quarter. Also, the potential for Syndros appears to be significant enough to allow Insys to more than overcome the revenue decline from Subsys.
It's important to how Syndros compares with AbbVie 's (NYSE: ABBV) Marinol. Both drugs have the same active ingredient, tetrahydrocannabinol (THC), which is a naturally occurring component of marijuana. Marinol, however, uses a synthetic form of THC, while Syndros is made from THC from marijuana. The big advantage for Syndros, though, is that it is a liquid rather than pill. Unlike a pill, the dosage can be titrated as needed.
Piper Jaffray analyst David Amsellem projects peak annual sales for Syndros of $300 million to $400 million. That doesn't seem unrealistic considering the differentiation the drug has versus Marinol. Even at the low end of that range, Insys stock should have plenty of upward potential.
Over the long run
Insys' pipeline also could have several winners. The company has two drugs in late-stage testing. Buprenorphine is being evaluated in treating moderate to severe pain. Naloxone is being evaluated for reversing opioid depression.
One of the hottest names among marijuana stocks, GW Pharmaceuticals (NASDAQ: GWPH) , could be given a run for its money down the road by Insys. GW anticipates filing for regulatory approval of its cannabidiol product, Epidiolex, soon for treating Dravet syndrome and Lennox-Gastaut syndrome (LGS). Insys has plans to evaluate its own cannabidiol product in late-stage clinical studies targeting the same indications. Both studies are scheduled to wrap up next year.
Short-sellers probably began to worry with Insys stock rising following news that the company hoped to work with the Justice Department to reach a resolution of the current probe. With solid prospects for Syndros and a promising pipeline, I think investors betting against Insys will be proved wrong over the long run -- and perhaps over the short run, too.
10 stocks we like better than Insys Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Insys Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It's important to how Syndros compares with AbbVie 's (NYSE: ABBV) Marinol. *Stock Advisor returns as of May 1, 2017 Keith Speights owns shares of AbbVie. The company's audit committee determined there were some miscalculations of rebate obligation on government payer and managed care contracts. | It's important to how Syndros compares with AbbVie 's (NYSE: ABBV) Marinol. *Stock Advisor returns as of May 1, 2017 Keith Speights owns shares of AbbVie. As of April 13, 2017, more than 10.4 million shares of Insys Therapeutics (NASDAQ: INSY) were sold short . | It's important to how Syndros compares with AbbVie 's (NYSE: ABBV) Marinol. *Stock Advisor returns as of May 1, 2017 Keith Speights owns shares of AbbVie. Potential end in sight for federal Subsys probe Some short-sellers might have been counting on federal and state probes into Insys' sales and marketing practices related to opioid breakthrough cancer pain drug Subsys. | It's important to how Syndros compares with AbbVie 's (NYSE: ABBV) Marinol. *Stock Advisor returns as of May 1, 2017 Keith Speights owns shares of AbbVie. Potential end in sight for federal Subsys probe Some short-sellers might have been counting on federal and state probes into Insys' sales and marketing practices related to opioid breakthrough cancer pain drug Subsys. |
26173.0 | 2017-05-09 00:00:00 UTC | Integrys Wealth Advisors LLC Buys Vanguard Small-Cap Growth ETF - DNQ, The Kroger Co, CME Group ... | ABBV | https://www.nasdaq.com/articles/integrys-wealth-advisors-llc-buys-vanguard-small-cap-growth-etf-dnq-kroger-co-cme-group | nan | nan | Integrys Wealth Advisors LLC
New Purchases: KR , CME , WMGI , JPM, TSLA, VOT,
Added Positions:VBK, VUG, IWS, VYM, VBR, VO, VB, IVV, VWO, VNQ,
Reduced Positions:BAC, ABBV, ABT, GE, TLP, GLD, DES, T, BAX, MCD,
Sold Out:WMT,
For the details of Integrys Wealth Advisors LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Integrys+Wealth+Advisors+LLC
These are the top 5 holdings of Integrys Wealth Advisors LLC
Vanguard High Dividend Yield ETF - DNQ ( VYM ) - 430,951 shares, 19.06% of the total portfolio. Shares added by 4.98%
Vanguard Growth ETF - DNQ ( VUG ) - 239,676 shares, 16.61% of the total portfolio. Shares added by 7.63%
AbbVie Inc ( ABBV ) - 203,277 shares, 7.54% of the total portfolio. Shares reduced by 1.25%
iShares Russell Mid-cap Value ( IWS ) - 156,710 shares, 7.41% of the total portfolio. Shares added by 16.78%
Vanguard Small-Cap Value ETF - DNQ ( VBR ) - 82,881 shares, 5.8% of the total portfolio. Shares added by 13.63%
New Purchase: The Kroger Co (KR)
Integrys Wealth Advisors LLC initiated holdings in The Kroger Co. The purchase prices were between $28.69 and $34.91, with an estimated average price of $31.95. The stock is now traded at around $28.92. The impact to the portfolio due to this purchase was 1.63%. The holdings were 97,170 shares as of 2017-03-31.
New Purchase: CME Group Inc (CME)
Integrys Wealth Advisors LLC initiated holdings in CME Group Inc. The purchase prices were between $114.4 and $127, with an estimated average price of $120.27. The stock is now traded at around $117.10. The impact to the portfolio due to this purchase was 0.82%. The holdings were 12,125 shares as of 2017-03-31.
New Purchase: Wright Medical Group NV (WMGI)
Integrys Wealth Advisors LLC initiated holdings in Wright Medical Group NV. The purchase prices were between $22.61 and $31.15, with an estimated average price of $27.12. The stock is now traded at around $27.85. The impact to the portfolio due to this purchase was 0.23%. The holdings were 13,000 shares as of 2017-03-31.
New Purchase: Tesla Inc (TSLA)
Integrys Wealth Advisors LLC initiated holdings in Tesla Inc. The purchase prices were between $216.99 and $280.98, with an estimated average price of $253.78. The stock is now traded at around $307.19. The impact to the portfolio due to this purchase was 0.12%. The holdings were 759 shares as of 2017-03-31.
New Purchase: Vanguard Mid-Cap Growth ETF - DNQ (VOT)
Integrys Wealth Advisors LLC initiated holdings in Vanguard Mid-Cap Growth ETF - DNQ. The purchase prices were between $105.67 and $113.8, with an estimated average price of $111.09. The stock is now traded at around $115.98. The impact to the portfolio due to this purchase was 0.12%. The holdings were 1,850 shares as of 2017-03-31.
New Purchase: JPMorgan Chase & Co (JPM)
Integrys Wealth Advisors LLC initiated holdings in JPMorgan Chase & Co. The purchase prices were between $83.3 and $93.6, with an estimated average price of $88.22. The stock is now traded at around $87.10. The impact to the portfolio due to this purchase was 0.12%. The holdings were 2,420 shares as of 2017-03-31.
Added: Vanguard Small-Cap Growth ETF - DNQ (VBK)
Integrys Wealth Advisors LLC added to the holdings in Vanguard Small-Cap Growth ETF - DNQ by 49.71%. The purchase prices were between $133.14 and $142.49, with an estimated average price of $138.44. The stock is now traded at around $142.56. The impact to the portfolio due to this purchase was 1.75%. The holdings were 65,818 shares as of 2017-03-31.
Added: Vanguard Mid-Cap ETF - DNQ (VO)
Integrys Wealth Advisors LLC added to the holdings in Vanguard Mid-Cap ETF - DNQ by 36.41%. The purchase prices were between $131.63 and $141.29, with an estimated average price of $137.34. The stock is now traded at around $141.20. The impact to the portfolio due to this purchase was 0.29%. The holdings were 13,872 shares as of 2017-03-31.
Added: Vanguard Small-Cap ETF - DNQ (VB)
Integrys Wealth Advisors LLC added to the holdings in Vanguard Small-Cap ETF - DNQ by 31.78%. The purchase prices were between $128.96 and $136.14, with an estimated average price of $132.29. The stock is now traded at around $134.01. The impact to the portfolio due to this purchase was 0.17%. The holdings were 9,081 shares as of 2017-03-31.
Added: Vanguard REIT ETF - DNQ (VNQ)
Integrys Wealth Advisors LLC added to the holdings in Vanguard REIT ETF - DNQ by 63.84%. The purchase prices were between $80.41 and $85.85, with an estimated average price of $82.94. The stock is now traded at around $81.82. The impact to the portfolio due to this purchase was 0.11%. The holdings were 6,049 shares as of 2017-03-31.
Sold Out: Wal-Mart Stores Inc (WMT)
Integrys Wealth Advisors LLC sold out the holdings in Wal-Mart Stores Inc. The sale prices were between $65.66 and $72.39, with an estimated average price of $69.04.
VBK 15-Year Financial Data
The intrinsic value of VBK
Peter Lynch Chart of VBK
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Integrys Wealth Advisors LLC New Purchases: KR , CME , WMGI , JPM, TSLA, VOT, Added Positions:VBK, VUG, IWS, VYM, VBR, VO, VB, IVV, VWO, VNQ, Reduced Positions:BAC, ABBV, ABT, GE, TLP, GLD, DES, T, BAX, MCD, Sold Out:WMT, For the details of Integrys Wealth Advisors LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Integrys+Wealth+Advisors+LLC These are the top 5 holdings of Integrys Wealth Advisors LLC Vanguard High Dividend Yield ETF - DNQ ( VYM ) - 430,951 shares, 19.06% of the total portfolio. Shares added by 7.63% AbbVie Inc ( ABBV ) - 203,277 shares, 7.54% of the total portfolio. New Purchase: Vanguard Mid-Cap Growth ETF - DNQ (VOT) Integrys Wealth Advisors LLC initiated holdings in Vanguard Mid-Cap Growth ETF - DNQ. | Integrys Wealth Advisors LLC New Purchases: KR , CME , WMGI , JPM, TSLA, VOT, Added Positions:VBK, VUG, IWS, VYM, VBR, VO, VB, IVV, VWO, VNQ, Reduced Positions:BAC, ABBV, ABT, GE, TLP, GLD, DES, T, BAX, MCD, Sold Out:WMT, For the details of Integrys Wealth Advisors LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Integrys+Wealth+Advisors+LLC These are the top 5 holdings of Integrys Wealth Advisors LLC Vanguard High Dividend Yield ETF - DNQ ( VYM ) - 430,951 shares, 19.06% of the total portfolio. Shares added by 7.63% AbbVie Inc ( ABBV ) - 203,277 shares, 7.54% of the total portfolio. New Purchase: Vanguard Mid-Cap Growth ETF - DNQ (VOT) Integrys Wealth Advisors LLC initiated holdings in Vanguard Mid-Cap Growth ETF - DNQ. | Integrys Wealth Advisors LLC New Purchases: KR , CME , WMGI , JPM, TSLA, VOT, Added Positions:VBK, VUG, IWS, VYM, VBR, VO, VB, IVV, VWO, VNQ, Reduced Positions:BAC, ABBV, ABT, GE, TLP, GLD, DES, T, BAX, MCD, Sold Out:WMT, For the details of Integrys Wealth Advisors LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Integrys+Wealth+Advisors+LLC These are the top 5 holdings of Integrys Wealth Advisors LLC Vanguard High Dividend Yield ETF - DNQ ( VYM ) - 430,951 shares, 19.06% of the total portfolio. Shares added by 7.63% AbbVie Inc ( ABBV ) - 203,277 shares, 7.54% of the total portfolio. New Purchase: Vanguard Mid-Cap Growth ETF - DNQ (VOT) Integrys Wealth Advisors LLC initiated holdings in Vanguard Mid-Cap Growth ETF - DNQ. | Integrys Wealth Advisors LLC New Purchases: KR , CME , WMGI , JPM, TSLA, VOT, Added Positions:VBK, VUG, IWS, VYM, VBR, VO, VB, IVV, VWO, VNQ, Reduced Positions:BAC, ABBV, ABT, GE, TLP, GLD, DES, T, BAX, MCD, Sold Out:WMT, For the details of Integrys Wealth Advisors LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Integrys+Wealth+Advisors+LLC These are the top 5 holdings of Integrys Wealth Advisors LLC Vanguard High Dividend Yield ETF - DNQ ( VYM ) - 430,951 shares, 19.06% of the total portfolio. Shares added by 7.63% AbbVie Inc ( ABBV ) - 203,277 shares, 7.54% of the total portfolio. Shares added by 13.63% New Purchase: The Kroger Co (KR) Integrys Wealth Advisors LLC initiated holdings in The Kroger Co. |
26174.0 | 2017-05-06 00:00:00 UTC | Which Big Pharma Is the Best Dividend Stock? | ABBV | https://www.nasdaq.com/articles/which-big-pharma-best-dividend-stock-2017-05-06 | nan | nan | Dividend-paying pharma stocks tend to be great long-term investing vehicles because of their stellar free cash flows, strong growth prospects, and ability to weather most markets. Even so, there are literally dozens of names to choose from when it comes to this particular group -- making it especially hard to separate the wheat from the chaff, so to speak.
Complicating matters further, the stocks with the highest yields, like GlaxoSmithKline (NYSE: GSK) , and even companies with the best recent track records from a payout perspective, such as the dividend aristocrat AbbVie (NYSE: ABBV) , can be deceptively attractive. Glaxo, for instance, offers a yield of almost 5%, but is staring down some hard choices from a capital allocation standpoint that might spark a sizable reduction in its payout going forward.
AbbVie, on the other hand, has grown its dividend faster than all of its major drug manufacturing peers over the past four years, and sports a juicy yield of 3.88%. But the company is overly reliant on its anti-inflammatory drug Humira for growth, which is a major red flag with several companies attempting to bring a copycat version to market soon.
Cutting to the chase, Johnson & Johnson (NYSE: JNJ) is, in my opinion, the valedictorian of the dividend-paying pharma stock class. And it's not even all that close of a race. Here's why.
Johnson & Johnson is an elite dividend stock
When it comes to the strength of its balance sheet, J&J is in a class by itself among major drug manufacturers. Despite its $30 billion acquisition of Actelion earlier this year, for instance, the company was able to maintain its coveted triple-A credit rating with both Moody's and Standard & Poor's . In fact, J&J is now the only U.S.-based pharma company to sport a triple-A rating.
The core issue is that J&J has shied away from credit-risky deals to drive growth over the course of its history, which simply can't be said for most of its peers. AbbVie, for example, has repeatedly relied on debt-financing to augment its clinical pipeline and product portfolio, causing its debt to equity ratio to balloon to jaw-dropping levels over the last few years. The point is that J&J has an exceptionally strong ability to meet its financial obligations moving forward, implying that its dividend program is about as safe as they come in the pharma space.
On the growth front, J&J is dealing with the introduction of biosimilar competitors to its top selling anti-inflammatory drug Remicade, and its prostate cancer drug Zytiga is starting to experience a pronounced slowdown in the United States. However, the drugmaker's significant investment in research and development has also allowed it to continually refresh its product portfolio.
The fairly new cancer drugs Darzalex and Imbruvica, for example, are both gobbling up significant share of their respective markets, helping to offset the weakness stemming from Remicade and Zytiga. The net result is that J&J's top line is forecast to grow by over 5% over the next two years, due, in large part, to its ability to bring major new drugs to market in an almost machine-like fashion.
Last but not least, J&J belongs to a select group of stocks known as "dividend aristocrats", reflecting the company's 54-consecutive year history of increases to its payout. In 2016, the company doled out a massive $8.6 billion in dividends to its shareholders, as well as another $7.3 billion in share repurchases. Put simply, J&J has an elite shareholders reward program in place, and its track record of paying dividends is among the best within its peer group, to put it mildly.
Investing takeaway
When it comes to dividends, it can be easy to get distracted by, say, AbbVie's rapidly escalating payout or Glaxo's junk bond-like yield. But the real name of the game in dividend investing is sustainability -- and that's where J&J excels. AbbVie and Glaxo may ultimately be able to maintain their rich payouts, but there's no question that J&J will be able to sustain -- and continually grow -- its dividend program going forward. And that's why J&J is my favorite dividend-paying pharma stock.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
George Budwell has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Johnson & Johnson and Moody's. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie, for example, has repeatedly relied on debt-financing to augment its clinical pipeline and product portfolio, causing its debt to equity ratio to balloon to jaw-dropping levels over the last few years. Complicating matters further, the stocks with the highest yields, like GlaxoSmithKline (NYSE: GSK) , and even companies with the best recent track records from a payout perspective, such as the dividend aristocrat AbbVie (NYSE: ABBV) , can be deceptively attractive. AbbVie, on the other hand, has grown its dividend faster than all of its major drug manufacturing peers over the past four years, and sports a juicy yield of 3.88%. | Complicating matters further, the stocks with the highest yields, like GlaxoSmithKline (NYSE: GSK) , and even companies with the best recent track records from a payout perspective, such as the dividend aristocrat AbbVie (NYSE: ABBV) , can be deceptively attractive. AbbVie, on the other hand, has grown its dividend faster than all of its major drug manufacturing peers over the past four years, and sports a juicy yield of 3.88%. AbbVie, for example, has repeatedly relied on debt-financing to augment its clinical pipeline and product portfolio, causing its debt to equity ratio to balloon to jaw-dropping levels over the last few years. | Complicating matters further, the stocks with the highest yields, like GlaxoSmithKline (NYSE: GSK) , and even companies with the best recent track records from a payout perspective, such as the dividend aristocrat AbbVie (NYSE: ABBV) , can be deceptively attractive. AbbVie, on the other hand, has grown its dividend faster than all of its major drug manufacturing peers over the past four years, and sports a juicy yield of 3.88%. AbbVie, for example, has repeatedly relied on debt-financing to augment its clinical pipeline and product portfolio, causing its debt to equity ratio to balloon to jaw-dropping levels over the last few years. | Complicating matters further, the stocks with the highest yields, like GlaxoSmithKline (NYSE: GSK) , and even companies with the best recent track records from a payout perspective, such as the dividend aristocrat AbbVie (NYSE: ABBV) , can be deceptively attractive. AbbVie and Glaxo may ultimately be able to maintain their rich payouts, but there's no question that J&J will be able to sustain -- and continually grow -- its dividend program going forward. AbbVie, on the other hand, has grown its dividend faster than all of its major drug manufacturing peers over the past four years, and sports a juicy yield of 3.88%. |
26175.0 | 2017-05-04 00:00:00 UTC | iShares Core Dividend Growth ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/ishares-core-dividend-growth-etf-experiences-big-inflow-2017-05-04 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $124.6 million dollar inflow -- that's a 8.8% increase week over week in outstanding units (from 46,050,000 to 50,100,000). Among the largest underlying components of DGRO, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.4%, AbbVie Inc (Symbol: ABBV) is up about 0.5%, and McDonald's Corp (Symbol: MCD) is up by about 0.1%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average:
Looking at the chart above, DGRO's low point in its 52 week range is $25.87 per share, with $31.09 as the 52 week high point - that compares with a last trade of $30.82. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of DGRO, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.4%, AbbVie Inc (Symbol: ABBV) is up about 0.5%, and McDonald's Corp (Symbol: MCD) is up by about 0.1%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average: Looking at the chart above, DGRO's low point in its 52 week range is $25.87 per share, with $31.09 as the 52 week high point - that compares with a last trade of $30.82. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of DGRO, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.4%, AbbVie Inc (Symbol: ABBV) is up about 0.5%, and McDonald's Corp (Symbol: MCD) is up by about 0.1%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average: Looking at the chart above, DGRO's low point in its 52 week range is $25.87 per share, with $31.09 as the 52 week high point - that compares with a last trade of $30.82. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of DGRO, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.4%, AbbVie Inc (Symbol: ABBV) is up about 0.5%, and McDonald's Corp (Symbol: MCD) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $124.6 million dollar inflow -- that's a 8.8% increase week over week in outstanding units (from 46,050,000 to 50,100,000). For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average: Looking at the chart above, DGRO's low point in its 52 week range is $25.87 per share, with $31.09 as the 52 week high point - that compares with a last trade of $30.82. | Among the largest underlying components of DGRO, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.4%, AbbVie Inc (Symbol: ABBV) is up about 0.5%, and McDonald's Corp (Symbol: MCD) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $124.6 million dollar inflow -- that's a 8.8% increase week over week in outstanding units (from 46,050,000 to 50,100,000). For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average: Looking at the chart above, DGRO's low point in its 52 week range is $25.87 per share, with $31.09 as the 52 week high point - that compares with a last trade of $30.82. |
26176.0 | 2017-05-04 00:00:00 UTC | A Big, New Threat to Gilead Sciences Is Coming | ABBV | https://www.nasdaq.com/articles/big-new-threat-gilead-sciences-coming-2017-05-04 | nan | nan | I own shares in Gilead Sciences (NASDAQ: GILD) , so it pains me to say this, but I think that Gilead Sciences' abysmal hepatitis C sales in the first quarter might not be as bad as it gets for the company. Why? Competition from AbbVie (NYSE: ABBV) is about to heat up, and that could cause Gilead Sciences to lose market share or cut (yet again) prices on its hepatitis C drugs.
What's at stake
Gilead Sciences' hepatitis C drugs hauled in revenue at a $20 billion annual clip two years ago, but the launch of alternative treatments with similar functional cure rates forced the drugmaker to compete on price to maintain market share, and that caused sales to nosedive.
In the first quarter, combined sales across its three hepatitis C drugs (Sovaldi, Harvoni, and Epclusa) were $2.6 billion, and that was far shy of the $4.3 billion reported in the same period in 2016.
In the U.S., HCV sales fell 18% from last year because of "increased competition." European HCV revenues fell 42% year over year and 22% sequentially because of "lower market share as a result of increased competition.. And, in Japan, HCV product sales were down 81% year over year and 35% sequentially "due to a decrease in patient starts and increased competition."
Those declines could have been worse if not for innovation that's given Gilead Sciences' HCV lineup an edge over other treatments. In particular, about 40% of genotype 1 HCV patients can take Harvoni over only eight weeks, rather than 12 weeks, and that lower burden is a plus for payers and patients alike. Epclusa's launch has also supported market share by improving cure rates and treatment burden for genotype 3 patients, which is historically tougher to treat.
Furthermore, Gilead Sciences' market share has been helped by some drawbacks of its competitors. AbbVie's Viekira Pak has had some success carving away sales in genotype 1, but it poses a much heavier pill burden on patients, and it often requires the co-administration of ribavirin, which can cause side effects. Merck & Co 's (NYSE: MRK) genotype 1 drug, Zepatier, has testing requirements that Harvoni doesn't, and that's given Gilead Sciences an edge there, too.
Unfortunately, the competitive advantages that Gilead Sciences' drugs have over their competition are fading as research and development programs allow these companies to advance better products toward the market.
Mounting a challenge
The closest of this new generation of HCV competitors is AbbVie's glecaprevir/pibrentasvir (G/P). The Food and Drug Administration accepted AbbVie's New Drug Application for G/P last quarter, and it granted that application a priority review that clears the way for a decision soon. European regulators are also reviewing G/P under their accelerated assessment pathway, and Japan's regulators have granted G/P a priority review, too.
It's not a lock that regulators give G/P a green light, but its efficacy in trials was very good, and that has AbbVie laying the groundwork for a launch this year.
In trials, 99% of patients with genotype 1, 2, 4, 5, or 6 achieved a sustained virologic response (SVR) at 12 weeks following treatment with G/P. A second study showed that 95% of genotype 3 patients without cirrhosis who took G/P for eight weeks also hit that SVR12 mark.
What is particularly concerning to Gilead Sciences investors, however, is that not only was there strong efficacy in the genotype 3 patients on an eight-week treatment course, but eight-week duration was effective in other genotypes as well. In November, AbbVie reported that taking G/P for 8 weeks delivered a 97.5% SVR12 rate in genotype 1 to 6 patients.
These trial results suggest that if G/P wins a regulatory OK, it could become the shortest-duration pan-genotype therapy on the market.
Looking ahead
The addressable HCV market is declining thanks to these functional cures, but that means a smaller pie for Gilead Sciences, AbbVie, and Merck & Co to split. Assuming AbbVie gets a go-ahead for G/P, aggressive pricing could make it the preferential treatment in insurance formularies, clearing the way for another wave of battling over price. Given G/P is taken once daily, it doesn't have the pill burden drawback that held back Viekira Pak, and G/P's top-shelf efficacy suggests it may be the toughest competition to Gilead Sciences yet.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
Todd Campbell owns shares of Gilead Sciences. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has the following options: short June 2017 $70 calls on Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie's Viekira Pak has had some success carving away sales in genotype 1, but it poses a much heavier pill burden on patients, and it often requires the co-administration of ribavirin, which can cause side effects. Competition from AbbVie (NYSE: ABBV) is about to heat up, and that could cause Gilead Sciences to lose market share or cut (yet again) prices on its hepatitis C drugs. Mounting a challenge The closest of this new generation of HCV competitors is AbbVie's glecaprevir/pibrentasvir (G/P). | Competition from AbbVie (NYSE: ABBV) is about to heat up, and that could cause Gilead Sciences to lose market share or cut (yet again) prices on its hepatitis C drugs. AbbVie's Viekira Pak has had some success carving away sales in genotype 1, but it poses a much heavier pill burden on patients, and it often requires the co-administration of ribavirin, which can cause side effects. Mounting a challenge The closest of this new generation of HCV competitors is AbbVie's glecaprevir/pibrentasvir (G/P). | Competition from AbbVie (NYSE: ABBV) is about to heat up, and that could cause Gilead Sciences to lose market share or cut (yet again) prices on its hepatitis C drugs. AbbVie's Viekira Pak has had some success carving away sales in genotype 1, but it poses a much heavier pill burden on patients, and it often requires the co-administration of ribavirin, which can cause side effects. Mounting a challenge The closest of this new generation of HCV competitors is AbbVie's glecaprevir/pibrentasvir (G/P). | Competition from AbbVie (NYSE: ABBV) is about to heat up, and that could cause Gilead Sciences to lose market share or cut (yet again) prices on its hepatitis C drugs. AbbVie's Viekira Pak has had some success carving away sales in genotype 1, but it poses a much heavier pill burden on patients, and it often requires the co-administration of ribavirin, which can cause side effects. Mounting a challenge The closest of this new generation of HCV competitors is AbbVie's glecaprevir/pibrentasvir (G/P). |
26177.0 | 2017-05-03 00:00:00 UTC | 5 Best Stocks for Investing in Cancer Treatments | ABBV | https://www.nasdaq.com/articles/5-best-stocks-investing-cancer-treatments-2017-05-03 | nan | nan | Medical science hasn't yet won the war on cancer, but it is scoring important victories in battles against many forms of the dreaded disease. Advances in new treatments have made cancer a hot investing theme over the past 18 months, helping to power fresh interest in biotechnology stocks.
See Also: 13 Tech Stocks with Big Promise
SPECIAL REPORT: Fighting Cancer
Living With Cancer
How to Cover the Cost of Cancer Care
Companies such as Medivation have fueled the renewed lure of striking it rich from novel cancer treatments. With Xtandi--its breakthrough treatment for prostate cancer--riding high, plus promising new drugs for breast cancer and blood cancers in development, the company was the object of a bidding war in 2016. It culminated last September with drug giant Pfizer (symbol PFE ) paying $14 billion for Medivation, or $81.50 per share--38 times the stock's level at its 2010 low.
In February, Japan's Takeda Pharmaceuticals ( TKPYY ) paid $5.2 billion for Ariad Pharmaceuticals ( ARIA ), which is developing drugs that target certain solid tumors. The buyout price was 75% above Ariad's market value before the deal was announced.
Plenty of volatility. Biotech shares had led the bull market overall, with a New York Stock Exchange-sponsored index of 30 biotech issues soaring 723% from early 2009 to mid 2015. But the stocks then dived 42% by February 2016, in part because of a political backlash against high drug prices.
That backlash remains a long-term threat to the industry's profit potential, and it continues to weigh on the stocks. Despite a rebound since early 2016, the NYSE biotech index is still down 20% from its 2015 peak. But that could also mean opportunity.
Investors surveying the cancer medicine field in 2017 can take one of two approaches. One is to own the companies that reign as the biggest names in oncology treatments, trusting that they can develop new blockbusters faster than their current stars fade, given inevitable competition and market saturation. This strategy is a bet on steady growth (and, in some cases, regular and steadily rising dividends) rather than on moonshots.
The higher-risk route is to invest in relatively new companies focused on cancer niches that could pay off exponentially if a new treatment succeeds--as Medivation's Xtandi did--or result in massive losses if a treatment fails.
At the top of the list of the oncology giants is Switzerland's Roche Holding ( RHHBY , $32). Thanks to its 2009 acquisition of biotech pioneer Genentech, Roche controls three of the world's top cancer drugs by sales: Avastin, for colon and lung cancers; Rituxan, for blood cancers; and Herceptin, for breast cancers. (Share prices and related data are as of March 31.)
All three drugs, known as monoclonal antibodies, were among the first wave of blockbusters developed as part of research into immunotherapy--that is, harnessing the power of the body's natural immune system to fight cancer. Some antibodies are molecules engineered to help the immune system recognize camouflaged cancer cells and destroy them. Other antibodies either kill malignant cells directly or halt their growth. Although immunotherapy can have side effects, it's a huge step up from chemotherapy, which can destroy healthy cells along with cancer cells.
See Also: 5 Good Dividend Stocks Owned by Bill Gates
All told, more than 60% of Roche's sales are cancer-related. In 2016, total revenue reached a record $51 billion. But Roche's spending on research is also enormous, and that has weighed on profit growth: Earnings in 2016 were only slightly above 2012 levels. And Roche's stock is 17% below its all-time high, reached in 2015.
One key investor concern is that Roche's patents on Avastin expire in 2019 in the U.S. and in 2022 in the European Union, opening the door to lower-cost copycats. Herceptin, first approved in the U.S. in 1998, may also face imitators soon.
Bulls say Roche's stock, which sells for a reasonable 17 times estimated year-ahead earnings, doesn't adequately reflect the potential in new immunotherapies. The company has about 90 experimental cancer treatments in its research pipeline. (Roche trades in the U.S. as American depositary receipts.) In March, Roche said a study showed improved survival rates in post-surgery breast cancer patients using Perjeta, a drug first approved in 2012, along with Herceptin. Analysts at JPMorgan Chase's brokerage unit say the Perjeta study, along with clinical-trial data expected this year on Roche's new antibody Tecentriq, for lung cancer, should drive the stock higher in 2017 as investor confidence rises.
AbbVie ( ABBV , $65) is another large player in cancer treatment that fans say is underappreciated. The firm is best known for its antibody Humira, which suppresses debilitating inflammation illnesses, including rheumatoid arthritis, Crohn's disease and psoriasis. Humira made up 63% of AbbVie's sales of $25.6 billion in 2016.
The stock has languished since mid 2015, partly because of investor fears that new competition will eventually dent Humira sales, and it now trades for a modest 12 times estimated 2017 earnings. To bolster its growth outlook, AbbVie in 2015 bought biotech firm Pharmacyclics, which developed the blood-cancer treatment Imbruvica in partnership with Johnson & Johnson ( JNJ ). So AbbVie shares Imbruvica's sales with J&J. "Looking ahead, AbbVie's pipeline is weighted heavily toward new cancer drugs," says research firm Morningstar. "In particular, AbbVie's pipeline should lead to an increasingly strong position in blood cancer," anchored by Imbruvica.
Brokerage William Blair agrees. "We believe the strength of AbbVie's pipeline is not being fully recognized" by investors, Blair says. Among the potential hits: Rova-T, a drug that shows promise in killing particularly aggressive lung tumors. Like Roche and AbbVie, Celgene ( CELG , $124) is an established--and profitable--developer of drugs to battle cancer and other diseases. From 2012 to 2016, annual revenues doubled, to $11.2 billion. Celgene's lead drug, Revlimid, fights multiple myeloma--a cancer of specialized bone-marrow cells that are critical for killing infections. In clinical trials, Revlimid was shown to destroy the rogue cells or prevent them from growing. Approved in the U.S. in 2005, the drug has become a global star: Sales reached $7 billion in 2016, or 62% of Celgene's total.
Revlimid won't face generic competition until 2022. In the meantime, brokerage UBS says, investors are underestimating prospects for improved Revlimid sales, including from expanded use in Europe and in extended patient treatment periods in the U.S. The company's outlook is also bolstered by Otezla, its three-year-old psoriasis drug, and by potential cancer treatments in its research pipeline.
All in all, "Celgene offers the cleanest, least-complicated growth story across larger-capitalization biotech" for the next few years, UBS says. It estimates that Celgene will earn $8.6 billion in 2019, or $10.75 per share, up 81% from $5.94 in 2016.
See Also: 3 Reasons to Buy Pfizer Stock for Retirement
If you're willing to take on more risk for a shot at a big long-term payoff, consider Kite Pharma ( KITE , $78), which went public in 2014. Kite is developing "CAR-T" technology, short for chimeric antigen receptor T-cell therapy. It's a new way to get immune-system cells to target and destroy specific cancers.
Here's how it works: T cells, a type of white blood cells, are collected from a patient's blood and genetically altered to place certain antigen receptors (proteins) on their surfaces. The T cells are then multiplied in the lab and reinjected into the patient's blood, where they will attach to specific proteins on the surface of cancer cells.
In February, Kite reported favorable results for the therapy in trials with patients suffering from non-Hodgkin's lymphoma, a blood cancer. The data caused brokerage Goldman Sachs to boost its probability of success for the drug from 75% to 90%--and triggered a surge in the stock, lifting its market value today to $4.3 billion.
Kite, which has no sales or earnings, is enormously risky. The attraction, Morningstar says, is that CAR-T therapy "is game-changing technology."
Another highly speculative investment idea in the war on cancer is Foundation Medicine ( FMI , $32). The seven-year-old company isn't a drug developer but rather performs tests on patients' cancer tissues and provides their doctors with genetic data--both about the individual patient and more broadly about the specific cancer. The idea is that the information can help doctors suggest the best therapies for patients. The data can also help drugmakers design new cancer treatments.
Over the long term, Foundation envisions being a central clearinghouse for cancer data that can be used by doctors, drug researchers, cancer-care centers and others. Foundation had $117 million in revenues last year, up 26% from 2015. But the firm remains deep in the red as it spends to build its business. It lost $113 million, or $3.25 per share, in 2016. A major hurdle for the company is persuading insurance companies to cover the cost of the tests, which can exceed $7,000. While Foundation fights that battle, it at least has the biggest name in cancer drugs on its side: Roche bought a controlling stake in the company in 2015 and owns 61%.
Targeting the killer cancers
Here are the four deadliest cancers in the U.S., some of the biggest drugmakers seeking cures and some next-generation treatment possibilities.
Lung cancer (155,870 deaths expected in the U.S. in 2017; 52 drugs approved). U.S. regulators in 2015 added two new drugs--Keytruda, from Merck (symbol MRK ), and Opdivo, from Bristol-Myers Squibb ( BMY )--to the arsenal fighting the most common type of lung cancer, known as non-small-cell cancer.
Colorectal cancer (50,260 deaths; 24 drugs). Avastin, from Roche ( RHHBY ), Erbitux, from Eli Lilly ( LLY ), and Stivarga, from Bayer, are common treatments.
Pancreatic cancer (43,090 deaths; 17 drugs). This cancer is usually diagnosed too late, so it's almost always fatal. Roche's Tarceva is one treatment, but the Cancer Research Institute cites a "great need for more-powerful treatments."
Breast cancer (41,070 deaths; 65 drugs). Lynparza, from AstraZeneca ( AZN ), now used to treat ovarian cancer, shows promise in boosting survival rates for some breast cancers.
Source: National Cancer Institute
See Also: Can This Fallen Biotech Be Revived?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie ( ABBV , $65) is another large player in cancer treatment that fans say is underappreciated. Humira made up 63% of AbbVie's sales of $25.6 billion in 2016. To bolster its growth outlook, AbbVie in 2015 bought biotech firm Pharmacyclics, which developed the blood-cancer treatment Imbruvica in partnership with Johnson & Johnson ( JNJ ). | AbbVie ( ABBV , $65) is another large player in cancer treatment that fans say is underappreciated. Humira made up 63% of AbbVie's sales of $25.6 billion in 2016. To bolster its growth outlook, AbbVie in 2015 bought biotech firm Pharmacyclics, which developed the blood-cancer treatment Imbruvica in partnership with Johnson & Johnson ( JNJ ). | AbbVie ( ABBV , $65) is another large player in cancer treatment that fans say is underappreciated. Humira made up 63% of AbbVie's sales of $25.6 billion in 2016. To bolster its growth outlook, AbbVie in 2015 bought biotech firm Pharmacyclics, which developed the blood-cancer treatment Imbruvica in partnership with Johnson & Johnson ( JNJ ). | So AbbVie shares Imbruvica's sales with J&J. AbbVie ( ABBV , $65) is another large player in cancer treatment that fans say is underappreciated. Humira made up 63% of AbbVie's sales of $25.6 billion in 2016. |
26178.0 | 2017-05-03 00:00:00 UTC | United Fire Group Inc Buys Enbridge Inc, Wells Fargo, Welltower Inc, Sells Spectra Energy Corp, ... | ABBV | https://www.nasdaq.com/articles/united-fire-group-inc-buys-enbridge-inc-wells-fargo-welltower-inc-sells-spectra-energy | nan | nan | United Fire Group Inc
New Purchases: ENB , ADI , UNIT ,
Added Positions:WFCPRL, HCNPRI,
Reduced Positions:USB, JEC, LUV,
Sold Out:SE, ENH, FDML, LLTC,
For the details of UNITED FIRE GROUP INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=UNITED+FIRE+GROUP+INC
These are the top 5 holdings of UNITED FIRE GROUP INC
US Bancorp ( USB ) - 602,959 shares, 11.22% of the total portfolio. Shares reduced by 3.41%
Cincinnati Financial Corp ( CINF ) - 320,276 shares, 8.37% of the total portfolio.
Wintrust Financial Corp ( WTFC ) - 230,523 shares, 5.76% of the total portfolio.
AbbVie Inc ( ABBV ) - 225,000 shares, 5.3% of the total portfolio.
Wells Fargo & Co ( WFC ) - 255,086 shares, 5.13% of the total portfolio.
New Purchase: Enbridge Inc (ENB)
United Fire Group Inc initiated holdings in Enbridge Inc. The purchase prices were between $40.31 and $44.37, with an estimated average price of $42.25. The stock is now traded at around $41.67. The impact to the portfolio due to this purchase was 1.4%. The holdings were 92,590 shares as of 2017-03-31.
New Purchase: Analog Devices Inc (ADI)
United Fire Group Inc initiated holdings in Analog Devices Inc. The purchase prices were between $71.32 and $83.85, with an estimated average price of $78.53. The stock is now traded at around $75.47. The impact to the portfolio due to this purchase was 0.03%. The holdings were 928 shares as of 2017-03-31.
New Purchase: Uniti Group Inc (UNIT)
United Fire Group Inc initiated holdings in Uniti Group Inc. The purchase prices were between $25.32 and $29.24, with an estimated average price of $26.65. The stock is now traded at around $26.91. The impact to the portfolio due to this purchase was 0.02%. The holdings were 2,588 shares as of 2017-03-31.
Added: Wells Fargo & Co (WFCPRL)
United Fire Group Inc added to the holdings in Wells Fargo & Co by 20.83%. The purchase prices were between $1197 and $1239.02, with an estimated average price of $1216.24. The stock is now traded at around $1265.00. The impact to the portfolio due to this purchase was 0.11%. The holdings were 1,450 shares as of 2017-03-31.
Added: Welltower Inc (HCNPRI)
United Fire Group Inc added to the holdings in Welltower Inc by 21.74%. The purchase prices were between $59.1 and $63.74, with an estimated average price of $61.01. The stock is now traded at around $63.26. The impact to the portfolio due to this purchase was 0.06%. The holdings were 14,000 shares as of 2017-03-31.
Sold Out: Spectra Energy Corp (SE)
United Fire Group Inc sold out the holdings in Spectra Energy Corp. The sale prices were between $40.68 and $43.45, with an estimated average price of $41.93.
Sold Out: Endurance Specialty Holdings Ltd (ENH)
United Fire Group Inc sold out the holdings in Endurance Specialty Holdings Ltd. The sale prices were between $92.5 and $93.07, with an estimated average price of $92.78.
Sold Out: Federal-Mogul Holdings Corp (FDML)
United Fire Group Inc sold out the holdings in Federal-Mogul Holdings Corp. The sale prices were between $9.87 and $10.15, with an estimated average price of $9.99.
Sold Out: Linear Technology Corp (LLTC)
United Fire Group Inc sold out the holdings in Linear Technology Corp. The sale prices were between $61.98 and $65.45, with an estimated average price of $63.61.
Warning! GuruFocus has detected 4 Warning Sign with WFCPRL. Click here to check it out.
WFCPRL 15-Year Financial Data
The intrinsic value of WFCPRL
Peter Lynch Chart of WFCPRL
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc ( ABBV ) - 225,000 shares, 5.3% of the total portfolio. United Fire Group Inc New Purchases: ENB , ADI , UNIT , Added Positions:WFCPRL, HCNPRI, Reduced Positions:USB, JEC, LUV, Sold Out:SE, ENH, FDML, LLTC, For the details of UNITED FIRE GROUP INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=UNITED+FIRE+GROUP+INC These are the top 5 holdings of UNITED FIRE GROUP INC US Bancorp ( USB ) - 602,959 shares, 11.22% of the total portfolio. Wintrust Financial Corp ( WTFC ) - 230,523 shares, 5.76% of the total portfolio. | AbbVie Inc ( ABBV ) - 225,000 shares, 5.3% of the total portfolio. United Fire Group Inc New Purchases: ENB , ADI , UNIT , Added Positions:WFCPRL, HCNPRI, Reduced Positions:USB, JEC, LUV, Sold Out:SE, ENH, FDML, LLTC, For the details of UNITED FIRE GROUP INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=UNITED+FIRE+GROUP+INC These are the top 5 holdings of UNITED FIRE GROUP INC US Bancorp ( USB ) - 602,959 shares, 11.22% of the total portfolio. Sold Out: Spectra Energy Corp (SE) United Fire Group Inc sold out the holdings in Spectra Energy Corp. | AbbVie Inc ( ABBV ) - 225,000 shares, 5.3% of the total portfolio. United Fire Group Inc New Purchases: ENB , ADI , UNIT , Added Positions:WFCPRL, HCNPRI, Reduced Positions:USB, JEC, LUV, Sold Out:SE, ENH, FDML, LLTC, For the details of UNITED FIRE GROUP INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=UNITED+FIRE+GROUP+INC These are the top 5 holdings of UNITED FIRE GROUP INC US Bancorp ( USB ) - 602,959 shares, 11.22% of the total portfolio. Sold Out: Endurance Specialty Holdings Ltd (ENH) United Fire Group Inc sold out the holdings in Endurance Specialty Holdings Ltd. | AbbVie Inc ( ABBV ) - 225,000 shares, 5.3% of the total portfolio. Wells Fargo & Co ( WFC ) - 255,086 shares, 5.13% of the total portfolio. Sold Out: Federal-Mogul Holdings Corp (FDML) United Fire Group Inc sold out the holdings in Federal-Mogul Holdings Corp. |
26179.0 | 2017-05-03 00:00:00 UTC | Gilead (GILD) Beats on Q1 Earnings, Revenues Miss Estimates | ABBV | https://www.nasdaq.com/articles/gilead-gild-beats-on-q1-earnings-revenues-miss-estimates-2017-05-03 | nan | nan | Gilead Sciences, Inc.' s GILD first-quarter 2017 earnings (including the impact of stock-based compensation expenses) of $2.20 per share beat the Zacks Consensus Estimate of $2.18. However, earnings were down from $2.98 in the year-ago quarter.
Moreover, total revenue in the reported quarter was $6.5 billion, down 16.5% year over year and missed the Zacks Consensus Estimate of $6.7 billion.
Shares of Gilead underperformed the Zacks classified Medical-Biomedical and Genetics industry in the last one year with the stock losing 19.9% during this period, compared with the industry's decline of 1.4%.
HCV Franchise Disappoints Again, HIV Impresses
Product sales came in at $6.4 billion, down 16.9% year over year. The decline was due to lower hepatitis C virus (HCV) sales, partially offset by higher sales across HIV and other therapeutic areas.
Antiviral product sales, which include Gilead's HIV and liver disease portfolios, came in at $5.8 billion in the reported quarter, down 18.7%.
HCV product sales, which include Harvoni, Sovaldi and the recently launched Epclusa, were $2.6 billion, down 39.5%. The downside was mainly attributed to lower sales of Harvoni and Sovaldi across all major markets, partially offset by sales of Epclusa (launched in 2016) across various locations. Sales in the U.S. declined sequentially due to lower Epclusa sales, resulting in lower inventory along with some loss of market share as a result of increased competition.
Sales of Harvoni declined 54.5% year over year to $1.4 billion in the reported quarter. The decline was mainly due to lower sales in the U.S. Further, Sovaldi sales recorded a steep year-over-year decline of 75.4% to $313 million.
Epclusa garnered sales of $892 million in the reported quarter, lower than the $1.0 billion in the prior quarter. We note that Epclusa was launched in the U.S. and Europe in June and Jul 2016 respectively.
Meanwhile, HIV and HBV product sales came in at $3.3 billion, up 13.8% year over year. The increase was primarily driven by continuous strong uptake of tenofovir alafenamide (TAF)-based products such as Genvoya, which generated sales of $769 million, up from $563 million in the prior quarter, Descovy, which recorded sales of $251 million, up from $149 million in the prior quarter, and Odefsey, which registered sales of $227 million, up from $155 million in the prior quarter.
HIV treatments like Stribild and Complera/Eviplera and Viread sales declined. Atripla sales tanked 33% to $452 million, while Truvada sales fell 20.4% to $714 million.
Other products like Letairis, Ranexa, AmBisome and Zydelig recorded sales of $211 million (up 20.6%), $153 million (up 6%), $92 million (up 6.9%) and $35 million (down 28.5%), respectively.
Research & development (R&D) expenses declined 26.4% to $931 million due to the impact of up-front collaboration expenses in 2016 related to Gilead's license and collaboration agreement with Galapagos NV and impairment charges related to in-process R&D. On the other hand, selling, general and administrative (SG&A) expenses were up 24% to $850 million due to higher branded prescription drug fee expense.
Adjusted product gross margin was 88.3%, up from 87.2% in the year-ago period.
2017 Guidance Reiterated
Gilead expects net product sales in the range of $22.5-$24.5 billion. Non-HCV product sales are projected between $15 billion and $15.5 billion. HCV product sales are projected between $7.5 billion and $9.0 billion. Adjusted R&D expenses and adjusted SG&A expenses are projected in the range of $3.1billion-$3.4 billion and $3.1billion-$3.4 billion, respectively. Adjusted product gross margin is estimated in the range of 86-88%. Earnings per share are projected around 84 cents - 91 cents.
Dividend and Share Repurchase
Concurrently, Gilead declared a cash dividend of 52 cents per share of common stock for second-quarter 2017. The dividend is payable on Jun 29 to stockholders of record at the close of business on Jun 16. During the first quarter, the company paid cash dividends of $687 million and repurchased 7.9 million shares of stock for $565 million.
Gilead Sciences, Inc. Price and Consensus
Gilead Sciences, Inc. Price and Consensus | Gilead Sciences, Inc. Quote
Our Take
Although the first quarter results beat on earnings, revenues missed expectations. The HCV franchise continues to be under competitive and pricing pressure leading to a massive decline in Harvoni and Sovaldi sales. The company expects that the persistent decline in HCV patient starts will be the primary factor behind the year-over-year decrease in revenues in 2017 along with increased competition which will impact patient share and pricing. This decline in patient starts is being driven by the evolving profile of patients that are in care. We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's ABBV Viekira Pak and Viekira XR and Bristol-Myers' BMY Daklinza among others. On a positive note, Epclusa's uptake has been encouraging and the drug is now launched in all the five major markets of Europe.
Meanwhile, the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens. The TAF-based regimens now represent 42% of total Gilead HIV prescription volume following the launch of Genvoya and the launches of Odefsey and Descovy in 2016. Genvoya is now the company's bestselling HIV product, surpassing both Truvada and Atripla since fourth-quarter 2016.
Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales as the company saw a significant uptick in PrEP usage in 2017 with an estimated 125,000 patients using Truvada by the end of the first quarter. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which should impact sales.
Zacks Rank & Key Pick
Gilead currently carries a Zacks Rank #2 (Buy). Another well placed stock in the healthcare sector is Infinity Pharmaceuticals, Inc. INFI which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Infinity' loss estimates narrowed to $1.03 from $1.43 for 2017 over the past 60 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 36.64%.Its share price increased 43.7% year to date.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's ABBV Viekira Pak and Viekira XR and Bristol-Myers' BMY Daklinza among others. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. Gilead Sciences, Inc.' s GILD first-quarter 2017 earnings (including the impact of stock-based compensation expenses) of $2.20 per share beat the Zacks Consensus Estimate of $2.18. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's ABBV Viekira Pak and Viekira XR and Bristol-Myers' BMY Daklinza among others. The increase was primarily driven by continuous strong uptake of tenofovir alafenamide (TAF)-based products such as Genvoya, which generated sales of $769 million, up from $563 million in the prior quarter, Descovy, which recorded sales of $251 million, up from $149 million in the prior quarter, and Odefsey, which registered sales of $227 million, up from $155 million in the prior quarter. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's ABBV Viekira Pak and Viekira XR and Bristol-Myers' BMY Daklinza among others. The increase was primarily driven by continuous strong uptake of tenofovir alafenamide (TAF)-based products such as Genvoya, which generated sales of $769 million, up from $563 million in the prior quarter, Descovy, which recorded sales of $251 million, up from $149 million in the prior quarter, and Odefsey, which registered sales of $227 million, up from $155 million in the prior quarter. | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's ABBV Viekira Pak and Viekira XR and Bristol-Myers' BMY Daklinza among others. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. Sales of Harvoni declined 54.5% year over year to $1.4 billion in the reported quarter. |
26180.0 | 2017-05-02 00:00:00 UTC | Gilead Sciences Inc.'s Revenue and Earnings Continue to Fall on Declining HCV Sales | ABBV | https://www.nasdaq.com/articles/gilead-sciences-incs-revenue-and-earnings-continue-fall-declining-hcv-sales-2017-05-02 | nan | nan | Just how bad will it be?
That was the question investors were asking in the days leading up to Gilead Sciences ' (NASDAQ: GILD) announcement of its first-quarter 2017 results. Gilead provided an answer when it reported those results after the market closed on Tuesday. But questions still remain.
Gilead Sciences results: The raw numbers
Data source: Gilead Sciences.
What happened with Gilead Sciences this quarter?
As expected, Gilead's hepatitis C virus (HCV) sales continued to drop. Combined HCV sales in the first quarter totaled $2.58 billion, down a whopping 40% from the prior-year period. Even with Epclusa's sales soaring to $892 million, the huge declines for Harvoni and Sovalid were simply too much for the newer HCV drug to offset.
A cursory glance at the biotech's big HIV drugs from the past few years might have also been discouraging. Sales fell in the first quarter for Truvada, Atripla, Stribild, Viread, and Complera/Eviplera compared with the prior-year period. However, newer HIV drugs Genvoya, Descovey, and Odefsey more than made up for those declines. Overall, sales for Gilead's HIV franchise increased 12.6% year over year.
Gilead's other products weren't nearly as important to the company's overall performance. Sales of pulmonary arterial hypertension drug Letairis jumped 20% over the prior-year period to $211 million. However, other drugs with less revenue experienced only single-digit-percentage increases. The only exception was blood cancer drug Zydelig, which continued to disappoint, with sales falling nearly 29% year over year to $35 million.
If you just looked at Gilead's GAAP results, you;d see the company's expenses were lower in the first quarter than in the prior-year period. However, a key reason for the decrease stemmed from higher research-and-development costs in 2016 related with Gilead's license and collaboration agreement with Galapagos NV (NASDAQ: GLPG) . On a non-GAAP basis, Gilead's first-quarter spending increased from the same period in 2016, primarily because of expenses associated with the purchase of an FDA priority review voucher and higher branded prescription-drug fee expenses.
Looking forward
Gilead reiterated its full-year 2017 guidance provided in February. The company continues to expect net product sales of $22.5 billion to $24.5 billion.
Despite the continued steep drop-off in HCV sales, there are some glimmers of hope. The decline in U.S. patient starts from the fourth quarter of 2016 to the first quarter of 2017 was relatively small. Patient starts in Europe held steady sequentially.
Major rivals aren't taking too much market share from Gilead. AbbVie (NYSE: ABBV) reported first-quarter sales totaling $263 million for its HCV drugs Viekiera, reflecting a 35.5% year-over-year decline. Gilead's Sovaldi, which is now its lowest-selling HCV drug, made higher revenue than Viekira despite a huge decline from the prior-year period.
Merck (NYSE: MRK) didn't have the same fate as AbbVie, though. The drugmaker reported first-quarter sales of $378 million for HCV drug Zepatier, a big jump from the $50 million in sales from the prior-year period. However, Gilead has much bigger HCV woes than the competition from Merck or AbbVie.
Gilead expects an FDA decision on approval for its sofosbuvir/velpatasvir/voxilaprevir combination treatment for HCV by Aug. 8. This final HCV product from the biotech could add some incremental revenue in the indication.
The biotech also has some promising late-stage pipeline candidates. A bictegravir/F/TAF combo could be Gilead's next big winner in HIV. Gilead expects to submit the combo treatment for regulatory approval in the U.S. and in Europe in the third quarter of this year.
Selonsertib (formerly GS-4997) is being evaluated in a phase 3 study targeting treatment of non-alcoholic steatohepatitis. Filgotinib, which Gilead licensed from partner Galapagos, is another late-stage candidate with tremendous potential in treating several autoimmune diseases. The problem is that late-stage candidates other than the bictegravir combo are probably a few years away from potential approval.
Perhaps the most encouraging news for Gilead's future is that its cash position continues to improve. At the end of the first quarter, the company reported cash, cash equivalents, and marketable securities of more than $34 billion -- up from $32.4 billion at the end of 2016. Gilead has plenty of money to spend on acquisitions that could improve its growth prospects. That prospect appears to be the most important thing for investors to look for in the days ahead.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
Keith Speights owns shares of AbbVie and Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has the following options: short June 2017 $70 calls on Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) reported first-quarter sales totaling $263 million for its HCV drugs Viekiera, reflecting a 35.5% year-over-year decline. Merck (NYSE: MRK) didn't have the same fate as AbbVie, though. However, Gilead has much bigger HCV woes than the competition from Merck or AbbVie. | AbbVie (NYSE: ABBV) reported first-quarter sales totaling $263 million for its HCV drugs Viekiera, reflecting a 35.5% year-over-year decline. Merck (NYSE: MRK) didn't have the same fate as AbbVie, though. However, Gilead has much bigger HCV woes than the competition from Merck or AbbVie. | AbbVie (NYSE: ABBV) reported first-quarter sales totaling $263 million for its HCV drugs Viekiera, reflecting a 35.5% year-over-year decline. Merck (NYSE: MRK) didn't have the same fate as AbbVie, though. However, Gilead has much bigger HCV woes than the competition from Merck or AbbVie. | AbbVie (NYSE: ABBV) reported first-quarter sales totaling $263 million for its HCV drugs Viekiera, reflecting a 35.5% year-over-year decline. Merck (NYSE: MRK) didn't have the same fate as AbbVie, though. However, Gilead has much bigger HCV woes than the competition from Merck or AbbVie. |
26181.0 | 2017-05-01 00:00:00 UTC | 3 Best Biotech Stocks During Trump's First 100 Days | ABBV | https://www.nasdaq.com/articles/3-best-biotech-stocks-during-trumps-first-100-days-2017-05-01 | nan | nan | Donald Trump won the U.S. presidency on promises to lower drug prices. Yet biotech stocks have outperformed the S&P 500 since his move into the White House, and some biotech stocks have more than doubled since his inauguration on Jan. 20. Among the best performing of these biotech stocks are Esperion Therapeutics (NASDAQ: ESPR) , TG Therapeutics (NASDAQ: TGTX) , and Aurinia Pharmaceuticals (NASDAQ: AUPH) , so let's learn more about them.
No. 1: Esperion Therapeutics -- up 223%
Roger Newton led the team responsible for developing Lipitor, the best-selling cholesterol drug of all time. Newton has assembled a team at Esperion Therapeutics that's working on what could turn out to be another top-selling medicine.
Esperion is working on bempedoic acid, an oral drug that can be taken alongside statins like Lipitor to lower bad cholesterol levels in patients who don't respond adequately to statins. In mid-stage clinical trials, combining bempedoic acid with statins lowered bad cholesterol levels by about an additional 20%.
The company has reported two important pieces of information that are exciting investors this year.
First, Esperion Therapeutics reported that it has fully enrolled patients in a phase 3 trial, and that data from that trial should be available next year. Second, the company said that the FDA has confirmed this trial can support an approval of bempedoic acid, removing any lingering doubt that the FDA would wait to see results from a separate cardiovascular outcomes trial before considering it for approval.
Because heart disease is the second most common cause of death, and studies show lowering bad cholesterol can reduce major cardiovascular events, this medicine could be a big hit. Tens of millions of patients are prescribed statins annually, and millions of them aren't reaching their cholesterol targets.
Only time will tell if bempedoic acid's trials confirm its efficacy and safety, but the potential for use in so many patients was more than enough good news to send this company's shares flying.
No. 2: Aurinia Pharmaceuticals -- up 177%
There are about 500,000 patients in the U.S. with systemic lupus erythematosus, and up to 60% of them suffer from lupus nephritis (LN), an inflammation of the kidneys that can cause end-stage renal failure.
Currently, patients with LN are treated off-label with CellCept, a medicine that delivers mixed response rates in patients.
In March, Aurinia Pharmaceuticals reported that using voclosporin and CellCept together resulted in complete remission rates of between 40% to 49% in LN patients, depending on dosage. The complete remission rate in patients receiving CellCept plus a placebo was only 24%.
Aurinia Pharmaceuticals announced in April that it will conduct a single phase 3 study to confirm these results, and if this global, 52-week, double-blind, placebo-controlled study is successful, it will support regulatory filings for approval in the U.S., Europe, and Japan.
CellCept's lackluster efficacy suggests that approvals could turn voclosporin into a big commercial success, and that's got some industry watchers thinking this drug could eventually rack up sales of $1 billion annually. While that's certainly possible, investors might want to temper a little of their enthusiasm. After all, there's no guarantee that Aurinia Pharmaceuticals' phase 3 trial will pan out.
No. 3: TG Therapeutics -- up 163%
TG Therapeutics shares have been on a tear since management announced in March that its experimental drug TG-1101, or ublituximab, could reshape how doctors treat leukemia.
A phase 3 trial evaluating TG-1101 in combination with AbbVie 's billion-dollar blockbuster blood cancer drug Imbruvica showed that 80% of patients with chronic lymphocytic leukemia and high-risk gene mutations responded to treatment. For comparison, only 47% of patients had an overall response to Imbruvica alone.
Management plans to share more complete data in an oral presentation at the American Society of Clinical Oncology conference in early June. Shortly thereafter, it plans on discussing its chances for an accelerated filing for TG-1101's approval with the FDA.
TG Therapeutics is also studying TG-1101 in multiple sclerosis, and it plans to begin a phase 3 trial of it in that indication this year. Additionally, the company is developing TGR-1202, and an abstract regarding its use with TG-1101 and Imbruvica is planned for ASCO too.
With so much going on at this company, it's easy to see why investors have looked beyond the potential negative impact of changes in Washington and driven the company's share price higher.
10 stocks we like better than TG Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and TG Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of April 3, 2017
Todd Campbell owns shares of Esperion Therapeutics. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A phase 3 trial evaluating TG-1101 in combination with AbbVie 's billion-dollar blockbuster blood cancer drug Imbruvica showed that 80% of patients with chronic lymphocytic leukemia and high-risk gene mutations responded to treatment. Because heart disease is the second most common cause of death, and studies show lowering bad cholesterol can reduce major cardiovascular events, this medicine could be a big hit. CellCept's lackluster efficacy suggests that approvals could turn voclosporin into a big commercial success, and that's got some industry watchers thinking this drug could eventually rack up sales of $1 billion annually. | A phase 3 trial evaluating TG-1101 in combination with AbbVie 's billion-dollar blockbuster blood cancer drug Imbruvica showed that 80% of patients with chronic lymphocytic leukemia and high-risk gene mutations responded to treatment. Among the best performing of these biotech stocks are Esperion Therapeutics (NASDAQ: ESPR) , TG Therapeutics (NASDAQ: TGTX) , and Aurinia Pharmaceuticals (NASDAQ: AUPH) , so let's learn more about them. In mid-stage clinical trials, combining bempedoic acid with statins lowered bad cholesterol levels by about an additional 20%. | A phase 3 trial evaluating TG-1101 in combination with AbbVie 's billion-dollar blockbuster blood cancer drug Imbruvica showed that 80% of patients with chronic lymphocytic leukemia and high-risk gene mutations responded to treatment. Among the best performing of these biotech stocks are Esperion Therapeutics (NASDAQ: ESPR) , TG Therapeutics (NASDAQ: TGTX) , and Aurinia Pharmaceuticals (NASDAQ: AUPH) , so let's learn more about them. Esperion is working on bempedoic acid, an oral drug that can be taken alongside statins like Lipitor to lower bad cholesterol levels in patients who don't respond adequately to statins. | A phase 3 trial evaluating TG-1101 in combination with AbbVie 's billion-dollar blockbuster blood cancer drug Imbruvica showed that 80% of patients with chronic lymphocytic leukemia and high-risk gene mutations responded to treatment. Among the best performing of these biotech stocks are Esperion Therapeutics (NASDAQ: ESPR) , TG Therapeutics (NASDAQ: TGTX) , and Aurinia Pharmaceuticals (NASDAQ: AUPH) , so let's learn more about them. Esperion is working on bempedoic acid, an oral drug that can be taken alongside statins like Lipitor to lower bad cholesterol levels in patients who don't respond adequately to statins. |
26182.0 | 2017-04-27 00:00:00 UTC | AbbVie (ABBV) Q1 Earnings Beat Estimates, Revenues Up Y/Y | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q1-earnings-beat-estimates-revenues-up-y-y-2017-04-27 | nan | nan | AbbVie Inc.ABBV reported better-than-expected results in the first-quarter of 2017. The company surpassed both earnings and sales expectations.
In the past one year, AbbVie's shares gained 3.9%, while the Zacks classified Large-Cap Pharma industry witnessed an increase of 5.9%.
The biopharmaceutical company reported first-quarter 2017 earnings of $1.28 per share that beat the Zacks Consensus Estimate of $1.26 per share by 1.6%. Earnings grew 11% year over year.
The company posted revenues of $6.54 billion in the reported quarter, which surpassed the Zacks Consensus Estimate of $6.51 billion. Revenues also jumped 9.7% year over year. On operational basis revenue increased 10.1%.
Quarter in Detail
Humira sales on an operational basis, excluding currency impact, rose 15.8% year over year to $4.1 billion.
First-quarter net revenue from Imbruvica was $551 million, up 44.7% year over year. U.S. sales of Imbruvica were $457 million. AbbVie recorded $94 million of international profit sharing with Johnson & Johnson JNJ .
Other products that delivered an impressive performance include Duodopa which showed revenue of $80 million up 22.8% on both operational and reported basis. Another product Creon reported revenue of $185 million up 19.8% and 17% on an operational and reported basis respectively.
HCV product Viekira recorded sales of $263 million, down 15.4% sequentially.
Adjusted SG&A expenses rose 0.7%, while R&D expenses increased 23.3% in the quarter. Adjusted operating margin was 42.3% of sales in the reported quarter.
2017 Outlook
AbbVie reiterated its previously issued outlook for 2017. The company maintains its adjusted EPS in the range of $5.44-$5.54 reflecting growth of 13.9% at the mid-point.
AbbVie Inc. Price, Consensus and EPS Surprise
AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote
Zacks Rank & Key Picks
AbbVie currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Heska Corporation HSKA and Galena Biopharma, Inc. GALE which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Heska's earnings per share estimates increased from $1.53 to $1.65 for 2017 and from $1.80 to $2.01 for 2018, over the last 60 days. The company posted positive surprises in three of the four trailing quarters with an average beat of 291.54%.
Galena's loss per share estimates narrowed from $2.03 to 58 cents for 2017, over the last 60 days. The company posted positive earnings surprises in two of the four trailing quarters with an average beat of 53.83%.
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 6X worse than the market. See these critical buys and sells free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Galena Biopharma, Inc. (GALE): Free Stock Analysis Report
Heska Corporation (HSKA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the past one year, AbbVie's shares gained 3.9%, while the Zacks classified Large-Cap Pharma industry witnessed an increase of 5.9%. AbbVie Inc.ABBV reported better-than-expected results in the first-quarter of 2017. AbbVie recorded $94 million of international profit sharing with Johnson & Johnson JNJ . | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Galena Biopharma, Inc. (GALE): Free Stock Analysis Report Heska Corporation (HSKA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV reported better-than-expected results in the first-quarter of 2017. | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Galena Biopharma, Inc. (GALE): Free Stock Analysis Report Heska Corporation (HSKA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV reported better-than-expected results in the first-quarter of 2017. | AbbVie Inc.ABBV reported better-than-expected results in the first-quarter of 2017. In the past one year, AbbVie's shares gained 3.9%, while the Zacks classified Large-Cap Pharma industry witnessed an increase of 5.9%. AbbVie recorded $94 million of international profit sharing with Johnson & Johnson JNJ . |
26183.0 | 2017-04-27 00:00:00 UTC | A Tax Cut in Progress | ABBV | https://www.nasdaq.com/articles/tax-cut-progress-2017-04-27 | nan | nan | From the market's reaction today, you might think that it just hated the President's long-awaited tax plan, as the major indices made a beeline to the negative side after it was announced. But that's not the case. Certainly, this market would LOVE a 15% corporate tax rate. Instead, several of the editors consider today's selloff as a classic case of "buy the rumor, sell the news".
And it certainly did sell! The major indices each looked like they were putting together a third straight session of solid gains. But by the closing bell, the S&P had slumped by 0.05% to 2387.5, while the Dow slipped 0.10% to 20,975.1 and the NASDAQ declined 0.27 of a point (or 0%) to 6025.2. Interestingly, the Russell 2000 was up 0.59% to 1419.4.
The market is aware that this is the first step in a long process that will hopefully end with passage sometime in late summer or fall. The plan could look very different by then, but it was good that we finally got some specifics from President Trump. Now it's in Congress' court.
In the portfolios, Healthcare Innovators added two more stocks, bringing the portfolio to 8 positions with a lot more to come. Home Run Investor cashed in a double-digit profit and then replaced it with a stock that could be on its way to a 13th straight beat-and-raise quarter next week. Finally, Reitmeister Trading Alert added more to a position that dipped lower today despite a strong quarterly report. Learn more in the highlights section below:
Today's Portfolio Highlights:
Healthcare Innovators: Day 2 brings two more additions, giving this brand new portfolio a total of 8 names so far on its way to 20-25. On Wednesday, Kevin added AbbVie (ABBV). This large-cap pharma company is expected to beat estimates on both the top and bottom lines when it reports tomorrow morning. At around $65 per share, the editor really likes this entry price.
The other buy is BioMarin Pharmaceutical (BMRN), which develops orphan drugs to treat rare diseases. The company recently received good regulatory news on both ends of the ocean for Brineura, a treatment for a fatal nervous system disorder. Shares have been moving higher this week, so Kevin decided to get in now while the risk-reward is still very favorable. Read the complete commentary for more specifics on each of these new buys. And don't forget to read the Guide for more on this new portfolio.
Home Run Investor: It was time to get out of Prestige Brands (PCH) since it moved to a Zacks Rank #4, but Dave still made a nice profit of 16.8% on the position. The editor replaced the name by picking up 2U (TWOU), a Zacks Rank #2 cloud-based education company that has put together 12 straight beat-and-raise quarters. The next report is scheduled for next week, so Dave wanted to make the move now. Read the full write-up for more on TWOU, including a breakdown of its chart.
Reitmeister Trading Alert: Steve loves when the market is "asleep at the wheel". For example, Evercore Partners (EVR) crushed expectations by nearly 50% earlier today…and yet shares moved lower. Now the editor gets a chance to add more shares of this investment management & investment banking company, bringing the total allocation to 7%. Read the full commentary for more.
Options Trader:"(The tax plan) was definitely well received (especially the corporate tax cut). But as I said yesterday, I wouldn't be surprised if the market pulls back a little after the announcement. Why? It's the classic 'buy the rumor, sell the fact' phenomenon. The market jumped on excitement that the tax plan was coming. But now that it was announced, it might be cause for some profit taking. Because it's not like it's going to be implemented tomorrow. It likely won't actually get passed until August or September (or so). And there's sure to be some revisions. Although, that's what the market has been pretty much expecting anyway.
"And while the market is forward looking, it doesn't have to immediately price in every great piece of news immediately.
"Over the coming months, the messy work of fleshing out the details of this plan will get worked out. But, as long as the corporate tax rate comes in somewhere in the 20% range (give or take a few percentage points) the market will celebrate it and the bull market will continue on. And it will ultimately usher in brand new highs for the market as analysts digest just how transformative a dramatic corporate tax cut will be for our economy!" -- Kevin Matras
All the Best,
Jim Giaquinto
Recommendations from Zacks' Private Portfolios:
Believe it or not, this article is not available on the Zacks.com website. The commentary is a partial overview of the daily activity from Zacks' private recommendation services. If you would like to follow our Buy and Sell signals in real time, we've made a special arrangement for readers of this website. Starting today you can see all the recommendations from all of Zacks' portfolios absolutely free for 7 days. Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises (which we've predicted with an astonishing 80%+ accuracy). Click here to "test drive" Zacks Ultimate for FREE >>
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On Wednesday, Kevin added AbbVie (ABBV). From the market's reaction today, you might think that it just hated the President's long-awaited tax plan, as the major indices made a beeline to the negative side after it was announced. The company recently received good regulatory news on both ends of the ocean for Brineura, a treatment for a fatal nervous system disorder. | On Wednesday, Kevin added AbbVie (ABBV). Finally, Reitmeister Trading Alert added more to a position that dipped lower today despite a strong quarterly report. Learn more in the highlights section below: Today's Portfolio Highlights: Healthcare Innovators: Day 2 brings two more additions, giving this brand new portfolio a total of 8 names so far on its way to 20-25. | On Wednesday, Kevin added AbbVie (ABBV). From the market's reaction today, you might think that it just hated the President's long-awaited tax plan, as the major indices made a beeline to the negative side after it was announced. But, as long as the corporate tax rate comes in somewhere in the 20% range (give or take a few percentage points) the market will celebrate it and the bull market will continue on. | On Wednesday, Kevin added AbbVie (ABBV). Instead, several of the editors consider today's selloff as a classic case of "buy the rumor, sell the news". And don't forget to read the Guide for more on this new portfolio. |
26184.0 | 2017-04-27 00:00:00 UTC | AbbVie (ABBV) Beats Earnings and Revenue in Q1 | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-beats-earnings-and-revenue-in-q1-2017-04-27 | nan | nan | North Chicago, IL-based AbbVie Inc.ABBV is best known for its autoimmune disease drug, Humira. AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to severe), axial spondyloarthritis, pediatric Crohn's disease, chronic plaque psoriasis (moderate to severe), and hidradenitis suppurativa (moderate to severe. Other key products include Imbruvica (cancer) and Viekira Pak (hepatitis C virus (HCV) treatment).
Humira, is a major contributor to AbbVie's top line. While Humira will remain the key growth driver at AbbVie, the coming quarters will see investor focus remaining primarily on Viekira's performance as well as pipeline updates.
Meanwhile, the Pharmacyclics acquisition has diversified AbbVie's product portfolio with the addition of Imbruvica.
AbbVie's performance has been mixed, with the pharmaceuticals company delivering positive surprises in the two of the past four quarter while recording in-line earnings in the other two. The average earnings beat over the last four quarters is 1.92%.
AbbVie Inc. Price and EPS Surprise
AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote
Currently, AbbVie has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: AbbVie's first-quarter earnings came in at $1.28 per share, beating the Zacks Consensus Estimate of $1.26.
Revenues: AbbVie posted revenues of $6.54 billion, marginally beating the Zacks Consensus Estimate of $6.51 billion.
Key Stats: Humira sales came in at $4.1 billion, up 15.8% year over year excluding currency impact. First-quarter Imbruvica net revenues were $551 million, up 44.7 % year over year.
2017 Outlook: AbbVie reiterated its previously issues outlook for 2017. The company maintains its adjusted EPS in the range of $5.44-$5.54. The Zacks Consensus Estimate is currently pegged at $5.50 per share.
Share Price Impact: Shares were up less than 1% in pre-market trading .
Check back later for our full write up on this AbbVie earnings report.
Looking for Ideas with Even Greater Upside?
Most of Zacks' investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie's performance has been mixed, with the pharmaceuticals company delivering positive surprises in the two of the past four quarter while recording in-line earnings in the other two. North Chicago, IL-based AbbVie Inc.ABBV is best known for its autoimmune disease drug, Humira. AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to severe), axial spondyloarthritis, pediatric Crohn's disease, chronic plaque psoriasis (moderate to severe), and hidradenitis suppurativa (moderate to severe. | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to severe), axial spondyloarthritis, pediatric Crohn's disease, chronic plaque psoriasis (moderate to severe), and hidradenitis suppurativa (moderate to severe. AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Currently, AbbVie has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. Revenues: AbbVie posted revenues of $6.54 billion, marginally beating the Zacks Consensus Estimate of $6.51 billion. | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to severe), axial spondyloarthritis, pediatric Crohn's disease, chronic plaque psoriasis (moderate to severe), and hidradenitis suppurativa (moderate to severe. AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Currently, AbbVie has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below: Earnings: AbbVie's first-quarter earnings came in at $1.28 per share, beating the Zacks Consensus Estimate of $1.26. | Meanwhile, the Pharmacyclics acquisition has diversified AbbVie's product portfolio with the addition of Imbruvica. AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Currently, AbbVie has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below: Earnings: AbbVie's first-quarter earnings came in at $1.28 per share, beating the Zacks Consensus Estimate of $1.26. |
26185.0 | 2017-04-27 00:00:00 UTC | Earnings Reaction History: AbbVie Inc., 36.4% Follow-Through Indicator, 3.0% Sensitive | ABBV | https://www.nasdaq.com/articles/earnings-reaction-history-abbvie-inc-364-follow-through-indicator-30-sensitive-2017-04-27 | nan | nan | Expected Earnings Release: 04/27/2017, Premarket
Avg. Extended-Hours Dollar Volume: $9,432,532
AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect very active trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close.
Last 12 Qtrs Positive Only Price Reactions
Percent of time added to extended-hours gains: 40%
Average next regular session additional gain: 3.2%
Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock posted additional gains in the following regular session by an average of 3.2%.
Last 12 Qtrs Negative Only Price Reactions
Percent of time added to extended-hours losses: 33.3%
Average next regular session additional loss: 1%
Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 33.3% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 1.0% by the following regular session close.
Data provided by the MT Pro service at MTNewswires.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 40% Average next regular session additional gain: 3.2% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock posted additional gains in the following regular session by an average of 3.2%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 33.3% Average next regular session additional loss: 1% Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 33.3% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 1.0% by the following regular session close. Extended-Hours Dollar Volume: $9,432,532 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 40% Average next regular session additional gain: 3.2% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock posted additional gains in the following regular session by an average of 3.2%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 33.3% Average next regular session additional loss: 1% Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 33.3% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 1.0% by the following regular session close. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 40% Average next regular session additional gain: 3.2% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock posted additional gains in the following regular session by an average of 3.2%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 33.3% Average next regular session additional loss: 1% Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 33.3% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 1.0% by the following regular session close. Extended-Hours Dollar Volume: $9,432,532 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Extended-Hours Dollar Volume: $9,432,532 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 40% Average next regular session additional gain: 3.2% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock posted additional gains in the following regular session by an average of 3.2%. |
26186.0 | 2017-04-26 00:00:00 UTC | Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY | ABBV | https://www.nasdaq.com/articles/pharma-stocks-q1-earnings-roster-for-apr-27%3A-celg-abbv-bmy-2017-04-26 | nan | nan | Things are certainly looking up as we get into the thick of the Q1 earnings season. By the end of this week, approximately half of the S&P 500 Index would be reporting, making the picture clearer.
As of Apr 21, 95 S&P 500 members, accounting for 24.9% of the index's total market capitalization has reported results. As per Earnings Preview , total earnings for these companies were up 14.3% year over year on 4.6% higher revenues. Of these, 72.6% beat on earnings estimates while 62.1% beat on revenue estimates resulting in a blended beat of 51.6%.
Most importantly, growth rates are steadily accelerating from the last quarter and on track to record the highest level in the last three years. Estimates for the second quarter are looking up too and if the trend persists it will further boost growth.
How have Drug Stocks Fared So Far?
Sector bellwether Johnson & Johnson JNJ reported mixed results, beating on earnings but missing on sales. Biogen, Inc. BIIB reported better-than-expected results as the company surpassed expectations both for earnings and sales.
We note that Medical is one of the sectors expected to record growth in the positive territory. Earnings for the sector are expected to inch up 0.8% on 6.3% improvement in revenues.
As of Apr 21, 9.3% companies in the Medical sector reported results, putting up a blended beat of 80% (the percentage of companies that have beaten both earnings and revenue estimates).
Let's find out what's in store for a few companies scheduled to report results on Apr 27.
Celgene Corporation CELG is scheduled to report first-quarter 2017 results, before the opening bell. Celgene's key product, Revlimid, should continue to act as the main growth driver in the first quarter, driven by share gains in important markets and longer treatment duration in newly diagnosed multiple myeloma (MM). Abraxane should maintain its position in the U.S. with stable market shares in breast, lung and pancreatic cancers. However, Abraxane sales are under pressure due to a highly competitive U.S. market. Celgene's track record has been pretty decent with the company beating earnings estimates thrice in the trailing four quarters. Overall, the company has delivered an average positive surprise of 5.08%. Celgene currently carries a Zacks Rank #3 (Hold) with an Earnings ESP of -0.68%. Although Celgene's Zacks Rank #3 increases the predictive power of ESP, its negative ESP makes it highly unlikely for the stock to beat earnings this quarter. Note that we caution against Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . (Read more: Celgene to Post Q1 Earnings: What's in the Cards? )
Celgene Corporation Price and EPS Surprise
Celgene Corporation Price and EPS Surprise | Celgene Corporation Quote
AbbVie Inc. ABBV is slated to release first-quarter 2017 earnings, before the opening bell. The company's key drug, Humira, is likely to remain the main growth driver in the first quarter. Increasing awareness, favorable clinical data, additional indications and expansion into new markets are expected to help the product to continue to make significant contributions to the top line. We note that AbbVie's earnings history is a mixed bag as the pharmaceuticals company delivered positive surprises in the two of the last four quarters but recorded in-line earnings in the other two. The average earnings beat for the last four quarters is 1.92%. AbbVie currently carries a Zacks Rank #3 with an Earnings ESP of 0.00%. While the Zacks Rank #3 is favorable, an Earnings ESP of 0.00% makes surprise prediction difficult. (Read more: What's in Store for AbbVie this Earnings Season? )
AbbVie Inc. Price and EPS Surprise
AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote
Bristol-Myers Squibb Company BMY is scheduled to report first-quarter 2017 results, before the opening bell. The company's high-profile immuno-oncology drug, Opdivo, should continue to drive the top line in the to-be-reported quarter. Further, recent label expansions into the classical Hodgkin lymphoma and head and neck cancer indications should boost the drug's sales. However, the lung-cancer market in the U.S became more competitive in 2016 due to the entry of Tecentriq. Bristol-Myers expects the second-line lung cancer business to be under competitive pressure. As a result, sales of the drug in the U.S is projected be flat in 2017. Bristol-Myers currently carries a Zacks Rank #3 which increases the predictive power of ESP. However, its negative ESP makes it highly unlikely for the stock to beat earnings this quarter. (Read more: Bristol-Myers to Post Q1 Earnings: What's in Store? )
Bristol-Myers Squibb Company Price and EPS Surprise
Bristol-Myers Squibb Company Price and EPS Surprise | Bristol-Myers Squibb Company Quote
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Celgene Corporation Price and EPS Surprise Celgene Corporation Price and EPS Surprise | Celgene Corporation Quote AbbVie Inc. ABBV is slated to release first-quarter 2017 earnings, before the opening bell. We note that AbbVie's earnings history is a mixed bag as the pharmaceuticals company delivered positive surprises in the two of the last four quarters but recorded in-line earnings in the other two. AbbVie currently carries a Zacks Rank #3 with an Earnings ESP of 0.00%. | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Bristol-Myers Squibb Company BMY is scheduled to report first-quarter 2017 results, before the opening bell. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Celgene Corporation Price and EPS Surprise Celgene Corporation Price and EPS Surprise | Celgene Corporation Quote AbbVie Inc. ABBV is slated to release first-quarter 2017 earnings, before the opening bell. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Celgene Corporation Price and EPS Surprise Celgene Corporation Price and EPS Surprise | Celgene Corporation Quote AbbVie Inc. ABBV is slated to release first-quarter 2017 earnings, before the opening bell. We note that AbbVie's earnings history is a mixed bag as the pharmaceuticals company delivered positive surprises in the two of the last four quarters but recorded in-line earnings in the other two. | Celgene Corporation Price and EPS Surprise Celgene Corporation Price and EPS Surprise | Celgene Corporation Quote AbbVie Inc. ABBV is slated to release first-quarter 2017 earnings, before the opening bell. We note that AbbVie's earnings history is a mixed bag as the pharmaceuticals company delivered positive surprises in the two of the last four quarters but recorded in-line earnings in the other two. AbbVie currently carries a Zacks Rank #3 with an Earnings ESP of 0.00%. |
26187.0 | 2017-04-21 00:00:00 UTC | What's in Store for AbbVie (ABBV) this Earnings Season? | ABBV | https://www.nasdaq.com/articles/whats-in-store-for-abbvie-abbv-this-earnings-season-2017-04-21 | nan | nan | AbbVie Inc.ABBV is slated to release first-quarter 2017 earnings, before the opening bell on Apr 27.
AbbVie's shares rose 1.8% so far this year while the Zacks classified Large Cap Pharma industry recorded an increase of 4%.
Last quarter, the company delivered in-line earnings. We note that AbbVie's earnings history is a mixed bag as the pharmaceuticals company delivered positive surprises in the two of the last four quarters but recorded in-line earnings in the other two. The average earnings beat for the last four quarters is 1.92%.
AbbVie Inc. Price and EPS Surprise
AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote
Let's see how things are shaping up for the company this quarter.
Factors to Consider
At the fourth-quarter 2016 conference call, management revealed that it expects first-quarter 2017 earnings in the range of $1.24-$1.26 per share. Revenues are expected to grow 10% on an operational basis. Currency headwinds are expected to hurt revenues by 1%.
The company's key drug, Humira, is likely to remain the main growth driver in the first quarter. Increasing awareness, favorable clinical data, additional indications and expansion into new markets are expected to help the product to continue making significant contributions to the top line. In the first quarter, AbbVie expects Humira sales growth to be above 20%.
Another area of focus is the performance of Imbruvica, which was added to AbbVie's portfolio following its May 2015 acquisition of Pharmacyclics. The drug recorded strong sales in the past two quarters, a trend that we expect to continue. Imbruvica has multi-billion dollar potential and the company is looking to expand Imbruvica's label for solid tumors and autoimmune diseases.
We note that Imbruvica's U.S. sales have displayed a slight sequential decline in the fourth quarter of 2016 due to slowing prescription trends. However, the company expects Imbruvica U.S. sales in the first quarter to rise in the high-single digit range sequentially.
Although Imbruvica has huge commercial potential, investors should know that revenues from it will be shared with Johnson & Johnson JNJ , which has a collaboration agreement with Pharmacyclics.
AbbVie is positioning Imbruvica as 'a pipeline in a molecule' - a treatment that is currently used in a wide range of studies.
Other drugs like Duopa and Creon are also expected to continue to perform well in the to-be-reported quarter.
However, Abbvie's Hepatitis C virus (HCV) treatment, Viekira, will continue to be adversely impacted by intense pricing and competitive pressure in the HCV market.
Earnings Whispers
Our proven model does not conclusively show that AbbVie is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: The Earnings ESP is 0.00% as the Most Accurate estimate as well as the Zacks Consensus Estimate stand at $1.26. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: AbbVie's Zacks Rank #3 increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident about an earnings beat.
We caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Proteostasis Therapeutics, Inc. PTI , which is expected to release results on May 12, has an Earnings ESP of +5.17% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
Ultragenyx Pharmaceutical Inc. RARE is expected to release results on May 8. The company has an Earnings ESP of +2.94% and a Zacks Rank #3.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report
Proteostasis Therapeutics, Inc. (PTI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie's shares rose 1.8% so far this year while the Zacks classified Large Cap Pharma industry recorded an increase of 4%. AbbVie Inc.ABBV is slated to release first-quarter 2017 earnings, before the opening bell on Apr 27. We note that AbbVie's earnings history is a mixed bag as the pharmaceuticals company delivered positive surprises in the two of the last four quarters but recorded in-line earnings in the other two. | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Let's see how things are shaping up for the company this quarter. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Proteostasis Therapeutics, Inc. (PTI): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV is slated to release first-quarter 2017 earnings, before the opening bell on Apr 27. | We note that AbbVie's earnings history is a mixed bag as the pharmaceuticals company delivered positive surprises in the two of the last four quarters but recorded in-line earnings in the other two. AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Let's see how things are shaping up for the company this quarter. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Proteostasis Therapeutics, Inc. (PTI): Free Stock Analysis Report To read this article on Zacks.com click here. | AbbVie Inc.ABBV is slated to release first-quarter 2017 earnings, before the opening bell on Apr 27. AbbVie's shares rose 1.8% so far this year while the Zacks classified Large Cap Pharma industry recorded an increase of 4%. We note that AbbVie's earnings history is a mixed bag as the pharmaceuticals company delivered positive surprises in the two of the last four quarters but recorded in-line earnings in the other two. |
26188.0 | 2017-04-20 00:00:00 UTC | AbbVie's PARP Inhibitor Comes Up Empty | ABBV | https://www.nasdaq.com/articles/abbvies-parp-inhibitor-comes-empty-2017-04-20 | nan | nan | AbbVie 's(NYSE: ABBV) attempt to expand the use of a new class of cancer drugs into new indications has failed to pan out, according to management.
The company announced yesterday that two trials evaluating its PARP inhibitor veliparib came up short of their primary endpoints, casting significant doubt on AbbVie's PARP program, and raising questions about ongoing trials for currently approved PARP inhibitors developed by AstraZeneca (NYSE: AZN) , Clovis Oncology (NASDAQ: CLVS) , and Tesaro (NASDAQ: TSRO) .
What's the news
Veliparib belongs to the poly (ADP-ribose) polymerase (PARP) inhibitor class of drugs, which work by preventing cancer cells from using the body's natural system to repair cell damage that's caused by cancer treatment.
Although other PARP inhibitors have been approved by the Food and Drug Administration (FDA) for use in ovarian cancer, AbbVie was hoping it could play catch-up by winning a green light in other cancer indications.
Sadly, those efforts came up short. Adding veliparib to chemotherapy didn't improve outcomes in triple-negative breast cancer and non-small-cell lung cancer patients.
In triple-negative breast cancer, veliparib was being evaluated for use alongside the chemotherapies carboplatin and paclitaxel. The trial involved 312 patients with early-stage triple-negative breast cancer, and the trial's primary endpoint was complete pathologic response.
In the non-small-cell lung cancer trial, veliparib was studied for use along with carboplatin and paclitaxel in patients with previously untreated metastatic or advanced squamous non-small-cell lung cancer. The trial was designed to evaluate overall survival in patients who are current smokers.
Unfortunately, the addition of veliparib to these chemotherapies failed to deliver on the primary endpoint measures in both trials. Detailed data from the trials will be reported at a future healthcare conference.
What's the impact
PARP inhibitors are already generating hundreds of millions of dollars in sales in ovarian cancer, but the market has become increasingly crowded in the past year.
AstraZeneca's Lynparza became the first PARP inhibitor to win FDA approval when it won the green light for use in ovarian patients with mutations to the BRCA gene in 2014. Clovis Oncology's Rubraca won the FDA go-ahead this past December, and most recently, Tesaro notched FDA approval for its drug -- Zejula -- in March.
Until now, PARP inhibitors' track record in late-stage clinical trials has been solid. However, those successes have been in ovarian cancer, not other cancers like triple-negative breast cancer and non-small-cell lung cancer.
Lynparza and Rubraca are approved for use in BRCA-positive patients (third-line and second-line treatment, respectively), while Zejula is approved for use in ovarian patients regardless of their BRCA status.
Since there are now three PARP inhibitors vying for market share, the peak sales potential for these drugs depends heavily on expanding their addressable patient populations by proving their effectiveness in earlier lines of treatment or in other cancer indications.
All three of these drugs are being evaluated for first-line use in ovarian cancer, and studies are also underway in other cancers, including the indications that veliparib just failed.
At AstraZeneca, Lynparza is being studied in triple-negative breast cancer and non-small-cell lung cancer. At Clovis, a study is underway of Rubraca in triple-negative breast cancer and solid tumor cancers. And Tesaro's Zejula is also being evaluated in triple-negative breast cancer.
Looking ahead
Small differences between these drugs could mean that AbbVie's setback might not be a setback for AstraZeneca, Clovis Oncology, and Tesaro. Furthermore, differences in trial design, including the use of different drugs in combination with these drugs, could make a difference, so investors shouldn't extrapolate AbbVie's failure too broadly across this class of drugs.
Having said that, investors won't know for sure if the differences are big enough to allow these competitors to succeed where AbbVie has failed until phase 3 trials wrap up. As a result, investors might want to temper a bit of enthusiasm for Lynparza, Rubraca, and Zejula's label-expansion opportunity until the therapies have proven that they work in the new indications.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of April 3, 2017
Todd Campbell has no position in any stocks mentioned.His clients may have positions in the companies mentioned.The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie 's(NYSE: ABBV) attempt to expand the use of a new class of cancer drugs into new indications has failed to pan out, according to management. The company announced yesterday that two trials evaluating its PARP inhibitor veliparib came up short of their primary endpoints, casting significant doubt on AbbVie's PARP program, and raising questions about ongoing trials for currently approved PARP inhibitors developed by AstraZeneca (NYSE: AZN) , Clovis Oncology (NASDAQ: CLVS) , and Tesaro (NASDAQ: TSRO) . Although other PARP inhibitors have been approved by the Food and Drug Administration (FDA) for use in ovarian cancer, AbbVie was hoping it could play catch-up by winning a green light in other cancer indications. | The company announced yesterday that two trials evaluating its PARP inhibitor veliparib came up short of their primary endpoints, casting significant doubt on AbbVie's PARP program, and raising questions about ongoing trials for currently approved PARP inhibitors developed by AstraZeneca (NYSE: AZN) , Clovis Oncology (NASDAQ: CLVS) , and Tesaro (NASDAQ: TSRO) . AbbVie 's(NYSE: ABBV) attempt to expand the use of a new class of cancer drugs into new indications has failed to pan out, according to management. Although other PARP inhibitors have been approved by the Food and Drug Administration (FDA) for use in ovarian cancer, AbbVie was hoping it could play catch-up by winning a green light in other cancer indications. | The company announced yesterday that two trials evaluating its PARP inhibitor veliparib came up short of their primary endpoints, casting significant doubt on AbbVie's PARP program, and raising questions about ongoing trials for currently approved PARP inhibitors developed by AstraZeneca (NYSE: AZN) , Clovis Oncology (NASDAQ: CLVS) , and Tesaro (NASDAQ: TSRO) . Although other PARP inhibitors have been approved by the Food and Drug Administration (FDA) for use in ovarian cancer, AbbVie was hoping it could play catch-up by winning a green light in other cancer indications. AbbVie 's(NYSE: ABBV) attempt to expand the use of a new class of cancer drugs into new indications has failed to pan out, according to management. | The company announced yesterday that two trials evaluating its PARP inhibitor veliparib came up short of their primary endpoints, casting significant doubt on AbbVie's PARP program, and raising questions about ongoing trials for currently approved PARP inhibitors developed by AstraZeneca (NYSE: AZN) , Clovis Oncology (NASDAQ: CLVS) , and Tesaro (NASDAQ: TSRO) . AbbVie 's(NYSE: ABBV) attempt to expand the use of a new class of cancer drugs into new indications has failed to pan out, according to management. Although other PARP inhibitors have been approved by the Food and Drug Administration (FDA) for use in ovarian cancer, AbbVie was hoping it could play catch-up by winning a green light in other cancer indications. |
26189.0 | 2017-04-20 00:00:00 UTC | Noteworthy Thursday Option Activity: NRZ, ILMN, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-nrz-ilmn-abbv-2017-04-20 | nan | nan | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in New Residential Investment Corp (Symbol: NRZ), where a total volume of 19,297 contracts has been traded thus far today, a contract volume which is representative of approximately 1.9 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 65% of NRZ's average daily trading volume over the past month, of 3.0 million shares. Especially high volume was seen for the $16 strike put option expiring April 21, 2017 , with 3,765 contracts trading so far today, representing approximately 376,500 underlying shares of NRZ. Below is a chart showing NRZ's trailing twelve month trading history, with the $16 strike highlighted in orange:
Illumina Inc (Symbol: ILMN) saw options trading volume of 5,140 contracts, representing approximately 514,000 underlying shares or approximately 58.9% of ILMN's average daily trading volume over the past month, of 872,385 shares. Especially high volume was seen for the $185 strike call option expiring May 19, 2017 , with 1,018 contracts trading so far today, representing approximately 101,800 underlying shares of ILMN. Below is a chart showing ILMN's trailing twelve month trading history, with the $185 strike highlighted in orange:
And AbbVie Inc (Symbol: ABBV) options are showing a volume of 26,513 contracts thus far today. That number of contracts represents approximately 2.7 million underlying shares, working out to a sizeable 56% of ABBV's average daily trading volume over the past month, of 4.7 million shares. Particularly high volume was seen for the $70 strike call option expiring August 18, 2017 , with 5,018 contracts trading so far today, representing approximately 501,800 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $70 strike highlighted in orange:
For the various different available expirations for NRZ options , ILMN options , or ABBV options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $70 strike call option expiring August 18, 2017 , with 5,018 contracts trading so far today, representing approximately 501,800 underlying shares of ABBV. Below is a chart showing ILMN's trailing twelve month trading history, with the $185 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 26,513 contracts thus far today. That number of contracts represents approximately 2.7 million underlying shares, working out to a sizeable 56% of ABBV's average daily trading volume over the past month, of 4.7 million shares. | Below is a chart showing ILMN's trailing twelve month trading history, with the $185 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 26,513 contracts thus far today. That number of contracts represents approximately 2.7 million underlying shares, working out to a sizeable 56% of ABBV's average daily trading volume over the past month, of 4.7 million shares. Particularly high volume was seen for the $70 strike call option expiring August 18, 2017 , with 5,018 contracts trading so far today, representing approximately 501,800 underlying shares of ABBV. | Particularly high volume was seen for the $70 strike call option expiring August 18, 2017 , with 5,018 contracts trading so far today, representing approximately 501,800 underlying shares of ABBV. Below is a chart showing ILMN's trailing twelve month trading history, with the $185 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 26,513 contracts thus far today. That number of contracts represents approximately 2.7 million underlying shares, working out to a sizeable 56% of ABBV's average daily trading volume over the past month, of 4.7 million shares. | Particularly high volume was seen for the $70 strike call option expiring August 18, 2017 , with 5,018 contracts trading so far today, representing approximately 501,800 underlying shares of ABBV. Below is a chart showing ILMN's trailing twelve month trading history, with the $185 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 26,513 contracts thus far today. That number of contracts represents approximately 2.7 million underlying shares, working out to a sizeable 56% of ABBV's average daily trading volume over the past month, of 4.7 million shares. |
26190.0 | 2017-04-20 00:00:00 UTC | AbbVie's (ABBV) Cancer Candidate Fails in Phase III Studies | ABBV | https://www.nasdaq.com/articles/abbvies-abbv-cancer-candidate-fails-in-phase-iii-studies-2017-04-20 | nan | nan | AbbVie Inc.ABBV recently announced disappointing top-line results from two phase III studies evaluating its PARP inhibitor, veliparib in combination with chemotherapy (such as carboplatin and paclitaxel) for treatment of patients with squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC).
AbbVie's shares underperformed the Zacks classified Large Cap Pharma industry so far this year. Shares of the company gained 1.3% while the industry registered an increase of 4.2%.
Coming back to the latest news, the two randomized, double-blind, multicenter, phase III studies failed to meet their primary endpoints. In the first study, the combination treatment failed to improve the overall survival of NSCLC patients, who had smoked within the past 12 months and had more than 100 smoking events in their lifetime. In the second study, which evaluated the treatment on patients with early-stage triple-negative breast cancer, the drug did not achieve the primary endpoint of complete pathologic response. The studies were conducted in a total number of 970 and 312 patients for the NSCLC and TNBC study, respectively.
We note that another phase III study is being conducted on veliparib, evaluating it for treatment of patients suffering from ovarian cancer.
Presently, Pfizer PFE has an approved drug for NSCLC, Xalkori. This apart, AstraZeneca Plc's AZN Lynparza, also known as olaparib, is approved for ovarian cancer.
AbbVie has been actively pursuing partnership deals and collaborations to enhance its oncology portfolio. In May 2015, AbbVie acquired Pharmacyclics in a deal worth approximately $21 billion. The acquisition added Imbruvica to AbbVie's portfolio, diversifying the acquirer's revenue base. Investors should know that Pharmacyclics has a partnership agreement with Johnson & Johnson JNJ for Imbruvica.
Moreover, in Jun 2016, AbbVie acquired cancer drugmaker Stemcentrx. Post buyout, the company gained a late-stage candidate (rovalpituzumab tesirine or Rova-T), four additional early-stage compounds in solid tumor indications and a significant portfolio of pre-clinical assets. Rova-T is currently in registration studies for small cell lung cancer (SCLC).
AbbVie Inc. Price
AbbVie Inc. Price | AbbVie Inc. Quote
Zacks Rank
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Astrazeneca PLC (AZN): Free Stock Analysis Report
Pfizer, Inc. (PFE): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc.ABBV recently announced disappointing top-line results from two phase III studies evaluating its PARP inhibitor, veliparib in combination with chemotherapy (such as carboplatin and paclitaxel) for treatment of patients with squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC). AbbVie's shares underperformed the Zacks classified Large Cap Pharma industry so far this year. AbbVie has been actively pursuing partnership deals and collaborations to enhance its oncology portfolio. | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV recently announced disappointing top-line results from two phase III studies evaluating its PARP inhibitor, veliparib in combination with chemotherapy (such as carboplatin and paclitaxel) for treatment of patients with squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC). | AbbVie Inc.ABBV recently announced disappointing top-line results from two phase III studies evaluating its PARP inhibitor, veliparib in combination with chemotherapy (such as carboplatin and paclitaxel) for treatment of patients with squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC). AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. | In May 2015, AbbVie acquired Pharmacyclics in a deal worth approximately $21 billion. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV recently announced disappointing top-line results from two phase III studies evaluating its PARP inhibitor, veliparib in combination with chemotherapy (such as carboplatin and paclitaxel) for treatment of patients with squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC). |
26191.0 | 2017-04-20 00:00:00 UTC | What's in Store for Biogen (BIIB) this Earnings Season? | ABBV | https://www.nasdaq.com/articles/whats-in-store-for-biogen-biib-this-earnings-season-2017-04-20 | nan | nan | Biogen Inc.BIIB , a well-known name in the multiple sclerosis (MS) market, will report first-quarter 2017 results on Apr 25, before the market opens. Last quarter, the company delivered a positive earnings surprise of 1.41%.
Biogen's shares rose 4% this year so far while the Zacks classified Biomed-Genetics industry recorded an increase of 2.9%.
Let's see how things are shaping up for this announcement.
Factors to Consider
At the fourth quarter 2016 conference call, management had informed that U.S. market share of its oral MS drug, Tecfidera, declined slightly in 2016 with increasing competition from oral medicines and slowdown in the overall MS market. However, Tecfidera is seeing patient growth in ex-U.S. markets. Sales of the drug also declined sequentially in the fourth quarter of 2016. Sales of another MS drug, Tysabri also declined in the quarter.
Biogen expects relatively stable demand for both Tecfidera and Tysabri in 2017 as patient growth in ex-U.S. markets offsets the modest decline in the U.S. It remains to be seen if sales trends of both these drugs improve in the first quarter of 2017.
Meanwhile, the combined number of patients using Avonex and Plegridy will continue to decline as patients shift to other oral MS therapies or other high-efficacy products.
Zinbryta, launched in collaboration with AbbVie Inc. ABBV in Aug 2016, is expected to contribute to revenues in the U.S. and the EU. The drug is also benefiting from increased use of high-efficacy products.
We remind investors that FDA approved Biogen and partner Ionis' Spinraza for spinal muscular atrophy in Dec 2016. Notably, Spinraza is the first approved treatment for the disease, which will allow it to address an untapped market, thereby offering the company a huge boost. Spinraza, which added $5 million to the top line in the fourth quarter of 2016, should contribute further to sales in the first quarter of 2017.
At the fourth quarter conference call, the company warned of possible logistics and access-related hurdles for Spinraza launch. We expect management to provide an update on the issue at the latest conference call.
Meanwhile, headcount reduction and restructuring initiatives are expected to continue to lower operating expenses. Cost of goods sold, as a percentage of sales, are expected to rise in 2017 due to higher royalty payments related to the sales of Spinraza.
Investor focus on the fourth-quarter call will remain on Tecfidera's scrip trends, launch progress on Spinraza, pipeline progress and acquisition plans.
Earnings Whispers
Our proven model does not conclusively show that Biogen is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: The Earnings ESP is -1.80% as the Most Accurate estimate stands at $4.90 while the Zacks Consensus Estimate is pegged higher at $4.99. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Biogen's Zacks Rank #3 increases the predictive power of ESP. However, we need to have a positive ESP to be confident about an earnings beat.
We caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Biogen Inc. Price and EPS Surprise
Biogen Inc. Price and EPS Surprise | Biogen Inc. Quote
Stocks to Consider
Stocks in the pharmaceuticals sector that have both a positive ESP and a favorable Zacks Rank are:
Amgen, Inc. AMGN is scheduled to release results on Apr 26. The company has an Earnings ESP of +1.99% and a Zacks Rank #3. You can see the complete list of today's Zacks #1 Rank stocks here .
Celldex Therapeutics, Inc. CLDX has an Earnings ESP of +7.14% and a Zacks Rank #3. The company is expected to release results early next month.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Zinbryta, launched in collaboration with AbbVie Inc. ABBV in Aug 2016, is expected to contribute to revenues in the U.S. and the EU. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen expects relatively stable demand for both Tecfidera and Tysabri in 2017 as patient growth in ex-U.S. markets offsets the modest decline in the U.S. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report To read this article on Zacks.com click here. Zinbryta, launched in collaboration with AbbVie Inc. ABBV in Aug 2016, is expected to contribute to revenues in the U.S. and the EU. Factors to Consider At the fourth quarter 2016 conference call, management had informed that U.S. market share of its oral MS drug, Tecfidera, declined slightly in 2016 with increasing competition from oral medicines and slowdown in the overall MS market. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report To read this article on Zacks.com click here. Zinbryta, launched in collaboration with AbbVie Inc. ABBV in Aug 2016, is expected to contribute to revenues in the U.S. and the EU. Factors to Consider At the fourth quarter 2016 conference call, management had informed that U.S. market share of its oral MS drug, Tecfidera, declined slightly in 2016 with increasing competition from oral medicines and slowdown in the overall MS market. | Zinbryta, launched in collaboration with AbbVie Inc. ABBV in Aug 2016, is expected to contribute to revenues in the U.S. and the EU. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report To read this article on Zacks.com click here. Factors to Consider At the fourth quarter 2016 conference call, management had informed that U.S. market share of its oral MS drug, Tecfidera, declined slightly in 2016 with increasing competition from oral medicines and slowdown in the overall MS market. |
26192.0 | 2017-04-19 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABBV | https://www.nasdaq.com/articles/5-dividend-growth-stocks-upside-analyst-targets-2017-04-19 | nan | nan | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention - and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets.
But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.
In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential:
Another consideration with dividend growth stocks is just how much the dividend is growing . We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another.
These five stocks are part of our full Dividend Aristocrats List . The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com .
Get the latest Zacks research report on ABT - FREE
Get the latest Zacks research report on PPG - FREE
Dividend Growth Stocks: 25 Aristocrats »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing . Get the latest Zacks research report on ABT - FREE Get the latest Zacks research report on PPG - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Get the latest Zacks research report on ABT - FREE Get the latest Zacks research report on PPG - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing . | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. Get the latest Zacks research report on ABT - FREE Get the latest Zacks research report on PPG - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
26193.0 | 2017-04-18 00:00:00 UTC | High-Yield Healthcare Investments You Can Buy Right Now | ABBV | https://www.nasdaq.com/articles/high-yield-healthcare-investments-you-can-buy-right-now-2017-04-18 | nan | nan | If you're looking for high-yield investments, you might want to consider the sector that accounts for nearly one-fifth of the nation's economy. I'm talking about healthcare, of course.
Three healthcare stocks in particular boast high dividend yields and good overall prospects. Here's why AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Novo Nordisk (NYSE: NVO) are high-yield healthcare investments you can buy right now.
AbbVie: Great dividend and a strong pipeline
AbbVie's dividend currently yields 3.91%. What makes the biotech's dividend even more attractive is that AbbVie has increased its dividend by 60% since 2013, when it was spun off from parent Abbott Laboratories (NYSE: ABT) . AbbVie uses around 63% of its earnings to pay out dividends, which leaves room for more increases in the future.
The company's earnings picture could improve quite a bit over the next few years. Sales for several of AbbVie's current products are growing. That's especially true for cancer drug Imbruvica, which saw sales more than double in 2016. AbbVie should also enjoy success with another cancer drug approved last year, Venclexta.
AbbVie's pipeline could produce multiple big winners. Elagolix is in late-stage clinical studies for the treatment of endometriosis and uterine fibroids. Two late-stage candidates for treating autoimmune diseases, risankizumab and ABT-494, also hold significant potential.
The biggest knock against AbbVie is that Humira could face heavier competition in the days ahead. One biosimilar to Humira has already won regulatory approval in the U.S. and Europe, although AbbVie is attempting to use the court system to fend off the rival in the U.S.
Pfizer: Ibrance and acquisitions leading the way
Pfizer isn't too far behind AbbVie, with a dividend yield of 3.75%. The big drugmaker's dividend has increased by 60% since 2011. Although Pfizer is currently paying out more in dividends than it's making in profit, that should change in the near future.
At least a dozen of Pfizer's top products enjoyed double-digit percentage sales increases in 2016. The fastest growth belonged to cancer drug Ibrance, which became the company's fourth best-selling drug in only its second full year on the market. Pfizer also experienced exceptionally strong revenue growth for rheumatoid arthritis drug Xeljanz.
Thanks in part to several acquisitions, Pfizer looks to be in good shape for more growth in the future. The company's purchase of Anacor in 2016 has already resulted in an approved product, atopic dermatitis drug Eucrisa. Pfizer also bought Medivation last year, gaining prostate cancer drug Xtandi. The drugmaker's pipeline is loaded with promising candidates, including cancer drug avelumab, which recently won approval for its first indication.
The most significant headwind for Pfizer is declining sales for products that have either lost patent exclusivity or will soon do so. Fall revenue for blockbuster cholesterol drug Lipitor is especially problematic. However, Pfizer's newer drugs and growing sterile injectables businesses should continue to offset these sales decreases.
Novo Nordisk: High-yield dividend and a winning diabetes franchise
Novo Nordisk claims a nice dividend yield of 3.15%. The drugmaker's dividend seems likely to increase in the future, since Novo Nordisk currently uses just over 62% of earnings to fund its dividend program.
Diabetes is the company's primary focus. Sales for Novo Nordisk's newer insulin products, particularly Tresiba, are growing. Type-2 diabetes drug Victoza also continues to perform well. In addition, growth hormone therapy Norditropin is enjoying considerable success.
Novo Nordisk has high expectations for Xultophy, which is a once-daily single-injection combination of Tresiba and Victoza. The drugmaker awaits regulatory approval for two other diabetes treatments, fast-acting insulin aspart and semaglutide.
The company's hemophilia business hasn't performed all that well recently. However, Novo Nordisk could see better results with hemophilia drug N9-GP wins approval. Another hemophilia candidate, N8-GP, is in a late-stage clinical study. The company also faces pricing pressure in the U.S. for its diabetes and growth hormone products. Still, Wall Street analysts expect Novo Nordisk to grow earnings by an average annual rate of nearly 10% over the next few years.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of April 3, 2017
Keith Speights owns shares of AbbVie and Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here's why AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Novo Nordisk (NYSE: NVO) are high-yield healthcare investments you can buy right now. AbbVie: Great dividend and a strong pipeline AbbVie's dividend currently yields 3.91%. What makes the biotech's dividend even more attractive is that AbbVie has increased its dividend by 60% since 2013, when it was spun off from parent Abbott Laboratories (NYSE: ABT) . | Here's why AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Novo Nordisk (NYSE: NVO) are high-yield healthcare investments you can buy right now. AbbVie: Great dividend and a strong pipeline AbbVie's dividend currently yields 3.91%. What makes the biotech's dividend even more attractive is that AbbVie has increased its dividend by 60% since 2013, when it was spun off from parent Abbott Laboratories (NYSE: ABT) . | Here's why AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Novo Nordisk (NYSE: NVO) are high-yield healthcare investments you can buy right now. One biosimilar to Humira has already won regulatory approval in the U.S. and Europe, although AbbVie is attempting to use the court system to fend off the rival in the U.S. Pfizer: Ibrance and acquisitions leading the way Pfizer isn't too far behind AbbVie, with a dividend yield of 3.75%. AbbVie: Great dividend and a strong pipeline AbbVie's dividend currently yields 3.91%. | AbbVie: Great dividend and a strong pipeline AbbVie's dividend currently yields 3.91%. AbbVie should also enjoy success with another cancer drug approved last year, Venclexta. Here's why AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Novo Nordisk (NYSE: NVO) are high-yield healthcare investments you can buy right now. |
26194.0 | 2017-04-17 00:00:00 UTC | Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain | ABBV | https://www.nasdaq.com/articles/lilly-and-incytes-loss-abbvie-and-regenerons-gain-2017-04-17 | nan | nan | The FDA has decided not to grant marketing approval for Eli Lilly & Co. 's and Incyte 's(NASDAQ: INCY) rheumatoid arthritis drug baricitinib, and that setback is potentially good news for AbbVie (NYSE: ABBV) and Regeneron (NASDAQ: REGN) .
A massive market
Baricitinib was being evaluated for approval for use in patients diagnosed with moderate to severe rheumatoid arthritis, a big addressable market that's worth billions of dollars in sales.
Baricitinib is an oral drug that can be taken once daily. It seeks to reduce rheumatoid arthritis symptoms by targeting a family of Janus kinase enzymes that produce cytokines that contribute to inflammation, and thus stiffness, joint swelling, and pain in patients.
Moderate to severe rheumatoid arthritis can be debilitating. Typically, treating moderate to severe rheumatoid arthritis begins with disease-modifying antirheumatic drugs such as methotrexate. However, the benefit of these drugs wears off over time, and often, that results in the addition of a biologic drug to a treatment, such as AbbVie's $14 billion-per-year Humira.
In severe rheumatoid arthritis cases, biologics often fall short in providing adequate relief from symptoms, with the result that doctors try to treat the condition with other medicines, such as the blockbuster drug Rituxan.
Because baricitinib helped relieve patients' symptoms in trials, industry watchers were predicting it would become a top seller. In the U.S. alone, 1.3 million people suffer from rheumatoid arthritis, and globally, industry watchers peg the size of the market for anti-rheumatics medicine at north of $40 billion.
Complete response letter
In January, the FDA extended its review timeline of baricitinib by an additional three months, and on Friday, the regulator finally determined that it had too many questions about baricitinib's dosing and safety to give it a green light.
Eli Lilly and Incyte didn't release the entirety of the complete response letter (CRL) they received from the FDA (a CRL is sent to companies when a regulator rejects the drug), but they did report that the agency says it needs more clinical studies to determine the most appropriate dose of baricitinib, and that they need greater insight into the drug's safety.
So far, Eli Lilly and Incyte have evaluated baricitinib in four phase 3 studies, including two studies that compared baricitinb to current therapies.
In one of those two studies, baricitinib monotherapy was found to be better than methotrexate, producing higher rates of clinical remission. In the other, it outperformed Humira in delivering at least a 20% improvement in disease activity. In the methotrexate study, the companies said that adverse events were similar between baricitinib and methotrexate. In the Humira study, the companies said baricitinib delivered similar numbers of serious adverse events to the placebo control, but higher rates than Humira.
Business as usual
Humira is the market share-leading drug used to treat rheumatoid arthrtis, so news of baricitinib's failure means that AbbVie's revenue from Humira in the indication won't be at risk. According to EvaluatePharma, Humira's market share in rheumatoid arthritis is north of 20%.
Humira, however, might not completely escape the risk of competition this year, because Regeneron and Sanofi (NYSE: SNY) could win an FDA OK for their rheumatoid arthritis drug, sarilumab.
Last fall, the FDA sent Regeneron and Sanofi a CRL, too, but the reason behind their rejection was concerns over manufacturing at one of Sanofi's facilities. Recently, the two companies won FDA approval for a new eczema drug, Dupixent, that's made at the same location, so it seems that the FDA's manufacturing concerns have been addressed.
Sarilumab is a IL-6 inhibitor, so it targets the disease differently than baricitinib, yet in trials, patients using sarilumab also achieved better-than-Humira results. Importantly, it did so with fewer severe adverse events. The rate of serious adverse events in the sarilumab arm was 5%, and it was 7% in the Humira arm. The rate of serious infections was 1% for both sarilumab and Humira patients.
Regeneron and Sanofi told investors earlier this year that they plan on resubmitting sarilumab for approval soon, so an approval could still be granted this year. Sarilumab, which will be sold under the brand name Kevzara, won approval for use in Canada in February, and at the time, Regeneron said it expects U.S. and EU decisions by the end of 2017.
Looking ahead
Eli Lilly and Incyte say that they disagree with the FDA's decision, and they'll be sitting down to talk with regulators more. A timeline for additional studies, or a potential resubmission for approval, won't be offered up to investors until after that meeting, so for now, Eli Lilly and Incyte are the losers, and Humira, and potentially Regeneron, are the winners following this decision.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of April 3, 2017
Todd Campbell has no position in any stocks mentioned.His clients may have positions in the companies mentioned.The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The FDA has decided not to grant marketing approval for Eli Lilly & Co. 's and Incyte 's(NASDAQ: INCY) rheumatoid arthritis drug baricitinib, and that setback is potentially good news for AbbVie (NYSE: ABBV) and Regeneron (NASDAQ: REGN) . However, the benefit of these drugs wears off over time, and often, that results in the addition of a biologic drug to a treatment, such as AbbVie's $14 billion-per-year Humira. Business as usual Humira is the market share-leading drug used to treat rheumatoid arthrtis, so news of baricitinib's failure means that AbbVie's revenue from Humira in the indication won't be at risk. | The FDA has decided not to grant marketing approval for Eli Lilly & Co. 's and Incyte 's(NASDAQ: INCY) rheumatoid arthritis drug baricitinib, and that setback is potentially good news for AbbVie (NYSE: ABBV) and Regeneron (NASDAQ: REGN) . However, the benefit of these drugs wears off over time, and often, that results in the addition of a biologic drug to a treatment, such as AbbVie's $14 billion-per-year Humira. Business as usual Humira is the market share-leading drug used to treat rheumatoid arthrtis, so news of baricitinib's failure means that AbbVie's revenue from Humira in the indication won't be at risk. | The FDA has decided not to grant marketing approval for Eli Lilly & Co. 's and Incyte 's(NASDAQ: INCY) rheumatoid arthritis drug baricitinib, and that setback is potentially good news for AbbVie (NYSE: ABBV) and Regeneron (NASDAQ: REGN) . Business as usual Humira is the market share-leading drug used to treat rheumatoid arthrtis, so news of baricitinib's failure means that AbbVie's revenue from Humira in the indication won't be at risk. However, the benefit of these drugs wears off over time, and often, that results in the addition of a biologic drug to a treatment, such as AbbVie's $14 billion-per-year Humira. | The FDA has decided not to grant marketing approval for Eli Lilly & Co. 's and Incyte 's(NASDAQ: INCY) rheumatoid arthritis drug baricitinib, and that setback is potentially good news for AbbVie (NYSE: ABBV) and Regeneron (NASDAQ: REGN) . However, the benefit of these drugs wears off over time, and often, that results in the addition of a biologic drug to a treatment, such as AbbVie's $14 billion-per-year Humira. Business as usual Humira is the market share-leading drug used to treat rheumatoid arthrtis, so news of baricitinib's failure means that AbbVie's revenue from Humira in the indication won't be at risk. |
26195.0 | 2017-04-17 00:00:00 UTC | CHICAGO TRUST Co NA Buys UniFirst, Horace Mann Educators, John Wiley & Sons, Sells Spectra ... | ABBV | https://www.nasdaq.com/articles/chicago-trust-co-na-buys-unifirst-horace-mann-educators-john-wiley-sons-sells-spectra-2017 | nan | nan | CHICAGO TRUST Co NA
New Purchases: UNF , HMN , JW.A , MCO, UN, SPGI, AVT, KHC, ENB, XLF,
Added Positions:HOG, CVS, ABT, MMM, MRK, EXC, MCK, LLY, IPI, CSCO,
Reduced Positions:DOW, LMT, PH, XOM, JPM, AAPL, HON, BAC, CVX, WFC,
Sold Out:SE, LMNX, ADTN, KORS, INT, GNTX, ATU, BHLB, THR, VDSI,
For the details of CHICAGO TRUST Co NA's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=CHICAGO+TRUST+Co+NA
These are the top 5 holdings of CHICAGO TRUST Co NA
Apple Inc ( AAPL ) - 52,896 shares, 3.67% of the total portfolio. Shares reduced by 8.35%
AbbVie Inc ( ABBV ) - 91,884 shares, 2.89% of the total portfolio. Shares reduced by 6.27%
Microsoft Corp ( MSFT ) - 90,918 shares, 2.89% of the total portfolio. Shares reduced by 3.83%
Exxon Mobil Corp ( XOM ) - 63,774 shares, 2.52% of the total portfolio. Shares reduced by 9.94%
General Electric Co ( GE ) - 172,524 shares, 2.48% of the total portfolio. Shares reduced by 5.25%
New Purchase: UniFirst Corp (UNF)
CHICAGO TRUST Co NA initiated holdings in UniFirst Corp. The purchase prices were between $125.8 and $145, with an estimated average price of $132.18. The stock is now traded at around $134.95. The impact to the portfolio due to this purchase was 0.13%. The holdings were 1,869 shares as of 2017-03-31.
New Purchase: John Wiley & Sons Inc (JW.A)
CHICAGO TRUST Co NA initiated holdings in John Wiley & Sons Inc. The purchase prices were between $51.75 and $57.5, with an estimated average price of $54.32. The stock is now traded at around $51.95. The impact to the portfolio due to this purchase was 0.13%. The holdings were 5,103 shares as of 2017-03-31.
New Purchase: Horace Mann Educators Corp (HMN)
CHICAGO TRUST Co NA initiated holdings in Horace Mann Educators Corp. The purchase prices were between $39.5 and $43.5, with an estimated average price of $41.92. The stock is now traded at around $37.60. The impact to the portfolio due to this purchase was 0.13%. The holdings were 6,558 shares as of 2017-03-31.
New Purchase: Moody's Corporation (MCO)
CHICAGO TRUST Co NA initiated holdings in Moody's Corporation. The purchase prices were between $94.67 and $113.56, with an estimated average price of $107.24. The stock is now traded at around $113.43. The impact to the portfolio due to this purchase was 0.11%. The holdings were 2,000 shares as of 2017-03-31.
New Purchase: Unilever NV (UN)
CHICAGO TRUST Co NA initiated holdings in Unilever NV. The purchase prices were between $40.27 and $50.6, with an estimated average price of $44.8. The stock is now traded at around $51.26. The impact to the portfolio due to this purchase was 0.11%. The holdings were 4,744 shares as of 2017-03-31.
New Purchase: Avnet Inc (AVT)
CHICAGO TRUST Co NA initiated holdings in Avnet Inc. The purchase prices were between $44.01 and $47.61, with an estimated average price of $46.25. The stock is now traded at around $43.82. The impact to the portfolio due to this purchase was 0.1%. The holdings were 4,712 shares as of 2017-03-31.
Added: Exelon Corp (EXC)
CHICAGO TRUST Co NA added to the holdings in Exelon Corp by 20.25%. The purchase prices were between $34.85 and $37.18, with an estimated average price of $35.73. The stock is now traded at around $35.90. The impact to the portfolio due to this purchase was 0.04%. The holdings were 13,000 shares as of 2017-03-31.
Added: Intrepid Potash Inc (IPI)
CHICAGO TRUST Co NA added to the holdings in Intrepid Potash Inc by 37.48%. The purchase prices were between $1.4 and $2.45, with an estimated average price of $1.93. The stock is now traded at around $1.83. The impact to the portfolio due to this purchase was 0.01%. The holdings were 41,931 shares as of 2017-03-31.
Sold Out: Spectra Energy Corp (SE)
CHICAGO TRUST Co NA sold out the holdings in Spectra Energy Corp. The sale prices were between $40.68 and $43.45, with an estimated average price of $41.93.
Sold Out: Luminex Corp (LMNX)
CHICAGO TRUST Co NA sold out the holdings in Luminex Corp. The sale prices were between $17.79 and $21.28, with an estimated average price of $19.04.
Sold Out: Michael Kors Holdings Ltd (KORS)
CHICAGO TRUST Co NA sold out the holdings in Michael Kors Holdings Ltd. The sale prices were between $36.02 and $43.56, with an estimated average price of $39.35.
Sold Out: Adtran Inc (ADTN)
CHICAGO TRUST Co NA sold out the holdings in Adtran Inc. The sale prices were between $20.75 and $23.2, with an estimated average price of $21.7.
Sold Out: Gentex Corp (GNTX)
CHICAGO TRUST Co NA sold out the holdings in Gentex Corp. The sale prices were between $20.14 and $22.07, with an estimated average price of $20.99.
Sold Out: Actuant Corp (ATU)
CHICAGO TRUST Co NA sold out the holdings in Actuant Corp. The sale prices were between $25.05 and $28.9, with an estimated average price of $26.87.
Warning! GuruFocus has detected 6 Warning Signs with EXC. Click here to check it out.
EXC 15-Year Financial Data
The intrinsic value of EXC
Peter Lynch Chart of EXC
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares reduced by 8.35% AbbVie Inc ( ABBV ) - 91,884 shares, 2.89% of the total portfolio. CHICAGO TRUST Co NA New Purchases: UNF , HMN , JW.A , MCO, UN, SPGI, AVT, KHC, ENB, XLF, Added Positions:HOG, CVS, ABT, MMM, MRK, EXC, MCK, LLY, IPI, CSCO, Reduced Positions:DOW, LMT, PH, XOM, JPM, AAPL, HON, BAC, CVX, WFC, Sold Out:SE, LMNX, ADTN, KORS, INT, GNTX, ATU, BHLB, THR, VDSI, For the details of CHICAGO TRUST Co NA's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=CHICAGO+TRUST+Co+NA These are the top 5 holdings of CHICAGO TRUST Co NA Apple Inc ( AAPL ) - 52,896 shares, 3.67% of the total portfolio. New Purchase: Horace Mann Educators Corp (HMN) CHICAGO TRUST Co NA initiated holdings in Horace Mann Educators Corp. | Shares reduced by 8.35% AbbVie Inc ( ABBV ) - 91,884 shares, 2.89% of the total portfolio. Shares reduced by 5.25% New Purchase: UniFirst Corp (UNF) CHICAGO TRUST Co NA initiated holdings in UniFirst Corp. New Purchase: John Wiley & Sons Inc (JW.A) CHICAGO TRUST Co NA initiated holdings in John Wiley & Sons Inc. | Shares reduced by 8.35% AbbVie Inc ( ABBV ) - 91,884 shares, 2.89% of the total portfolio. CHICAGO TRUST Co NA New Purchases: UNF , HMN , JW.A , MCO, UN, SPGI, AVT, KHC, ENB, XLF, Added Positions:HOG, CVS, ABT, MMM, MRK, EXC, MCK, LLY, IPI, CSCO, Reduced Positions:DOW, LMT, PH, XOM, JPM, AAPL, HON, BAC, CVX, WFC, Sold Out:SE, LMNX, ADTN, KORS, INT, GNTX, ATU, BHLB, THR, VDSI, For the details of CHICAGO TRUST Co NA's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=CHICAGO+TRUST+Co+NA These are the top 5 holdings of CHICAGO TRUST Co NA Apple Inc ( AAPL ) - 52,896 shares, 3.67% of the total portfolio. Shares reduced by 5.25% New Purchase: UniFirst Corp (UNF) CHICAGO TRUST Co NA initiated holdings in UniFirst Corp. | Shares reduced by 8.35% AbbVie Inc ( ABBV ) - 91,884 shares, 2.89% of the total portfolio. CHICAGO TRUST Co NA New Purchases: UNF , HMN , JW.A , MCO, UN, SPGI, AVT, KHC, ENB, XLF, Added Positions:HOG, CVS, ABT, MMM, MRK, EXC, MCK, LLY, IPI, CSCO, Reduced Positions:DOW, LMT, PH, XOM, JPM, AAPL, HON, BAC, CVX, WFC, Sold Out:SE, LMNX, ADTN, KORS, INT, GNTX, ATU, BHLB, THR, VDSI, For the details of CHICAGO TRUST Co NA's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=CHICAGO+TRUST+Co+NA These are the top 5 holdings of CHICAGO TRUST Co NA Apple Inc ( AAPL ) - 52,896 shares, 3.67% of the total portfolio. Shares reduced by 5.25% New Purchase: UniFirst Corp (UNF) CHICAGO TRUST Co NA initiated holdings in UniFirst Corp. |
26196.0 | 2017-04-14 00:00:00 UTC | AbbVie Inc.: The Bear Case From a Bull | ABBV | https://www.nasdaq.com/articles/abbvie-inc-bear-case-bull-2017-04-14 | nan | nan | It's not hard to find reasons to like AbbVie (NYSE: ABBV) stock. There's the impressive revenue and earnings growth. And, of course, who wouldn't like the biotech's high dividend yield?
I have a positive view about AbbVie and even own the stock. However, I also recognize that there are several challenges facing the company. Here's the bear case for AbbVie -- from someone who is an unabashed bull.
Humira could be in trouble
The single biggest argument against buying AbbVie stock is that Humira could face serious headwinds in the near future. Amgen (NASDAQ: AMGN) won approval in 2016 for Amjevita, the first biosimilar to Humira to be given a green light from the U.S. Food and Drug Administration (FDA). Amjevita also received European regulatory approval in March.
AbbVie filed a lawsuit in a U.S. district court alleging that Amgen's biosimilar infringes on several of its patents for Humira. Rick Gonzalez, AbbVie's CEO, has stated that the company believes it will be able to hold off U.S. competition through 2022. However, many observers expect competition from European biosimilars by the fourth quarter of 2018. And there's no guarantee that AbbVie will be successful in its attempts to fend off Amgen and others in the U.S. for too much longer.
It's not just biosimilars that AbbVie has to worry about. The autoimmune disease market is becoming quite crowded with new drugs that could steal some of Humira's market share.
Humira generated sales of more than $16 billion last year. That's a whopping 63% of AbbVie's total revenue. The investing case for AbbVie hinges on the company being able to preserve much of that block of revenue while it rolls out new drugs. It's fair to say that there are significant doubts about whether AbbVie can do so.
AbbVie's pipeline might not be so solid
There are several new and existing drugs that AbbVie is counting on to replace revenue that will be lost to Humira's competition at some point. Blood cancer drugs Imbruvica and Venclexta play key roles in the company's strategy. Both are already approved for initial indications, with additional clinical studies in progress targeting other indications.
AbbVie also has high hopes for Rova-T, a drug gained in the company's acquisition last year of Stemcentrx. Rova-T is currently being evaluated in a pivotal study as a third-line treatment for small cell lung cancer (SCLC) and in another study in combination with Bristol-Myers Squibb 's(NYSE: BMY) Opdivo and Yervoy as a second-line SCLC treatment. The drug is also the focus of an early-stage study targeting treatment of neuroendocrine tumors.
In addition, AbbVie's pipeline includes a couple of candidates that could potentially join Humira. ABT-494 and risankizumab are in late-stage studies for rheumatoid arthritis and psoriasis, respectively. There are other important candidates as well, especially experimental cancer drug veliparib and elagolix, which is in late-stage studies for treatment of endometriosis and uterine fibroids.
The risk, though, is that AbbVie's pipeline isn't as solid as it might seem. Hepatitis C drug Viekira hasn't been nearly as successful as the company hoped. At one point, some analysts were projecting that multiple myeloma drug Empliciti, which was co-developed by AbbVie and Bristol-Myers Squibb, would become a blockbuster by 2018. That now seems highly unlikely.
The reality is that promising drugs don't always deliver on their promise. That could be a problem for AbbVie because of its dependence on its pipeline producing significant revenue.
Debt could be a constraint
AbbVie gained several of its drugs through acquisitions, including Imbruvica, Rova-T, and risankizumab. Making additional acquisitions could be more challenging because of the company's debt of more than $36 billion.
After AbbVie added significantly to its debt last year, both S&P Global Ratings and Moody's Investor Service lowered the company's credit rating. These lower ratings could be another factor that limits the company's ability to do much more on the acquisition front. If AbbVie's pipeline candidates run into problems, constraints on making acquisitions could turn into a serious issue for the company.
Still a bull
These are all legitimate risks that AbbVie faces. However, as I said earlier, I'm still bullish about the stock. I think the potential rewards from owning AbbVie outweigh the risks.
Humira's sales will no doubt decrease at some point, but my view is that revenue will taper off rather than drop off a cliff. That will give AbbVie time for its other drugs and pipeline candidates to flourish. While there's always the possibility that some won't perform as well as expected, I think that many of them will be huge winners.
If I'm right, AbbVie won't have the need to make big acquisitions in the near term. However, the company's solid cash flow should allow it to continue looking at smaller opportunities.
Even though there are questions about AbbVie's future, I'm not the only one who thinks the stock is a solid pick. The consensus among Wall Street analysts is that AbbVie will be able to grow earnings by an average annual rate of nearly 15% over the next several years. That's a pretty bullish outlook.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of April 3, 2017
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | At one point, some analysts were projecting that multiple myeloma drug Empliciti, which was co-developed by AbbVie and Bristol-Myers Squibb, would become a blockbuster by 2018. It's not hard to find reasons to like AbbVie (NYSE: ABBV) stock. I have a positive view about AbbVie and even own the stock. | AbbVie also has high hopes for Rova-T, a drug gained in the company's acquisition last year of Stemcentrx. Debt could be a constraint AbbVie gained several of its drugs through acquisitions, including Imbruvica, Rova-T, and risankizumab. If AbbVie's pipeline candidates run into problems, constraints on making acquisitions could turn into a serious issue for the company. | Humira could be in trouble The single biggest argument against buying AbbVie stock is that Humira could face serious headwinds in the near future. AbbVie's pipeline might not be so solid There are several new and existing drugs that AbbVie is counting on to replace revenue that will be lost to Humira's competition at some point. AbbVie also has high hopes for Rova-T, a drug gained in the company's acquisition last year of Stemcentrx. | AbbVie also has high hopes for Rova-T, a drug gained in the company's acquisition last year of Stemcentrx. The risk, though, is that AbbVie's pipeline isn't as solid as it might seem. It's not hard to find reasons to like AbbVie (NYSE: ABBV) stock. |
26197.0 | 2017-04-11 00:00:00 UTC | Repros' Proellex Continues to be Under Partial Clinical Hold | ABBV | https://www.nasdaq.com/articles/repros-proellex-continues-to-be-under-partial-clinical-hold-2017-04-11 | nan | nan | Repros TherapeuticsRPRX announced that the FDA will continue to maintain partial clinical hold on its pipeline candidate Proellex for uterine fibroids indication as the agency internally reviews data related to the effect of the same on the liver. Regulators will be consulting agency experts on the liver effects of Proellex identified during the phase II study. Repros Therapeutics and its panel of liver experts will submit additional information to the FDA and offer a proposed clinical protocol in a month.
The meeting was supposed to be an end of phase II study and phase III requirement discussion but was later changed to a guidance meeting by the FDA.
We remind investors that Proellex studies on oral dose for the treatment of endometriosis and uterine fibroids were placed under clinical hold in 2009. But later the FDA allowed the studies to be conducted under partial clinical hold with low oral dosage.
We note that Repros' shares have outperformed the Zacks classified Medical - Biomedical and Genetics industry in the last one year. Repros shares returned 37.1% against a decline of 10.6% for the industry.
In a separate press release, the company announced that Larry Dillaha will become its permanent President and CEO effective Apr 10. She was working on an interim basis at the same position since Feb 1. Dillaha has experience in handling an inception stage biotechnology company as well as a specialty pharmaceutical company.
We note that the company is also evaluating Proellex in a phase IIb study for uterine fibroids by vaginal delivery. However, this study has no clinical hold issues. The company presented positive topline data from this study in November last year.
Repros' other key pipeline candidate enclomiphene is being evaluated for the treatment of low testosterone level in overweight men. The drug was approved in the EU in 2016 while the phase II study data is under review in the U.S.
AbbVie Inc. ABBV in collaboration with Neurocrine Biosciences, Inc. NBIX is also developing a drug, elagolix for the treatment of endometriosis and uterine fibroids. We note that with AbbVie being a much bigger company, elagolix, if approved, may offer stiff competition to Repros's Proellex in the long run.
Zacks Rank & Stock to Consider
Repros currently has a Zacks Rank #3 (Hold). Progenics Pharmaceuticals Inc. PGNX is a better-ranked stock in the generic drug sector, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Progenics' loss estimates narrowed from 82 cents per share to 62 cents for 2017 over the last seven days. The company posted an average positive surprise of 8.45% for the trailing four quarters. . Its shares increased 72.6% in the last one year.
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Progenics Pharmaceuticals Inc. (PGNX): Free Stock Analysis Report
Repros Therapeutics Inc. (RPRX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We note that with AbbVie being a much bigger company, elagolix, if approved, may offer stiff competition to Repros's Proellex in the long run. The drug was approved in the EU in 2016 while the phase II study data is under review in the U.S. AbbVie Inc. ABBV in collaboration with Neurocrine Biosciences, Inc. NBIX is also developing a drug, elagolix for the treatment of endometriosis and uterine fibroids. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Progenics Pharmaceuticals Inc. (PGNX): Free Stock Analysis Report Repros Therapeutics Inc. (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Progenics Pharmaceuticals Inc. (PGNX): Free Stock Analysis Report Repros Therapeutics Inc. (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here. The drug was approved in the EU in 2016 while the phase II study data is under review in the U.S. AbbVie Inc. ABBV in collaboration with Neurocrine Biosciences, Inc. NBIX is also developing a drug, elagolix for the treatment of endometriosis and uterine fibroids. We note that with AbbVie being a much bigger company, elagolix, if approved, may offer stiff competition to Repros's Proellex in the long run. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Progenics Pharmaceuticals Inc. (PGNX): Free Stock Analysis Report Repros Therapeutics Inc. (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here. The drug was approved in the EU in 2016 while the phase II study data is under review in the U.S. AbbVie Inc. ABBV in collaboration with Neurocrine Biosciences, Inc. NBIX is also developing a drug, elagolix for the treatment of endometriosis and uterine fibroids. We note that with AbbVie being a much bigger company, elagolix, if approved, may offer stiff competition to Repros's Proellex in the long run. | The drug was approved in the EU in 2016 while the phase II study data is under review in the U.S. AbbVie Inc. ABBV in collaboration with Neurocrine Biosciences, Inc. NBIX is also developing a drug, elagolix for the treatment of endometriosis and uterine fibroids. We note that with AbbVie being a much bigger company, elagolix, if approved, may offer stiff competition to Repros's Proellex in the long run. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Progenics Pharmaceuticals Inc. (PGNX): Free Stock Analysis Report Repros Therapeutics Inc. (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here. |
26198.0 | 2017-04-11 00:00:00 UTC | AbbVie (ABBV) Shares Cross 4% Yield Mark | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-shares-cross-4-yield-mark-2017-04-11 | nan | nan | Looking at the universe of stocks we cover at Dividend Channel , in trading on Tuesday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $2.56), with the stock changing hands as low as $63.32 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return. To illustrate, suppose for example you purchased shares of the S&P 500 ETF ( SPY ) back on 12/31/1999 - you would have paid $146.88 per share. Fast forward to 12/31/2012 and each share was worth $142.41 on that date, a decrease of $4.67/share over all those years. But now consider that you collected a whopping $25.98 per share in dividends over the same period, for a positive total return of 23.36%. Even with dividends reinvested, that only amounts to an average annual total return of about 1.6%; so by comparison collecting a yield above 4% would appear considerably attractive if that yield is sustainable. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index.
In general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of AbbVie Inc, looking at the history chart for ABBV below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 4% annual yield.
According to the ETF Finder at ETF Channel, ABBV makes up 9.76% of the First Trust US Equity Opportunities ETF (Symbol: FPX) which is trading lower by about 0.3% on the day Tuesday.
ABBV has been growing its dividend for more than 20 years consecutively. For more dividend growth stocks view our Dividend Aristocrats List on Dividend Channel.
Click here to find out which 9 other dividend stocks just recently went on sale »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the universe of stocks we cover at Dividend Channel , in trading on Tuesday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $2.56), with the stock changing hands as low as $63.32 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of AbbVie Inc, looking at the history chart for ABBV below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 4% annual yield. | Looking at the universe of stocks we cover at Dividend Channel , in trading on Tuesday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $2.56), with the stock changing hands as low as $63.32 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of AbbVie Inc, looking at the history chart for ABBV below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 4% annual yield. | Looking at the universe of stocks we cover at Dividend Channel , in trading on Tuesday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $2.56), with the stock changing hands as low as $63.32 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of AbbVie Inc, looking at the history chart for ABBV below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 4% annual yield. | Looking at the universe of stocks we cover at Dividend Channel , in trading on Tuesday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $2.56), with the stock changing hands as low as $63.32 on the day. According to the ETF Finder at ETF Channel, ABBV makes up 9.76% of the First Trust US Equity Opportunities ETF (Symbol: FPX) which is trading lower by about 0.3% on the day Tuesday. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. |
26199.0 | 2017-04-11 00:00:00 UTC | First American Bank Buys JPMorgan Chase, Medtronic PLC, Exelon, Sells NXP Semiconductors NV, ... | ABBV | https://www.nasdaq.com/articles/first-american-bank-buys-jpmorgan-chase-medtronic-plc-exelon-sells-nxp-semiconductors-nv | nan | nan | First American Bank
New Purchases: EXC , RY , IBM , VEA, LCII, CC, ACIA, VGT, VHT,
Added Positions:JPM, MDT, BA, AMZN, UNH, BAC, ETR, MSFT, GD, AVGO,
Reduced Positions:EW, STI, LOW, EEFT, GPC, GILD, MLM, SBUX, RTN, FRC,
Sold Out:NXPI, UFS, DUK, PPG, FCB, APA, MRO, PE, NTNX, MET,
For the details of FIRST AMERICAN BANK's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=FIRST+AMERICAN+BANK
These are the top 5 holdings of FIRST AMERICAN BANK
PepsiCo Inc ( PEP ) - 326,221 shares, 6.4% of the total portfolio. Shares reduced by 0.91%
Apple Inc ( AAPL ) - 208,270 shares, 5.25% of the total portfolio. Shares added by 4.23%
Microsoft Corp ( MSFT ) - 212,509 shares, 2.45% of the total portfolio. Shares added by 12.80%
Exxon Mobil Corp ( XOM ) - 169,820 shares, 2.44% of the total portfolio. Shares reduced by 3.89%
AbbVie Inc ( ABBV ) - 186,953 shares, 2.14% of the total portfolio. Shares reduced by 7.3%
New Purchase: Exelon Corp (EXC)
First American Bank initiated holdings in Exelon Corp. The purchase prices were between $34.85 and $37.18, with an estimated average price of $35.73. The stock is now traded at around $36.03. The impact to the portfolio due to this purchase was 0.49%. The holdings were 78,413 shares as of 2017-03-31.
New Purchase: Royal Bank of Canada (RY)
First American Bank initiated holdings in Royal Bank of Canada. The purchase prices were between $68.14 and $75.63, with an estimated average price of $72.46. The stock is now traded at around $72.62. The impact to the portfolio due to this purchase was 0.48%. The holdings were 37,252 shares as of 2017-03-31.
New Purchase: International Business Machines Corp (IBM)
First American Bank initiated holdings in International Business Machines Corp. The purchase prices were between $165.52 and $181.95, with an estimated average price of $175.39. The stock is now traded at around $170.41. The impact to the portfolio due to this purchase was 0.4%. The holdings were 13,257 shares as of 2017-03-31.
New Purchase: Vanguard FTSE Developed Markets (VEA)
First American Bank initiated holdings in Vanguard FTSE Developed Markets. The purchase prices were between $36.54 and $39.51, with an estimated average price of $38.3. The stock is now traded at around $39.12. The impact to the portfolio due to this purchase was 0.08%. The holdings were 10,960 shares as of 2017-03-31.
New Purchase: LCI Industries Inc (LCII)
First American Bank initiated holdings in LCI Industries Inc. The purchase prices were between $98.5 and $116.8, with an estimated average price of $107.6. The stock is now traded at around $93.60. The impact to the portfolio due to this purchase was 0.07%. The holdings were 4,195 shares as of 2017-03-31.
New Purchase: The Chemours Co (CC)
First American Bank initiated holdings in The Chemours Co. The purchase prices were between $21.22 and $38.5, with an estimated average price of $30.1. The stock is now traded at around $37.26. The impact to the portfolio due to this purchase was 0.05%. The holdings were 6,807 shares as of 2017-03-31.
Added: JPMorgan Chase & Co (JPM)
First American Bank added to the holdings in JPMorgan Chase & Co by 31.29%. The purchase prices were between $83.3 and $93.6, with an estimated average price of $88.22. The stock is now traded at around $85.27. The impact to the portfolio due to this purchase was 0.51%. The holdings were 138,195 shares as of 2017-03-31.
Added: Medtronic PLC (MDT)
First American Bank added to the holdings in Medtronic PLC by 152.77%. The purchase prices were between $70.61 and $83.3, with an estimated average price of $78.11. The stock is now traded at around $80.06. The impact to the portfolio due to this purchase was 0.5%. The holdings were 58,760 shares as of 2017-03-31.
Added: Boeing Co (BA)
First American Bank added to the holdings in Boeing Co by 51.19%. The purchase prices were between $156.97 and $183.91, with an estimated average price of $170.33. The stock is now traded at around $178.13. The impact to the portfolio due to this purchase was 0.42%. The holdings were 40,099 shares as of 2017-03-31.
Added: Amazon.com Inc (AMZN)
First American Bank added to the holdings in Amazon.com Inc by 52.10%. The purchase prices were between $753.67 and $886.54, with an estimated average price of $833.5. The stock is now traded at around $902.22. The impact to the portfolio due to this purchase was 0.33%. The holdings were 6,110 shares as of 2017-03-31.
Added: UnitedHealth Group Inc (UNH)
First American Bank added to the holdings in UnitedHealth Group Inc by 71.87%. The purchase prices were between $157.62 and $171.78, with an estimated average price of $163.77. The stock is now traded at around $165.53. The impact to the portfolio due to this purchase was 0.31%. The holdings were 26,063 shares as of 2017-03-31.
Added: Entergy Corp (ETR)
First American Bank added to the holdings in Entergy Corp by 303.03%. The purchase prices were between $70.44 and $76.81, with an estimated average price of $73.29. The stock is now traded at around $76.20. The impact to the portfolio due to this purchase was 0.29%. The holdings were 28,615 shares as of 2017-03-31.
Sold Out: NXP Semiconductors NV (NXPI)
First American Bank sold out the holdings in NXP Semiconductors NV. The sale prices were between $96 and $104.22, with an estimated average price of $101.12.
Sold Out: Domtar Corp (UFS)
First American Bank sold out the holdings in Domtar Corp. The sale prices were between $36.36 and $43.69, with an estimated average price of $39.61.
Sold Out: Duke Energy Corp (DUK)
First American Bank sold out the holdings in Duke Energy Corp. The sale prices were between $76.5 and $82.99, with an estimated average price of $79.49.
Sold Out: PPG Industries Inc (PPG)
First American Bank sold out the holdings in PPG Industries Inc. The sale prices were between $95.25 and $106.83, with an estimated average price of $101.25.
Sold Out: FCB Financial Holdings Inc (FCB)
First American Bank sold out the holdings in FCB Financial Holdings Inc. The sale prices were between $44.85 and $50.05, with an estimated average price of $47.77.
Sold Out: Marathon Oil Corp (MRO)
First American Bank sold out the holdings in Marathon Oil Corp. The sale prices were between $14.61 and $18.18, with an estimated average price of $16.4.
JPM 15-Year Financial Data
The intrinsic value of JPM
Peter Lynch Chart of JPM
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares reduced by 3.89% AbbVie Inc ( ABBV ) - 186,953 shares, 2.14% of the total portfolio. First American Bank New Purchases: EXC , RY , IBM , VEA, LCII, CC, ACIA, VGT, VHT, Added Positions:JPM, MDT, BA, AMZN, UNH, BAC, ETR, MSFT, GD, AVGO, Reduced Positions:EW, STI, LOW, EEFT, GPC, GILD, MLM, SBUX, RTN, FRC, Sold Out:NXPI, UFS, DUK, PPG, FCB, APA, MRO, PE, NTNX, MET, For the details of FIRST AMERICAN BANK's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=FIRST+AMERICAN+BANK These are the top 5 holdings of FIRST AMERICAN BANK PepsiCo Inc ( PEP ) - 326,221 shares, 6.4% of the total portfolio. New Purchase: International Business Machines Corp (IBM) First American Bank initiated holdings in International Business Machines Corp. | Shares reduced by 3.89% AbbVie Inc ( ABBV ) - 186,953 shares, 2.14% of the total portfolio. First American Bank New Purchases: EXC , RY , IBM , VEA, LCII, CC, ACIA, VGT, VHT, Added Positions:JPM, MDT, BA, AMZN, UNH, BAC, ETR, MSFT, GD, AVGO, Reduced Positions:EW, STI, LOW, EEFT, GPC, GILD, MLM, SBUX, RTN, FRC, Sold Out:NXPI, UFS, DUK, PPG, FCB, APA, MRO, PE, NTNX, MET, For the details of FIRST AMERICAN BANK's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=FIRST+AMERICAN+BANK These are the top 5 holdings of FIRST AMERICAN BANK PepsiCo Inc ( PEP ) - 326,221 shares, 6.4% of the total portfolio. New Purchase: International Business Machines Corp (IBM) First American Bank initiated holdings in International Business Machines Corp. | Shares reduced by 3.89% AbbVie Inc ( ABBV ) - 186,953 shares, 2.14% of the total portfolio. First American Bank New Purchases: EXC , RY , IBM , VEA, LCII, CC, ACIA, VGT, VHT, Added Positions:JPM, MDT, BA, AMZN, UNH, BAC, ETR, MSFT, GD, AVGO, Reduced Positions:EW, STI, LOW, EEFT, GPC, GILD, MLM, SBUX, RTN, FRC, Sold Out:NXPI, UFS, DUK, PPG, FCB, APA, MRO, PE, NTNX, MET, For the details of FIRST AMERICAN BANK's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=FIRST+AMERICAN+BANK These are the top 5 holdings of FIRST AMERICAN BANK PepsiCo Inc ( PEP ) - 326,221 shares, 6.4% of the total portfolio. Shares reduced by 7.3% New Purchase: Exelon Corp (EXC) First American Bank initiated holdings in Exelon Corp. | Shares reduced by 3.89% AbbVie Inc ( ABBV ) - 186,953 shares, 2.14% of the total portfolio. Shares added by 4.23% Microsoft Corp ( MSFT ) - 212,509 shares, 2.45% of the total portfolio. Shares reduced by 7.3% New Purchase: Exelon Corp (EXC) First American Bank initiated holdings in Exelon Corp. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.